AIMed.d0.s5.p0	N	Cytokines measurements during PROTEIN1 treatment showed a trend to decreasing levels of PROTEIN2 at 4, 12, and 24 weeks.
AIMed.d0.s6.p0	N	Levels of PROTEIN1 were slightly increased following PROTEIN2 treatment (P = 0.09).
AIMed.d0.s7.p0	N	In patients with a complete response to PROTEIN1 , the levels of PROTEIN2 were higher at 24 weeks following PROTEIN treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d0.s7.p1	N	In patients with a complete response to PROTEIN1 , the levels of PROTEIN were higher at 24 weeks following PROTEIN2 treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d0.s7.p2	N	In patients with a complete response to PROTEIN1 , the levels of PROTEIN were higher at 24 weeks following PROTEIN treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN2 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d0.s7.p3	N	In patients with a complete response to PROTEIN , the levels of PROTEIN1 were higher at 24 weeks following PROTEIN2 treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d0.s7.p4	N	In patients with a complete response to PROTEIN , the levels of PROTEIN1 were higher at 24 weeks following PROTEIN treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN2 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d0.s7.p5	N	In patients with a complete response to PROTEIN , the levels of PROTEIN were higher at 24 weeks following PROTEIN1 treatment than that of pre-treatment (P = 0.04), and the levels of PROTEIN2 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.
AIMed.d1.s12.p0	N	This study describes the distributions of PROTEIN1 as well as mRNAs for PROTEIN2 ( PROTEIN ). collagen types II ( PROTEIN ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p1	N	This study describes the distributions of PROTEIN1 as well as mRNAs for PROTEIN ( PROTEIN2 ). collagen types II ( PROTEIN ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p2	N	This study describes the distributions of PROTEIN1 as well as mRNAs for PROTEIN ( PROTEIN ). collagen types II ( PROTEIN2 ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p3	N	This study describes the distributions of PROTEIN1 as well as mRNAs for PROTEIN ( PROTEIN ). collagen types II ( PROTEIN ) and III ( PROTEIN2 ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p4	N	This study describes the distributions of PROTEIN as well as mRNAs for PROTEIN1 ( PROTEIN2 ). collagen types II ( PROTEIN ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p5	N	This study describes the distributions of PROTEIN as well as mRNAs for PROTEIN1 ( PROTEIN ). collagen types II ( PROTEIN2 ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p7	N	This study describes the distributions of PROTEIN as well as mRNAs for PROTEIN ( PROTEIN1 ). collagen types II ( PROTEIN2 ) and III ( PROTEIN ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p8	N	This study describes the distributions of PROTEIN as well as mRNAs for PROTEIN ( PROTEIN1 ). collagen types II ( PROTEIN ) and III ( PROTEIN2 ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s12.p9	N	This study describes the distributions of PROTEIN as well as mRNAs for PROTEIN ( PROTEIN ). collagen types II ( PROTEIN1 ) and III ( PROTEIN2 ) in a growing "cartilage cap" of osteochondroma.
AIMed.d1.s14.p0	N	PROTEIN1 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for PROTEIN2 and PROTEIN , respectively.
AIMed.d1.s14.p1	N	PROTEIN1 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for PROTEIN and PROTEIN2 , respectively.
AIMed.d1.s14.p2	N	PROTEIN was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix, positive for PROTEIN1 and PROTEIN2 , respectively.
AIMed.d1.s16.p0	N	This is the first study to provide observational evidence of the involvement of PROTEIN1 signaling in the pathogenesis of cartilage cap of osteochondroma. and suggests the role of PROTEIN2 in the growth of cartilage cap in osteochondroma.
AIMed.d2.s17.p0	N	The molar ratio of serum PROTEIN1 ( PROTEIN2 ) to PROTEIN ( PROTEIN ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s17.p1	N	The molar ratio of serum PROTEIN1 ( PROTEIN ) to PROTEIN2 ( PROTEIN ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s17.p2	N	The molar ratio of serum PROTEIN1 ( PROTEIN ) to PROTEIN ( PROTEIN2 ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s17.p3	N	The molar ratio of serum PROTEIN ( PROTEIN1 ) to PROTEIN2 ( PROTEIN ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s17.p4	N	The molar ratio of serum PROTEIN ( PROTEIN1 ) to PROTEIN ( PROTEIN2 ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s17.p5	N	The molar ratio of serum PROTEIN ( PROTEIN ) to PROTEIN1 ( PROTEIN2 ) is not useful to assess vitamin A status during infection in hospitalised children.
AIMed.d2.s18.p0	N	OBJECTIVE: To assess the usefulness of the molar ratio of serum PROTEIN1 ( PROTEIN2 ) to PROTEIN ( PROTEIN ) to determine vitamin A (VA) status during infection.
AIMed.d2.s18.p1	N	OBJECTIVE: To assess the usefulness of the molar ratio of serum PROTEIN1 ( PROTEIN ) to PROTEIN2 ( PROTEIN ) to determine vitamin A (VA) status during infection.
AIMed.d2.s18.p2	N	OBJECTIVE: To assess the usefulness of the molar ratio of serum PROTEIN1 ( PROTEIN ) to PROTEIN ( PROTEIN2 ) to determine vitamin A (VA) status during infection.
AIMed.d2.s18.p4	N	OBJECTIVE: To assess the usefulness of the molar ratio of serum PROTEIN ( PROTEIN1 ) to PROTEIN ( PROTEIN2 ) to determine vitamin A (VA) status during infection.
AIMed.d2.s18.p5	N	OBJECTIVE: To assess the usefulness of the molar ratio of serum PROTEIN ( PROTEIN ) to PROTEIN1 ( PROTEIN2 ) to determine vitamin A (VA) status during infection.
AIMed.d2.s19.p0	N	DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the PROTEIN1 / PROTEIN2 ratio and its relationship to infection and VA status.
AIMed.d2.s23.p0	N	MAIN OUTCOME MEASURES: PROTEIN1 / PROTEIN2 molar ratio after 7 days hospitalisation.
AIMed.d2.s24.p0	N	RESULTS: After 7 days hospitalisation, molar PROTEIN1 : PROTEIN2 ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p1	N	RESULTS: After 7 days hospitalisation, molar PROTEIN1 : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN2 : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p2	N	RESULTS: After 7 days hospitalisation, molar PROTEIN1 : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN2 ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p4	N	RESULTS: After 7 days hospitalisation, molar PROTEIN1 : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN2 ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p5	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN1 ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN2 : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p6	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN1 ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN2 ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p7	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN1 ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN2 : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p8	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN1 ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN2 ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p10	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN1 : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN2 : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p11	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN1 : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN2 ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p12	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN1 ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN2 : PROTEIN ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p13	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN1 ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN : PROTEIN2 ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d2.s24.p14	N	RESULTS: After 7 days hospitalisation, molar PROTEIN : PROTEIN ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in PROTEIN : PROTEIN ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar PROTEIN1 : PROTEIN2 ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.
AIMed.d3.s30.p2	N	Temporally following this growth arrest, the cells develop a senescence morphology and express PROTEIN1 ( PROTEIN2 ).
AIMed.d3.s31.p0	N	Levels of PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) rise in HUCs during progressive passages, whereas only PROTEIN increases in HPEC cultures.
AIMed.d3.s31.p1	N	Levels of PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) rise in HUCs during progressive passages, whereas only PROTEIN increases in HPEC cultures.
AIMed.d3.s31.p2	N	Levels of PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) rise in HUCs during progressive passages, whereas only PROTEIN increases in HPEC cultures.
AIMed.d3.s31.p3	N	Levels of PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN ) rise in HUCs during progressive passages, whereas only PROTEIN2 increases in HPEC cultures.
AIMed.d3.s31.p5	N	Levels of PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) rise in HUCs during progressive passages, whereas only PROTEIN increases in HPEC cultures.
AIMed.d3.s31.p6	N	Levels of PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN ) rise in HUCs during progressive passages, whereas only PROTEIN2 increases in HPEC cultures.
AIMed.d3.s31.p7	N	Levels of PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) rise in HUCs during progressive passages, whereas only PROTEIN increases in HPEC cultures.
AIMed.d3.s31.p8	N	Levels of PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN ) rise in HUCs during progressive passages, whereas only PROTEIN2 increases in HPEC cultures.
AIMed.d3.s31.p9	N	Levels of PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 ) rise in HUCs during progressive passages, whereas only PROTEIN2 increases in HPEC cultures.
AIMed.d3.s32.p0	N	The induced expression of PROTEIN1 , similar to PROTEIN2 , produces a senescent-like phenotype.
AIMed.d3.s33.p1	N	PROTEIN1 , PROTEIN , PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p2	N	PROTEIN1 , PROTEIN , PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p3	N	PROTEIN1 , PROTEIN , PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p4	N	PROTEIN1 , PROTEIN , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN2 ) decrease in both cell types.
AIMed.d3.s33.p5	N	PROTEIN , PROTEIN1 , PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p6	N	PROTEIN , PROTEIN1 , PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p7	N	PROTEIN , PROTEIN1 , PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p8	N	PROTEIN , PROTEIN1 , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN2 ) decrease in both cell types.
AIMed.d3.s33.p9	N	PROTEIN , PROTEIN , PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p11	N	PROTEIN , PROTEIN , PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) decrease in both cell types.
AIMed.d3.s33.p12	N	PROTEIN , PROTEIN , PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) decrease in both cell types.
AIMed.d3.s33.p14	N	PROTEIN , PROTEIN , PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) decrease in both cell types.
AIMed.d3.s34.p0	N	We find that PROTEIN1 , PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p1	N	We find that PROTEIN1 , PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p2	N	We find that PROTEIN1 , PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p3	N	We find that PROTEIN1 , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN2 ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p4	N	We find that PROTEIN , PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p5	N	We find that PROTEIN , PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p6	N	We find that PROTEIN , PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s34.p7	N	We find that PROTEIN , PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
AIMed.d3.s35.p0	N	Analysis of PROTEIN1 , PROTEIN2 ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p1	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN2 ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p2	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN ), PROTEIN2 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p3	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN2 ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p4	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p5	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p6	N	Analysis of PROTEIN1 , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p9	N	Analysis of PROTEIN , PROTEIN1 ( PROTEIN ), PROTEIN2 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p10	N	Analysis of PROTEIN , PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN2 ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p11	N	Analysis of PROTEIN , PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p13	N	Analysis of PROTEIN , PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p14	N	Analysis of PROTEIN , PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN2 ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p15	N	Analysis of PROTEIN , PROTEIN ( PROTEIN1 ), PROTEIN2 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p17	N	Analysis of PROTEIN , PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p18	N	Analysis of PROTEIN , PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p19	N	Analysis of PROTEIN , PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p20	N	Analysis of PROTEIN , PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN2 ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p21	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN2 ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p22	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p23	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p24	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p25	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN2 ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p26	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p27	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p28	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p31	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p32	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), and PROTEIN ( PROTEIN2 ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p33	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), and PROTEIN2 ( PROTEIN ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d3.s35.p34	N	Analysis of PROTEIN , PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), and PROTEIN ( PROTEIN2 ) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
AIMed.d4.s37.p0	N	Positive inotropic responses mediated by endothelin PROTEIN1 and PROTEIN2 receptors in human myocardial trabeculae.
AIMed.d4.s38.p0	N	The aim of the present study was to determine possible inotropic effects mediated by endothelin PROTEIN1 and PROTEIN2 receptors in human myocardial trabeculae from the right atrium and the left ventricle.
AIMed.d4.s40.p0	N	PROTEIN1 ( PROTEIN2 ) and PROTEIN had a strong positive inotropic effect in all trabeculae.
AIMed.d4.s40.p1	N	PROTEIN1 ( PROTEIN ) and PROTEIN2 had a strong positive inotropic effect in all trabeculae.
AIMed.d4.s40.p2	N	PROTEIN ( PROTEIN1 ) and PROTEIN2 had a strong positive inotropic effect in all trabeculae.
AIMed.d4.s41.p0	N	PROTEIN1 was significantly more potent than PROTEIN2 in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.
AIMed.d4.s42.p0	N	Preincubation with the PROTEIN1 antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of PROTEIN2 in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).
AIMed.d4.s43.p0	N	The PROTEIN1 agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the PROTEIN2 antagonist BQ 788 (1 microM) almost completely blocked this effect.
AIMed.d4.s44.p0	N	These results suggest that both PROTEIN1 and PROTEIN2 receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.
AIMed.d6.s51.p0	N	PROTEIN1 and PROTEIN2 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.
AIMed.d7.s53.p0	N	A comparative study of PROTEIN1 and PROTEIN2 expression in de novo and ex adenoma carcinoma of the colorectum.
AIMed.d7.s56.p0	N	The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( PROTEIN1 ) and protease [ PROTEIN2 ( PROTEIN )] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.
AIMed.d7.s56.p1	N	The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( PROTEIN1 ) and protease [ PROTEIN ( PROTEIN2 )] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.
AIMed.d7.s56.p2	N	The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( PROTEIN ) and protease [ PROTEIN1 ( PROTEIN2 )] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.
AIMed.d7.s57.p0	N	The rates of extensive PROTEIN1 expression and decreased PROTEIN2 expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).
AIMed.d8.s60.p0	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN1 , PROTEIN2 , PROTEIN and PROTEIN / PROTEIN .
AIMed.d8.s60.p1	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN1 , PROTEIN , PROTEIN2 and PROTEIN / PROTEIN .
AIMed.d8.s60.p2	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN1 , PROTEIN , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d8.s60.p3	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN1 , PROTEIN , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d8.s60.p5	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN , PROTEIN1 , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d8.s60.p6	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN , PROTEIN1 , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d8.s60.p7	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN , PROTEIN , PROTEIN1 and PROTEIN2 / PROTEIN .
AIMed.d8.s60.p8	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN , PROTEIN , PROTEIN1 and PROTEIN / PROTEIN2 .
AIMed.d8.s60.p9	N	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of PROTEIN , PROTEIN , PROTEIN and PROTEIN1 / PROTEIN2 .
AIMed.d8.s61.p0	N	The PROTEIN1 , PROTEIN2 , PROTEIN and PROTEIN genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s61.p1	N	The PROTEIN1 , PROTEIN , PROTEIN2 and PROTEIN genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s61.p2	N	The PROTEIN1 , PROTEIN , PROTEIN and PROTEIN2 genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s61.p3	N	The PROTEIN , PROTEIN1 , PROTEIN2 and PROTEIN genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s61.p4	N	The PROTEIN , PROTEIN1 , PROTEIN and PROTEIN2 genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s61.p5	N	The PROTEIN , PROTEIN , PROTEIN1 and PROTEIN2 genes are among those most frequently altered in pancreatic ductal carcinoma.
AIMed.d8.s63.p0	N	These cell lines showed mutations in PROTEIN1 and PROTEIN2 at frequencies of 91% and 95%, respectively.
AIMed.d8.s66.p0	N	The most typical mutational profile involved PROTEIN1 , PROTEIN2 , and PROTEIN , concurrently aberrated in 20 cases (91%).
AIMed.d8.s66.p1	N	The most typical mutational profile involved PROTEIN1 , PROTEIN , and PROTEIN2 , concurrently aberrated in 20 cases (91%).
AIMed.d8.s66.p2	N	The most typical mutational profile involved PROTEIN , PROTEIN1 , and PROTEIN2 , concurrently aberrated in 20 cases (91%).
AIMed.d9.s73.p0	N	We investigated the mechanism of calcium-stimulated PROTEIN1 release from gastrinoma cells in vitro with a particular focus on the PROTEIN2 ( PROTEIN ).
AIMed.d9.s73.p2	N	We investigated the mechanism of calcium-stimulated PROTEIN release from gastrinoma cells in vitro with a particular focus on the PROTEIN1 ( PROTEIN2 ).
AIMed.d9.s80.p0	N	Our results demonstrated that PROTEIN1 was expressed in human gastrinoma cells and could be involved in the mechanism of calcium-evoked PROTEIN2 release.
AIMed.d10.s81.p0	N	PROTEIN1 and PROTEIN2 involvement in the osteogenic properties of the HeLa cell line.
AIMed.d10.s84.p0	N	We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins PROTEIN1 and PROTEIN2 by the grafted HeLa cells.
AIMed.d11.s88.p0	N	BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ( PROTEIN1 , neu/ PROTEIN2 , PROTEIN , and PROTEIN ) and tumor recurrence.
AIMed.d11.s88.p1	N	BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ( PROTEIN1 , neu/ PROTEIN , PROTEIN2 , and PROTEIN ) and tumor recurrence.
AIMed.d11.s88.p2	N	BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ( PROTEIN1 , neu/ PROTEIN , PROTEIN , and PROTEIN2 ) and tumor recurrence.
AIMed.d11.s88.p5	N	BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ( PROTEIN , neu/ PROTEIN , PROTEIN1 , and PROTEIN2 ) and tumor recurrence.
AIMed.d11.s90.p0	N	RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that PROTEIN1 and PROTEIN2 were also significant predictors.
AIMed.d12.s96.p2	N	Soluble PROTEIN1 and PROTEIN2 in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.
AIMed.d12.s102.p0	N	MAIN OUTCOME MEASURES: Measurement of soluble PROTEIN1 ( PROTEIN2 ) and PROTEIN in serum samples and fluid of recent blisters.
AIMed.d12.s102.p1	N	MAIN OUTCOME MEASURES: Measurement of soluble PROTEIN1 ( PROTEIN ) and PROTEIN2 in serum samples and fluid of recent blisters.
AIMed.d12.s102.p2	N	MAIN OUTCOME MEASURES: Measurement of soluble PROTEIN ( PROTEIN1 ) and PROTEIN2 in serum samples and fluid of recent blisters.
AIMed.d12.s103.p0	N	RESULTS: In the blister fluid of patients with TEN, we found significantly higher levels of PROTEIN1 than in patients with burns, whereas PROTEIN2 levels were higher in the blister fluid of burned patients.
AIMed.d12.s104.p0	N	No significant differences were found in serum samples of patients with TEN and burns, in either PROTEIN1 or PROTEIN2 .
AIMed.d12.s105.p0	N	In TEN we also found significantly higher levels of PROTEIN1 in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of PROTEIN2 in the blister fluid of burned patients.
AIMed.d13.s109.p0	N	We performed cell-free in vitro infection of primary bone marrow derived PROTEIN1 + cells using semi-purified HHV8 and a mature PROTEIN2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.
AIMed.d13.s112.p0	N	Of these 400, PROTEIN1 ( PROTEIN2 ), PROTEIN , TBP-associated factor, eukaryotic elongation factor and PROTEIN were up-regulated more than 3.5 fold.
AIMed.d13.s112.p1	N	Of these 400, PROTEIN1 ( PROTEIN ), PROTEIN2 , TBP-associated factor, eukaryotic elongation factor and PROTEIN were up-regulated more than 3.5 fold.
AIMed.d13.s112.p2	N	Of these 400, PROTEIN1 ( PROTEIN ), PROTEIN , TBP-associated factor, eukaryotic elongation factor and PROTEIN2 were up-regulated more than 3.5 fold.
AIMed.d13.s112.p3	N	Of these 400, PROTEIN ( PROTEIN1 ), PROTEIN2 , TBP-associated factor, eukaryotic elongation factor and PROTEIN were up-regulated more than 3.5 fold.
AIMed.d13.s112.p4	N	Of these 400, PROTEIN ( PROTEIN1 ), PROTEIN , TBP-associated factor, eukaryotic elongation factor and PROTEIN2 were up-regulated more than 3.5 fold.
AIMed.d13.s112.p5	N	Of these 400, PROTEIN ( PROTEIN ), PROTEIN1 , TBP-associated factor, eukaryotic elongation factor and PROTEIN2 were up-regulated more than 3.5 fold.
AIMed.d14.s117.p0	N	Concentrations of PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s117.p1	N	Concentrations of PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s117.p2	N	Concentrations of PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s117.p3	N	Concentrations of PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s117.p4	N	Concentrations of PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s117.p5	N	Concentrations of PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.
AIMed.d14.s118.p0	N	Correlations between PROTEIN1 and PROTEIN2 in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated.
AIMed.d14.s119.p0	N	Abnormal levels of PROTEIN1 and PROTEIN2 were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate.
AIMed.d15.s126.p0	N	We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely PROTEIN1 , PROTEIN2 and PROTEIN versus PROTEIN .
AIMed.d15.s126.p1	N	We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely PROTEIN1 , PROTEIN and PROTEIN2 versus PROTEIN .
AIMed.d15.s126.p2	N	We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely PROTEIN1 , PROTEIN and PROTEIN versus PROTEIN2 .
AIMed.d15.s126.p3	N	We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely PROTEIN , PROTEIN1 and PROTEIN2 versus PROTEIN .
AIMed.d15.s126.p5	N	We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely PROTEIN , PROTEIN and PROTEIN1 versus PROTEIN2 .
AIMed.d15.s128.p0	N	MATERIALS AND METHODS: We measured levels of PROTEIN1 , PROTEIN2 , PROTEIN and PROTEIN in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s128.p1	N	MATERIALS AND METHODS: We measured levels of PROTEIN1 , PROTEIN , PROTEIN2 and PROTEIN in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s128.p2	N	MATERIALS AND METHODS: We measured levels of PROTEIN1 , PROTEIN , PROTEIN and PROTEIN2 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s128.p3	N	MATERIALS AND METHODS: We measured levels of PROTEIN , PROTEIN1 , PROTEIN2 and PROTEIN in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s128.p4	N	MATERIALS AND METHODS: We measured levels of PROTEIN , PROTEIN1 , PROTEIN and PROTEIN2 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s128.p5	N	MATERIALS AND METHODS: We measured levels of PROTEIN , PROTEIN , PROTEIN1 and PROTEIN2 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.
AIMed.d15.s131.p0	N	PROTEIN1 , PROTEIN2 and PROTEIN levels were statistically greater in patients.
AIMed.d15.s131.p1	N	PROTEIN1 , PROTEIN and PROTEIN2 levels were statistically greater in patients.
AIMed.d15.s131.p2	N	PROTEIN , PROTEIN1 and PROTEIN2 levels were statistically greater in patients.
AIMed.d16.s136.p0	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN1 ( PROTEIN2 ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p2	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p3	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p4	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN2 , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p5	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN1 ), PROTEIN2 ( PROTEIN ), and PROTEIN ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p6	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN2 ), and PROTEIN ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p7	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), and PROTEIN2 ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p8	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN ), and PROTEIN ( PROTEIN2 , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p9	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN2 ), and PROTEIN ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p10	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), and PROTEIN2 ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p11	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN ), and PROTEIN ( PROTEIN2 , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p12	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), and PROTEIN2 ( PROTEIN , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p13	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN1 ), and PROTEIN ( PROTEIN2 , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s136.p14	N	METHODS: The genes for dopamine synthetic enzymes, PROTEIN ( PROTEIN ), PROTEIN ( PROTEIN ), and PROTEIN1 ( PROTEIN2 , an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.
AIMed.d16.s137.p0	N	Expressions of PROTEIN1 , PROTEIN2 and PROTEIN were detected by Western blot analysis.
AIMed.d16.s137.p1	N	Expressions of PROTEIN1 , PROTEIN and PROTEIN2 were detected by Western blot analysis.
AIMed.d16.s137.p2	N	Expressions of PROTEIN , PROTEIN1 and PROTEIN2 were detected by Western blot analysis.
AIMed.d16.s139.p0	N	RESULTS: PROTEIN1 , PROTEIN2 and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p1	N	RESULTS: PROTEIN1 , PROTEIN and PROTEIN2 were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p2	N	RESULTS: PROTEIN1 , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN2 , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p3	N	RESULTS: PROTEIN1 , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN2 and AAV- PROTEIN .
AIMed.d16.s139.p4	N	RESULTS: PROTEIN1 , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN2 .
AIMed.d16.s139.p5	N	RESULTS: PROTEIN , PROTEIN1 and PROTEIN2 were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p6	N	RESULTS: PROTEIN , PROTEIN1 and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN2 , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p7	N	RESULTS: PROTEIN , PROTEIN1 and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN2 and AAV- PROTEIN .
AIMed.d16.s139.p8	N	RESULTS: PROTEIN , PROTEIN1 and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN2 .
AIMed.d16.s139.p9	N	RESULTS: PROTEIN , PROTEIN and PROTEIN1 were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN2 , AAV- PROTEIN and AAV- PROTEIN .
AIMed.d16.s139.p10	N	RESULTS: PROTEIN , PROTEIN and PROTEIN1 were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN2 and AAV- PROTEIN .
AIMed.d16.s139.p11	N	RESULTS: PROTEIN , PROTEIN and PROTEIN1 were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN and AAV- PROTEIN2 .
AIMed.d16.s139.p12	N	RESULTS: PROTEIN , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN1 , AAV- PROTEIN2 and AAV- PROTEIN .
AIMed.d16.s139.p13	N	RESULTS: PROTEIN , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN1 , AAV- PROTEIN and AAV- PROTEIN2 .
AIMed.d16.s139.p14	N	RESULTS: PROTEIN , PROTEIN and PROTEIN were effectively coexpressed in transduced cells with three separate AAV vectors, AAV- PROTEIN , AAV- PROTEIN1 and AAV- PROTEIN2 .
AIMed.d16.s141.p0	N	CONCLUSION: The triple transduction of PROTEIN1 , PROTEIN2 and PROTEIN genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.
AIMed.d16.s141.p1	N	CONCLUSION: The triple transduction of PROTEIN1 , PROTEIN and PROTEIN2 genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.
AIMed.d16.s141.p2	N	CONCLUSION: The triple transduction of PROTEIN , PROTEIN1 and PROTEIN2 genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.
AIMed.d17.s146.p0	N	This overview summarizes the current knowledge on PROTEIN1 ( PROTEIN2 ) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.
AIMed.d17.s147.p0	N	In addition, a possible role for PROTEIN1 , the product of PROTEIN2 , in atherosclerotic lesion development is put into perspective.
AIMed.d18.s151.p0	N	Cytokines PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p1	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p2	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p3	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p4	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN2 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p5	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p6	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p8	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p9	N	Cytokines PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p10	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p11	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p12	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p13	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN2 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p14	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p15	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p16	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p17	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p18	N	Cytokines PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p19	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p20	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p21	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN2 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p22	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p23	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p24	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p25	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p26	N	Cytokines PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p27	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p29	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p30	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p31	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p32	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p33	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p34	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 (Immunotech, France), PROTEIN2 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p35	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 (Immunotech, France), PROTEIN , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p36	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p37	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p38	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p40	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN1 , and PROTEIN2 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p41	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN1 , and PROTEIN ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p42	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN1 , and PROTEIN ( PROTEIN ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p43	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN1 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p44	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN1 , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p45	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN1 ( PROTEIN2 ) sP- and PROTEIN , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p47	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN1 ( PROTEIN ) sP- and PROTEIN , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p48	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN1 ( PROTEIN ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p49	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN1 ) sP- and PROTEIN2 , PROTEIN , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p51	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN1 ) sP- and PROTEIN , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p52	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN1 , PROTEIN2 , and PROTEIN (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p53	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN1 , PROTEIN , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s151.p54	N	Cytokines PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN (Immunotech, France), PROTEIN , and PROTEIN ( PROTEIN ) sP- and PROTEIN , PROTEIN1 , and PROTEIN2 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).
AIMed.d18.s156.p0	N	PROTEIN1 and sP- and PROTEIN2 levels were not related to function of lymphocytes (by MDM data) as seen in both tests; it is probable that another cell-cell communication mechanism had been switched on.
AIMed.d18.s157.p0	N	We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of PROTEIN1 , PROTEIN2 , and PROTEIN , which are the active participants in the pro- and anti-inflammatory program in atherogenesis.
AIMed.d18.s157.p2	N	We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of PROTEIN , PROTEIN1 , and PROTEIN2 , which are the active participants in the pro- and anti-inflammatory program in atherogenesis.
AIMed.d19.s162.p0	N	Several genes are involved in this process, and two have been the focus of recent interest: the PROTEIN1 ( PROTEIN2 ) gene and the genes coding for the PROTEIN .
AIMed.d19.s162.p1	N	Several genes are involved in this process, and two have been the focus of recent interest: the PROTEIN1 ( PROTEIN ) gene and the genes coding for the PROTEIN2 .
AIMed.d19.s162.p2	N	Several genes are involved in this process, and two have been the focus of recent interest: the PROTEIN ( PROTEIN1 ) gene and the genes coding for the PROTEIN2 .
AIMed.d20.s168.p0	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN1 and beta, PROTEIN2 and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p1	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN1 and beta, PROTEIN and 2, PROTEIN2 and its receptor antagonist ( PROTEIN ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p2	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN1 and beta, PROTEIN and 2, PROTEIN and its receptor antagonist ( PROTEIN2 ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p3	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN1 and beta, PROTEIN and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN2 (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p4	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN1 and beta, PROTEIN and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN2 .
AIMed.d20.s168.p6	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN1 and 2, PROTEIN and its receptor antagonist ( PROTEIN2 ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p7	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN1 and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN2 (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p8	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN1 and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN2 .
AIMed.d20.s168.p9	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN and 2, PROTEIN1 and its receptor antagonist ( PROTEIN2 ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p10	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN and 2, PROTEIN1 and its receptor antagonist ( PROTEIN ), PROTEIN2 (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN .
AIMed.d20.s168.p11	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN and 2, PROTEIN1 and its receptor antagonist ( PROTEIN ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN2 .
AIMed.d20.s168.p13	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN and 2, PROTEIN and its receptor antagonist ( PROTEIN1 ), PROTEIN (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN2 .
AIMed.d20.s168.p14	N	Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules PROTEIN and beta, PROTEIN and 2, PROTEIN and its receptor antagonist ( PROTEIN ), PROTEIN1 (the receptor for lipopolysaccharide), P and E selectins, and PROTEIN2 .
AIMed.d21.s176.p0	N	Many of the same signaling molecules, including PROTEIN1 ( PROTEIN2 ), PROTEIN ( PROTEIN ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d21.s176.p1	N	Many of the same signaling molecules, including PROTEIN1 ( PROTEIN ), PROTEIN2 ( PROTEIN ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d21.s176.p2	N	Many of the same signaling molecules, including PROTEIN1 ( PROTEIN ), PROTEIN ( PROTEIN2 ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d21.s176.p3	N	Many of the same signaling molecules, including PROTEIN ( PROTEIN1 ), PROTEIN2 ( PROTEIN ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d21.s176.p4	N	Many of the same signaling molecules, including PROTEIN ( PROTEIN1 ), PROTEIN ( PROTEIN2 ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d21.s176.p5	N	Many of the same signaling molecules, including PROTEIN ( PROTEIN ), PROTEIN1 ( PROTEIN2 ), and protein phosphatase, regulate the transporters for different neurotransmitters.
AIMed.d22.s181.p0	N	Present data concerning the PROTEIN1 - PROTEIN2 system of extrarenal origin.
AIMed.d22.s182.p0	N	After a brief historical incursion regarding PROTEIN1 of renal origin, we present the main extrarenal PROTEIN2 -forming enzymes, starting with PROTEIN , PROTEIN , D and PROTEIN and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p1	N	After a brief historical incursion regarding PROTEIN1 of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN2 , PROTEIN , D and PROTEIN and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p2	N	After a brief historical incursion regarding PROTEIN1 of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN , PROTEIN2 , D and PROTEIN and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p3	N	After a brief historical incursion regarding PROTEIN1 of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN , PROTEIN , D and PROTEIN2 and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p6	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN1 -forming enzymes, starting with PROTEIN , PROTEIN2 , D and PROTEIN and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p7	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN1 -forming enzymes, starting with PROTEIN , PROTEIN , D and PROTEIN2 and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p8	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN1 -forming enzymes, starting with PROTEIN , PROTEIN , D and PROTEIN and ending with the conversion enzyme and PROTEIN2 .
AIMed.d22.s182.p9	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN1 , PROTEIN2 , D and PROTEIN and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p10	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN1 , PROTEIN , D and PROTEIN2 and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p11	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN1 , PROTEIN , D and PROTEIN and ending with the conversion enzyme and PROTEIN2 .
AIMed.d22.s182.p12	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN , PROTEIN1 , D and PROTEIN2 and ending with the conversion enzyme and PROTEIN .
AIMed.d22.s182.p13	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN , PROTEIN1 , D and PROTEIN and ending with the conversion enzyme and PROTEIN2 .
AIMed.d22.s182.p14	N	After a brief historical incursion regarding PROTEIN of renal origin, we present the main extrarenal PROTEIN -forming enzymes, starting with PROTEIN , PROTEIN , D and PROTEIN1 and ending with the conversion enzyme and PROTEIN2 .
AIMed.d22.s184.p0	N	In the end we refer to the relations between circulating PROTEIN1 of renal origin and the extrarenal PROTEIN2 specific to tissue underlying the fact that the two PROTEIN components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
AIMed.d22.s184.p1	N	In the end we refer to the relations between circulating PROTEIN1 of renal origin and the extrarenal PROTEIN specific to tissue underlying the fact that the two PROTEIN2 components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
AIMed.d22.s184.p2	N	In the end we refer to the relations between circulating PROTEIN of renal origin and the extrarenal PROTEIN1 specific to tissue underlying the fact that the two PROTEIN2 components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
AIMed.d22.s185.p0	N	While the circulating PROTEIN1 of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue PROTEIN2 , in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.
AIMed.d23.s189.p0	N	In the present study, we examined the presence of glucocorticoid receptors (GRs) and PROTEIN1 ( PROTEIN2 ) in the nasal polyps of nonallergic patients as compared with normal controls.
AIMed.d23.s194.p0	N	In contrast, in normal nasal tissues, PROTEIN1 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that PROTEIN2 is upregulated in nasal polyps.
AIMed.d23.s195.p0	N	Therefore, 1) the presence of GRs and PROTEIN1 in nasal polyps from nonallergic patients, as well as upregulation of PROTEIN2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.
AIMed.d24.s200.p0	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p1	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p2	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p3	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p4	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p5	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p6	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p7	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p8	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p9	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p10	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p11	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p12	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p13	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p15	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p16	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p17	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p19	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p20	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p21	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p22	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p24	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p25	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p26	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p27	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p28	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p30	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p31	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p32	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p33	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p34	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d24.s200.p35	N	Comparison of messenger RNA gene expression of extracellular matrix proteins ( PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 ) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
AIMed.d25.s203.p0	N	Assaying of PROTEIN1 , complement factors, and PROTEIN2 in the diagnosis of malignant serous effusions.
AIMed.d25.s204.p0	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN2 ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p1	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN2 , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p2	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN2 ( PROTEIN ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p3	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN2 ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p4	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN2 and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p5	N	The objective of this study was to measure the concentrations of PROTEIN1 ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p6	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN1 ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN2 , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p8	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN1 ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN2 ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p9	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN1 ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN2 and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p10	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN1 ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p11	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN1 , PROTEIN2 ( PROTEIN ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p12	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN1 , PROTEIN ( PROTEIN2 ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p14	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN1 , PROTEIN ( PROTEIN ), and complement factors PROTEIN and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p15	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN1 ( PROTEIN2 ), and complement factors PROTEIN and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p16	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN1 ( PROTEIN ), and complement factors PROTEIN2 and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p17	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN1 ( PROTEIN ), and complement factors PROTEIN and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p18	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN1 ), and complement factors PROTEIN2 and PROTEIN can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p19	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN1 ), and complement factors PROTEIN and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s204.p20	N	The objective of this study was to measure the concentrations of PROTEIN ( PROTEIN ) in pleural and peritoneal effusions of different causes and to verify whether PROTEIN , PROTEIN ( PROTEIN ), and complement factors PROTEIN1 and PROTEIN2 can be used in the differential diagnosis of serous effusion.
AIMed.d25.s206.p0	N	PROTEIN1 , PROTEIN2 , and complement factors PROTEIN and PROTEIN concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s206.p1	N	PROTEIN1 , PROTEIN , and complement factors PROTEIN2 and PROTEIN concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s206.p2	N	PROTEIN1 , PROTEIN , and complement factors PROTEIN and PROTEIN2 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s206.p3	N	PROTEIN , PROTEIN1 , and complement factors PROTEIN2 and PROTEIN concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s206.p4	N	PROTEIN , PROTEIN1 , and complement factors PROTEIN and PROTEIN2 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s206.p5	N	PROTEIN , PROTEIN , and complement factors PROTEIN1 and PROTEIN2 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
AIMed.d25.s210.p0	N	Their order of selection was PROTEIN1 effusion, PROTEIN2 serum, PROTEIN -effusion, and PROTEIN effusion.
AIMed.d25.s210.p2	N	Their order of selection was PROTEIN1 effusion, PROTEIN serum, PROTEIN -effusion, and PROTEIN2 effusion.
AIMed.d25.s210.p3	N	Their order of selection was PROTEIN effusion, PROTEIN1 serum, PROTEIN2 -effusion, and PROTEIN effusion.
AIMed.d25.s210.p4	N	Their order of selection was PROTEIN effusion, PROTEIN1 serum, PROTEIN -effusion, and PROTEIN2 effusion.
AIMed.d25.s210.p5	N	Their order of selection was PROTEIN effusion, PROTEIN serum, PROTEIN1 -effusion, and PROTEIN2 effusion.
AIMed.d25.s212.p0	N	Determination of PROTEIN1 , complement factors PROTEIN2 and PROTEIN , and PROTEIN may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d25.s212.p1	N	Determination of PROTEIN1 , complement factors PROTEIN and PROTEIN2 , and PROTEIN may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d25.s212.p2	N	Determination of PROTEIN1 , complement factors PROTEIN and PROTEIN , and PROTEIN2 may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d25.s212.p3	N	Determination of PROTEIN , complement factors PROTEIN1 and PROTEIN2 , and PROTEIN may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d25.s212.p4	N	Determination of PROTEIN , complement factors PROTEIN1 and PROTEIN , and PROTEIN2 may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d25.s212.p5	N	Determination of PROTEIN , complement factors PROTEIN and PROTEIN1 , and PROTEIN2 may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
AIMed.d26.s214.p0	N	Differential expression of PROTEIN1 and PROTEIN2 by NK cells in cancer patients and correlation of impaired PROTEIN expression withprogression of cancer.
AIMed.d26.s214.p1	N	Differential expression of PROTEIN1 and PROTEIN by NK cells in cancer patients and correlation of impaired PROTEIN2 expression withprogression of cancer.
AIMed.d26.s214.p2	N	Differential expression of PROTEIN and PROTEIN1 by NK cells in cancer patients and correlation of impaired PROTEIN2 expression withprogression of cancer.
AIMed.d26.s215.p1	N	PROTEIN1 has been identified as an effector molecule co-localized with PROTEIN in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of PROTEIN2 and to induce a cytotoxic effect against tumor cells.
AIMed.d26.s215.p2	N	PROTEIN has been identified as an effector molecule co-localized with PROTEIN1 in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of PROTEIN2 and to induce a cytotoxic effect against tumor cells.
AIMed.d26.s217.p0	N	Flow cytometric analysis demonstrated high levels of PROTEIN1 and PROTEIN2 expression by PROTEIN (-) PROTEIN (+) cells in healthy controls.
AIMed.d26.s217.p1	N	Flow cytometric analysis demonstrated high levels of PROTEIN1 and PROTEIN expression by PROTEIN2 (-) PROTEIN (+) cells in healthy controls.
AIMed.d26.s217.p2	N	Flow cytometric analysis demonstrated high levels of PROTEIN1 and PROTEIN expression by PROTEIN (-) PROTEIN2 (+) cells in healthy controls.
AIMed.d26.s217.p3	N	Flow cytometric analysis demonstrated high levels of PROTEIN and PROTEIN1 expression by PROTEIN2 (-) PROTEIN (+) cells in healthy controls.
AIMed.d26.s217.p4	N	Flow cytometric analysis demonstrated high levels of PROTEIN and PROTEIN1 expression by PROTEIN (-) PROTEIN2 (+) cells in healthy controls.
AIMed.d26.s217.p5	N	Flow cytometric analysis demonstrated high levels of PROTEIN and PROTEIN expression by PROTEIN1 (-) PROTEIN2 (+) cells in healthy controls.
AIMed.d26.s218.p0	N	In contrast, cancer patients exhibited significantly decreased levels of PROTEIN1 expression ( P<0.005), despite having equally high levels of PROTEIN2 expression in comparison with healthy controls.
AIMed.d26.s219.p0	N	The tumor-free patients expressed PROTEIN1 at levels similar to healthy controls, while the progressive tumor-bearing patients expressed remarkably lower levels of PROTEIN2 compared to healthy controls ( P<0.0001).
AIMed.d26.s223.p0	N	In conclusion, impaired expression of PROTEIN1 by NK cells correlates with progression of cancer, and determination of PROTEIN2 expression might prove informative for assessing the immunological condition of cancer patients.
AIMed.d27.s229.p0	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN1 and PROTEIN2 and regulators of apoptosis such as PROTEIN and members of the PROTEIN family.
AIMed.d27.s229.p1	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN1 and PROTEIN and regulators of apoptosis such as PROTEIN2 and members of the PROTEIN family.
AIMed.d27.s229.p2	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN1 and PROTEIN and regulators of apoptosis such as PROTEIN and members of the PROTEIN2 family.
AIMed.d27.s229.p3	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN and PROTEIN1 and regulators of apoptosis such as PROTEIN2 and members of the PROTEIN family.
AIMed.d27.s229.p4	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN and PROTEIN1 and regulators of apoptosis such as PROTEIN and members of the PROTEIN2 family.
AIMed.d27.s229.p5	N	Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as PROTEIN and PROTEIN and regulators of apoptosis such as PROTEIN1 and members of the PROTEIN2 family.
AIMed.d28.s234.p5	N	We have identified a new TNF-related ligand, designated human PROTEIN1 ( PROTEIN2 ), and its human receptor ( PROTEIN ), an ortholog of the recently discovered murine PROTEIN [4].
AIMed.d28.s234.p8	N	We have identified a new TNF-related ligand, designated human PROTEIN1 ( PROTEIN ), and its human receptor ( PROTEIN ), an ortholog of the recently discovered murine PROTEIN2 [4].
AIMed.d28.s234.p9	P	We have identified a new TNF-related ligand, designated human PROTEIN ( PROTEIN1 ), and its human receptor ( PROTEIN2 ), an ortholog of the recently discovered murine PROTEIN [4].
AIMed.d28.s234.p11	N	We have identified a new TNF-related ligand, designated human PROTEIN ( PROTEIN1 ), and its human receptor ( PROTEIN ), an ortholog of the recently discovered murine PROTEIN2 [4].
AIMed.d28.s234.p13	N	We have identified a new TNF-related ligand, designated human PROTEIN ( PROTEIN ), and its human receptor ( PROTEIN1 ), an ortholog of the recently discovered murine PROTEIN2 [4].
AIMed.d28.s235.p0	N	The PROTEIN1 gene mapped to chromosome 1q23, near the gene for the TNF homolog PROTEIN2 / PROTEIN [5].
AIMed.d28.s235.p1	N	The PROTEIN1 gene mapped to chromosome 1q23, near the gene for the TNF homolog PROTEIN / PROTEIN2 [5].
AIMed.d28.s235.p2	N	The PROTEIN gene mapped to chromosome 1q23, near the gene for the TNF homolog PROTEIN1 / PROTEIN2 [5].
AIMed.d28.s237.p0	N	We found PROTEIN1 mRNA in several peripheral tissues, and detected PROTEIN2 protein on cultured vascular endothelial cells.
AIMed.d28.s238.p0	N	The levels of PROTEIN1 mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of PROTEIN2 transcripts.
AIMed.d28.s239.p0	N	Cotransfection of PROTEIN1 and PROTEIN2 in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p1	N	Cotransfection of PROTEIN1 and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN2 , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p2	N	Cotransfection of PROTEIN1 and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN2 ( PROTEIN ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p5	N	Cotransfection of PROTEIN1 and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN2 ( PROTEIN ) [8].
AIMed.d28.s239.p6	N	Cotransfection of PROTEIN1 and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN2 ) [8].
AIMed.d28.s239.p7	N	Cotransfection of PROTEIN and PROTEIN1 in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN2 , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p9	N	Cotransfection of PROTEIN and PROTEIN1 in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN2 ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p11	N	Cotransfection of PROTEIN and PROTEIN1 in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN2 ( PROTEIN ) [8].
AIMed.d28.s239.p12	N	Cotransfection of PROTEIN and PROTEIN1 in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN2 ) [8].
AIMed.d28.s239.p13	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN1 , via a pathway that appeared to involve PROTEIN2 ( PROTEIN ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p16	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN1 , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN2 ( PROTEIN ) [8].
AIMed.d28.s239.p17	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN1 , via a pathway that appeared to involve PROTEIN ( PROTEIN ) [7] and PROTEIN ( PROTEIN2 ) [8].
AIMed.d28.s239.p18	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN1 ( PROTEIN2 ) [7] and PROTEIN ( PROTEIN ) [8].
AIMed.d28.s239.p20	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN1 ( PROTEIN ) [7] and PROTEIN2 ( PROTEIN ) [8].
AIMed.d28.s239.p21	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN1 ( PROTEIN ) [7] and PROTEIN ( PROTEIN2 ) [8].
AIMed.d28.s239.p23	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN1 ) [7] and PROTEIN2 ( PROTEIN ) [8].
AIMed.d28.s239.p24	N	Cotransfection of PROTEIN and PROTEIN in embryonic kidney 293 cells activated the anti-apoptotic transcription factor PROTEIN , via a pathway that appeared to involve PROTEIN ( PROTEIN1 ) [7] and PROTEIN ( PROTEIN2 ) [8].
AIMed.d28.s240.p0	N	Cotransfection of PROTEIN1 and PROTEIN2 in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.
AIMed.d28.s241.p0	N	Thus, PROTEIN1 and PROTEIN2 may modulate T lymphocyte survival in peripheral tissues.
AIMed.d29.s243.p0	N	We have probed an epitope sequence (His18-Pro19-Lys20-Phe21) in PROTEIN1 ( PROTEIN2 ) by site-directed mutagenesis.
AIMed.d29.s244.p1	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN1 reduced up to 77-fold the binding affinity to PROTEIN2 ( PROTEIN ) and B ( PROTEIN ) and to the PROTEIN .
AIMed.d29.s244.p2	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN1 reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN2 ) and B ( PROTEIN ) and to the PROTEIN .
AIMed.d29.s244.p3	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN1 reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN ) and B ( PROTEIN2 ) and to the PROTEIN .
AIMed.d29.s244.p4	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN1 reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN ) and B ( PROTEIN ) and to the PROTEIN2 .
AIMed.d29.s244.p9	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN1 ( PROTEIN2 ) and B ( PROTEIN ) and to the PROTEIN .
AIMed.d29.s244.p10	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN1 ( PROTEIN ) and B ( PROTEIN2 ) and to the PROTEIN .
AIMed.d29.s244.p11	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN1 ( PROTEIN ) and B ( PROTEIN ) and to the PROTEIN2 .
AIMed.d29.s244.p12	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN1 ) and B ( PROTEIN2 ) and to the PROTEIN .
AIMed.d29.s244.p13	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN1 ) and B ( PROTEIN ) and to the PROTEIN2 .
AIMed.d29.s244.p14	N	This work shows that single and double Ala substitutions of His18 and Phe21 in PROTEIN reduced up to 77-fold the binding affinity to PROTEIN ( PROTEIN ) and B ( PROTEIN1 ) and to the PROTEIN2 .
AIMed.d29.s245.p0	N	These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by PROTEIN1 and PROTEIN2 .
AIMed.d29.s246.p0	N	Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to PROTEIN1 , PROTEIN2 , and the PROTEIN .
AIMed.d29.s246.p1	N	Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to PROTEIN1 , PROTEIN , and the PROTEIN2 .
AIMed.d29.s246.p2	N	Single Asp or Ser substitutions, H18D, F21D, F21S, and double substitutions, H18A/F21D, H18A/F21S, and H18D/F21D, reduced up to 431-fold the binding affinity to PROTEIN , PROTEIN1 , and the PROTEIN2 .
AIMed.d29.s249.p0	P	This study demonstrates that PROTEIN1 recognizes and activates PROTEIN2 , PROTEIN , and the PROTEIN by distinct mechanisms.
AIMed.d29.s249.p1	P	This study demonstrates that PROTEIN1 recognizes and activates PROTEIN , PROTEIN2 , and the PROTEIN by distinct mechanisms.
AIMed.d29.s249.p2	P	This study demonstrates that PROTEIN1 recognizes and activates PROTEIN , PROTEIN , and the PROTEIN2 by distinct mechanisms.
AIMed.d29.s249.p3	N	This study demonstrates that PROTEIN recognizes and activates PROTEIN1 , PROTEIN2 , and the PROTEIN by distinct mechanisms.
AIMed.d29.s249.p4	N	This study demonstrates that PROTEIN recognizes and activates PROTEIN1 , PROTEIN , and the PROTEIN2 by distinct mechanisms.
AIMed.d29.s249.p5	N	This study demonstrates that PROTEIN recognizes and activates PROTEIN , PROTEIN1 , and the PROTEIN2 by distinct mechanisms.
AIMed.d30.s250.p0	P	Isolation of human PROTEIN1 and its binding specificity with PROTEIN2 .
AIMed.d30.s251.p0	P	We screened proteins for interaction with PROTEIN1 , and cloned the full-length cDNA of human PROTEIN2 , which encoded 1225 amino acids.
AIMed.d30.s252.p0	P	Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that PROTEIN1 interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PROTEIN2 , but not with that of PROTEIN .
AIMed.d30.s252.p1	N	Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that PROTEIN1 interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PROTEIN , but not with that of PROTEIN2 .
AIMed.d30.s252.p2	N	Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that PROTEIN interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PROTEIN1 , but not with that of PROTEIN2 .
AIMed.d30.s253.p0	N	These results suggest that PROTEIN1 and PROTEIN2 partly differ in function.
AIMed.d30.s255.p0	N	We also found another PROTEIN1 , PROTEIN2 , interacted with PROTEIN .
AIMed.d30.s255.p2	P	We also found another PROTEIN , PROTEIN1 , interacted with PROTEIN2 .
AIMed.d31.s256.p0	N	A newly identified member of tumor necrosis factor receptor superfamily ( PROTEIN1 ) suppresses PROTEIN2 -mediated apoptosis.
AIMed.d31.s257.p0	N	PROTEIN1 ( PROTEIN2 ( PROTEIN )) is a new member of the tumor necrosis factor receptor (TNFR) family.
AIMed.d31.s257.p1	N	PROTEIN1 ( PROTEIN ( PROTEIN2 )) is a new member of the tumor necrosis factor receptor (TNFR) family.
AIMed.d31.s257.p2	N	PROTEIN ( PROTEIN1 ( PROTEIN2 )) is a new member of the tumor necrosis factor receptor (TNFR) family.
AIMed.d31.s262.p0	P	Here, we demonstrate that PROTEIN1 specifically binds two cellular ligands, PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p2	P	Here, we demonstrate that PROTEIN1 specifically binds two cellular ligands, PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p3	P	Here, we demonstrate that PROTEIN1 specifically binds two cellular ligands, PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p5	P	Here, we demonstrate that PROTEIN1 specifically binds two cellular ligands, PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN / PROTEIN2 ).
AIMed.d31.s262.p7	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p8	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p9	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 / PROTEIN ).
AIMed.d31.s262.p10	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN / PROTEIN2 ).
AIMed.d31.s262.p15	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN / PROTEIN ).
AIMed.d31.s262.p16	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 / PROTEIN ).
AIMed.d31.s262.p17	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN / PROTEIN2 ).
AIMed.d31.s262.p18	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 / PROTEIN ).
AIMed.d31.s262.p19	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN / PROTEIN2 ).
AIMed.d31.s262.p20	N	Here, we demonstrate that PROTEIN specifically binds two cellular ligands, PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 / PROTEIN2 ).
AIMed.d31.s264.p0	N	PROTEIN1 inhibited PROTEIN2 -induced cytotoxicity in HT29 cells.
AIMed.d31.s265.p1	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN2 ( PROTEIN ) and PROTEIN / PROTEIN receptors.
AIMed.d31.s265.p2	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN2 ) and PROTEIN / PROTEIN receptors.
AIMed.d31.s265.p3	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN2 / PROTEIN receptors.
AIMed.d31.s265.p4	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN / PROTEIN2 receptors.
AIMed.d31.s265.p9	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN1 ( PROTEIN2 ) and PROTEIN / PROTEIN receptors.
AIMed.d31.s265.p10	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN1 ( PROTEIN ) and PROTEIN2 / PROTEIN receptors.
AIMed.d31.s265.p11	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN1 ( PROTEIN ) and PROTEIN / PROTEIN2 receptors.
AIMed.d31.s265.p12	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN1 ) and PROTEIN2 / PROTEIN receptors.
AIMed.d31.s265.p13	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN1 ) and PROTEIN / PROTEIN2 receptors.
AIMed.d31.s265.p14	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN1 / PROTEIN2 receptors.
AIMed.d31.s266.p0	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN2 with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p1	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN2 / PROTEIN and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p2	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN / PROTEIN2 and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p3	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p4	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 - mediated HT29 cell death.
AIMed.d31.s266.p5	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN2 / PROTEIN and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p6	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN2 and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p7	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p8	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 - mediated HT29 cell death.
AIMed.d31.s266.p9	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN2 and PROTEIN , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p10	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p11	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 - mediated HT29 cell death.
AIMed.d31.s266.p12	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN1 and PROTEIN2 , thereby suppressing PROTEIN - mediated HT29 cell death.
AIMed.d31.s266.p13	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN1 and PROTEIN , thereby suppressing PROTEIN2 - mediated HT29 cell death.
AIMed.d31.s266.p14	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN1 , thereby suppressing PROTEIN2 - mediated HT29 cell death.
AIMed.d31.s267.p0	N	Thus, PROTEIN1 may play a regulatory role for suppressing in PROTEIN2 - and PROTEIN -mediated cell death.
AIMed.d31.s267.p1	N	Thus, PROTEIN1 may play a regulatory role for suppressing in PROTEIN - and PROTEIN2 -mediated cell death.
AIMed.d31.s267.p2	N	Thus, PROTEIN may play a regulatory role for suppressing in PROTEIN1 - and PROTEIN2 -mediated cell death.
AIMed.d32.s268.p9	P	Shared and unique determinants of the erythropoietin (EPO) receptor  PROTEIN1 are important for binding PROTEIN2 and PROTEIN .
AIMed.d32.s268.p11	N	Shared and unique determinants of the erythropoietin (EPO) receptor  PROTEIN1 are important for binding PROTEIN and PROTEIN2 .
AIMed.d32.s269.p17	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN1 ( PROTEIN2 ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p18	P	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN1 ( PROTEIN ) is crucial for binding PROTEIN2 .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p20	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN1 ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN2 ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p22	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN1 ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN2 or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p23	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN1 ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p24	P	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN1 ) is crucial for binding PROTEIN2 .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p25	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN1 ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN2 binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p26	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN1 ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN2 ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p28	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN1 ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN2 or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p29	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN1 ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p31	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN1 .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN2 ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p33	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN1 .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN2 or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p34	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN1 .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p35	P	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN1 binding to the Escherichia coli-expressed extracellular domain of the PROTEIN2 ( PROTEIN or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p37	P	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN1 binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN2 or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p38	P	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN1 binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p40	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN1 ( PROTEIN2 or PROTEIN ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p41	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN1 ( PROTEIN or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s269.p44	N	We have shown previously that Phe93 in the extracellular domain of the erythropoietin (EPO) receptor  PROTEIN ( PROTEIN ) is crucial for binding PROTEIN .Substitution of Phe93 with alanine resulted in a dramatic decrease in PROTEIN binding to the Escherichia coli-expressed extracellular domain of the PROTEIN ( PROTEIN1 or PROTEIN2 ) and no detectable binding to full-length mutant receptor expressed in COS cells.
AIMed.d32.s270.p1	N	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN1 bound to an PROTEIN2 ( PROTEIN ), suggesting that Phe93 is also important for PROTEIN binding.
AIMed.d32.s270.p2	P	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN1 bound to an PROTEIN ( PROTEIN2 ), suggesting that Phe93 is also important for PROTEIN binding.
AIMed.d32.s270.p3	P	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN1 bound to an PROTEIN ( PROTEIN ), suggesting that Phe93 is also important for PROTEIN2 binding.
AIMed.d32.s270.p7	N	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN bound to an PROTEIN1 ( PROTEIN2 ), suggesting that Phe93 is also important for PROTEIN binding.
AIMed.d32.s270.p8	N	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN bound to an PROTEIN1 ( PROTEIN ), suggesting that Phe93 is also important for PROTEIN2 binding.
AIMed.d32.s270.p9	N	Remarkably, Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the PROTEIN bound to an PROTEIN ( PROTEIN1 ), suggesting that Phe93 is also important for PROTEIN2 binding.
AIMed.d32.s271.p0	P	We used alanine substitution of PROTEIN1 residues that contact PROTEIN2 in the crystal structure to investigate the function of these residues in both PROTEIN and PROTEIN binding.
AIMed.d32.s271.p2	P	We used alanine substitution of PROTEIN1 residues that contact PROTEIN in the crystal structure to investigate the function of these residues in both PROTEIN and PROTEIN2 binding.
AIMed.d32.s271.p3	N	We used alanine substitution of PROTEIN residues that contact PROTEIN1 in the crystal structure to investigate the function of these residues in both PROTEIN2 and PROTEIN binding.
AIMed.d32.s271.p4	N	We used alanine substitution of PROTEIN residues that contact PROTEIN1 in the crystal structure to investigate the function of these residues in both PROTEIN and PROTEIN2 binding.
AIMed.d32.s271.p5	N	We used alanine substitution of PROTEIN residues that contact PROTEIN in the crystal structure to investigate the function of these residues in both PROTEIN1 and PROTEIN2 binding.
AIMed.d32.s273.p0	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN1 and PROTEIN2 binding, Met150 is not important for PROTEIN binding but is critical for PROTEIN binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s273.p1	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN1 and PROTEIN binding, Met150 is not important for PROTEIN2 binding but is critical for PROTEIN binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s273.p2	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN1 and PROTEIN binding, Met150 is not important for PROTEIN binding but is critical for PROTEIN2 binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s273.p3	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN and PROTEIN1 binding, Met150 is not important for PROTEIN2 binding but is critical for PROTEIN binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s273.p4	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN and PROTEIN1 binding, Met150 is not important for PROTEIN binding but is critical for PROTEIN2 binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s273.p5	N	Our results indicate that Phe93 and Phe205 are important for both PROTEIN and PROTEIN binding, Met150 is not important for PROTEIN1 binding but is critical for PROTEIN2 binding, and Thr151 is not important for binding either ligand.
AIMed.d32.s274.p0	N	Thus, Phe93 and Phe205 are important binding determinants for both PROTEIN1 and PROTEIN2 , even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the PROTEIN for productive ligand binding.
AIMed.d32.s274.p1	P	Thus, Phe93 and Phe205 are important binding determinants for both PROTEIN1 and PROTEIN , even though these ligands share no sequence or structural homology, suggesting that these residues may represent a minimum epitope on the PROTEIN2 for productive ligand binding.
AIMed.d33.s277.p0	P	Native PROTEIN1 and PROTEIN2 formed a heterodimer in solution of physiological ionic strength with a free-energy change DeltaG degrees of -8.3 kcal/mol and a dissociation constant Kd of 0.6 microM (at 20 degrees C) that was ionic strength- and temperature-dependent.
AIMed.d33.s278.p0	P	A van't Hoff plot of the change in Kd was linear between 10 and 37 degrees C and yielded values of DeltaH degrees = -12.9 kcal/mol and DeltaS degrees = -15.9 cal mol-1 deg-1, suggesting that electrostatic forces play a prominent role in the interaction of PROTEIN1 with PROTEIN2 .
AIMed.d33.s279.p0	P	Native PROTEIN1 also formed a heterodimer with PROTEIN2 ,and low concentrations of polyionic ligands such as protamine and suramin inhibited the interaction.
AIMed.d33.s280.p0	N	Suramin induced high-affinity trimerization of PROTEIN1 (Kd = 0.10 microM at 20 degrees C) and dimerization of PROTEIN2 (Kd = 0.86 microM at 20 degrees C).
AIMed.d33.s282.p0	N	Analysis of sedimentation equilibria and also of the fluorescence enhancement of suramin when bound to protein provided evidence for two suramin-binding sites on each PROTEIN1 and three on each PROTEIN2 in the oligomers.
AIMed.d34.s285.p0	N	PROTEIN1 ( PROTEIN2 ) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.
AIMed.d34.s288.p0	N	We report an interaction between the human PROTEIN1 or PROTEIN2 hydrophilic loop and PROTEIN , a small GTPase belonging to the Ras-related superfamily.
AIMed.d34.s288.p1	P	We report an interaction between the human PROTEIN1 or PROTEIN hydrophilic loop and PROTEIN2 , a small GTPase belonging to the Ras-related superfamily.
AIMed.d34.s288.p2	P	We report an interaction between the human PROTEIN or PROTEIN1 hydrophilic loop and PROTEIN2 , a small GTPase belonging to the Ras-related superfamily.
AIMed.d34.s289.p0	P	Interaction domains were mapped to codons 374-400 for PROTEIN1 and to codons 106-179 for PROTEIN2 , a region including the fourth GTP-binding domain.
AIMed.d35.s292.p0	N	Most familial early-onset Alzheimer's disease cases are caused by mutations in the PROTEIN1 ( PROTEIN2 ) gene.
AIMed.d35.s294.p0	N	Although numerous studies revealed predominant localization of PROTEIN1 to endoplasmic reticulum and Golgi, there are conflicting reports on the localization of PROTEIN2 to the cell surface.
AIMed.d35.s299.p1	P	Cell surface PROTEIN1 formed complexes in vivo with actin-binding protein PROTEIN ( PROTEIN2 ), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.
AIMed.d35.s299.p2	N	Cell surface PROTEIN formed complexes in vivo with actin-binding protein PROTEIN1 ( PROTEIN2 ), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.
AIMed.d36.s301.p0	P	Molecular determinants of the interaction between the C-terminal domain of Alzheimer's PROTEIN1 and PROTEIN2 alpha-helices.
AIMed.d36.s302.p0	N	In a previous work, we predicted and demonstrated that the 29-42-residue fragment of PROTEIN1 ( PROTEIN2 ) has in vitro capacities close to those of the tilted fragment of viral fusion proteins.
AIMed.d36.s303.p0	N	We further demonstrated that PROTEIN1 and E3 but not PROTEIN2 can decrease the fusogenic activity of PROTEIN (29-42) via a direct interaction.
AIMed.d36.s303.p1	P	We further demonstrated that PROTEIN1 and E3 but not PROTEIN can decrease the fusogenic activity of PROTEIN2 (29-42) via a direct interaction.
AIMed.d36.s303.p2	N	We further demonstrated that PROTEIN and E3 but not PROTEIN1 can decrease the fusogenic activity of PROTEIN2 (29-42) via a direct interaction.
AIMed.d36.s304.p0	N	Therefore, we suggested that this fragment is implicated in the neurotoxicity of PROTEIN1 and in the protective effects of PROTEIN2 in Alzheimer's disease.
AIMed.d36.s306.p0	N	In this study, we simulated interactions of all amphipathic helices of PROTEIN1 and A-I with PROTEIN2 and simian immunodeficiency virus (SIV) fusogenic fragments by molecular modeling.
AIMed.d37.s310.p0	N	PROTEIN1 binds multiple CC-chemokines: PROTEIN2 acts as a natural antagonist.
AIMed.d37.s311.p0	P	PROTEIN1 was first characterized as a receptor for PROTEIN2 , PROTEIN , and PROTEIN , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s311.p1	P	PROTEIN1 was first characterized as a receptor for PROTEIN , PROTEIN2 , and PROTEIN , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s311.p2	P	PROTEIN1 was first characterized as a receptor for PROTEIN , PROTEIN , and PROTEIN2 , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s311.p3	N	PROTEIN was first characterized as a receptor for PROTEIN1 , PROTEIN2 , and PROTEIN , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s311.p4	N	PROTEIN was first characterized as a receptor for PROTEIN1 , PROTEIN , and PROTEIN2 , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s311.p5	N	PROTEIN was first characterized as a receptor for PROTEIN , PROTEIN1 , and PROTEIN2 , and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
AIMed.d37.s314.p0	N	All CC-chemokines currently available were tested for their ability to compete with [(125)I]- PROTEIN1 binding on a stable cell line expressing recombinant PROTEIN2 , and/or to induce a functional response in these cells.
AIMed.d37.s315.p0	N	We found that in addition to PROTEIN1 , PROTEIN2 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p1	N	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN2 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p2	P	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN2 binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p3	N	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p4	N	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p5	N	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p6	N	We found that in addition to PROTEIN1 , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p8	N	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN2 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p9	P	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN2 binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p10	N	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p12	N	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p13	N	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p14	N	We found that in addition to PROTEIN , PROTEIN1 , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p15	P	We found that in addition to PROTEIN , PROTEIN , and PROTEIN1 , five other CC-chemokines could compete for [(125)I]- PROTEIN2 binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p16	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN1 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p17	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN1 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p18	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN1 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p20	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN1 , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p23	P	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN1 binding: PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p24	P	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN1 binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p25	P	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN1 binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p26	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p27	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p28	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p29	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p30	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p31	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p32	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p33	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p34	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s315.p35	N	We found that in addition to PROTEIN , PROTEIN , and PROTEIN , five other CC-chemokines could compete for [(125)I]- PROTEIN binding: PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.
AIMed.d37.s316.p0	P	Among these ligands, PROTEIN1 had the remarkable property of binding PROTEIN2 with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p1	N	Among these ligands, PROTEIN1 had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN2 could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p2	N	Among these ligands, PROTEIN1 had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN2 by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p3	N	Among these ligands, PROTEIN1 had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN2 and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p4	N	Among these ligands, PROTEIN1 had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN2 .
AIMed.d37.s316.p5	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN1 with high affinity without eliciting a functional response, PROTEIN2 could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p6	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN1 with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN2 by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p7	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN1 with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN2 and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p8	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN1 with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN2 .
AIMed.d37.s316.p10	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN1 could also inhibit the activation of PROTEIN by PROTEIN2 and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p11	P	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN1 could also inhibit the activation of PROTEIN by PROTEIN and may therefore be considered as a natural antagonist for PROTEIN2 .
AIMed.d37.s316.p12	P	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN1 by PROTEIN2 and may therefore be considered as a natural antagonist for PROTEIN .
AIMed.d37.s316.p14	N	Among these ligands, PROTEIN had the remarkable property of binding PROTEIN with high affinity without eliciting a functional response, PROTEIN could also inhibit the activation of PROTEIN by PROTEIN1 and may therefore be considered as a natural antagonist for PROTEIN2 .
AIMed.d37.s318.p0	N	Chemokines that could compete with high affinity for PROTEIN1 binding could also compete for monomeric PROTEIN2 binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN , but only 30% for PROTEIN .
AIMed.d37.s318.p1	N	Chemokines that could compete with high affinity for PROTEIN1 binding could also compete for monomeric PROTEIN binding, although with variable potencies; maximal PROTEIN2 binding inhibition was 80% for PROTEIN , but only 30% for PROTEIN .
AIMed.d37.s318.p2	N	Chemokines that could compete with high affinity for PROTEIN1 binding could also compete for monomeric PROTEIN binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN2 , but only 30% for PROTEIN .
AIMed.d37.s318.p3	N	Chemokines that could compete with high affinity for PROTEIN1 binding could also compete for monomeric PROTEIN binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN , but only 30% for PROTEIN2 .
AIMed.d37.s318.p4	N	Chemokines that could compete with high affinity for PROTEIN binding could also compete for monomeric PROTEIN1 binding, although with variable potencies; maximal PROTEIN2 binding inhibition was 80% for PROTEIN , but only 30% for PROTEIN .
AIMed.d37.s318.p5	N	Chemokines that could compete with high affinity for PROTEIN binding could also compete for monomeric PROTEIN1 binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN2 , but only 30% for PROTEIN .
AIMed.d37.s318.p6	N	Chemokines that could compete with high affinity for PROTEIN binding could also compete for monomeric PROTEIN1 binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN , but only 30% for PROTEIN2 .
AIMed.d37.s318.p7	P	Chemokines that could compete with high affinity for PROTEIN binding could also compete for monomeric PROTEIN binding, although with variable potencies; maximal PROTEIN1 binding inhibition was 80% for PROTEIN2 , but only 30% for PROTEIN .
AIMed.d37.s318.p9	N	Chemokines that could compete with high affinity for PROTEIN binding could also compete for monomeric PROTEIN binding, although with variable potencies; maximal PROTEIN binding inhibition was 80% for PROTEIN1 , but only 30% for PROTEIN2 .
AIMed.d37.s319.p0	P	PROTEIN1 could compete efficiently for PROTEIN2 binding but was, however, found to be a weak inhibitor of HIV infection, probably as a consequence of its inability to downregulate the receptor.
AIMed.d38.s320.p0	P	Molecular cloning of a novel human CC chemokine ( PROTEIN1 ) that is a functional ligand of PROTEIN2 .
AIMed.d38.s321.p1	N	Previously, we mapped the novel CC chemokine PROTEIN1 ( PROTEIN )/ PROTEIN2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).
AIMed.d38.s321.p2	N	Previously, we mapped the novel CC chemokine PROTEIN ( PROTEIN1 )/ PROTEIN2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).
AIMed.d38.s323.p0	N	Prompted by this hypothesis, we analyzed the genomic region containing the gene for PROTEIN1 / PROTEIN2 ( PROTEIN ) and have identified a novel CC chemokine termed PROTEIN .
AIMed.d38.s323.p1	N	Prompted by this hypothesis, we analyzed the genomic region containing the gene for PROTEIN1 / PROTEIN ( PROTEIN2 ) and have identified a novel CC chemokine termed PROTEIN .
AIMed.d38.s323.p2	N	Prompted by this hypothesis, we analyzed the genomic region containing the gene for PROTEIN1 / PROTEIN ( PROTEIN ) and have identified a novel CC chemokine termed PROTEIN2 .
AIMed.d38.s323.p3	N	Prompted by this hypothesis, we analyzed the genomic region containing the gene for PROTEIN / PROTEIN1 ( PROTEIN2 ) and have identified a novel CC chemokine termed PROTEIN .
AIMed.d38.s323.p4	N	Prompted by this hypothesis, we analyzed the genomic region containing the gene for PROTEIN / PROTEIN1 ( PROTEIN ) and have identified a novel CC chemokine termed PROTEIN2 .
AIMed.d38.s324.p0	N	The genes for PROTEIN1 / PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p1	N	The genes for PROTEIN1 / PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p2	N	The genes for PROTEIN1 / PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p3	N	The genes for PROTEIN1 / PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN2 ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p4	N	The genes for PROTEIN / PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p5	N	The genes for PROTEIN / PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p7	N	The genes for PROTEIN / PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p8	N	The genes for PROTEIN / PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s324.p9	N	The genes for PROTEIN / PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) are localized within a region of approximately 40 kilobases.
AIMed.d38.s327.p0	N	PROTEIN1 induced transient calcium mobilization specifically in PROTEIN2 ( PROTEIN )-expressing L1.2 cells with an EC(50) of 3 nM.
AIMed.d38.s327.p1	N	PROTEIN1 induced transient calcium mobilization specifically in PROTEIN ( PROTEIN2 )-expressing L1.2 cells with an EC(50) of 3 nM.
AIMed.d38.s327.p2	N	PROTEIN induced transient calcium mobilization specifically in PROTEIN1 ( PROTEIN2 )-expressing L1.2 cells with an EC(50) of 3 nM.
AIMed.d38.s328.p0	N	PROTEIN1 competed the binding of (125) PROTEIN2 to PROTEIN -expressing L1.2 cells with an IC(50) of 13 nM.
AIMed.d38.s328.p1	P	PROTEIN1 competed the binding of (125) PROTEIN to PROTEIN2 -expressing L1.2 cells with an IC(50) of 13 nM.
AIMed.d38.s328.p2	P	PROTEIN competed the binding of (125) PROTEIN1 to PROTEIN2 -expressing L1.2 cells with an IC(50) of 13 nM.
AIMed.d38.s330.p0	P	Collectively, PROTEIN1 is yet another functional ligand for PROTEIN2 .
AIMed.d38.s331.p0	P	The potency of PROTEIN1 as a PROTEIN2 ligand seems, however, to be approximately 10-fold less than that of PROTEIN .
AIMed.d38.s331.p1	N	The potency of PROTEIN1 as a PROTEIN ligand seems, however, to be approximately 10-fold less than that of PROTEIN2 .
AIMed.d38.s331.p2	P	The potency of PROTEIN as a PROTEIN1 ligand seems, however, to be approximately 10-fold less than that of PROTEIN2 .
AIMed.d38.s332.p0	N	Identification of PROTEIN1 will further promote our understanding of the control of eosinophil trafficking and other PROTEIN2 -mediated biological phenomena.
AIMed.d39.s334.p0	N	PROTEIN1 suppresses the function of PROTEIN2 homodimers via interaction with PROTEIN / PROTEIN .
AIMed.d39.s334.p1	P	PROTEIN1 suppresses the function of PROTEIN homodimers via interaction with PROTEIN2 / PROTEIN .
AIMed.d39.s334.p2	P	PROTEIN1 suppresses the function of PROTEIN homodimers via interaction with PROTEIN / PROTEIN2 .
AIMed.d39.s334.p3	N	PROTEIN suppresses the function of PROTEIN1 homodimers via interaction with PROTEIN2 / PROTEIN .
AIMed.d39.s334.p4	N	PROTEIN suppresses the function of PROTEIN1 homodimers via interaction with PROTEIN / PROTEIN2 .
AIMed.d39.s334.p5	N	PROTEIN suppresses the function of PROTEIN homodimers via interaction with PROTEIN1 / PROTEIN2 .
AIMed.d39.s335.p0	N	PROTEIN1 ( PROTEIN2 ) is the causative gene for an autosomal dominant familial Alzheimer's disease (AD) mapped to chromosome 14.
AIMed.d39.s336.p0	N	Here we show that PROTEIN1 / PROTEIN2 , a negative regulator of PROTEIN , is a candidate to mediate the function of PROTEIN in the cell.
AIMed.d39.s336.p1	P	Here we show that PROTEIN1 / PROTEIN , a negative regulator of PROTEIN2 , is a candidate to mediate the function of PROTEIN in the cell.
AIMed.d39.s336.p2	N	Here we show that PROTEIN1 / PROTEIN , a negative regulator of PROTEIN , is a candidate to mediate the function of PROTEIN2 in the cell.
AIMed.d39.s336.p3	P	Here we show that PROTEIN / PROTEIN1 , a negative regulator of PROTEIN2 , is a candidate to mediate the function of PROTEIN in the cell.
AIMed.d39.s336.p4	N	Here we show that PROTEIN / PROTEIN1 , a negative regulator of PROTEIN , is a candidate to mediate the function of PROTEIN2 in the cell.
AIMed.d39.s336.p5	N	Here we show that PROTEIN / PROTEIN , a negative regulator of PROTEIN1 , is a candidate to mediate the function of PROTEIN2 in the cell.
AIMed.d39.s337.p0	P	We screened for proteins that bind to PROTEIN1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the PROTEIN2 / PROTEIN gene.
AIMed.d39.s337.p1	P	We screened for proteins that bind to PROTEIN1 from a human embryonic brain cDNA library using the two-hybrid method and isolated one clone encoding the PROTEIN / PROTEIN2 gene.
AIMed.d39.s338.p0	N	The binding of PROTEIN1 / PROTEIN2 to full-length PROTEIN was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.
AIMed.d39.s338.p1	P	The binding of PROTEIN1 / PROTEIN to full-length PROTEIN2 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.
AIMed.d39.s338.p2	P	The binding of PROTEIN / PROTEIN1 to full-length PROTEIN2 was confirmed in vitro by pull-down assay, and in vivo by immunoprecipitation assays with human samples, including AD brains.
AIMed.d39.s339.p0	N	Immunoelectronmicroscopic analysis showed that PROTEIN1 / PROTEIN2 and PROTEIN are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.
AIMed.d39.s339.p1	N	Immunoelectronmicroscopic analysis showed that PROTEIN1 / PROTEIN and PROTEIN2 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.
AIMed.d39.s339.p2	N	Immunoelectronmicroscopic analysis showed that PROTEIN / PROTEIN1 and PROTEIN2 are colocalized at the endoplasmic reticulum, and the nuclear matrix in human brain neurons.
AIMed.d39.s340.p1	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN1 suppresses transactivation by PROTEIN / PROTEIN2 but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p2	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN1 suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN2 / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p3	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN1 suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN2 heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p4	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN1 suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN2 / PROTEIN .
AIMed.d39.s340.p5	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN1 suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN2 .
AIMed.d39.s340.p6	P	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN1 / PROTEIN2 but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p7	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN1 / PROTEIN but not by PROTEIN2 / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p8	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN1 / PROTEIN but not by PROTEIN / PROTEIN2 heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p9	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN1 / PROTEIN but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN2 / PROTEIN .
AIMed.d39.s340.p10	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN1 / PROTEIN but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN2 .
AIMed.d39.s340.p11	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN1 but not by PROTEIN2 / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p12	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN1 but not by PROTEIN / PROTEIN2 heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p13	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN1 but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN2 / PROTEIN .
AIMed.d39.s340.p14	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN1 but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN2 .
AIMed.d39.s340.p15	P	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN1 / PROTEIN2 heterodimers, consistent with the reported function of PROTEIN / PROTEIN .
AIMed.d39.s340.p16	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN1 / PROTEIN heterodimers, consistent with the reported function of PROTEIN2 / PROTEIN .
AIMed.d39.s340.p17	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN1 / PROTEIN heterodimers, consistent with the reported function of PROTEIN / PROTEIN2 .
AIMed.d39.s340.p18	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN1 heterodimers, consistent with the reported function of PROTEIN2 / PROTEIN .
AIMed.d39.s340.p19	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN1 heterodimers, consistent with the reported function of PROTEIN / PROTEIN2 .
AIMed.d39.s340.p20	N	Chloramphenicol acetyltransferase assays in F9 cells showed that PROTEIN suppresses transactivation by PROTEIN / PROTEIN but not by PROTEIN / PROTEIN heterodimers, consistent with the reported function of PROTEIN1 / PROTEIN2 .
AIMed.d39.s341.p0	N	By monitoring fluorescent recombinant protein and by gel mobility shift assays, PROTEIN1 was shown to accelerate the translocation of PROTEIN2 from the cytoplasm to the nucleus and to thereby suppress the binding of PROTEIN homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).
AIMed.d39.s341.p1	N	By monitoring fluorescent recombinant protein and by gel mobility shift assays, PROTEIN1 was shown to accelerate the translocation of PROTEIN from the cytoplasm to the nucleus and to thereby suppress the binding of PROTEIN2 homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).
AIMed.d39.s341.p2	N	By monitoring fluorescent recombinant protein and by gel mobility shift assays, PROTEIN was shown to accelerate the translocation of PROTEIN1 from the cytoplasm to the nucleus and to thereby suppress the binding of PROTEIN2 homodimer to 12-O-tetradecanoylphorbol-13- acetate (TPA)-responsive element (TRE).
AIMed.d39.s342.p1	N	PROTEIN1 suppressed PROTEIN -associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PROTEIN2 .
AIMed.d39.s342.p2	N	PROTEIN suppressed PROTEIN1 -associated apoptosis by retinoic acid in F9 embryonic carcinoma cells, whereas this suppression of apoptosis is attenuated by mutation in PROTEIN2 .
AIMed.d39.s343.p1	N	Collectively, the novel function of PROTEIN1 via PROTEIN / PROTEIN2 influences PROTEIN -mediated transcription and apoptosis.
AIMed.d39.s343.p2	N	Collectively, the novel function of PROTEIN1 via PROTEIN / PROTEIN influences PROTEIN2 -mediated transcription and apoptosis.
AIMed.d39.s343.p3	N	Collectively, the novel function of PROTEIN via PROTEIN1 / PROTEIN2 influences PROTEIN -mediated transcription and apoptosis.
AIMed.d39.s343.p4	N	Collectively, the novel function of PROTEIN via PROTEIN1 / PROTEIN influences PROTEIN2 -mediated transcription and apoptosis.
AIMed.d39.s343.p5	N	Collectively, the novel function of PROTEIN via PROTEIN / PROTEIN1 influences PROTEIN2 -mediated transcription and apoptosis.
AIMed.d40.s347.p0	P	We have crystallized a complex between human PROTEIN1 and a two-domain extracellular fragment of human PROTEIN2 .
AIMed.d41.s352.p1	P	Crystal structure of the hereditary haemochromatosis protein PROTEIN1 complexed with PROTEIN2 .
AIMed.d41.s354.p1	P	PROTEIN1 binds to the PROTEIN2 ( PROTEIN ), a receptor by which cells acquire iron-loaded PROTEIN .
AIMed.d41.s354.p2	P	PROTEIN1 binds to the PROTEIN ( PROTEIN2 ), a receptor by which cells acquire iron-loaded PROTEIN .
AIMed.d41.s354.p3	N	PROTEIN1 binds to the PROTEIN ( PROTEIN ), a receptor by which cells acquire iron-loaded PROTEIN2 .
AIMed.d41.s354.p7	N	PROTEIN binds to the PROTEIN1 ( PROTEIN2 ), a receptor by which cells acquire iron-loaded PROTEIN .
AIMed.d41.s354.p8	N	PROTEIN binds to the PROTEIN1 ( PROTEIN ), a receptor by which cells acquire iron-loaded PROTEIN2 .
AIMed.d41.s354.p9	N	PROTEIN binds to the PROTEIN ( PROTEIN1 ), a receptor by which cells acquire iron-loaded PROTEIN2 .
AIMed.d41.s355.p0	P	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN1 and PROTEIN2 shows two PROTEIN molecules which grasp each side of a twofold symmetric PROTEIN dimer.
AIMed.d41.s355.p1	N	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN1 and PROTEIN shows two PROTEIN2 molecules which grasp each side of a twofold symmetric PROTEIN dimer.
AIMed.d41.s355.p2	N	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN1 and PROTEIN shows two PROTEIN molecules which grasp each side of a twofold symmetric PROTEIN2 dimer.
AIMed.d41.s355.p3	N	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN and PROTEIN1 shows two PROTEIN2 molecules which grasp each side of a twofold symmetric PROTEIN dimer.
AIMed.d41.s355.p4	N	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN and PROTEIN1 shows two PROTEIN molecules which grasp each side of a twofold symmetric PROTEIN2 dimer.
AIMed.d41.s355.p5	P	The 2.8 A crystal structure of a complex between the extracellular portions of PROTEIN and PROTEIN shows two PROTEIN1 molecules which grasp each side of a twofold symmetric PROTEIN2 dimer.
AIMed.d41.s356.p0	N	On a cell membrane containing both proteins, PROTEIN1 would 'lie down' parallel to the membrane, such that the PROTEIN2 helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the PROTEIN dimerization domain.
AIMed.d41.s356.p1	N	On a cell membrane containing both proteins, PROTEIN1 would 'lie down' parallel to the membrane, such that the PROTEIN helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the PROTEIN2 dimerization domain.
AIMed.d41.s356.p2	P	On a cell membrane containing both proteins, PROTEIN would 'lie down' parallel to the membrane, such that the PROTEIN1 helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the PROTEIN2 dimerization domain.
AIMed.d41.s357.p0	P	The structures of PROTEIN1 alone and complexed with PROTEIN2 differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between PROTEIN chains.
AIMed.d41.s357.p1	N	The structures of PROTEIN1 alone and complexed with PROTEIN differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between PROTEIN2 chains.
AIMed.d41.s357.p2	N	The structures of PROTEIN alone and complexed with PROTEIN1 differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between PROTEIN2 chains.
AIMed.d41.s358.p0	P	The PROTEIN1 - PROTEIN2 complex suggests a binding site for transferrin on PROTEIN and sheds light upon the function of PROTEIN in regulating iron homeostasis.
AIMed.d41.s358.p1	N	The PROTEIN1 - PROTEIN complex suggests a binding site for transferrin on PROTEIN2 and sheds light upon the function of PROTEIN in regulating iron homeostasis.
AIMed.d41.s358.p2	N	The PROTEIN1 - PROTEIN complex suggests a binding site for transferrin on PROTEIN and sheds light upon the function of PROTEIN2 in regulating iron homeostasis.
AIMed.d41.s358.p3	N	The PROTEIN - PROTEIN1 complex suggests a binding site for transferrin on PROTEIN2 and sheds light upon the function of PROTEIN in regulating iron homeostasis.
AIMed.d41.s358.p4	N	The PROTEIN - PROTEIN1 complex suggests a binding site for transferrin on PROTEIN and sheds light upon the function of PROTEIN2 in regulating iron homeostasis.
AIMed.d41.s358.p5	N	The PROTEIN - PROTEIN complex suggests a binding site for transferrin on PROTEIN1 and sheds light upon the function of PROTEIN2 in regulating iron homeostasis.
AIMed.d42.s364.p1	N	Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( PROTEIN1 and PROTEIN ) and the PROTEIN2 ( PROTEIN ).
AIMed.d42.s364.p2	N	Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( PROTEIN1 and PROTEIN ) and the PROTEIN ( PROTEIN2 ).
AIMed.d42.s364.p3	N	Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( PROTEIN and PROTEIN1 ) and the PROTEIN2 ( PROTEIN ).
AIMed.d42.s364.p4	N	Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( PROTEIN and PROTEIN1 ) and the PROTEIN ( PROTEIN2 ).
AIMed.d42.s364.p5	N	Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( PROTEIN and PROTEIN ) and the PROTEIN1 ( PROTEIN2 ).
AIMed.d42.s367.p0	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN2 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p1	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p2	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p4	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p6	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p7	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p8	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p9	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p10	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN1 / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p11	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p12	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p13	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p14	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p15	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p16	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p17	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p18	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p19	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p20	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN1 and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p21	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p22	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p23	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p24	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p25	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p26	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p27	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p28	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p29	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN1 / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p31	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p32	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p33	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p34	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p35	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p36	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p37	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN1 ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p38	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN2 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p39	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p40	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p41	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p42	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p43	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p44	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p45	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN2 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p46	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p47	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p48	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p49	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p50	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p51	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN1 / PROTEIN2 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p53	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN1 / PROTEIN , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p54	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p55	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN1 / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p56	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , PROTEIN2 / PROTEIN , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p57	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , PROTEIN / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p58	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p59	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , PROTEIN / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p60	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN1 / PROTEIN2 , and also PROTEIN / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p61	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN1 / PROTEIN , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p62	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN1 / PROTEIN , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p63	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , and also PROTEIN2 / PROTEIN ) oligomers in the absence of ligand.
AIMed.d42.s367.p64	N	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN1 , and also PROTEIN / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s367.p65	P	Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ( PROTEIN / PROTEIN and PROTEIN / PROTEIN ) and homomeric ( PROTEIN / PROTEIN , PROTEIN / PROTEIN , PROTEIN / PROTEIN , and also PROTEIN1 / PROTEIN2 ) oligomers in the absence of ligand.
AIMed.d42.s368.p0	P	PROTEIN1 binding significantly increased hetero- and homo-oligomerization (except for the PROTEIN2 homo-oligomer, which binds ligand poorly in the absence of PROTEIN ).
AIMed.d42.s368.p1	N	PROTEIN1 binding significantly increased hetero- and homo-oligomerization (except for the PROTEIN homo-oligomer, which binds ligand poorly in the absence of PROTEIN2 ).
AIMed.d42.s368.p2	P	PROTEIN binding significantly increased hetero- and homo-oligomerization (except for the PROTEIN1 homo-oligomer, which binds ligand poorly in the absence of PROTEIN2 ).
AIMed.d43.s375.p0	P	Although the individual amino acids in PROTEIN1 involved in binding to PROTEIN2 ( PROTEIN ) and those in PROTEIN involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p1	P	Although the individual amino acids in PROTEIN1 involved in binding to PROTEIN ( PROTEIN2 ) and those in PROTEIN involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p2	N	Although the individual amino acids in PROTEIN1 involved in binding to PROTEIN ( PROTEIN ) and those in PROTEIN2 involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p4	N	Although the individual amino acids in PROTEIN involved in binding to PROTEIN1 ( PROTEIN2 ) and those in PROTEIN involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p5	N	Although the individual amino acids in PROTEIN involved in binding to PROTEIN1 ( PROTEIN ) and those in PROTEIN2 involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p6	N	Although the individual amino acids in PROTEIN involved in binding to PROTEIN1 ( PROTEIN ) and those in PROTEIN involved in binding to PROTEIN2 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p7	N	Although the individual amino acids in PROTEIN involved in binding to PROTEIN ( PROTEIN1 ) and those in PROTEIN2 involved in binding to PROTEIN have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s375.p8	N	Although the individual amino acids in PROTEIN involved in binding to PROTEIN ( PROTEIN1 ) and those in PROTEIN involved in binding to PROTEIN2 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.
AIMed.d43.s376.p0	N	In this study, a minimum set of residues in the human PROTEIN1 second immunoglobulin-like domain, which does not bind PROTEIN2 ( PROTEIN ), were substituted with those from human PROTEIN .
AIMed.d43.s376.p1	N	In this study, a minimum set of residues in the human PROTEIN1 second immunoglobulin-like domain, which does not bind PROTEIN ( PROTEIN2 ), were substituted with those from human PROTEIN .
AIMed.d43.s376.p2	N	In this study, a minimum set of residues in the human PROTEIN1 second immunoglobulin-like domain, which does not bind PROTEIN ( PROTEIN ), were substituted with those from human PROTEIN2 .
AIMed.d43.s376.p4	N	In this study, a minimum set of residues in the human PROTEIN second immunoglobulin-like domain, which does not bind PROTEIN1 ( PROTEIN ), were substituted with those from human PROTEIN2 .
AIMed.d43.s376.p5	N	In this study, a minimum set of residues in the human PROTEIN second immunoglobulin-like domain, which does not bind PROTEIN ( PROTEIN1 ), were substituted with those from human PROTEIN2 .
AIMed.d43.s377.p0	P	The resulting Trk variant recruited binding of PROTEIN1 equivalent to PROTEIN2 , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p1	N	The resulting Trk variant recruited binding of PROTEIN1 equivalent to PROTEIN , maintained PROTEIN2 binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p2	N	The resulting Trk variant recruited binding of PROTEIN1 equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN2 , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p3	N	The resulting Trk variant recruited binding of PROTEIN1 equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN2 , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p4	N	The resulting Trk variant recruited binding of PROTEIN1 equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN2 .
AIMed.d43.s377.p5	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN1 , maintained PROTEIN2 binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p6	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN1 , maintained PROTEIN binding equivalent to PROTEIN2 , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p7	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN1 , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN2 , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p8	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN1 , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN2 .
AIMed.d43.s377.p9	P	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN , maintained PROTEIN1 binding equivalent to PROTEIN2 , and also bound PROTEIN , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p11	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN , maintained PROTEIN1 binding equivalent to PROTEIN , and also bound PROTEIN , although with lower affinity compared with PROTEIN2 .
AIMed.d43.s377.p12	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN1 , and also bound PROTEIN2 , although with lower affinity compared with PROTEIN .
AIMed.d43.s377.p13	N	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN1 , and also bound PROTEIN , although with lower affinity compared with PROTEIN2 .
AIMed.d43.s377.p14	P	The resulting Trk variant recruited binding of PROTEIN equivalent to PROTEIN , maintained PROTEIN binding equivalent to PROTEIN , and also bound PROTEIN1 , although with lower affinity compared with PROTEIN2 .
AIMed.d44.s379.p0	P	Characterization of the PROTEIN1 binding domain on the human PROTEIN2 molecule using anti- PROTEIN antibodies.
AIMed.d44.s379.p2	N	Characterization of the PROTEIN binding domain on the human PROTEIN1 molecule using anti- PROTEIN2 antibodies.
AIMed.d44.s380.p1	P	PROTEIN1 and its counter-receptor PROTEIN2 ( PROTEIN ) are members of the TNF-receptor/ PROTEIN superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s380.p2	P	PROTEIN1 and its counter-receptor PROTEIN ( PROTEIN2 ) are members of the TNF-receptor/ PROTEIN superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s380.p3	N	PROTEIN1 and its counter-receptor PROTEIN ( PROTEIN ) are members of the TNF-receptor/ PROTEIN2 superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s380.p7	N	PROTEIN and its counter-receptor PROTEIN1 ( PROTEIN2 ) are members of the TNF-receptor/ PROTEIN superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s380.p8	N	PROTEIN and its counter-receptor PROTEIN1 ( PROTEIN ) are members of the TNF-receptor/ PROTEIN2 superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s380.p9	N	PROTEIN and its counter-receptor PROTEIN ( PROTEIN1 ) are members of the TNF-receptor/ PROTEIN2 superfamily and function to regulate lymphocyte survival and differentiation.
AIMed.d44.s383.p0	N	Using a soluble PROTEIN1 / PROTEIN2 chimeric protein, we assessed the ability of anti- PROTEIN MAb to inhibit the binding of PROTEIN to PROTEIN expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p1	N	Using a soluble PROTEIN1 / PROTEIN chimeric protein, we assessed the ability of anti- PROTEIN2 MAb to inhibit the binding of PROTEIN to PROTEIN expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p3	N	Using a soluble PROTEIN1 / PROTEIN chimeric protein, we assessed the ability of anti- PROTEIN MAb to inhibit the binding of PROTEIN to PROTEIN2 expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p4	N	Using a soluble PROTEIN / PROTEIN1 chimeric protein, we assessed the ability of anti- PROTEIN2 MAb to inhibit the binding of PROTEIN to PROTEIN expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p5	N	Using a soluble PROTEIN / PROTEIN1 chimeric protein, we assessed the ability of anti- PROTEIN MAb to inhibit the binding of PROTEIN2 to PROTEIN expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p6	N	Using a soluble PROTEIN / PROTEIN1 chimeric protein, we assessed the ability of anti- PROTEIN MAb to inhibit the binding of PROTEIN to PROTEIN2 expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p7	N	Using a soluble PROTEIN / PROTEIN chimeric protein, we assessed the ability of anti- PROTEIN1 MAb to inhibit the binding of PROTEIN2 to PROTEIN expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p8	N	Using a soluble PROTEIN / PROTEIN chimeric protein, we assessed the ability of anti- PROTEIN1 MAb to inhibit the binding of PROTEIN to PROTEIN2 expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s383.p9	P	Using a soluble PROTEIN / PROTEIN chimeric protein, we assessed the ability of anti- PROTEIN MAb to inhibit the binding of PROTEIN1 to PROTEIN2 expressed by the CD30+ Karpas 299 cell line.
AIMed.d44.s384.p0	P	PROTEIN1 binding by PROTEIN2 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44).
AIMed.d44.s385.p0	P	Cluster Group B antibodies, including M67 and Ki-1, do not affect PROTEIN1 binding to PROTEIN2 .
AIMed.d44.s386.p0	N	The pattern of PROTEIN1 binding inhibition shows only limited correspondence to the functional capacity of some anti- PROTEIN2 MAb to trigger PROTEIN signaling.
AIMed.d44.s386.p1	N	The pattern of PROTEIN1 binding inhibition shows only limited correspondence to the functional capacity of some anti- PROTEIN MAb to trigger PROTEIN2 signaling.
AIMed.d44.s386.p2	N	The pattern of PROTEIN binding inhibition shows only limited correspondence to the functional capacity of some anti- PROTEIN1 MAb to trigger PROTEIN2 signaling.
AIMed.d44.s387.p0	N	Finally, we demonstrate that the anti- PROTEIN1 MAb M81 also completely inhibits PROTEIN2 / PROTEIN interaction.
AIMed.d44.s387.p2	P	Finally, we demonstrate that the anti- PROTEIN MAb M81 also completely inhibits PROTEIN1 / PROTEIN2 interaction.
AIMed.d44.s388.p0	N	This information is useful for applying these MAbs in functional studies to further investigate the PROTEIN1 / PROTEIN2 system and for designing assays for soluble PROTEIN .
AIMed.d44.s388.p1	N	This information is useful for applying these MAbs in functional studies to further investigate the PROTEIN1 / PROTEIN system and for designing assays for soluble PROTEIN2 .
AIMed.d44.s388.p2	N	This information is useful for applying these MAbs in functional studies to further investigate the PROTEIN / PROTEIN1 system and for designing assays for soluble PROTEIN2 .
AIMed.d45.s390.p1	N	A mutant form of human PROTEIN1 ( PROTEIN2 ) that binds one PROTEIN ( PROTEIN ) has been designed and characterized.
AIMed.d45.s390.p4	N	A mutant form of human PROTEIN1 ( PROTEIN ) that binds one PROTEIN2 ( PROTEIN ) has been designed and characterized.
AIMed.d45.s390.p6	N	A mutant form of human PROTEIN1 ( PROTEIN ) that binds one PROTEIN ( PROTEIN2 ) has been designed and characterized.
AIMed.d45.s390.p15	P	A mutant form of human PROTEIN ( PROTEIN1 ) that binds one PROTEIN2 ( PROTEIN ) has been designed and characterized.
AIMed.d45.s390.p26	N	A mutant form of human PROTEIN ( PROTEIN ) that binds one PROTEIN1 ( PROTEIN2 ) has been designed and characterized.
AIMed.d45.s392.p4	P	Isothermal titration calorimetry shows that PROTEIN1 forms a 1:1 complex with its high-affinity receptor ( PROTEIN2 ) with an affinity of 27(+/- 9) nM.
AIMed.d45.s396.p0	N	The AB loops of PROTEIN1 adopt conformations similar to the ordered loops of PROTEIN2 observed in the crystal structure of the PROTEIN / PROTEIN complex.
AIMed.d45.s396.p1	N	The AB loops of PROTEIN1 adopt conformations similar to the ordered loops of PROTEIN observed in the crystal structure of the PROTEIN2 / PROTEIN complex.
AIMed.d45.s396.p3	N	The AB loops of PROTEIN1 adopt conformations similar to the ordered loops of PROTEIN observed in the crystal structure of the PROTEIN / PROTEIN2 complex.
AIMed.d45.s396.p4	N	The AB loops of PROTEIN adopt conformations similar to the ordered loops of PROTEIN1 observed in the crystal structure of the PROTEIN2 / PROTEIN complex.
AIMed.d45.s396.p6	N	The AB loops of PROTEIN adopt conformations similar to the ordered loops of PROTEIN1 observed in the crystal structure of the PROTEIN / PROTEIN2 complex.
AIMed.d45.s396.p8	P	The AB loops of PROTEIN adopt conformations similar to the ordered loops of PROTEIN observed in the crystal structure of the PROTEIN1 / PROTEIN2 complex.
AIMed.d45.s398.p2	N	The structure also reveals the final six C-terminal amino acid residues of PROTEIN1 (residues 253-258) that have not been observed in any other reported PROTEIN2 structures.
AIMed.d45.s399.p2	P	Despite binding to only one PROTEIN1 , PROTEIN2 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.
AIMed.d45.s400.p1	P	This suggests that one domain of PROTEIN1 is sufficient to recruit PROTEIN2 and PROTEIN into a complex competent for eliciting biological activity.
AIMed.d45.s401.p0	N	The current data are consistent with the main role of the PROTEIN1 dimer being to decrease the dissociation constant of PROTEIN2 for its cellular receptors.
AIMed.d46.s402.p0	N	PROTEIN1 antagonists emerge from alterations in the low-affinity binding epitope for receptor PROTEIN2 .
AIMed.d46.s403.p0	N	PROTEIN1 ( PROTEIN2 ) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals.
AIMed.d46.s404.p1	N	PROTEIN1 is a homodimeric cysteine knot protein that, as a member of the PROTEIN ( PROTEIN2 ) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.
AIMed.d46.s404.p2	N	PROTEIN is a homodimeric cysteine knot protein that, as a member of the PROTEIN1 ( PROTEIN2 ) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.
AIMed.d46.s405.p0	P	The binding epitopes of PROTEIN1 for PROTEIN2 (type I) and PROTEIN or PROTEIN (type II) were characterized using PROTEIN mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p1	P	The binding epitopes of PROTEIN1 for PROTEIN (type I) and PROTEIN2 or PROTEIN (type II) were characterized using PROTEIN mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p2	P	The binding epitopes of PROTEIN1 for PROTEIN (type I) and PROTEIN or PROTEIN2 (type II) were characterized using PROTEIN mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p3	N	The binding epitopes of PROTEIN1 for PROTEIN (type I) and PROTEIN or PROTEIN (type II) were characterized using PROTEIN2 mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p4	N	The binding epitopes of PROTEIN for PROTEIN1 (type I) and PROTEIN2 or PROTEIN (type II) were characterized using PROTEIN mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p5	N	The binding epitopes of PROTEIN for PROTEIN1 (type I) and PROTEIN or PROTEIN2 (type II) were characterized using PROTEIN mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p6	N	The binding epitopes of PROTEIN for PROTEIN1 (type I) and PROTEIN or PROTEIN (type II) were characterized using PROTEIN2 mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p8	N	The binding epitopes of PROTEIN for PROTEIN (type I) and PROTEIN1 or PROTEIN (type II) were characterized using PROTEIN2 mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s405.p9	N	The binding epitopes of PROTEIN for PROTEIN (type I) and PROTEIN or PROTEIN1 (type II) were characterized using PROTEIN2 mutant proteins for analysis of interactions with receptor ectodomains.
AIMed.d46.s406.p0	P	A large epitope 1 for high-affinity PROTEIN1 binding was detected spanning the interface of the PROTEIN2 dimer.
AIMed.d47.s411.p0	P	Crystal structure of the PROTEIN1 - PROTEIN2 ectodomain complex.
AIMed.d47.s415.p1	P	Here we report the crystal structure of human dimeric PROTEIN1 in complex with two high affinity PROTEIN2 s( PROTEIN ).
AIMed.d47.s415.p2	P	Here we report the crystal structure of human dimeric PROTEIN1 in complex with two high affinity PROTEIN s( PROTEIN2 ).
AIMed.d47.s415.p5	N	Here we report the crystal structure of human dimeric PROTEIN in complex with two high affinity PROTEIN1 s( PROTEIN2 ).
AIMed.d47.s416.p0	N	The receptor chains bind to the 'wrist' epitopes of the PROTEIN1 dimer and contact both PROTEIN2 monomers.
AIMed.d48.s419.p0	P	PROTEIN1 induces chemotaxis and adhesion by interacting with PROTEIN2 and PROTEIN .
AIMed.d48.s419.p1	P	PROTEIN1 induces chemotaxis and adhesion by interacting with PROTEIN and PROTEIN2 .
AIMed.d48.s419.p2	N	PROTEIN induces chemotaxis and adhesion by interacting with PROTEIN1 and PROTEIN2 .
AIMed.d48.s420.p0	N	PROTEIN1 ( PROTEIN2 ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN , PROTEIN , and PROTEIN .
AIMed.d48.s420.p1	N	PROTEIN1 ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN .
AIMed.d48.s420.p3	N	PROTEIN1 ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d48.s420.p4	N	PROTEIN1 ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d48.s420.p5	N	PROTEIN ( PROTEIN1 ) is an unusually large CC chemokine, which is also known as PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN .
AIMed.d48.s420.p6	N	PROTEIN ( PROTEIN1 ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d48.s420.p7	N	PROTEIN ( PROTEIN1 ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d48.s420.p9	N	PROTEIN ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d48.s420.p10	N	PROTEIN ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d48.s420.p12	N	PROTEIN ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN .
AIMed.d48.s420.p13	N	PROTEIN ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 .
AIMed.d48.s420.p14	N	PROTEIN ( PROTEIN ) is an unusually large CC chemokine, which is also known as PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 .
AIMed.d48.s422.p0	P	We report chemotaxis and competitive binding studies that show PROTEIN1 binds to and activates PROTEIN2 and PROTEIN transfected HEK-293 cells.
AIMed.d48.s422.p1	P	We report chemotaxis and competitive binding studies that show PROTEIN1 binds to and activates PROTEIN and PROTEIN2 transfected HEK-293 cells.
AIMed.d48.s422.p2	N	We report chemotaxis and competitive binding studies that show PROTEIN binds to and activates PROTEIN1 and PROTEIN2 transfected HEK-293 cells.
AIMed.d48.s423.p0	N	PROTEIN1 induced maximal migration of PROTEIN2 and PROTEIN transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
AIMed.d48.s423.p1	N	PROTEIN1 induced maximal migration of PROTEIN and PROTEIN2 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
AIMed.d48.s423.p2	N	PROTEIN induced maximal migration of PROTEIN1 and PROTEIN2 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
AIMed.d48.s424.p0	N	The molar concentration of PROTEIN1 required to induce maximum cell migration is 20- to 200-fold greater than that required for PROTEIN2 or PROTEIN , respectively.
AIMed.d48.s424.p1	N	The molar concentration of PROTEIN1 required to induce maximum cell migration is 20- to 200-fold greater than that required for PROTEIN or PROTEIN2 , respectively.
AIMed.d48.s424.p2	N	The molar concentration of PROTEIN required to induce maximum cell migration is 20- to 200-fold greater than that required for PROTEIN1 or PROTEIN2 , respectively.
AIMed.d48.s426.p0	N	A neutralizing polyclonal antibody to PROTEIN1 was developed to demonstrate that the unusually high concentration of PROTEIN2 required to induce chemotaxis was a property of PROTEIN and not as a result of an irrelevant protein contamination.
AIMed.d48.s426.p1	N	A neutralizing polyclonal antibody to PROTEIN1 was developed to demonstrate that the unusually high concentration of PROTEIN required to induce chemotaxis was a property of PROTEIN2 and not as a result of an irrelevant protein contamination.
AIMed.d48.s426.p2	N	A neutralizing polyclonal antibody to PROTEIN was developed to demonstrate that the unusually high concentration of PROTEIN1 required to induce chemotaxis was a property of PROTEIN2 and not as a result of an irrelevant protein contamination.
AIMed.d49.s431.p0	P	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN2 isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p2	P	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN2 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p3	P	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN2 ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p5	N	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN2 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p6	N	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN2 , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p7	N	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p8	N	PROTEIN1 recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p10	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN2 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p11	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN ( PROTEIN2 ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p12	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN ( PROTEIN ), whereas PROTEIN2 binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p13	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN2 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p15	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p16	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN1 isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p24	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN2 ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p25	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN ), whereas PROTEIN2 binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p26	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN2 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p27	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN2 , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p28	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p29	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN1 ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p30	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN1 ), whereas PROTEIN2 binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p31	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN1 ), whereas PROTEIN binds well to PROTEIN2 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p32	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN1 ), whereas PROTEIN binds well to PROTEIN , PROTEIN2 , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p33	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN1 ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p34	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN1 ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p35	P	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN1 binds well to PROTEIN2 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p36	P	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN1 binds well to PROTEIN , PROTEIN2 , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p37	P	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN1 binds well to PROTEIN , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p38	P	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN1 binds well to PROTEIN , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p39	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN1 , PROTEIN2 , and PROTEIN but interacts poorly with PROTEIN .
AIMed.d49.s431.p40	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN1 , PROTEIN , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p41	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN1 , PROTEIN , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p42	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN1 , and PROTEIN2 but interacts poorly with PROTEIN .
AIMed.d49.s431.p43	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN1 , and PROTEIN but interacts poorly with PROTEIN2 .
AIMed.d49.s431.p44	N	PROTEIN recognizes one FGFR isoform known as the PROTEIN isoform or PROTEIN ( PROTEIN ), whereas PROTEIN binds well to PROTEIN , PROTEIN , and PROTEIN1 but interacts poorly with PROTEIN2 .
AIMed.d49.s433.p0	P	PROTEIN1 contains this primary site as well as a region that restricts interaction with PROTEIN2 .
AIMed.d49.s435.p0	P	By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of PROTEIN1 contributes to high affinity receptor binding and is critical for PROTEIN2 recognition.
AIMed.d49.s436.p0	N	Replacement of this loop with the homologous loop from PROTEIN1 dramatically reduced both the affinity of PROTEIN2 for PROTEIN and its biological potency but did not result in the ability to bind PROTEIN .
AIMed.d49.s436.p1	N	Replacement of this loop with the homologous loop from PROTEIN1 dramatically reduced both the affinity of PROTEIN for PROTEIN2 and its biological potency but did not result in the ability to bind PROTEIN .
AIMed.d49.s436.p2	N	Replacement of this loop with the homologous loop from PROTEIN1 dramatically reduced both the affinity of PROTEIN for PROTEIN and its biological potency but did not result in the ability to bind PROTEIN2 .
AIMed.d49.s436.p3	P	Replacement of this loop with the homologous loop from PROTEIN dramatically reduced both the affinity of PROTEIN1 for PROTEIN2 and its biological potency but did not result in the ability to bind PROTEIN .
AIMed.d49.s436.p4	N	Replacement of this loop with the homologous loop from PROTEIN dramatically reduced both the affinity of PROTEIN1 for PROTEIN and its biological potency but did not result in the ability to bind PROTEIN2 .
AIMed.d49.s438.p0	N	The reciprocal loop replacement mutant ( PROTEIN1 -L4/7) retained PROTEIN2 like affinity for PROTEIN and for PROTEIN .
AIMed.d49.s438.p1	N	The reciprocal loop replacement mutant ( PROTEIN1 -L4/7) retained PROTEIN like affinity for PROTEIN2 and for PROTEIN .
AIMed.d49.s438.p4	P	The reciprocal loop replacement mutant ( PROTEIN -L4/7) retained PROTEIN1 like affinity for PROTEIN and for PROTEIN2 .
AIMed.d49.s438.p5	N	The reciprocal loop replacement mutant ( PROTEIN -L4/7) retained PROTEIN like affinity for PROTEIN1 and for PROTEIN2 .
AIMed.d50.s441.p0	N	Type I interferons bind to two cell surface receptors, PROTEIN1 and PROTEIN2 , as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response.
AIMed.d50.s442.p0	P	Here, we quantitatively mapped the complete binding region of PROTEIN1 on PROTEIN2 by 35 individual mutations to alanine and isosteric residues.
AIMed.d50.s445.p0	P	Interestingly, the PROTEIN1 binding site overlaps the largest continuous hydrophobic patch on PROTEIN2 .
AIMed.d50.s447.p0	N	Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward PROTEIN1 results in linear function over the whole range of affinities investigated, suggesting that PROTEIN2 binding is the rate-determining step in cellular activation.
AIMed.d51.s455.p0	P	Here we report the crystal structure of the PROTEIN1 ectodomain in a dimeric form that is induced by simultaneous binding to PROTEIN2 and a heparin decasaccharide.
AIMed.d51.s458.p0	P	The structure of the PROTEIN1 - PROTEIN2 -heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.
AIMed.d52.s464.p0	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN2 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p1	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN2 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p2	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN2 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p3	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN2 ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p5	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p6	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d52.s464.p7	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN1 ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p8	P	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN2 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p9	P	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN2 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p10	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN2 ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p11	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN2 ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p12	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p13	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN1 ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d52.s464.p15	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN2 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p16	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN and the epithelial splice form of PROTEIN2 ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p17	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN2 ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p18	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p19	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d52.s464.p20	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN1 or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p22	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN1 and the epithelial splice form of PROTEIN ( PROTEIN2 ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p23	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN1 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p24	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN1 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d52.s464.p25	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN1 and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p26	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN1 ( PROTEIN2 ) to be activated by PROTEIN , PROTEIN , and PROTEIN .
AIMed.d52.s464.p27	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN1 ( PROTEIN ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p29	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN1 ( PROTEIN ) to be activated by PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p30	P	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN1 ) to be activated by PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d52.s464.p32	P	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN1 ) to be activated by PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p33	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN1 , PROTEIN2 , and PROTEIN .
AIMed.d52.s464.p34	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN1 , PROTEIN , and PROTEIN2 .
AIMed.d52.s464.p35	N	We show that the S252W mutation allows the mesenchymal splice form of PROTEIN ( PROTEIN ) to bind and to be activated by the mesenchymally expressed ligands PROTEIN or PROTEIN and the epithelial splice form of PROTEIN ( PROTEIN ) to be activated by PROTEIN , PROTEIN1 , and PROTEIN2 .
AIMed.d53.s469.p0	N	Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human PROTEIN1 ( PROTEIN2 ) that activates human PROTEIN .
AIMed.d53.s469.p1	P	Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human PROTEIN1 ( PROTEIN ) that activates human PROTEIN2 .
AIMed.d53.s470.p0	P	In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral PROTEIN1 and human PROTEIN2 , two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of PROTEIN and site III of viral PROTEIN , which is necessary for receptor activation.
AIMed.d53.s470.p2	N	In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral PROTEIN1 and human PROTEIN , two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of PROTEIN and site III of viral PROTEIN2 , which is necessary for receptor activation.
AIMed.d53.s470.p3	N	In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral PROTEIN and human PROTEIN1 , two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of PROTEIN2 and site III of viral PROTEIN , which is necessary for receptor activation.
AIMed.d53.s470.p4	N	In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral PROTEIN and human PROTEIN1 , two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of PROTEIN and site III of viral PROTEIN2 , which is necessary for receptor activation.
AIMed.d53.s470.p5	P	In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral PROTEIN and human PROTEIN , two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of PROTEIN1 and site III of viral PROTEIN2 , which is necessary for receptor activation.
AIMed.d53.s471.p0	P	Unlike human PROTEIN1 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact PROTEIN2 , which enhances the complementarity of the viral PROTEIN - PROTEIN binding interfaces.
AIMed.d53.s471.p1	N	Unlike human PROTEIN1 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact PROTEIN , which enhances the complementarity of the viral PROTEIN2 - PROTEIN binding interfaces.
AIMed.d53.s471.p2	N	Unlike human PROTEIN1 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact PROTEIN , which enhances the complementarity of the viral PROTEIN - PROTEIN2 binding interfaces.
AIMed.d53.s471.p3	N	Unlike human PROTEIN (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact PROTEIN1 , which enhances the complementarity of the viral PROTEIN2 - PROTEIN binding interfaces.
AIMed.d53.s471.p4	N	Unlike human PROTEIN (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact PROTEIN1 , which enhances the complementarity of the viral PROTEIN - PROTEIN2 binding interfaces.
AIMed.d54.s473.p0	N	PROTEIN1 ( PROTEIN2 ), a novel growth factor that binds to PROTEIN and beta receptor.
AIMed.d54.s473.p1	P	PROTEIN1 ( PROTEIN ), a novel growth factor that binds to PROTEIN2 and beta receptor.
AIMed.d54.s473.p2	P	PROTEIN ( PROTEIN1 ), a novel growth factor that binds to PROTEIN2 and beta receptor.
AIMed.d54.s475.p0	N	PROTEIN1 is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of PROTEIN2 , and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular PROTEIN (25%) and PROTEIN -chain (23%).
AIMed.d54.s475.p2	N	PROTEIN1 is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of PROTEIN , and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular PROTEIN (25%) and PROTEIN2 -chain (23%).
AIMed.d54.s475.p3	N	PROTEIN is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of PROTEIN1 , and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular PROTEIN2 (25%) and PROTEIN -chain (23%).
AIMed.d54.s475.p4	N	PROTEIN is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of PROTEIN1 , and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular PROTEIN (25%) and PROTEIN2 -chain (23%).
AIMed.d54.s475.p5	N	PROTEIN is a multidomain protein with the N-terminal region homologous to the extracellular CUB domain of PROTEIN , and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular PROTEIN1 (25%) and PROTEIN2 -chain (23%).
AIMed.d54.s477.p0	N	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN1 and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN2 ) to PROTEIN homodimers and PROTEIN /beta heterodimers.
AIMed.d54.s477.p1	N	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN1 and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN ) to PROTEIN2 homodimers and PROTEIN /beta heterodimers.
AIMed.d54.s477.p2	N	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN1 and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN ) to PROTEIN homodimers and PROTEIN2 /beta heterodimers.
AIMed.d54.s477.p3	P	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN1 ) to PROTEIN2 homodimers and PROTEIN /beta heterodimers.
AIMed.d54.s477.p4	P	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN1 ) to PROTEIN homodimers and PROTEIN2 /beta heterodimers.
AIMed.d54.s477.p5	N	Competition binding and immunoprecipitation studies on cells bearing both PROTEIN and beta receptors reveal a high affinity binding of recombinant GFD ( PROTEIN ) to PROTEIN1 homodimers and PROTEIN2 /beta heterodimers.
AIMed.d54.s478.p0	N	PROTEIN1 exhibits greater mitogenic potency than PROTEIN2 and comparable or greater mitogenic activity than PROTEIN and PROTEIN on several mesenchymal cell types.
AIMed.d54.s478.p1	N	PROTEIN1 exhibits greater mitogenic potency than PROTEIN and comparable or greater mitogenic activity than PROTEIN2 and PROTEIN on several mesenchymal cell types.
AIMed.d54.s478.p2	N	PROTEIN1 exhibits greater mitogenic potency than PROTEIN and comparable or greater mitogenic activity than PROTEIN and PROTEIN2 on several mesenchymal cell types.
AIMed.d54.s478.p3	N	PROTEIN exhibits greater mitogenic potency than PROTEIN1 and comparable or greater mitogenic activity than PROTEIN2 and PROTEIN on several mesenchymal cell types.
AIMed.d54.s478.p4	N	PROTEIN exhibits greater mitogenic potency than PROTEIN1 and comparable or greater mitogenic activity than PROTEIN and PROTEIN2 on several mesenchymal cell types.
AIMed.d54.s478.p5	N	PROTEIN exhibits greater mitogenic potency than PROTEIN and comparable or greater mitogenic activity than PROTEIN1 and PROTEIN2 on several mesenchymal cell types.
AIMed.d54.s479.p0	N	Analysis of PROTEIN1 in vivo in a diabetic mouse model of delayed wound healing showed that PROTEIN2 significantly enhanced repair of a full-thickness skin excision.
AIMed.d54.s480.p0	N	Together, these studies describe a third member of the PDGF family ( PROTEIN1 ) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PROTEIN2 .
AIMed.d55.s481.p0	N	Human PROTEIN1 / PROTEIN2 is a functional ligand for PROTEIN , PROTEIN and PROTEIN , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p1	P	Human PROTEIN1 / PROTEIN is a functional ligand for PROTEIN2 , PROTEIN and PROTEIN , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p3	P	Human PROTEIN1 / PROTEIN is a functional ligand for PROTEIN , PROTEIN and PROTEIN2 , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p4	P	Human PROTEIN / PROTEIN1 is a functional ligand for PROTEIN2 , PROTEIN and PROTEIN , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p5	P	Human PROTEIN / PROTEIN1 is a functional ligand for PROTEIN , PROTEIN2 and PROTEIN , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p6	P	Human PROTEIN / PROTEIN1 is a functional ligand for PROTEIN , PROTEIN and PROTEIN2 , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p7	N	Human PROTEIN / PROTEIN is a functional ligand for PROTEIN1 , PROTEIN2 and PROTEIN , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p8	N	Human PROTEIN / PROTEIN is a functional ligand for PROTEIN1 , PROTEIN and PROTEIN2 , and constitutively expressed by hepatocytes.
AIMed.d55.s481.p9	N	Human PROTEIN / PROTEIN is a functional ligand for PROTEIN , PROTEIN1 and PROTEIN2 , and constitutively expressed by hepatocytes.
AIMed.d55.s482.p0	N	PROTEIN1 ( PROTEIN2 )/ PROTEIN is a human CC chemokine selectively expressed in the liver.
AIMed.d55.s482.p1	N	PROTEIN1 ( PROTEIN )/ PROTEIN2 is a human CC chemokine selectively expressed in the liver.
AIMed.d55.s484.p0	P	At relatively high concentrations, PROTEIN1 induced calcium mobilization and chemotaxis via PROTEIN2 and PROTEIN .
AIMed.d55.s484.p2	N	At relatively high concentrations, PROTEIN induced calcium mobilization and chemotaxis via PROTEIN1 and PROTEIN2 .
AIMed.d55.s485.p0	P	PROTEIN1 also induced calcium mobilization, but marginal chemotaxis via PROTEIN2 .
AIMed.d55.s486.p0	P	Consistently, PROTEIN1 was found to bind to PROTEIN2 , PROTEIN and PROTEIN with relatively low affinities.
AIMed.d55.s486.p1	P	Consistently, PROTEIN1 was found to bind to PROTEIN , PROTEIN2 and PROTEIN with relatively low affinities.
AIMed.d55.s486.p2	P	Consistently, PROTEIN1 was found to bind to PROTEIN , PROTEIN and PROTEIN2 with relatively low affinities.
AIMed.d55.s486.p3	N	Consistently, PROTEIN was found to bind to PROTEIN1 , PROTEIN2 and PROTEIN with relatively low affinities.
AIMed.d55.s486.p4	N	Consistently, PROTEIN was found to bind to PROTEIN1 , PROTEIN and PROTEIN2 with relatively low affinities.
AIMed.d55.s486.p5	N	Consistently, PROTEIN was found to bind to PROTEIN , PROTEIN1 and PROTEIN2 with relatively low affinities.
AIMed.d55.s487.p0	P	The binding of PROTEIN1 to PROTEIN2 was much less significant.
AIMed.d55.s488.p0	P	In spite of its binding to PROTEIN1 , PROTEIN2 was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.
AIMed.d55.s492.p0	P	Taken together, PROTEIN1 is a new low-affinity functional ligand for PROTEIN2 , PROTEIN and PROTEIN , and is constitutively expressed by liver parenchymal cells.
AIMed.d55.s492.p1	P	Taken together, PROTEIN1 is a new low-affinity functional ligand for PROTEIN , PROTEIN2 and PROTEIN , and is constitutively expressed by liver parenchymal cells.
AIMed.d55.s492.p3	N	Taken together, PROTEIN is a new low-affinity functional ligand for PROTEIN1 , PROTEIN2 and PROTEIN , and is constitutively expressed by liver parenchymal cells.
AIMed.d55.s492.p4	N	Taken together, PROTEIN is a new low-affinity functional ligand for PROTEIN1 , PROTEIN and PROTEIN2 , and is constitutively expressed by liver parenchymal cells.
AIMed.d56.s494.p0	P	Cloning of PROTEIN1 , a ligand for PROTEIN2 on human T cells.
AIMed.d56.s499.p0	N	PROTEIN1 is highly similar to an identified murine PROTEIN2 both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/ PROTEIN .
AIMed.d56.s499.p1	N	PROTEIN1 is highly similar to an identified murine PROTEIN both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/ PROTEIN2 .
AIMed.d56.s499.p2	N	PROTEIN is highly similar to an identified murine PROTEIN1 both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/ PROTEIN2 .
AIMed.d56.s500.p0	P	Expressed in a murine myeloma, PROTEIN1 was identified as a ligand for PROTEIN2 by binding to a soluble PROTEIN construct.
AIMed.d56.s500.p1	P	Expressed in a murine myeloma, PROTEIN1 was identified as a ligand for PROTEIN by binding to a soluble PROTEIN2 construct.
AIMed.d57.s503.p0	P	Reconstitution of the multiprotein complex of PROTEIN1 , PROTEIN2 , and PROTEIN in a cell-free system.
AIMed.d57.s503.p1	N	Reconstitution of the multiprotein complex of PROTEIN1 , PROTEIN , and PROTEIN2 in a cell-free system.
AIMed.d57.s503.p2	N	Reconstitution of the multiprotein complex of PROTEIN , PROTEIN1 , and PROTEIN2 in a cell-free system.
AIMed.d57.s504.p0	N	A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( PROTEIN1 ) has been used here to form complexes between the PROTEIN2 tyrosine kinase and PROTEIN .
AIMed.d57.s504.p1	N	A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( PROTEIN1 ) has been used here to form complexes between the PROTEIN tyrosine kinase and PROTEIN2 .
AIMed.d57.s504.p2	P	A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( PROTEIN ) has been used here to form complexes between the PROTEIN1 tyrosine kinase and PROTEIN2 .
AIMed.d57.s505.p0	P	Reticulocyte lysate forms complexes between PROTEIN1 and a temperature-sensitive mutant of Rous sarcoma virus PROTEIN2 , which is normally present in cytosol virtually entirely in the multiprotein complex form.
AIMed.d57.s506.p0	P	In addition, PROTEIN1 in the lysate complexes with wild-type PROTEIN2 , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN .
AIMed.d57.s506.p1	P	In addition, PROTEIN1 in the lysate complexes with wild-type PROTEIN , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN2 , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN .
AIMed.d57.s506.p2	N	In addition, PROTEIN1 in the lysate complexes with wild-type PROTEIN , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN2 .
AIMed.d57.s506.p3	N	In addition, PROTEIN in the lysate complexes with wild-type PROTEIN1 , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN2 , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN .
AIMed.d57.s506.p4	N	In addition, PROTEIN in the lysate complexes with wild-type PROTEIN1 , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN2 .
AIMed.d57.s506.p5	N	In addition, PROTEIN in the lysate complexes with wild-type PROTEIN , of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, PROTEIN1 , which has never been recovered in cytosol in the form of a native multiprotein complex with PROTEIN2 .
AIMed.d57.s508.p0	P	The native and reconstituted PROTEIN1 - PROTEIN2 complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate.
AIMed.d57.s509.p0	P	As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted PROTEIN1 multiprotein complex contains PROTEIN2 , which is a major candidate for providing the protein unfoldase activity required for PROTEIN association.
AIMed.d57.s509.p1	N	As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted PROTEIN1 multiprotein complex contains PROTEIN , which is a major candidate for providing the protein unfoldase activity required for PROTEIN2 association.
AIMed.d57.s509.p2	N	As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted PROTEIN multiprotein complex contains PROTEIN1 , which is a major candidate for providing the protein unfoldase activity required for PROTEIN2 association.
AIMed.d58.s511.p0	N	A cDNA clone encoding a novel, widely expressed protein (called PROTEIN1 or PROTEIN2 ) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.
AIMed.d58.s516.p0	N	While injection of PROTEIN1 or PROTEIN2 proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN together with PROTEIN protein stimulated DNA synthesis.
AIMed.d58.s516.p1	N	While injection of PROTEIN1 or PROTEIN proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN2 together with PROTEIN protein stimulated DNA synthesis.
AIMed.d58.s516.p2	N	While injection of PROTEIN1 or PROTEIN proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN together with PROTEIN2 protein stimulated DNA synthesis.
AIMed.d58.s516.p3	N	While injection of PROTEIN or PROTEIN1 proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN2 together with PROTEIN protein stimulated DNA synthesis.
AIMed.d58.s516.p4	N	While injection of PROTEIN or PROTEIN1 proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN together with PROTEIN2 protein stimulated DNA synthesis.
AIMed.d58.s516.p5	N	While injection of PROTEIN or PROTEIN proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of PROTEIN1 together with PROTEIN2 protein stimulated DNA synthesis.
AIMed.d58.s517.p0	N	These results suggest that PROTEIN1 / PROTEIN2 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.
AIMed.d59.s518.p0	N	Analysis of the oligomerization of PROTEIN1 and PROTEIN2 products in vivo using a two-hybrid assay system.
AIMed.d59.s520.p0	N	PROTEIN1 is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the PROTEIN2 gene products PROTEIN and PROTEIN .
AIMed.d59.s520.p2	P	PROTEIN1 is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the PROTEIN gene products PROTEIN and PROTEIN2 .
AIMed.d59.s520.p3	N	PROTEIN is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the PROTEIN1 gene products PROTEIN2 and PROTEIN .
AIMed.d59.s520.p4	N	PROTEIN is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the PROTEIN1 gene products PROTEIN and PROTEIN2 .
AIMed.d59.s520.p5	N	PROTEIN is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the PROTEIN gene products PROTEIN1 and PROTEIN2 .
AIMed.d59.s523.p0	P	The results show that PROTEIN1 heterodimerizes with PROTEIN2 and PROTEIN in vivo, but it does not homodimerize to a measurable extent.
AIMed.d59.s523.p1	P	The results show that PROTEIN1 heterodimerizes with PROTEIN and PROTEIN2 in vivo, but it does not homodimerize to a measurable extent.
AIMed.d59.s523.p2	N	The results show that PROTEIN heterodimerizes with PROTEIN1 and PROTEIN2 in vivo, but it does not homodimerize to a measurable extent.
AIMed.d59.s524.p0	N	Peptide growth factors, as well as the immediate early gene products PROTEIN1 , PROTEIN2 , and PROTEIN , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN products.
AIMed.d59.s524.p1	N	Peptide growth factors, as well as the immediate early gene products PROTEIN1 , PROTEIN , and PROTEIN2 , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN products.
AIMed.d59.s524.p2	N	Peptide growth factors, as well as the immediate early gene products PROTEIN1 , PROTEIN , and PROTEIN , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN2 products.
AIMed.d59.s524.p3	N	Peptide growth factors, as well as the immediate early gene products PROTEIN , PROTEIN1 , and PROTEIN2 , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN products.
AIMed.d59.s524.p4	N	Peptide growth factors, as well as the immediate early gene products PROTEIN , PROTEIN1 , and PROTEIN , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN2 products.
AIMed.d59.s524.p5	N	Peptide growth factors, as well as the immediate early gene products PROTEIN , PROTEIN , and PROTEIN1 , inhibit the activity of myogenin through a mechanism independent of its association with PROTEIN2 products.
AIMed.d60.s525.p2	P	Activation of PROTEIN1 by PROTEIN2 in NIH 3T3 cells and in vitro.
AIMed.d60.s527.p0	P	PROTEIN1 and the protein kinase that activates it ( PROTEIN2 ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the PROTEIN protein kinase.
AIMed.d60.s527.p1	P	PROTEIN1 and the protein kinase that activates it ( PROTEIN ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the PROTEIN2 protein kinase.
AIMed.d60.s527.p2	P	PROTEIN and the protein kinase that activates it ( PROTEIN1 ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the PROTEIN2 protein kinase.
AIMed.d60.s528.p1	P	The PROTEIN1 proteins purified from cells infected with EC12 or 22W viruses activated PROTEIN2 from skeletal muscle in vitro.
AIMed.d60.s529.p1	N	Furthermore, a bacterially expressed PROTEIN1 fusion protein (glutathione S-transferase-p3722W) also activated PROTEIN2 in vitro.
AIMed.d60.s530.p1	P	These findings suggest that one function of PROTEIN1 in mitogenic signaling is to phosphorylate and activate PROTEIN2 .
AIMed.d61.s532.p0	N	An expression plasmid encoding the human 75-kDa PROTEIN1 ( PROTEIN2 ) was constructed and used to generate a stable human cell line (293/ PROTEIN ) overexpressing PROTEIN .
AIMed.d61.s532.p1	N	An expression plasmid encoding the human 75-kDa PROTEIN1 ( PROTEIN ) was constructed and used to generate a stable human cell line (293/ PROTEIN2 ) overexpressing PROTEIN .
AIMed.d61.s532.p2	N	An expression plasmid encoding the human 75-kDa PROTEIN1 ( PROTEIN ) was constructed and used to generate a stable human cell line (293/ PROTEIN ) overexpressing PROTEIN2 .
AIMed.d61.s532.p3	N	An expression plasmid encoding the human 75-kDa PROTEIN ( PROTEIN1 ) was constructed and used to generate a stable human cell line (293/ PROTEIN2 ) overexpressing PROTEIN .
AIMed.d61.s532.p5	N	An expression plasmid encoding the human 75-kDa PROTEIN ( PROTEIN ) was constructed and used to generate a stable human cell line (293/ PROTEIN1 ) overexpressing PROTEIN2 .
AIMed.d61.s533.p0	N	Ligand binding analysis revealed high affinity binding (Kd = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for 125I- PROTEIN1 and approximately 5-fold lower affinity for PROTEIN2 (Kd = 1.1 nM) with 264,000 +/- 2,000 sites/cell.
AIMed.d61.s534.p0	N	Cross-linking of 125I- PROTEIN1 and 125I- PROTEIN2 to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p1	N	Cross-linking of 125I- PROTEIN1 and 125I- PROTEIN to 293/ PROTEIN2 cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p2	N	Cross-linking of 125I- PROTEIN1 and 125I- PROTEIN to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN2 and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p3	N	Cross-linking of 125I- PROTEIN1 and 125I- PROTEIN to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN2 , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p5	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN1 to 293/ PROTEIN2 cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p6	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN1 to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN2 and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p7	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN1 to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN2 , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p8	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN1 to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN2 molecules.
AIMed.d61.s534.p9	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN1 cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN2 and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p10	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN1 cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN2 , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p11	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN1 cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN2 molecules.
AIMed.d61.s534.p12	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN1 and 205,000 and 244,000 for PROTEIN2 , suggesting these complexes contain two or three PROTEIN molecules.
AIMed.d61.s534.p13	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN1 and 205,000 and 244,000 for PROTEIN , suggesting these complexes contain two or three PROTEIN2 molecules.
AIMed.d61.s534.p14	N	Cross-linking of 125I- PROTEIN and 125I- PROTEIN to 293/ PROTEIN cells yielded predominant complexes with apparent molecular weights of 211,000 for PROTEIN and 205,000 and 244,000 for PROTEIN1 , suggesting these complexes contain two or three PROTEIN2 molecules.
AIMed.d61.s535.p0	N	Immunoprecipitation of PROTEIN1 from 32P-labeled 293/ PROTEIN2 cells demonstrated that the receptor is phosphorylated.
AIMed.d61.s537.p0	N	PROTEIN1 treatment of 293/ PROTEIN2 cells did not significantly affect the degree or pattern of phosphorylation.
AIMed.d61.s539.p0	N	Shedding of the extracellular domain of PROTEIN1 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by PROTEIN2 or PROTEIN .
AIMed.d61.s539.p1	N	Shedding of the extracellular domain of PROTEIN1 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by PROTEIN or PROTEIN2 .
AIMed.d61.s539.p2	N	Shedding of the extracellular domain of PROTEIN was induced by 4 beta-phorbol 12-myristate 13-acetate but not by PROTEIN1 or PROTEIN2 .
AIMed.d62.s541.p0	N	The crystal structure of the homodimeric PROTEIN1 ( PROTEIN2 ) has been determined by X-ray analysis to 3.0 A resolution.
AIMed.d63.s544.p0	N	Coassociation of PROTEIN1 ( PROTEIN2 ) with PROTEIN on the surface of human T lymphocytes.
AIMed.d63.s544.p1	P	Coassociation of PROTEIN1 ( PROTEIN ) with PROTEIN2 on the surface of human T lymphocytes.
AIMed.d63.s544.p2	P	Coassociation of PROTEIN ( PROTEIN1 ) with PROTEIN2 on the surface of human T lymphocytes.
AIMed.d63.s545.p0	N	In the present report, we demonstrated that modulation of PROTEIN1 from T cell surface induced by anti PROTEIN2 (1F7) led to enhanced phosphorylation of PROTEIN zeta tyrosine residues and increased PROTEIN associated p56lck tyrosine kinase activity.
AIMed.d63.s545.p1	N	In the present report, we demonstrated that modulation of PROTEIN1 from T cell surface induced by anti PROTEIN (1F7) led to enhanced phosphorylation of PROTEIN2 zeta tyrosine residues and increased PROTEIN associated p56lck tyrosine kinase activity.
AIMed.d63.s545.p3	N	In the present report, we demonstrated that modulation of PROTEIN from T cell surface induced by anti PROTEIN1 (1F7) led to enhanced phosphorylation of PROTEIN2 zeta tyrosine residues and increased PROTEIN associated p56lck tyrosine kinase activity.
AIMed.d63.s545.p4	N	In the present report, we demonstrated that modulation of PROTEIN from T cell surface induced by anti PROTEIN1 (1F7) led to enhanced phosphorylation of PROTEIN zeta tyrosine residues and increased PROTEIN2 associated p56lck tyrosine kinase activity.
AIMed.d63.s545.p5	N	In the present report, we demonstrated that modulation of PROTEIN from T cell surface induced by anti PROTEIN (1F7) led to enhanced phosphorylation of PROTEIN1 zeta tyrosine residues and increased PROTEIN2 associated p56lck tyrosine kinase activity.
AIMed.d63.s546.p0	N	We further showed that PROTEIN1 was comodulated on the T cell surface with PROTEIN2 , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN was capable of precipitating PROTEIN from T cell lysates.
AIMed.d63.s546.p1	N	We further showed that PROTEIN1 was comodulated on the T cell surface with PROTEIN , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN2 was capable of precipitating PROTEIN from T cell lysates.
AIMed.d63.s546.p2	N	We further showed that PROTEIN1 was comodulated on the T cell surface with PROTEIN , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN was capable of precipitating PROTEIN2 from T cell lysates.
AIMed.d63.s546.p3	N	We further showed that PROTEIN was comodulated on the T cell surface with PROTEIN1 , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN2 was capable of precipitating PROTEIN from T cell lysates.
AIMed.d63.s546.p4	N	We further showed that PROTEIN was comodulated on the T cell surface with PROTEIN1 , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN was capable of precipitating PROTEIN2 from T cell lysates.
AIMed.d63.s546.p5	N	We further showed that PROTEIN was comodulated on the T cell surface with PROTEIN , a known membrane-linked protein tyrosine phosphatase and that anti- PROTEIN1 was capable of precipitating PROTEIN2 from T cell lysates.
AIMed.d63.s547.p0	N	These findings strongly suggest that PROTEIN1 may be closely associated with the PROTEIN2 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN with PROTEIN results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d63.s547.p1	N	These findings strongly suggest that PROTEIN1 may be closely associated with the PROTEIN protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN2 with PROTEIN results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d63.s547.p2	N	These findings strongly suggest that PROTEIN1 may be closely associated with the PROTEIN protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN with PROTEIN2 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d63.s547.p3	N	These findings strongly suggest that PROTEIN may be closely associated with the PROTEIN1 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN2 with PROTEIN results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d63.s547.p4	N	These findings strongly suggest that PROTEIN may be closely associated with the PROTEIN1 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN with PROTEIN2 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d63.s547.p5	P	These findings strongly suggest that PROTEIN may be closely associated with the PROTEIN protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of PROTEIN1 with PROTEIN2 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
AIMed.d64.s549.p0	N	We have isolated and characterized a cDNA clone, PROTEIN1 , encoding a human fibroblast growth factor (FGF) receptor. PROTEIN2 contains an open reading frame which encodes an 820 amino acid polypeptide with three immunoglobulin-like domains in the extracellular part and an intracellular split tyrosine kinase domain.
AIMed.d64.s550.p0	N	Transient expression in COS-1 cells and immunoprecipitation using an antiserum raised against a C-terminal peptide, gave rise to two components, representing mature (130 kDa) and precursor (115 kDa) forms of the PROTEIN1 encoded polypeptide, which was denoted PROTEIN2 .
AIMed.d64.s551.p0	N	Crosslinking of iodinated PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p1	N	Crosslinking of iodinated PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p2	N	Crosslinking of iodinated PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p3	N	Crosslinking of iodinated PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN2 and PROTEIN .
AIMed.d64.s551.p4	N	Crosslinking of iodinated PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN2 .
AIMed.d64.s551.p5	N	Crosslinking of iodinated PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p6	N	Crosslinking of iodinated PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p7	N	Crosslinking of iodinated PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN2 and PROTEIN .
AIMed.d64.s551.p8	N	Crosslinking of iodinated PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN2 .
AIMed.d64.s551.p9	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN .
AIMed.d64.s551.p10	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN2 and PROTEIN .
AIMed.d64.s551.p11	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN2 .
AIMed.d64.s551.p12	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN2 and PROTEIN .
AIMed.d64.s551.p13	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN and PROTEIN2 .
AIMed.d64.s551.p14	N	Crosslinking of iodinated PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN ) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both PROTEIN1 and PROTEIN2 .
AIMed.d64.s552.p1	P	From Scatchard analyses, the Kd:s for binding of PROTEIN1 and PROTEIN to PROTEIN2 were estimated to 25 pM and 41 pM, respectively.
AIMed.d64.s552.p2	P	From Scatchard analyses, the Kd:s for binding of PROTEIN and PROTEIN1 to PROTEIN2 were estimated to 25 pM and 41 pM, respectively.
AIMed.d64.s553.p0	P	Thus, PROTEIN1 encodes a human FGF receptor with high affinity for both PROTEIN2 and PROTEIN .
AIMed.d64.s553.p1	P	Thus, PROTEIN1 encodes a human FGF receptor with high affinity for both PROTEIN and PROTEIN2 .
AIMed.d64.s553.p2	N	Thus, PROTEIN encodes a human FGF receptor with high affinity for both PROTEIN1 and PROTEIN2 .
AIMed.d65.s554.p0	P	Cross-family dimerization of transcription factors PROTEIN1 / PROTEIN2 and PROTEIN / PROTEIN alters DNA binding specificity.
AIMed.d65.s554.p1	N	Cross-family dimerization of transcription factors PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN alters DNA binding specificity.
AIMed.d65.s554.p2	N	Cross-family dimerization of transcription factors PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 alters DNA binding specificity.
AIMed.d65.s554.p3	N	Cross-family dimerization of transcription factors PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN alters DNA binding specificity.
AIMed.d65.s554.p4	N	Cross-family dimerization of transcription factors PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 alters DNA binding specificity.
AIMed.d65.s554.p5	P	Cross-family dimerization of transcription factors PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 alters DNA binding specificity.
AIMed.d65.s555.p0	N	The PROTEIN1 / PROTEIN2 and PROTEIN / PROTEIN families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s555.p1	N	The PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s555.p2	N	The PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s555.p3	N	The PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s555.p4	N	The PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s555.p5	N	The PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
AIMed.d65.s558.p1	N	Although PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
AIMed.d65.s558.p2	N	Although PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
AIMed.d65.s558.p3	N	Although PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
AIMed.d65.s558.p4	N	Although PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
AIMed.d65.s558.p5	N	Although PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
AIMed.d65.s560.p0	N	These findings indicate that the PROTEIN1 / PROTEIN2 and PROTEIN / PROTEIN families of transcription factors are not as distinct as was previously thought.
AIMed.d65.s560.p1	N	These findings indicate that the PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN families of transcription factors are not as distinct as was previously thought.
AIMed.d65.s560.p2	N	These findings indicate that the PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 families of transcription factors are not as distinct as was previously thought.
AIMed.d65.s560.p3	N	These findings indicate that the PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN families of transcription factors are not as distinct as was previously thought.
AIMed.d65.s560.p4	N	These findings indicate that the PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 families of transcription factors are not as distinct as was previously thought.
AIMed.d65.s560.p5	N	These findings indicate that the PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 families of transcription factors are not as distinct as was previously thought.
AIMed.d66.s562.p0	N	Human PROTEIN1 , a new cyclin that interacts with two members of the PROTEIN2 gene family.
AIMed.d66.s564.p0	P	PROTEIN1 showed genetic interactions with the PROTEIN2 gene, suggesting that it functioned at START by interacting with the PROTEIN protein.
AIMed.d66.s564.p2	N	PROTEIN showed genetic interactions with the PROTEIN1 gene, suggesting that it functioned at START by interacting with the PROTEIN2 protein.
AIMed.d66.s565.p0	N	Two human genes were identified that could interact with PROTEIN1 to perform START in yeast containing a PROTEIN2 mutation.
AIMed.d66.s566.p2	N	One was PROTEIN1 , and the second was the human homolog of Xenopus PROTEIN2 .
AIMed.d66.s567.p0	P	PROTEIN1 produced in E. coli bound and activated the PROTEIN2 protein in extracts from human G1 cells, and antibodies against PROTEIN immunoprecipitated a histone H1 kinase from HeLa cells.
AIMed.d66.s567.p1	N	PROTEIN1 produced in E. coli bound and activated the PROTEIN protein in extracts from human G1 cells, and antibodies against PROTEIN2 immunoprecipitated a histone H1 kinase from HeLa cells.
AIMed.d66.s568.p0	P	The interactions between PROTEIN1 and PROTEIN2 , or PROTEIN , may be important at the G1 to S transition in human cells.
AIMed.d66.s568.p1	P	The interactions between PROTEIN1 and PROTEIN , or PROTEIN2 , may be important at the G1 to S transition in human cells.
AIMed.d66.s568.p2	N	The interactions between PROTEIN and PROTEIN1 , or PROTEIN2 , may be important at the G1 to S transition in human cells.
AIMed.d68.s578.p0	N	Two previously unidentified human PROTEIN1 genes have been isolated, PROTEIN2 and PROTEIN .
AIMed.d68.s578.p1	N	Two previously unidentified human PROTEIN1 genes have been isolated, PROTEIN and PROTEIN2 .
AIMed.d68.s578.p2	N	Two previously unidentified human PROTEIN genes have been isolated, PROTEIN1 and PROTEIN2 .
AIMed.d68.s580.p0	N	Microinjection of anti- PROTEIN1 antibodies into HeLa cells causes their arrest in mitosis. PROTEIN2 and PROTEIN display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either PROTEIN or B2 but not A or D1.
AIMed.d68.s580.p1	N	Microinjection of anti- PROTEIN1 antibodies into HeLa cells causes their arrest in mitosis. PROTEIN and PROTEIN2 display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either PROTEIN or B2 but not A or D1.
AIMed.d68.s580.p3	N	Microinjection of anti- PROTEIN antibodies into HeLa cells causes their arrest in mitosis. PROTEIN1 and PROTEIN2 display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either PROTEIN or B2 but not A or D1.
AIMed.d68.s580.p4	N	Microinjection of anti- PROTEIN antibodies into HeLa cells causes their arrest in mitosis. PROTEIN1 and PROTEIN display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either PROTEIN2 or B2 but not A or D1.
AIMed.d68.s580.p5	N	Microinjection of anti- PROTEIN antibodies into HeLa cells causes their arrest in mitosis. PROTEIN and PROTEIN1 display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either PROTEIN2 or B2 but not A or D1.
AIMed.d68.s581.p0	P	Association between PROTEIN1 and PROTEIN2 / PROTEIN was detected in the HeLa cells.
AIMed.d68.s581.p2	N	Association between PROTEIN and PROTEIN1 / PROTEIN2 was detected in the HeLa cells.
AIMed.d68.s582.p1	N	These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the PROTEIN1 protein kinase, but also activate the PROTEIN tyrosine phosphatase, of which PROTEIN2 is the physiological substrate.
AIMed.d68.s582.p2	N	These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the PROTEIN protein kinase, but also activate the PROTEIN1 tyrosine phosphatase, of which PROTEIN2 is the physiological substrate.
AIMed.d68.s585.p0	N	The motif may represent an activating domain that has to be provided to PROTEIN1 by intermolecular interaction with PROTEIN2 .
AIMed.d69.s586.p0	P	Activation of PROTEIN1 decreases phosphorylation of PROTEIN2 at sites that negatively regulate its DNA-binding activity.
AIMed.d69.s587.p0	P	In resting human epithelial and fibroblastic cells, PROTEIN1 is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by PROTEIN2 ( PROTEIN ).
AIMed.d69.s587.p1	P	In resting human epithelial and fibroblastic cells, PROTEIN1 is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by PROTEIN ( PROTEIN2 ).
AIMed.d69.s587.p2	N	In resting human epithelial and fibroblastic cells, PROTEIN is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by PROTEIN1 ( PROTEIN2 ).
AIMed.d69.s589.p0	P	Activation of PROTEIN1 results in rapid, site-specific dephosphorylation of PROTEIN2 at one or more of these three sites and is coincident with increased PROTEIN -binding activity.
AIMed.d69.s589.p1	N	Activation of PROTEIN1 results in rapid, site-specific dephosphorylation of PROTEIN at one or more of these three sites and is coincident with increased PROTEIN2 -binding activity.
AIMed.d69.s589.p2	N	Activation of PROTEIN results in rapid, site-specific dephosphorylation of PROTEIN1 at one or more of these three sites and is coincident with increased PROTEIN2 -binding activity.
AIMed.d69.s590.p0	P	Phosphorylation of recombinant human PROTEIN1 proteins in vitro by PROTEIN2 decreases their DNA-binding activity.
AIMed.d69.s592.p0	P	We propose that PROTEIN1 is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to PROTEIN2 activation.
AIMed.d70.s593.p0	N	Interaction of the regulatory subunit ( PROTEIN1 ) of PROTEIN2 with PROTEIN -anchoring proteins occurs through an amphipathic helix binding motif.
AIMed.d70.s593.p1	N	Interaction of the regulatory subunit ( PROTEIN1 ) of PROTEIN with PROTEIN2 -anchoring proteins occurs through an amphipathic helix binding motif.
AIMed.d70.s593.p2	N	Interaction of the regulatory subunit ( PROTEIN ) of PROTEIN1 with PROTEIN2 -anchoring proteins occurs through an amphipathic helix binding motif.
AIMed.d70.s594.p0	N	The PROTEIN1 is localized to specific subcellular environments through the binding of the regulatory subunit ( PROTEIN2 ) dimer to PROTEIN -anchoring proteins.
AIMed.d70.s595.p0	N	Computer-aided analysis of secondary structure, performed on four PROTEIN1 -anchoring protein sequences (the PROTEIN2 , PROTEIN , and two thyroid proteins PROTEIN and PROTEIN ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p1	N	Computer-aided analysis of secondary structure, performed on four PROTEIN1 -anchoring protein sequences (the PROTEIN , PROTEIN2 , and two thyroid proteins PROTEIN and PROTEIN ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p2	N	Computer-aided analysis of secondary structure, performed on four PROTEIN1 -anchoring protein sequences (the PROTEIN , PROTEIN , and two thyroid proteins PROTEIN2 and PROTEIN ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p3	N	Computer-aided analysis of secondary structure, performed on four PROTEIN1 -anchoring protein sequences (the PROTEIN , PROTEIN , and two thyroid proteins PROTEIN and PROTEIN2 ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p5	N	Computer-aided analysis of secondary structure, performed on four PROTEIN -anchoring protein sequences (the PROTEIN1 , PROTEIN , and two thyroid proteins PROTEIN2 and PROTEIN ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p6	N	Computer-aided analysis of secondary structure, performed on four PROTEIN -anchoring protein sequences (the PROTEIN1 , PROTEIN , and two thyroid proteins PROTEIN and PROTEIN2 ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p7	N	Computer-aided analysis of secondary structure, performed on four PROTEIN -anchoring protein sequences (the PROTEIN , PROTEIN1 , and two thyroid proteins PROTEIN2 and PROTEIN ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p8	N	Computer-aided analysis of secondary structure, performed on four PROTEIN -anchoring protein sequences (the PROTEIN , PROTEIN1 , and two thyroid proteins PROTEIN and PROTEIN2 ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s595.p9	N	Computer-aided analysis of secondary structure, performed on four PROTEIN -anchoring protein sequences (the PROTEIN , PROTEIN , and two thyroid proteins PROTEIN1 and PROTEIN2 ), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.
AIMed.d70.s597.p1	P	A bacterially expressed 318-amino acid fragment, PROTEIN1 (418-736), containing the amphipathic helix region, was able to bind PROTEIN2 .
AIMed.d71.s603.p0	N	The proto-oncogene PROTEIN1 is a component of the PROTEIN2 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli.
AIMed.d71.s606.p0	N	We present evidence that PROTEIN1 ( PROTEIN2 and PROTEIN /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN .
AIMed.d71.s606.p1	N	We present evidence that PROTEIN1 ( PROTEIN and PROTEIN2 /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN .
AIMed.d71.s606.p2	N	We present evidence that PROTEIN1 ( PROTEIN and PROTEIN /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN2 .
AIMed.d71.s606.p3	N	We present evidence that PROTEIN ( PROTEIN1 and PROTEIN2 /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN .
AIMed.d71.s606.p4	P	We present evidence that PROTEIN ( PROTEIN1 and PROTEIN /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN2 .
AIMed.d71.s606.p5	P	We present evidence that PROTEIN ( PROTEIN and PROTEIN1 /44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of PROTEIN2 .
AIMed.d71.s607.p1	N	The PROTEIN1 enzymes PROTEIN and PROTEIN2 /44 are regulated by tyrosine as well as serine/threonine phosphorylation.
AIMed.d71.s607.p2	N	The PROTEIN enzymes PROTEIN1 and PROTEIN2 /44 are regulated by tyrosine as well as serine/threonine phosphorylation.
AIMed.d71.s608.p0	N	PROTEIN1 activation of PROTEIN2 may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.
AIMed.d72.s609.p0	N	A cellular protein that competes with PROTEIN1 for binding to the PROTEIN2 gene product.
AIMed.d72.s612.p0	N	How PROTEIN1 acts to bring about this suppression is not clear but one clue is that the PROTEIN2 protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of PROTEIN essential for such binding frequently contain mutations in tumour cells.
AIMed.d72.s612.p1	N	How PROTEIN1 acts to bring about this suppression is not clear but one clue is that the PROTEIN protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of PROTEIN2 essential for such binding frequently contain mutations in tumour cells.
AIMed.d72.s614.p2	N	We report here the identification of one such human cellular PROTEIN1 of relative molecular mass 46,000 (46K) ( PROTEIN2 ).
AIMed.d72.s615.p0	N	Two lines of evidence support the notion that PROTEIN1 and PROTEIN2 have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p1	P	Two lines of evidence support the notion that PROTEIN1 and PROTEIN have homologous PROTEIN2 -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p3	N	Two lines of evidence support the notion that PROTEIN1 and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN2 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p4	N	Two lines of evidence support the notion that PROTEIN1 and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN2 for binding to PROTEIN .
AIMed.d72.s615.p5	N	Two lines of evidence support the notion that PROTEIN1 and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN2 .
AIMed.d72.s615.p6	P	Two lines of evidence support the notion that PROTEIN and PROTEIN1 have homologous PROTEIN2 -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p7	N	Two lines of evidence support the notion that PROTEIN and PROTEIN1 have homologous PROTEIN -binding properties: first, several mutated PROTEIN2 proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p8	N	Two lines of evidence support the notion that PROTEIN and PROTEIN1 have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN2 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p9	N	Two lines of evidence support the notion that PROTEIN and PROTEIN1 have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN2 for binding to PROTEIN .
AIMed.d72.s615.p10	N	Two lines of evidence support the notion that PROTEIN and PROTEIN1 have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN2 .
AIMed.d72.s615.p11	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN1 -binding properties: first, several mutated PROTEIN2 proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p12	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN1 -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN2 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p13	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN1 -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN2 for binding to PROTEIN .
AIMed.d72.s615.p14	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN1 -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN2 .
AIMed.d72.s615.p15	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN1 proteins that failed to bind to T also did not associate with PROTEIN2 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN .
AIMed.d72.s615.p16	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN1 proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN2 for binding to PROTEIN .
AIMed.d72.s615.p17	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN1 proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN2 .
AIMed.d72.s615.p18	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN1 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN2 for binding to PROTEIN .
AIMed.d72.s615.p19	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN1 ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN for binding to PROTEIN2 .
AIMed.d72.s615.p20	N	Two lines of evidence support the notion that PROTEIN and PROTEIN have homologous PROTEIN -binding properties: first, several mutated PROTEIN proteins that failed to bind to T also did not associate with PROTEIN ; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with PROTEIN1 for binding to PROTEIN2 .
AIMed.d72.s616.p0	P	The apparent targeting of the PROTEIN1 - PROTEIN2 interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.
AIMed.d73.s621.p0	N	The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the PROTEIN1  PROTEIN2 .
AIMed.d73.s623.p0	N	Unlabeled PROTEIN1 and PROTEIN2 were equally effective at displacing the binding of labeled PROTEIN to TNF-R expressing cells.
AIMed.d73.s623.p1	N	Unlabeled PROTEIN1 and PROTEIN were equally effective at displacing the binding of labeled PROTEIN2 to TNF-R expressing cells.
AIMed.d73.s623.p2	N	Unlabeled PROTEIN and PROTEIN1 were equally effective at displacing the binding of labeled PROTEIN2 to TNF-R expressing cells.
AIMed.d74.s630.p0	N	It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for PROTEIN1 , PROTEIN2 and PROTEIN (beta-chain) and also to the prolactin receptor.
AIMed.d74.s630.p1	N	It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for PROTEIN1 , PROTEIN and PROTEIN2 (beta-chain) and also to the prolactin receptor.
AIMed.d74.s630.p2	N	It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for PROTEIN , PROTEIN1 and PROTEIN2 (beta-chain) and also to the prolactin receptor.
AIMed.d74.s631.p0	P	When transfected into COS cells the cloned cDNA directed the expression of a PROTEIN1 showing a single class of affinity (KD = 2(-8) nM) and specificity for human PROTEIN2 but not PROTEIN .
AIMed.d74.s631.p1	N	When transfected into COS cells the cloned cDNA directed the expression of a PROTEIN1 showing a single class of affinity (KD = 2(-8) nM) and specificity for human PROTEIN but not PROTEIN2 .
AIMed.d74.s631.p2	N	When transfected into COS cells the cloned cDNA directed the expression of a PROTEIN showing a single class of affinity (KD = 2(-8) nM) and specificity for human PROTEIN1 but not PROTEIN2 .
AIMed.d76.s637.p0	P	The T-cell antigen PROTEIN1 acts as a receptor and substrate for the protein-tyrosine kinase PROTEIN2 .
AIMed.d76.s639.p4	N	PROTEIN1 associates with the T-cell receptor zeta chain (TcR zeta)/CD3  T-cell receptor zeta chain (TcR zeta)/CD3  PROTEIN complex and is rapidly phosphosphorylated on tyrosine residues as a result of PROTEIN2 / PROTEIN ligation.
AIMed.d76.s639.p5	N	PROTEIN1 associates with the T-cell receptor zeta chain (TcR zeta)/CD3  T-cell receptor zeta chain (TcR zeta)/CD3  PROTEIN complex and is rapidly phosphosphorylated on tyrosine residues as a result of PROTEIN / PROTEIN2 ligation.
AIMed.d76.s639.p18	N	PROTEIN associates with the T-cell receptor zeta chain (TcR zeta)/CD3  T-cell receptor zeta chain (TcR zeta)/CD3  PROTEIN1 complex and is rapidly phosphosphorylated on tyrosine residues as a result of PROTEIN2 / PROTEIN ligation.
AIMed.d76.s639.p19	N	PROTEIN associates with the T-cell receptor zeta chain (TcR zeta)/CD3  T-cell receptor zeta chain (TcR zeta)/CD3  PROTEIN1 complex and is rapidly phosphosphorylated on tyrosine residues as a result of PROTEIN / PROTEIN2 ligation.
AIMed.d76.s639.p20	N	PROTEIN associates with the T-cell receptor zeta chain (TcR zeta)/CD3  T-cell receptor zeta chain (TcR zeta)/CD3  PROTEIN complex and is rapidly phosphosphorylated on tyrosine residues as a result of PROTEIN1 / PROTEIN2 ligation.
AIMed.d76.s641.p0	P	In this study, we demonstrate that PROTEIN1 is coupled to the protein-tyrosine kinase PROTEIN2 and can act as a substrate for PROTEIN .
AIMed.d76.s641.p2	N	In this study, we demonstrate that PROTEIN is coupled to the protein-tyrosine kinase PROTEIN1 and can act as a substrate for PROTEIN2 .
AIMed.d76.s642.p0	N	Coexpression of PROTEIN1 with PROTEIN2 in the baculovirus expression system resulted in the phosphorylation of PROTEIN on tyrosine residues.
AIMed.d76.s642.p1	N	Coexpression of PROTEIN1 with PROTEIN in the baculovirus expression system resulted in the phosphorylation of PROTEIN2 on tyrosine residues.
AIMed.d76.s642.p2	N	Coexpression of PROTEIN with PROTEIN1 in the baculovirus expression system resulted in the phosphorylation of PROTEIN2 on tyrosine residues.
AIMed.d76.s643.p0	N	Further, anti- PROTEIN1 and anti- PROTEIN2 coprecipitated each other in a variety of detergents, including Nonidet P-40 and Triton X-100.
AIMed.d76.s644.p0	N	Anti- PROTEIN1 also precipitated the kinase from various T cells irrespective of the expression of PROTEIN2 / PROTEIN or PROTEIN .
AIMed.d76.s644.p1	N	Anti- PROTEIN1 also precipitated the kinase from various T cells irrespective of the expression of PROTEIN / PROTEIN2 or PROTEIN .
AIMed.d76.s644.p2	N	Anti- PROTEIN1 also precipitated the kinase from various T cells irrespective of the expression of PROTEIN / PROTEIN or PROTEIN2 .
AIMed.d76.s644.p4	N	Anti- PROTEIN also precipitated the kinase from various T cells irrespective of the expression of PROTEIN1 / PROTEIN or PROTEIN2 .
AIMed.d76.s644.p5	N	Anti- PROTEIN also precipitated the kinase from various T cells irrespective of the expression of PROTEIN / PROTEIN1 or PROTEIN2 .
AIMed.d76.s645.p0	N	No binding between PROTEIN1 (T) and PROTEIN2 was detected in T cells.
AIMed.d76.s646.p0	P	The binding of PROTEIN1 to PROTEIN2 induced a 10- to 15-fold increase in PROTEIN catalytic activity, as measured by in vitro kinase analysis.
AIMed.d76.s646.p1	N	The binding of PROTEIN1 to PROTEIN induced a 10- to 15-fold increase in PROTEIN2 catalytic activity, as measured by in vitro kinase analysis.
AIMed.d76.s646.p2	N	The binding of PROTEIN to PROTEIN1 induced a 10- to 15-fold increase in PROTEIN2 catalytic activity, as measured by in vitro kinase analysis.
AIMed.d76.s647.p0	P	In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in PROTEIN1 when associated with PROTEIN2 .
AIMed.d76.s648.p0	P	The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of PROTEIN1 could recognize PROTEIN2 as expressed in the baculovirus expression system.
AIMed.d76.s649.p2	N	PROTEIN1 interaction w PROTEIN  PROTEIN represents a novel variant of a receptor-kinas PROTEIN2 ex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )
AIMed.d76.s649.p3	N	PROTEIN interaction w PROTEIN1  PROTEIN2 represents a novel variant of a receptor-kinas PROTEIN ex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )
AIMed.d76.s649.p4	N	PROTEIN interaction w PROTEIN1  PROTEIN represents a novel variant of a receptor-kinas PROTEIN2 ex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )
AIMed.d76.s649.p5	N	PROTEIN interaction w PROTEIN  PROTEIN1 represents a novel variant of a receptor-kinas PROTEIN2 ex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )
AIMed.d77.s652.p0	N	PROTEIN1 ( PROTEIN2 ), a desmosomal component lacking a transmembrane domain, has been implicated in this interaction, although most studies have been conducted with cells that contain few or no desmosomes, and efforts to demonstrate direct interactions between desmoplakin and intermediate filaments have not been successful.
AIMed.d77.s654.p0	P	We show that the carboxy terminal "tail" of PROTEIN1 associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN .
AIMed.d77.s654.p1	P	We show that the carboxy terminal "tail" of PROTEIN1 associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d77.s654.p2	P	We show that the carboxy terminal "tail" of PROTEIN1 associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d77.s654.p3	P	We show that the carboxy terminal "tail" of PROTEIN1 associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d77.s654.p4	N	We show that the carboxy terminal "tail" of PROTEIN associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d77.s654.p6	N	We show that the carboxy terminal "tail" of PROTEIN associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d77.s654.p8	N	We show that the carboxy terminal "tail" of PROTEIN associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 .
AIMed.d77.s654.p9	N	We show that the carboxy terminal "tail" of PROTEIN associates directly with the amino terminal "head" of type II epidermal keratins, including PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 .
AIMed.d77.s655.p0	P	We have engineered and purified recombinant PROTEIN1 head and PROTEIN2 tail, and we demonstrate direct interaction in vitro by solution-binding assays and by ligand blot assays.
AIMed.d77.s657.p0	P	We have identified an 18-amino acid residue stretch in the PROTEIN1 head that is conserved only among type II epidermal keratins and that appears to play some role in PROTEIN2 tail binding.
AIMed.d78.s659.p0	N	A newly identified member of tumor necrosis factor receptor superfamily ( PROTEIN1 ) suppresses PROTEIN2 -mediated apoptosis .
AIMed.d78.s660.p0	N	PROTEIN1 ( PROTEIN2 ( PROTEIN ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .
AIMed.d78.s660.p1	N	PROTEIN1 ( PROTEIN ( PROTEIN2 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .
AIMed.d78.s660.p2	N	PROTEIN ( PROTEIN1 ( PROTEIN2 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .
AIMed.d78.s665.p0	P	Here , we demonstrate that PROTEIN1 specifically binds two cellular ligands , PROTEIN2 ( PROTEIN ) and PROTEIN ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p1	P	Here , we demonstrate that PROTEIN1 specifically binds two cellular ligands , PROTEIN ( PROTEIN2 ) and PROTEIN ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p3	P	Here , we demonstrate that PROTEIN1 specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN2 ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p4	P	Here , we demonstrate that PROTEIN1 specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN2 / PROTEIN ) .
AIMed.d78.s665.p5	P	Here , we demonstrate that PROTEIN1 specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN / PROTEIN2 ) .
AIMed.d78.s665.p6	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p8	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p9	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 / PROTEIN ) .
AIMed.d78.s665.p12	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN / PROTEIN ) .
AIMed.d78.s665.p13	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 / PROTEIN ) .
AIMed.d78.s665.p18	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 / PROTEIN ) .
AIMed.d78.s665.p19	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN / PROTEIN2 ) .
AIMed.d78.s665.p20	N	Here , we demonstrate that PROTEIN specifically binds two cellular ligands , PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 / PROTEIN2 ) .
AIMed.d78.s667.p0	N	PROTEIN1 inhibited PROTEIN2 -induced cytotoxicity in HT29 cells .
AIMed.d78.s668.p1	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN2 ( PROTEIN ) and PROTEIN / PROTEIN receptors .
AIMed.d78.s668.p2	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN2 ) and PROTEIN / PROTEIN receptors .
AIMed.d78.s668.p3	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN2 / PROTEIN receptors .
AIMed.d78.s668.p4	N	It has been shown that PROTEIN1 triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN / PROTEIN2 receptors .
AIMed.d78.s668.p10	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN1 ( PROTEIN ) and PROTEIN2 / PROTEIN receptors .
AIMed.d78.s668.p12	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN1 ) and PROTEIN2 / PROTEIN receptors .
AIMed.d78.s668.p13	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN1 ) and PROTEIN / PROTEIN2 receptors .
AIMed.d78.s668.p14	N	It has been shown that PROTEIN triggers apoptosis of various tumor cells including HT29 cells that express both PROTEIN ( PROTEIN ) and PROTEIN1 / PROTEIN2 receptors .
AIMed.d78.s669.p0	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN2 with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p1	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN2 / PROTEIN and PROTEIN , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p3	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p4	N	Our data suggest that PROTEIN1 inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 -mediated HT29 cell death .
AIMed.d78.s669.p5	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN2 / PROTEIN and PROTEIN , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p6	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN2 and PROTEIN , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p7	P	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p8	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN1 with PROTEIN / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 -mediated HT29 cell death .
AIMed.d78.s669.p9	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN2 and PROTEIN , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p10	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN and PROTEIN2 , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p11	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN1 / PROTEIN and PROTEIN , thereby suppressing PROTEIN2 -mediated HT29 cell death .
AIMed.d78.s669.p12	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN1 and PROTEIN2 , thereby suppressing PROTEIN -mediated HT29 cell death .
AIMed.d78.s669.p13	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN1 and PROTEIN , thereby suppressing PROTEIN2 -mediated HT29 cell death .
AIMed.d78.s669.p14	N	Our data suggest that PROTEIN inhibits the interactions of PROTEIN with PROTEIN / PROTEIN and PROTEIN1 , thereby suppressing PROTEIN2 -mediated HT29 cell death .
AIMed.d78.s670.p0	N	Thus , PROTEIN1 may play a regulatory role for suppressing in PROTEIN2 - and PROTEIN -mediated cell death .
AIMed.d78.s670.p1	N	Thus , PROTEIN1 may play a regulatory role for suppressing in PROTEIN - and PROTEIN2 -mediated cell death .
AIMed.d78.s670.p2	N	Thus , PROTEIN may play a regulatory role for suppressing in PROTEIN1 - and PROTEIN2 -mediated cell death .
AIMed.d79.s671.p0	P	The PROTEIN1 protein binds to PROTEIN2 , a zinc-finger protein that shares an epitope with the adenovirus PROTEIN protein.
AIMed.d79.s671.p1	N	The PROTEIN1 protein binds to PROTEIN , a zinc-finger protein that shares an epitope with the adenovirus PROTEIN2 protein.
AIMed.d79.s671.p2	N	The PROTEIN protein binds to PROTEIN1 , a zinc-finger protein that shares an epitope with the adenovirus PROTEIN2 protein.
AIMed.d79.s672.p0	N	The PROTEIN1 ( PROTEIN2 ) is a target of viral oncoproteins.
AIMed.d79.s676.p0	N	It contains an PROTEIN1 -binding motif that shares an antigenic epitope with the C terminus of PROTEIN2 .
AIMed.d79.s677.p0	N	A domain is conserved between PROTEIN1 and the PROTEIN2 / PROTEIN differentiation factor.
AIMed.d79.s677.p1	N	A domain is conserved between PROTEIN1 and the PROTEIN / PROTEIN2 differentiation factor.
AIMed.d79.s677.p2	N	A domain is conserved between PROTEIN and the PROTEIN1 / PROTEIN2 differentiation factor.
AIMed.d79.s681.p0	N	While the function of PROTEIN1 is not yet clear, its structure and pattern of expression suggest a role for PROTEIN2 in transcriptional regulation during neuronal differentiation and pathogenesis of retinoblastoma.
AIMed.d80.s682.p0	P	PROTEIN1 , a novel death domain-containing protein, interacts with the death domain of PROTEIN2 and initiates apoptosis.
AIMed.d80.s683.p0	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN2 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p1	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN2 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p2	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN2 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p3	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN2 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p4	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN2 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p5	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p7	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p8	N	Using the cytoplasmic domain of PROTEIN1 in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p9	P	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN2 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p11	P	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN2 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p12	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN2 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p13	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p14	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p15	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p16	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN1 , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p17	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN2 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p18	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN - PROTEIN2 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p20	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p21	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p22	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p23	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN1 and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p24	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN2 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p25	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN , a mutant of PROTEIN2 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p26	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p27	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p28	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p29	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN1 - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p31	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN1 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p32	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN1 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p33	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN1 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p34	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN1 , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p35	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN1 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN2 - PROTEIN and PROTEIN - PROTEIN .
AIMed.d80.s683.p36	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN1 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p37	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN1 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p38	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN1 possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p39	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN1 - PROTEIN2 and PROTEIN - PROTEIN .
AIMed.d80.s683.p40	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN1 - PROTEIN and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p41	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN1 - PROTEIN and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p42	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN1 and PROTEIN2 - PROTEIN .
AIMed.d80.s683.p43	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN1 and PROTEIN - PROTEIN2 .
AIMed.d80.s683.p44	N	Using the cytoplasmic domain of PROTEIN in the yeast two-hybrid system, we have identified a novel interacting protein, PROTEIN , which binds PROTEIN and PROTEIN - PROTEIN , a mutant of PROTEIN possessing enhanced killing activity, but not the functionally inactive mutants PROTEIN - PROTEIN and PROTEIN1 - PROTEIN2 .
AIMed.d80.s684.p0	N	PROTEIN1 contains a death domain homologous to the death domains of PROTEIN2 and PROTEIN .
AIMed.d80.s684.p1	N	PROTEIN1 contains a death domain homologous to the death domains of PROTEIN and PROTEIN2 .
AIMed.d80.s684.p2	N	PROTEIN contains a death domain homologous to the death domains of PROTEIN1 and PROTEIN2 .
AIMed.d80.s685.p0	N	A point mutation in PROTEIN1 , analogous to the lpr mutation of PROTEIN2 , abolishes its ability to bind PROTEIN , suggesting a death domain to death domain interaction.
AIMed.d80.s685.p1	P	A point mutation in PROTEIN1 , analogous to the lpr mutation of PROTEIN , abolishes its ability to bind PROTEIN2 , suggesting a death domain to death domain interaction.
AIMed.d80.s685.p2	N	A point mutation in PROTEIN , analogous to the lpr mutation of PROTEIN1 , abolishes its ability to bind PROTEIN2 , suggesting a death domain to death domain interaction.
AIMed.d80.s686.p0	N	Overexpression of PROTEIN1 in MCF7 and BJAB cells induces apoptosis, which, like PROTEIN2 -induced apoptosis, is blocked by PROTEIN , a specific inhibitor of the PROTEIN .
AIMed.d80.s686.p1	N	Overexpression of PROTEIN1 in MCF7 and BJAB cells induces apoptosis, which, like PROTEIN -induced apoptosis, is blocked by PROTEIN2 , a specific inhibitor of the PROTEIN .
AIMed.d80.s686.p3	N	Overexpression of PROTEIN1 in MCF7 and BJAB cells induces apoptosis, which, like PROTEIN -induced apoptosis, is blocked by PROTEIN , a specific inhibitor of the PROTEIN2 .
AIMed.d80.s686.p4	N	Overexpression of PROTEIN in MCF7 and BJAB cells induces apoptosis, which, like PROTEIN1 -induced apoptosis, is blocked by PROTEIN2 , a specific inhibitor of the PROTEIN .
AIMed.d80.s686.p6	N	Overexpression of PROTEIN in MCF7 and BJAB cells induces apoptosis, which, like PROTEIN1 -induced apoptosis, is blocked by PROTEIN , a specific inhibitor of the PROTEIN2 .
AIMed.d80.s687.p0	N	These findings suggest that PROTEIN1 may play an important role in the proximal signal transduction of PROTEIN2 .
AIMed.d81.s688.p0	P	PROTEIN1 : a novel protein containing a death domain that interacts with PROTEIN2 / PROTEIN ( PROTEIN ) in yeast and causes cell death.
AIMed.d81.s688.p1	P	PROTEIN1 : a novel protein containing a death domain that interacts with PROTEIN / PROTEIN2 ( PROTEIN ) in yeast and causes cell death.
AIMed.d81.s688.p2	P	PROTEIN1 : a novel protein containing a death domain that interacts with PROTEIN / PROTEIN ( PROTEIN2 ) in yeast and causes cell death.
AIMed.d81.s688.p3	N	PROTEIN : a novel protein containing a death domain that interacts with PROTEIN1 / PROTEIN2 ( PROTEIN ) in yeast and causes cell death.
AIMed.d81.s688.p4	N	PROTEIN : a novel protein containing a death domain that interacts with PROTEIN1 / PROTEIN ( PROTEIN2 ) in yeast and causes cell death.
AIMed.d81.s688.p5	N	PROTEIN : a novel protein containing a death domain that interacts with PROTEIN / PROTEIN1 ( PROTEIN2 ) in yeast and causes cell death.
AIMed.d81.s689.p0	N	Ligation of the extracellular domain of the cell surface receptor PROTEIN1 / PROTEIN2 ( PROTEIN ) elicits a characteristic programmed death response in susceptible cells.
AIMed.d81.s689.p1	N	Ligation of the extracellular domain of the cell surface receptor PROTEIN1 / PROTEIN ( PROTEIN2 ) elicits a characteristic programmed death response in susceptible cells.
AIMed.d81.s689.p2	N	Ligation of the extracellular domain of the cell surface receptor PROTEIN / PROTEIN1 ( PROTEIN2 ) elicits a characteristic programmed death response in susceptible cells.
AIMed.d81.s690.p2	P	Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of PROTEIN1 : PROTEIN itself, and a novel 74 kDa protein we have named PROTEIN , for PROTEIN2 .
AIMed.d81.s690.p3	N	Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of PROTEIN : PROTEIN1 itself, and a novel 74 kDa protein we have named PROTEIN2 , for PROTEIN .
AIMed.d81.s690.p4	N	Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of PROTEIN : PROTEIN1 itself, and a novel 74 kDa protein we have named PROTEIN , for PROTEIN2 .
AIMed.d81.s690.p5	N	Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of PROTEIN : PROTEIN itself, and a novel 74 kDa protein we have named PROTEIN1 , for PROTEIN2 .
AIMed.d81.s691.p0	N	PROTEIN1 also interacts weakly with the PROTEIN2 tumor necrosis factor receptor ( PROTEIN ) intracellular domain, but not with a mutant version of PROTEIN corresponding to the murine lprcg mutation.
AIMed.d81.s691.p1	P	PROTEIN1 also interacts weakly with the PROTEIN tumor necrosis factor receptor ( PROTEIN2 ) intracellular domain, but not with a mutant version of PROTEIN corresponding to the murine lprcg mutation.
AIMed.d81.s691.p2	N	PROTEIN1 also interacts weakly with the PROTEIN tumor necrosis factor receptor ( PROTEIN ) intracellular domain, but not with a mutant version of PROTEIN2 corresponding to the murine lprcg mutation.
AIMed.d81.s691.p3	N	PROTEIN also interacts weakly with the PROTEIN1 tumor necrosis factor receptor ( PROTEIN2 ) intracellular domain, but not with a mutant version of PROTEIN corresponding to the murine lprcg mutation.
AIMed.d81.s691.p4	N	PROTEIN also interacts weakly with the PROTEIN1 tumor necrosis factor receptor ( PROTEIN ) intracellular domain, but not with a mutant version of PROTEIN2 corresponding to the murine lprcg mutation.
AIMed.d81.s691.p5	N	PROTEIN also interacts weakly with the PROTEIN tumor necrosis factor receptor ( PROTEIN1 ) intracellular domain, but not with a mutant version of PROTEIN2 corresponding to the murine lprcg mutation.
AIMed.d81.s692.p0	N	PROTEIN1 contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the PROTEIN2 and PROTEIN intracellular domains.
AIMed.d81.s692.p1	N	PROTEIN1 contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the PROTEIN and PROTEIN2 intracellular domains.
AIMed.d81.s692.p2	N	PROTEIN contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the PROTEIN1 and PROTEIN2 intracellular domains.
AIMed.d82.s695.p0	N	Identification of an 11-kDa PROTEIN1 -rapamycin-binding domain within the 289-kDa PROTEIN2 and characterization of a critical serine residue.
AIMed.d82.s697.p0	P	Previously, a mammalian protein that directly associates with PROTEIN1 -rapamycin has been identified and its encoding gene has been cloned from both human (designated PROTEIN2 ) [Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. (1994) Nature (London) 369, 756-758] and rat (designated PROTEIN ) [Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S.H. (1994) Cell 78, 35-43].
AIMed.d82.s697.p1	N	Previously, a mammalian protein that directly associates with PROTEIN1 -rapamycin has been identified and its encoding gene has been cloned from both human (designated PROTEIN ) [Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. (1994) Nature (London) 369, 756-758] and rat (designated PROTEIN2 ) [Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S.H. (1994) Cell 78, 35-43].
AIMed.d82.s699.p0	P	Using an in vitro transcription/translation assay method coupled with proteolysis studies, we have identified an 11-kDa PROTEIN1 -rapamycin-binding domain within PROTEIN2 .
AIMed.d83.s704.p0	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN1 ( PROTEIN2 ) with PROTEIN and not with the beta-components, PROTEIN and PROTEIN .
AIMed.d83.s704.p1	P	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN1 ( PROTEIN ) with PROTEIN2 and not with the beta-components, PROTEIN and PROTEIN .
AIMed.d83.s704.p2	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN1 ( PROTEIN ) with PROTEIN and not with the beta-components, PROTEIN2 and PROTEIN .
AIMed.d83.s704.p3	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN1 ( PROTEIN ) with PROTEIN and not with the beta-components, PROTEIN and PROTEIN2 .
AIMed.d83.s704.p4	P	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN1 ) with PROTEIN2 and not with the beta-components, PROTEIN and PROTEIN .
AIMed.d83.s704.p5	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN1 ) with PROTEIN and not with the beta-components, PROTEIN2 and PROTEIN .
AIMed.d83.s704.p6	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN1 ) with PROTEIN and not with the beta-components, PROTEIN and PROTEIN2 .
AIMed.d83.s704.p7	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN ) with PROTEIN1 and not with the beta-components, PROTEIN2 and PROTEIN .
AIMed.d83.s704.p8	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN ) with PROTEIN1 and not with the beta-components, PROTEIN and PROTEIN2 .
AIMed.d83.s704.p9	N	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of PROTEIN ( PROTEIN ) with PROTEIN and not with the beta-components, PROTEIN1 and PROTEIN2 .
AIMed.d83.s707.p0	N	Superposition of the PROTEIN1 and growth hormone structures showed that the location of these epitopes on PROTEIN2 is analogous to the location of the first and second receptor epitopes on the surface of growth hormone.
AIMed.d84.s711.p4	N	Evidence for a differential interaction of PROTEIN1 and the PROTEIN ( PROTEIN ) with the insulin-like growth factor-I (IGF-I) receptor  PROTEIN2 in the yeast two-hybrid system.
AIMed.d84.s711.p5	N	Evidence for a differential interaction of PROTEIN and the PROTEIN1 ( PROTEIN2 ) with the insulin-like growth factor-I (IGF-I) receptor  PROTEIN in the yeast two-hybrid system.
AIMed.d84.s711.p8	P	Evidence for a differential interaction of PROTEIN and the PROTEIN1 ( PROTEIN ) with the insulin-like growth factor-I (IGF-I) receptor  PROTEIN2 in the yeast two-hybrid system.
AIMed.d84.s712.p8	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN1 ( PROTEIN2 ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p9	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN1 ( PROTEIN ) and the PROTEIN2 ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p10	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN1 ( PROTEIN ) and the PROTEIN ( PROTEIN2 ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p13	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN1 ( PROTEIN ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN2 ( PROTEIN ).
AIMed.d84.s712.p14	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN1 ( PROTEIN ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN2 ).
AIMed.d84.s712.p15	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN1 ) and the PROTEIN2 ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p16	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN1 ) and the PROTEIN ( PROTEIN2 ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p17	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN1 ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN2 and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p19	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN1 ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN2 ( PROTEIN ).
AIMed.d84.s712.p20	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN1 ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN2 ).
AIMed.d84.s712.p21	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN1 ( PROTEIN2 ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p22	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN1 ( PROTEIN ) with their two known substrates PROTEIN2 and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p24	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN1 ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN2 ( PROTEIN ).
AIMed.d84.s712.p25	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN1 ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN2 ).
AIMed.d84.s712.p26	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN1 ) with their two known substrates PROTEIN2 and the PROTEIN ( PROTEIN ).
AIMed.d84.s712.p29	P	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN1 ) with their two known substrates PROTEIN and the PROTEIN ( PROTEIN2 ).
AIMed.d84.s712.p31	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN1 and the PROTEIN2 ( PROTEIN ).
AIMed.d84.s712.p35	N	Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN ) with their two known substrates PROTEIN and the PROTEIN1 ( PROTEIN2 ).
AIMed.d84.s713.p0	N	We also mapped the specific domains of the PROTEIN1 and PROTEIN2 participating in these interactions.
AIMed.d84.s714.p0	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN2 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p1	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN2 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p2	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN2 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p3	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN2 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p5	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p6	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p7	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p8	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p9	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p10	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN1 is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p11	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN2 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p12	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN2 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p13	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN2 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p14	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN2 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p15	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p16	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p17	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p18	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p19	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p20	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN1 and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p21	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN2 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p22	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN2 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p23	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN2 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p24	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p25	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p26	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p27	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p29	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN1 , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p30	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN2 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p31	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN2 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p32	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p33	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p34	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p35	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p36	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p37	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN1 and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p38	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN2 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p39	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p40	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p41	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p42	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p43	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p44	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN1 bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p45	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN2 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p46	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p47	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p48	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p49	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p50	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN1 in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p51	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN1 , PROTEIN2 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p53	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN1 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p54	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN1 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p55	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN1 , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p56	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN2 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p57	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p58	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p59	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p60	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN1 , and (iv) the amino-terminal domain of PROTEIN2 is required for its association with the PROTEIN and the PROTEIN .
AIMed.d84.s714.p61	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN1 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p62	N	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN1 , and (iv) the amino-terminal domain of PROTEIN is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s714.p63	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN1 is required for its association with the PROTEIN2 and the PROTEIN .
AIMed.d84.s714.p64	P	Our findings can be summarized as follows: (i) the tyrosine kinase activity of the PROTEIN is essential for the interaction with PROTEIN and PROTEIN , (ii) PROTEIN and PROTEIN bind to the PROTEIN in the NPEY-juxtamembrane motif, (iii) contrary to PROTEIN , PROTEIN binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the PROTEIN , and (iv) the amino-terminal domain of PROTEIN1 is required for its association with the PROTEIN and the PROTEIN2 .
AIMed.d84.s715.p0	N	We propose that (i) the PROTEIN1 and the PROTEIN2 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p1	P	We propose that (i) the PROTEIN1 and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN2 and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p2	P	We propose that (i) the PROTEIN1 and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN2 , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p3	N	We propose that (i) the PROTEIN1 and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN2 interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p4	N	We propose that (i) the PROTEIN1 and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN2 in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p5	N	We propose that (i) the PROTEIN1 and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN2 .
AIMed.d84.s715.p6	P	We propose that (i) the PROTEIN and the PROTEIN1 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN2 and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p7	P	We propose that (i) the PROTEIN and the PROTEIN1 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN2 , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p8	N	We propose that (i) the PROTEIN and the PROTEIN1 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN2 interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p9	N	We propose that (i) the PROTEIN and the PROTEIN1 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN2 in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p10	N	We propose that (i) the PROTEIN and the PROTEIN1 share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN2 .
AIMed.d84.s715.p11	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN1 and PROTEIN2 , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p13	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN1 and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN2 in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p14	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN1 and PROTEIN , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN2 .
AIMed.d84.s715.p15	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN1 , and (ii) PROTEIN2 interacts with the PROTEIN in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p16	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN1 , and (ii) PROTEIN interacts with the PROTEIN2 in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p17	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN1 , and (ii) PROTEIN interacts with the PROTEIN in a fashion that is different from that used by PROTEIN2 .
AIMed.d84.s715.p18	P	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN1 interacts with the PROTEIN2 in a fashion that is different from that used by PROTEIN .
AIMed.d84.s715.p19	N	We propose that (i) the PROTEIN and the PROTEIN share at least in part the same molecular mechanism underlying their interplay with their two substrates, PROTEIN and PROTEIN , and (ii) PROTEIN1 interacts with the PROTEIN in a fashion that is different from that used by PROTEIN2 .
AIMed.d84.s716.p0	N	Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the PROTEIN1 and the PROTEIN2 .
AIMed.d85.s717.p0	P	PROTEIN1 physically associates with PROTEIN2 through Src homology 3 domains.
AIMed.d85.s718.p0	N	In the second of a series of experiments designed to identify PROTEIN1 -Src homology 3 (SH3)-binding molecules, we report the cloning of PROTEIN2 ( PROTEIN ) from an HL60 cDNA expression library.
AIMed.d85.s718.p1	N	In the second of a series of experiments designed to identify PROTEIN1 -Src homology 3 (SH3)-binding molecules, we report the cloning of PROTEIN ( PROTEIN2 ) from an HL60 cDNA expression library.
AIMed.d85.s718.p2	N	In the second of a series of experiments designed to identify PROTEIN -Src homology 3 (SH3)-binding molecules, we report the cloning of PROTEIN1 ( PROTEIN2 ) from an HL60 cDNA expression library.
AIMed.d85.s720.p0	P	Studies in vivo and in vitro demonstrated a highly specific interaction between the SH3 domains of PROTEIN1 and PROTEIN2 .
AIMed.d85.s722.p0	N	In vitro translation studies identified the 66-kDa protein as the protein product of PROTEIN1 , and subcellular fractionation experiments showed that PROTEIN2 is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.
AIMed.d85.s723.p0	P	The main PROTEIN1 region implicated in the association with PROTEIN2 was found to be the carboxy-terminal SH3 domain.
AIMed.d86.s728.p0	N	For the calibration, we used two sets of proteins, the PROTEIN1 - PROTEIN2 - PROTEIN helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
AIMed.d86.s728.p1	N	For the calibration, we used two sets of proteins, the PROTEIN1 - PROTEIN - PROTEIN2 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
AIMed.d86.s728.p2	N	For the calibration, we used two sets of proteins, the PROTEIN - PROTEIN1 - PROTEIN2 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
AIMed.d87.s733.p0	N	Interaction of PROTEIN1 subunit of PROTEIN2 with PROTEIN and PROTEIN receptors analysed by using the two-hybrid system.
AIMed.d87.s733.p1	N	Interaction of PROTEIN1 subunit of PROTEIN with PROTEIN2 and PROTEIN receptors analysed by using the two-hybrid system.
AIMed.d87.s733.p3	N	Interaction of PROTEIN subunit of PROTEIN1 with PROTEIN2 and PROTEIN receptors analysed by using the two-hybrid system.
AIMed.d87.s733.p4	N	Interaction of PROTEIN subunit of PROTEIN1 with PROTEIN and PROTEIN2 receptors analysed by using the two-hybrid system.
AIMed.d87.s733.p5	N	Interaction of PROTEIN subunit of PROTEIN with PROTEIN1 and PROTEIN2 receptors analysed by using the two-hybrid system.
AIMed.d87.s734.p0	N	Interaction of the PROTEIN1 subunit of PROTEIN2 with the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p2	N	Interaction of the PROTEIN1 subunit of PROTEIN with the PROTEIN2 ( PROTEIN ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p3	N	Interaction of the PROTEIN1 subunit of PROTEIN with the PROTEIN ( PROTEIN2 ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p8	P	Interaction of the PROTEIN subunit of PROTEIN1 with the PROTEIN2 ( PROTEIN ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p9	P	Interaction of the PROTEIN subunit of PROTEIN1 with the PROTEIN ( PROTEIN2 ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p11	P	Interaction of the PROTEIN subunit of PROTEIN1 with the PROTEIN ( PROTEIN ) and the PROTEIN2 ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p12	P	Interaction of the PROTEIN subunit of PROTEIN1 with the PROTEIN ( PROTEIN ) and the PROTEIN ( PROTEIN2 ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p18	N	Interaction of the PROTEIN subunit of PROTEIN with the PROTEIN1 ( PROTEIN2 ) and the PROTEIN ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p20	N	Interaction of the PROTEIN subunit of PROTEIN with the PROTEIN1 ( PROTEIN ) and the PROTEIN2 ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p21	N	Interaction of the PROTEIN subunit of PROTEIN with the PROTEIN1 ( PROTEIN ) and the PROTEIN ( PROTEIN2 ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p23	N	Interaction of the PROTEIN subunit of PROTEIN with the PROTEIN ( PROTEIN1 ) and the PROTEIN2 ( PROTEIN ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s734.p27	N	Interaction of the PROTEIN subunit of PROTEIN with the PROTEIN ( PROTEIN ) and the PROTEIN1 ( PROTEIN2 ) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
AIMed.d87.s735.p0	N	The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of PROTEIN1 and PROTEIN2 and PROTEIN or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
AIMed.d87.s735.p1	N	The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of PROTEIN1 and PROTEIN and PROTEIN2 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
AIMed.d87.s735.p2	N	The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of PROTEIN and PROTEIN1 and PROTEIN2 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
AIMed.d87.s736.p1	P	The results of his3 activation indicated that PROTEIN1 , N + C-SH2 and C-SH2 interact with both PROTEIN2 and PROTEIN , whereas N-SH2 and SH3 + N-SH2 interact only with PROTEIN .
AIMed.d87.s736.p3	P	The results of his3 activation indicated that PROTEIN1 , N + C-SH2 and C-SH2 interact with both PROTEIN and PROTEIN2 , whereas N-SH2 and SH3 + N-SH2 interact only with PROTEIN .
AIMed.d87.s736.p5	N	The results of his3 activation indicated that PROTEIN1 , N + C-SH2 and C-SH2 interact with both PROTEIN and PROTEIN , whereas N-SH2 and SH3 + N-SH2 interact only with PROTEIN2 .
AIMed.d87.s736.p12	N	The results of his3 activation indicated that PROTEIN , N + C-SH2 and C-SH2 interact with both PROTEIN1 and PROTEIN2 , whereas N-SH2 and SH3 + N-SH2 interact only with PROTEIN .
AIMed.d87.s736.p19	N	The results of his3 activation indicated that PROTEIN , N + C-SH2 and C-SH2 interact with both PROTEIN and PROTEIN1 , whereas N-SH2 and SH3 + N-SH2 interact only with PROTEIN2 .
AIMed.d87.s737.p0	P	Interaction of PROTEIN1 and N+C-SH2 with PROTEIN2 ( PROTEIN ) or PROTEIN ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p1	N	Interaction of PROTEIN1 and N+C-SH2 with PROTEIN ( PROTEIN2 ) or PROTEIN ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p3	P	Interaction of PROTEIN1 and N+C-SH2 with PROTEIN ( PROTEIN ) or PROTEIN2 ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p4	N	Interaction of PROTEIN1 and N+C-SH2 with PROTEIN ( PROTEIN ) or PROTEIN ( PROTEIN2 ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p5	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN1 ( PROTEIN2 ) or PROTEIN ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p7	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN1 ( PROTEIN ) or PROTEIN2 ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p8	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN1 ( PROTEIN ) or PROTEIN ( PROTEIN2 ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p10	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN ( PROTEIN1 ) or PROTEIN2 ( PROTEIN ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p11	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN ( PROTEIN1 ) or PROTEIN ( PROTEIN2 ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s737.p14	N	Interaction of PROTEIN and N+C-SH2 with PROTEIN ( PROTEIN ) or PROTEIN1 ( PROTEIN2 ) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
AIMed.d87.s738.p0	N	The internal binding site thus revealed was not altered by further mutating Y960/F for PROTEIN1 or Y950/F for PROTEIN2 .
AIMed.d87.s739.p0	P	Activation of lacZ upon interaction of PROTEIN1 with PROTEIN2 ( PROTEIN ) was 4-fold less as compared to PROTEIN .
AIMed.d87.s739.p1	N	Activation of lacZ upon interaction of PROTEIN1 with PROTEIN ( PROTEIN2 ) was 4-fold less as compared to PROTEIN .
AIMed.d87.s739.p2	P	Activation of lacZ upon interaction of PROTEIN1 with PROTEIN ( PROTEIN ) was 4-fold less as compared to PROTEIN2 .
AIMed.d87.s739.p3	N	Activation of lacZ upon interaction of PROTEIN with PROTEIN1 ( PROTEIN2 ) was 4-fold less as compared to PROTEIN .
AIMed.d87.s739.p4	N	Activation of lacZ upon interaction of PROTEIN with PROTEIN1 ( PROTEIN ) was 4-fold less as compared to PROTEIN2 .
AIMed.d87.s739.p5	N	Activation of lacZ upon interaction of PROTEIN with PROTEIN ( PROTEIN1 ) was 4-fold less as compared to PROTEIN2 .
AIMed.d87.s740.p1	P	This activation with PROTEIN1 and PROTEIN2 was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN ( PROTEIN 3).
AIMed.d87.s740.p2	P	This activation with PROTEIN1 and PROTEIN was 4-fold less as compared to PROTEIN2 and was somewhat increased (2-fold) for PROTEIN ( PROTEIN 3).
AIMed.d87.s740.p4	P	This activation with PROTEIN1 and PROTEIN was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN2 ( PROTEIN 3).
AIMed.d87.s740.p5	N	This activation with PROTEIN1 and PROTEIN was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN ( PROTEIN2 3).
AIMed.d87.s740.p11	N	This activation with PROTEIN and PROTEIN1 was 4-fold less as compared to PROTEIN2 and was somewhat increased (2-fold) for PROTEIN ( PROTEIN 3).
AIMed.d87.s740.p13	N	This activation with PROTEIN and PROTEIN1 was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN2 ( PROTEIN 3).
AIMed.d87.s740.p14	N	This activation with PROTEIN and PROTEIN1 was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN ( PROTEIN2 3).
AIMed.d87.s740.p17	N	This activation with PROTEIN and PROTEIN was 4-fold less as compared to PROTEIN1 and was somewhat increased (2-fold) for PROTEIN ( PROTEIN2 3).
AIMed.d87.s740.p20	N	This activation with PROTEIN and PROTEIN was 4-fold less as compared to PROTEIN and was somewhat increased (2-fold) for PROTEIN1 ( PROTEIN2 3).
AIMed.d87.s741.p0	P	Thus, the C-terminal domain in PROTEIN1 appears to exert a negative control on binding of PROTEIN2 thereby providing a possible regulatory mechanism for direct activation of the PROTEIN pathway.
AIMed.d87.s741.p1	N	Thus, the C-terminal domain in PROTEIN1 appears to exert a negative control on binding of PROTEIN thereby providing a possible regulatory mechanism for direct activation of the PROTEIN2 pathway.
AIMed.d87.s741.p2	N	Thus, the C-terminal domain in PROTEIN appears to exert a negative control on binding of PROTEIN1 thereby providing a possible regulatory mechanism for direct activation of the PROTEIN2 pathway.
AIMed.d88.s742.p0	P	Interaction of the protein PROTEIN1 with PROTEIN2 , as revealed by the yeast two-hybrid system.
AIMed.d88.s750.p0	N	Transfection of PROTEIN1 and PROTEIN2 in COS cells increased PROTEIN expression relative to cells transfected with PROTEIN and mock vector.
AIMed.d88.s750.p1	N	Transfection of PROTEIN1 and PROTEIN in COS cells increased PROTEIN2 expression relative to cells transfected with PROTEIN and mock vector.
AIMed.d88.s750.p2	N	Transfection of PROTEIN1 and PROTEIN in COS cells increased PROTEIN expression relative to cells transfected with PROTEIN2 and mock vector.
AIMed.d88.s750.p3	N	Transfection of PROTEIN and PROTEIN1 in COS cells increased PROTEIN2 expression relative to cells transfected with PROTEIN and mock vector.
AIMed.d88.s750.p4	N	Transfection of PROTEIN and PROTEIN1 in COS cells increased PROTEIN expression relative to cells transfected with PROTEIN2 and mock vector.
AIMed.d88.s750.p5	N	Transfection of PROTEIN and PROTEIN in COS cells increased PROTEIN1 expression relative to cells transfected with PROTEIN2 and mock vector.
AIMed.d89.s753.p0	P	The mitogenic effects of the PROTEIN1 are mediated through cell surface PROTEIN2 .
AIMed.d89.s761.p0	N	Immunoprecipitation experiments employing a polyclonal anti- PROTEIN1 antibody provided further evidence that the 60-kDa protein isolated in this study was PROTEIN2 .
AIMed.d89.s762.p0	N	Further, polyclonal antibodies to human PROTEIN1 significantly inhibited the mitogenic activity of PROTEIN2 on human fibroblasts.
AIMed.d89.s763.p0	P	The present study has shown that cell surface PROTEIN1 binds to the PROTEIN2 mediating its mitogenic activity.
AIMed.d90.s764.p0	N	Multiple proteins physically interact with PROTEIN1 . Transcriptional synergy with PROTEIN2 (C/ PROTEIN , PROTEIN ).
AIMed.d90.s764.p1	N	Multiple proteins physically interact with PROTEIN1 . Transcriptional synergy with PROTEIN (C/ PROTEIN2 , PROTEIN ).
AIMed.d90.s764.p2	N	Multiple proteins physically interact with PROTEIN1 . Transcriptional synergy with PROTEIN (C/ PROTEIN , PROTEIN2 ).
AIMed.d90.s764.p3	N	Multiple proteins physically interact with PROTEIN . Transcriptional synergy with PROTEIN1 (C/ PROTEIN2 , PROTEIN ).
AIMed.d90.s764.p4	N	Multiple proteins physically interact with PROTEIN . Transcriptional synergy with PROTEIN1 (C/ PROTEIN , PROTEIN2 ).
AIMed.d90.s764.p5	N	Multiple proteins physically interact with PROTEIN . Transcriptional synergy with PROTEIN (C/ PROTEIN1 , PROTEIN2 ).
AIMed.d90.s767.p0	N	Using radiolabeled PROTEIN1 protein as a probe, we screened a B cell cDNA expression library and isolated a number of clones encoding PROTEIN2 interacting proteins.
AIMed.d90.s768.p0	N	Three of these clones encode DNA binding proteins ( PROTEIN1 , PROTEIN2 , and PROTEIN ), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
AIMed.d90.s768.p1	N	Three of these clones encode DNA binding proteins ( PROTEIN1 , PROTEIN , and PROTEIN2 ), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
AIMed.d90.s768.p2	N	Three of these clones encode DNA binding proteins ( PROTEIN , PROTEIN1 , and PROTEIN2 ), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
AIMed.d90.s769.p0	P	We have characterized the physical and functional interactions between PROTEIN1 and PROTEIN2 , a leucine zipper transcription factor implicated in inflammatory responses.
AIMed.d90.s770.p0	N	We found that deletion of the carboxyl-terminal 28 amino acids of PROTEIN1 disrupted PROTEIN2 - PROTEIN physical interaction.
AIMed.d90.s770.p2	P	We found that deletion of the carboxyl-terminal 28 amino acids of PROTEIN disrupted PROTEIN1 - PROTEIN2 physical interaction.
AIMed.d90.s773.p0	N	In transient expression assays, we found that PROTEIN1 and PROTEIN2 can functionally cooperate to synergistically activate transcription.
AIMed.d90.s774.p0	N	Electrophoretic mobility shift assays showed that PROTEIN1 and PROTEIN2 can simultaneously bind to adjacent DNA binding sites, but apparently do not influence the kinetics or affinity of each other's DNA binding.
AIMed.d91.s776.p0	N	Molecular cloning and expression of the 32-kDa subunit of human PROTEIN1 reveals interactions with PROTEIN2 and PROTEIN that mediate transcriptional activation.
AIMed.d91.s776.p1	N	Molecular cloning and expression of the 32-kDa subunit of human PROTEIN1 reveals interactions with PROTEIN and PROTEIN2 that mediate transcriptional activation.
AIMed.d91.s776.p2	N	Molecular cloning and expression of the 32-kDa subunit of human PROTEIN reveals interactions with PROTEIN1 and PROTEIN2 that mediate transcriptional activation.
AIMed.d91.s777.p0	N	Transcription factor PROTEIN1 consists of PROTEIN2 ( PROTEIN ) and at least eight PROTEIN -associated factors (TAFs).
AIMed.d91.s777.p1	N	Transcription factor PROTEIN1 consists of PROTEIN ( PROTEIN2 ) and at least eight PROTEIN -associated factors (TAFs).
AIMed.d91.s777.p2	N	Transcription factor PROTEIN1 consists of PROTEIN ( PROTEIN ) and at least eight PROTEIN2 -associated factors (TAFs).
AIMed.d91.s777.p3	N	Transcription factor PROTEIN consists of PROTEIN1 ( PROTEIN2 ) and at least eight PROTEIN -associated factors (TAFs).
AIMed.d91.s777.p5	N	Transcription factor PROTEIN consists of PROTEIN ( PROTEIN1 ) and at least eight PROTEIN2 -associated factors (TAFs).
AIMed.d91.s779.p0	N	Here we report the cloning, expression, and biochemical characterization of the 32-kDa subunit of human (h) PROTEIN1 , termed PROTEIN2 .
AIMed.d91.s780.p0	N	We find that PROTEIN1 is the human homologue of Drosophila PROTEIN2 .
AIMed.d91.s781.p0	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN1 , PROTEIN2 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p1	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN1 , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN2 ( PROTEIN ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p2	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN1 , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN2 ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p3	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN1 , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN ) as well as with the general transcription factor PROTEIN2 .
AIMed.d91.s781.p4	P	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN1 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN2 ( PROTEIN ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p5	P	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN1 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN2 ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p6	P	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN1 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN ) as well as with the general transcription factor PROTEIN2 .
AIMed.d91.s781.p7	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN1 ( PROTEIN2 ) as well as with the general transcription factor PROTEIN .
AIMed.d91.s781.p8	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN1 ( PROTEIN ) as well as with the general transcription factor PROTEIN2 .
AIMed.d91.s781.p9	N	In vitro protein-protein interaction assays reveal that as observed with Drosophila PROTEIN , PROTEIN interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator PROTEIN ( PROTEIN1 ) as well as with the general transcription factor PROTEIN2 .
AIMed.d91.s782.p0	N	Moreover, a partial recombinant PROTEIN1 complex containing PROTEIN2 was capable of mediating in vitro transcriptional activation by the PROTEIN activation domain.
AIMed.d91.s782.p2	N	Moreover, a partial recombinant PROTEIN complex containing PROTEIN1 was capable of mediating in vitro transcriptional activation by the PROTEIN2 activation domain.
AIMed.d92.s784.p0	N	A potential interaction of PROTEIN1 and PROTEIN2  PROTEIN receptors revealed by affinity crosslinking and immunoprecipitation.
AIMed.d92.s784.p1	N	A potential interaction of PROTEIN1 and PROTEIN  PROTEIN2 receptors revealed by affinity crosslinking and immunoprecipitation.
AIMed.d92.s784.p2	N	A potential interaction of PROTEIN and PROTEIN1  PROTEIN2 receptors revealed by affinity crosslinking and immunoprecipitation.
AIMed.d92.s785.p4	P	PROTEIN1 binds independently to two transmembrane receptors, the PROTEIN and the p140trk (trkA) tyrosine kinase receptor  PROTEIN2 , which are both co-expressed in the majority of neuronal cells that respond to PROTEIN .
AIMed.d92.s785.p5	N	PROTEIN1 binds independently to two transmembrane receptors, the PROTEIN and the p140trk (trkA) tyrosine kinase receptor  PROTEIN , which are both co-expressed in the majority of neuronal cells that respond to PROTEIN2 .
AIMed.d92.s785.p14	N	PROTEIN binds independently to two transmembrane receptors, the PROTEIN1 and the p140trk (trkA) tyrosine kinase receptor  PROTEIN , which are both co-expressed in the majority of neuronal cells that respond to PROTEIN2 .
AIMed.d92.s785.p20	N	PROTEIN binds independently to two transmembrane receptors, the PROTEIN and the p140trk (trkA) tyrosine kinase receptor  PROTEIN1 , which are both co-expressed in the majority of neuronal cells that respond to PROTEIN2 .
AIMed.d92.s787.p0	N	Here we have utilized affinity crosslinking agents with 125I-NGF to detect an association of PROTEIN1 and PROTEIN2 receptors in embryonic spinal cord and brain tissues enriched in the two receptors.
AIMed.d92.s788.p0	N	Although multimeric complexes of PROTEIN1 and PROTEIN2 were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN .
AIMed.d92.s788.p3	N	Although multimeric complexes of PROTEIN1 and PROTEIN were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN2 -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN .
AIMed.d92.s788.p4	N	Although multimeric complexes of PROTEIN1 and PROTEIN were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN2 .
AIMed.d92.s788.p6	N	Although multimeric complexes of PROTEIN and PROTEIN1 were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN2 complexes with PROTEIN -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN .
AIMed.d92.s788.p7	N	Although multimeric complexes of PROTEIN and PROTEIN1 were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN2 -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN .
AIMed.d92.s788.p8	N	Although multimeric complexes of PROTEIN and PROTEIN1 were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN2 .
AIMed.d92.s788.p12	N	Although multimeric complexes of PROTEIN and PROTEIN were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN1 complexes with PROTEIN2 -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN .
AIMed.d92.s788.p13	N	Although multimeric complexes of PROTEIN and PROTEIN were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN1 complexes with PROTEIN -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN2 .
AIMed.d92.s788.p14	N	Although multimeric complexes of PROTEIN and PROTEIN were not detected by affinity crosslinking, immunoprecipitation of cross-linked PROTEIN complexes with PROTEIN1 -specific antibodies resulted in selective immunoprecipitation of crosslinked PROTEIN2 .
AIMed.d92.s789.p0	N	Our results indicate that the PROTEIN1 and PROTEIN2 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity PROTEIN binding sites.
AIMed.d92.s789.p1	N	Our results indicate that the PROTEIN1 and PROTEIN receptors can potentially interact, and that such an association may be responsible for the generation of high affinity PROTEIN2 binding sites.
AIMed.d92.s789.p2	N	Our results indicate that the PROTEIN and PROTEIN1 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity PROTEIN2 binding sites.
AIMed.d94.s796.p0	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN1 , regulated on activation, normal T expressed and secreted ( PROTEIN2 ), and PROTEIN ( PROTEIN ), but the receptors involved have not been defined.
AIMed.d94.s796.p1	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN1 , regulated on activation, normal T expressed and secreted ( PROTEIN ), and PROTEIN2 ( PROTEIN ), but the receptors involved have not been defined.
AIMed.d94.s796.p2	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN1 , regulated on activation, normal T expressed and secreted ( PROTEIN ), and PROTEIN ( PROTEIN2 ), but the receptors involved have not been defined.
AIMed.d94.s796.p3	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN , regulated on activation, normal T expressed and secreted ( PROTEIN1 ), and PROTEIN2 ( PROTEIN ), but the receptors involved have not been defined.
AIMed.d94.s796.p4	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN , regulated on activation, normal T expressed and secreted ( PROTEIN1 ), and PROTEIN ( PROTEIN2 ), but the receptors involved have not been defined.
AIMed.d94.s796.p5	N	Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein PROTEIN , regulated on activation, normal T expressed and secreted ( PROTEIN ), and PROTEIN1 ( PROTEIN2 ), but the receptors involved have not been defined.
AIMed.d94.s797.p0	N	We have isolated a human cDNA encoding the first eosinophil-selective chemokine receptor, designated PROTEIN1 ( PROTEIN2 ).
AIMed.d94.s798.p0	N	PROTEIN1 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN2 (also known as the PROTEIN / PROTEIN receptor).
AIMed.d94.s798.p1	N	PROTEIN1 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN (also known as the PROTEIN2 / PROTEIN receptor).
AIMed.d94.s798.p2	N	PROTEIN1 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN (also known as the PROTEIN / PROTEIN2 receptor).
AIMed.d94.s798.p3	N	PROTEIN is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN1 (also known as the PROTEIN2 / PROTEIN receptor).
AIMed.d94.s798.p4	N	PROTEIN is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN1 (also known as the PROTEIN / PROTEIN2 receptor).
AIMed.d94.s798.p5	N	PROTEIN is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor PROTEIN (also known as the PROTEIN1 / PROTEIN2 receptor).
AIMed.d94.s799.p0	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN1  PROTEIN2 and PROTEIN were both potent agonists for PROTEIN and PROTEIN .
AIMed.d94.s799.p1	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN1  PROTEIN and PROTEIN2 were both potent agonists for PROTEIN and PROTEIN .
AIMed.d94.s799.p2	P	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN1  PROTEIN and PROTEIN were both potent agonists for PROTEIN2 and PROTEIN .
AIMed.d94.s799.p3	P	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN1  PROTEIN and PROTEIN were both potent agonists for PROTEIN and PROTEIN2 .
AIMed.d94.s799.p4	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN1 and PROTEIN2 were both potent agonists for PROTEIN and PROTEIN .
AIMed.d94.s799.p5	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN1 and PROTEIN were both potent agonists for PROTEIN2 and PROTEIN .
AIMed.d94.s799.p6	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN1 and PROTEIN were both potent agonists for PROTEIN and PROTEIN2 .
AIMed.d94.s799.p7	P	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN and PROTEIN1 were both potent agonists for PROTEIN2 and PROTEIN .
AIMed.d94.s799.p8	P	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN and PROTEIN1 were both potent agonists for PROTEIN and PROTEIN2 .
AIMed.d94.s799.p9	N	When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, PROTEIN  PROTEIN and PROTEIN were both potent agonists for PROTEIN1 and PROTEIN2 .
AIMed.d94.s800.p0	P	However, PROTEIN1 was also an agonist for PROTEIN2 but not PROTEIN ; PROTEIN was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p1	N	However, PROTEIN1 was also an agonist for PROTEIN but not PROTEIN2 ; PROTEIN was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p2	N	However, PROTEIN1 was also an agonist for PROTEIN but not PROTEIN ; PROTEIN2 was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p3	N	However, PROTEIN1 was also an agonist for PROTEIN but not PROTEIN ; PROTEIN was an agonist for PROTEIN2 but not PROTEIN .
AIMed.d94.s800.p5	N	However, PROTEIN was also an agonist for PROTEIN1 but not PROTEIN2 ; PROTEIN was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p6	N	However, PROTEIN was also an agonist for PROTEIN1 but not PROTEIN ; PROTEIN2 was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p7	N	However, PROTEIN was also an agonist for PROTEIN1 but not PROTEIN ; PROTEIN was an agonist for PROTEIN2 but not PROTEIN .
AIMed.d94.s800.p8	N	However, PROTEIN was also an agonist for PROTEIN1 but not PROTEIN ; PROTEIN was an agonist for PROTEIN but not PROTEIN2 .
AIMed.d94.s800.p9	N	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN1 ; PROTEIN2 was an agonist for PROTEIN but not PROTEIN .
AIMed.d94.s800.p10	N	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN1 ; PROTEIN was an agonist for PROTEIN2 but not PROTEIN .
AIMed.d94.s800.p11	N	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN1 ; PROTEIN was an agonist for PROTEIN but not PROTEIN2 .
AIMed.d94.s800.p12	P	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN ; PROTEIN1 was an agonist for PROTEIN2 but not PROTEIN .
AIMed.d94.s800.p13	N	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN ; PROTEIN1 was an agonist for PROTEIN but not PROTEIN2 .
AIMed.d94.s800.p14	N	However, PROTEIN was also an agonist for PROTEIN but not PROTEIN ; PROTEIN was an agonist for PROTEIN1 but not PROTEIN2 .
AIMed.d95.s802.p0	P	Mechanism of CDK activation revealed by the structure of a PROTEIN1 - PROTEIN2 complex.
AIMed.d95.s803.p0	P	The crystal structure of the human PROTEIN1 - PROTEIN2 ( PROTEIN )-ATP complex has been determined at 2.3 A resolution.
AIMed.d95.s803.p2	N	The crystal structure of the human PROTEIN - PROTEIN1 ( PROTEIN2 )-ATP complex has been determined at 2.3 A resolution.
AIMed.d96.s808.p0	P	It binds homophilically, i.e., PROTEIN1 on the surface of one cell binds to PROTEIN2 on an apposing cell, and the binding site lies within the immunoglobulin domain.
AIMed.d96.s811.p0	N	In this article, we demonstrate that PROTEIN1 associates with a complex containing PROTEIN2 - and PROTEIN in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.
AIMed.d96.s811.p1	P	In this article, we demonstrate that PROTEIN1 associates with a complex containing PROTEIN - and PROTEIN2 in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.
AIMed.d96.s811.p2	N	In this article, we demonstrate that PROTEIN associates with a complex containing PROTEIN1 - and PROTEIN2 in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.
AIMed.d96.s813.p0	P	In vitro binding studies demonstrated that the intracellular segment of PROTEIN1 binds directly to the intracellular domain of PROTEIN2 , but not to alpha- or PROTEIN .
AIMed.d96.s813.p1	N	In vitro binding studies demonstrated that the intracellular segment of PROTEIN1 binds directly to the intracellular domain of PROTEIN , but not to alpha- or PROTEIN2 .
AIMed.d96.s813.p2	N	In vitro binding studies demonstrated that the intracellular segment of PROTEIN binds directly to the intracellular domain of PROTEIN1 , but not to alpha- or PROTEIN2 .
AIMed.d96.s815.p0	N	After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PROTEIN1 , the cadherins associated with PROTEIN2 are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PROTEIN .
AIMed.d96.s815.p2	N	After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PROTEIN , the cadherins associated with PROTEIN1 are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PROTEIN2 .
AIMed.d97.s820.p1	N	Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( PROTEIN1 ), which is distantly related to PROTEIN , a PROTEIN2 from Caenorhabditis elegans.
AIMed.d97.s820.p2	N	Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( PROTEIN ), which is distantly related to PROTEIN1 , a PROTEIN2 from Caenorhabditis elegans.
AIMed.d97.s821.p0	N	In transfected COS-1 cells, PROTEIN1 / PROTEIN2 , and less efficiently PROTEIN , bound to PROTEIN .
AIMed.d97.s821.p1	N	In transfected COS-1 cells, PROTEIN1 / PROTEIN , and less efficiently PROTEIN2 , bound to PROTEIN .
AIMed.d97.s821.p2	P	In transfected COS-1 cells, PROTEIN1 / PROTEIN , and less efficiently PROTEIN , bound to PROTEIN2 .
AIMed.d97.s821.p3	N	In transfected COS-1 cells, PROTEIN / PROTEIN1 , and less efficiently PROTEIN2 , bound to PROTEIN .
AIMed.d97.s821.p4	P	In transfected COS-1 cells, PROTEIN / PROTEIN1 , and less efficiently PROTEIN , bound to PROTEIN2 .
AIMed.d97.s821.p5	P	In transfected COS-1 cells, PROTEIN / PROTEIN , and less efficiently PROTEIN1 , bound to PROTEIN2 .
AIMed.d97.s823.p0	N	Binding of PROTEIN1 / PROTEIN2 to PROTEIN was also observed in nontransfected cell lines.
AIMed.d97.s823.p2	P	Binding of PROTEIN / PROTEIN1 to PROTEIN2 was also observed in nontransfected cell lines.
AIMed.d97.s824.p0	P	Moreover, a transcriptional activation signal was transduced by PROTEIN1 in the presence of type I receptors after stimulation by PROTEIN2 / PROTEIN .
AIMed.d97.s824.p1	P	Moreover, a transcriptional activation signal was transduced by PROTEIN1 in the presence of type I receptors after stimulation by PROTEIN / PROTEIN2 .
AIMed.d97.s824.p2	N	Moreover, a transcriptional activation signal was transduced by PROTEIN in the presence of type I receptors after stimulation by PROTEIN1 / PROTEIN2 .
AIMed.d98.s832.p0	P	PROTEIN1 , which is known to bind 14-3-3 proteins, has recently been shown to associate with PROTEIN2 and to stimulate its phosphatase activity.
AIMed.d98.s833.p0	N	14-3-3 protein, however, has no effect on the PROTEIN1 -kinase activity of PROTEIN2 .
AIMed.d98.s834.p0	P	Instead, 14-3-3 may facilitate the association of PROTEIN1 with PROTEIN2 in vivo, participating in the linkage between mitogenic signaling and the cell cycle machinery.
AIMed.d99.s838.p0	N	The cloned PROTEIN1 gene encodes a member of a protein family that includes the yeast PROTEIN2 protein, a component of the transcriptional regulator PROTEIN / PROTEIN .
AIMed.d99.s838.p1	N	The cloned PROTEIN1 gene encodes a member of a protein family that includes the yeast PROTEIN protein, a component of the transcriptional regulator PROTEIN2 / PROTEIN .
AIMed.d99.s838.p2	N	The cloned PROTEIN1 gene encodes a member of a protein family that includes the yeast PROTEIN protein, a component of the transcriptional regulator PROTEIN / PROTEIN2 .
AIMed.d99.s838.p3	N	The cloned PROTEIN gene encodes a member of a protein family that includes the yeast PROTEIN1 protein, a component of the transcriptional regulator PROTEIN2 / PROTEIN .
AIMed.d99.s838.p4	N	The cloned PROTEIN gene encodes a member of a protein family that includes the yeast PROTEIN1 protein, a component of the transcriptional regulator PROTEIN / PROTEIN2 .
AIMed.d99.s838.p5	N	The cloned PROTEIN gene encodes a member of a protein family that includes the yeast PROTEIN protein, a component of the transcriptional regulator PROTEIN1 / PROTEIN2 .
AIMed.d99.s841.p0	P	PROTEIN1 protein interacts with PROTEIN2 protein and with PROTEIN protein, a subunit of the human RNA polymerase II transcription factor IIH.
AIMed.d99.s841.p1	P	PROTEIN1 protein interacts with PROTEIN protein and with PROTEIN2 protein, a subunit of the human RNA polymerase II transcription factor IIH.
AIMed.d99.s841.p2	N	PROTEIN protein interacts with PROTEIN1 protein and with PROTEIN2 protein, a subunit of the human RNA polymerase II transcription factor IIH.
AIMed.d100.s846.p0	N	Biochemical studies established that some coactivators are associated with the PROTEIN1 ( PROTEIN2 ) to form the PROTEIN complex.
AIMed.d100.s846.p1	N	Biochemical studies established that some coactivators are associated with the PROTEIN1 ( PROTEIN ) to form the PROTEIN2 complex.
AIMed.d100.s846.p2	N	Biochemical studies established that some coactivators are associated with the PROTEIN ( PROTEIN1 ) to form the PROTEIN2 complex.
AIMed.d100.s849.p0	N	The PROTEIN1 gene is identical to a gene, PROTEIN2 , (ref 7,8), implicated in cell-cycle progression.
AIMed.d100.s850.p0	P	Recombinant PROTEIN1 binds directly to PROTEIN2 both in vitro and in yeast, and participates in the formation of the PROTEIN complex.
AIMed.d100.s850.p2	N	Recombinant PROTEIN binds directly to PROTEIN1 both in vitro and in yeast, and participates in the formation of the PROTEIN2 complex.
AIMed.d100.s851.p0	N	This largest TAF may therefore play a central role in PROTEIN1 assembly by interacting with both PROTEIN2 and other TAFs, as well as serving to link the control of transcription to the cell cycle.
AIMed.d101.s852.p0	N	The bZIP domains of PROTEIN1 and PROTEIN2 mediate a physical association with the PROTEIN .
AIMed.d101.s852.p1	P	The bZIP domains of PROTEIN1 and PROTEIN mediate a physical association with the PROTEIN2 .
AIMed.d101.s852.p2	P	The bZIP domains of PROTEIN and PROTEIN1 mediate a physical association with the PROTEIN2 .
AIMed.d101.s853.p0	P	PROTEIN1 and PROTEIN2 oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.
AIMed.d101.s855.p0	N	The ability of PROTEIN1 and PROTEIN2 proteins to interact directly with the PROTEIN ( PROTEIN ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s855.p1	P	The ability of PROTEIN1 and PROTEIN proteins to interact directly with the PROTEIN2 ( PROTEIN ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s855.p2	P	The ability of PROTEIN1 and PROTEIN proteins to interact directly with the PROTEIN ( PROTEIN2 ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s855.p3	P	The ability of PROTEIN and PROTEIN1 proteins to interact directly with the PROTEIN2 ( PROTEIN ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s855.p4	P	The ability of PROTEIN and PROTEIN1 proteins to interact directly with the PROTEIN ( PROTEIN2 ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s855.p5	N	The ability of PROTEIN and PROTEIN proteins to interact directly with the PROTEIN1 ( PROTEIN2 ), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.
AIMed.d101.s856.p0	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN1 and PROTEIN2 bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p1	P	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN1 and PROTEIN bind specifically and stably to PROTEIN2 .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p2	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN1 and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN2 and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p3	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN1 and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN2 are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p4	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN1 and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN2 .
AIMed.d101.s856.p5	P	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN1 bind specifically and stably to PROTEIN2 .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p6	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN1 bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN2 and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p7	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN1 bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN2 are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p8	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN1 bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN2 .
AIMed.d101.s856.p9	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN1 .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN2 and PROTEIN are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p10	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN1 .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN2 are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p11	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN1 .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN are necessary and sufficient for stable association with PROTEIN2 .
AIMed.d101.s856.p12	N	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN1 and PROTEIN2 are necessary and sufficient for stable association with PROTEIN .
AIMed.d101.s856.p13	P	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN1 and PROTEIN are necessary and sufficient for stable association with PROTEIN2 .
AIMed.d101.s856.p14	P	Using co-immunoprecipitation and protein-protein association assays, we show that both PROTEIN and PROTEIN bind specifically and stably to PROTEIN .Mutational analysis demonstrates that both the basic region and leucine zipper domains of PROTEIN and PROTEIN1 are necessary and sufficient for stable association with PROTEIN2 .
AIMed.d101.s857.p0	P	A 51-residue region from the conserved C-terminal region of PROTEIN1 , previously shown to be the binding site for the viral activator protein PROTEIN2 , interacts with PROTEIN and PROTEIN proteins.
AIMed.d101.s857.p3	N	A 51-residue region from the conserved C-terminal region of PROTEIN , previously shown to be the binding site for the viral activator protein PROTEIN1 , interacts with PROTEIN2 and PROTEIN proteins.
AIMed.d101.s857.p4	N	A 51-residue region from the conserved C-terminal region of PROTEIN , previously shown to be the binding site for the viral activator protein PROTEIN1 , interacts with PROTEIN and PROTEIN2 proteins.
AIMed.d101.s857.p5	N	A 51-residue region from the conserved C-terminal region of PROTEIN , previously shown to be the binding site for the viral activator protein PROTEIN , interacts with PROTEIN1 and PROTEIN2 proteins.
AIMed.d101.s858.p0	N	We propose that PROTEIN1 and PROTEIN2 proteins function as transcriptional activators, in part by recruiting PROTEIN to form complexes to initiate RNA synthesis.
AIMed.d101.s858.p1	P	We propose that PROTEIN1 and PROTEIN proteins function as transcriptional activators, in part by recruiting PROTEIN2 to form complexes to initiate RNA synthesis.
AIMed.d101.s858.p2	P	We propose that PROTEIN and PROTEIN1 proteins function as transcriptional activators, in part by recruiting PROTEIN2 to form complexes to initiate RNA synthesis.
AIMed.d102.s859.p1	N	The PROTEIN1 -susceptibility gene product binds directly to the human PROTEIN2  PROTEIN .
AIMed.d102.s859.p2	P	The PROTEIN1 -susceptibility gene product binds directly to the human PROTEIN  PROTEIN2 .
AIMed.d102.s859.p5	N	The PROTEIN -susceptibility gene product binds directly to the human PROTEIN1  PROTEIN2 .
AIMed.d102.s860.p0	N	PROTEIN1 , the protein product of the PROTEIN2 tumor-suppressor gene, regulates the activity of specific transcription factors.
AIMed.d102.s862.p0	N	Here we report that stimulation of PROTEIN1 -mediated transcription by PROTEIN2 is partially abrogated at the nonpermissive temperature in ts13 cells.
AIMed.d102.s863.p4	N	These cells contain a temperature-sensitive mutation in the PROTEIN1  PROTEIN , first identified as the cell cycle regulatory protein PROTEIN2 .
AIMed.d102.s863.p5	N	These cells contain a temperature-sensitive mutation in the PROTEIN  PROTEIN1 , first identified as the cell cycle regulatory protein PROTEIN2 .
AIMed.d102.s864.p0	N	The stimulation of PROTEIN1 -mediated transcription by PROTEIN2 in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human PROTEIN .
AIMed.d102.s864.p1	N	The stimulation of PROTEIN1 -mediated transcription by PROTEIN in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human PROTEIN2 .
AIMed.d102.s864.p2	N	The stimulation of PROTEIN -mediated transcription by PROTEIN1 in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human PROTEIN2 .
AIMed.d102.s865.p0	P	Furthermore, we demonstrate that PROTEIN1 binds directly to PROTEIN2 in vitro and in vivo.
AIMed.d102.s866.p0	N	These results suggest that PROTEIN1 can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with PROTEIN2 , in particular with PROTEIN .
AIMed.d102.s866.p1	P	These results suggest that PROTEIN1 can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with PROTEIN , in particular with PROTEIN2 .
AIMed.d102.s866.p2	N	These results suggest that PROTEIN can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with PROTEIN1 , in particular with PROTEIN2 .
AIMed.d103.s867.p0	P	Cloning and characterization of PROTEIN1 , PROTEIN2 and PROTEIN : three subunits of the human transcription factor PROTEIN .
AIMed.d103.s867.p1	P	Cloning and characterization of PROTEIN1 , PROTEIN and PROTEIN2 : three subunits of the human transcription factor PROTEIN .
AIMed.d103.s867.p2	N	Cloning and characterization of PROTEIN1 , PROTEIN and PROTEIN : three subunits of the human transcription factor PROTEIN2 .
AIMed.d103.s867.p3	P	Cloning and characterization of PROTEIN , PROTEIN1 and PROTEIN2 : three subunits of the human transcription factor PROTEIN .
AIMed.d103.s867.p4	N	Cloning and characterization of PROTEIN , PROTEIN1 and PROTEIN : three subunits of the human transcription factor PROTEIN2 .
AIMed.d103.s868.p0	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN2 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p1	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN2 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p2	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN2 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p3	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN2 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p4	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN2 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p5	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p6	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p7	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p8	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p10	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p12	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p13	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p14	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p15	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p16	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN1 ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p17	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN2 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p18	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN2 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p19	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN2 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p20	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN2 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p21	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p22	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p23	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p24	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p26	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p28	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p29	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p30	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p31	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p32	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN1 )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p33	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN2 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p34	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN2 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p36	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p37	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p38	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p39	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p41	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p43	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p44	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p46	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p47	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN1 complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p48	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN2 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p49	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN2 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p50	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p51	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p52	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p53	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p55	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p57	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p58	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p60	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p61	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN1 , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p62	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN2 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p63	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p64	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p65	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p66	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p68	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p70	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p71	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p72	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p74	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN1 and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p75	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN2 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p76	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p77	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p78	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p80	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p82	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p83	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p84	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p85	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p86	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN1 . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p87	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN2 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p89	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p91	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p93	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p94	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p95	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p97	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN1 is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p98	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN2 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p99	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p101	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p103	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p104	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p105	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p106	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p107	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN1 present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p108	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN2 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p110	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p112	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p113	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p114	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p115	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p116	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN1 species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p118	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN1 ( PROTEIN2 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p120	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN1 ( PROTEIN and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p122	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN1 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p124	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN1 ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p133	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN1 and PROTEIN2 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p134	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN1 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN2 . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p135	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN1 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p136	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN1 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p137	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN1 and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p144	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN1 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p146	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN1 respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p147	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN1 . PROTEIN2 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p148	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN1 . PROTEIN is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p150	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN1 is a novel PROTEIN2 which shows homology to the N-terminal region of the yeast PROTEIN , but has no known Drosophila counterpart.
AIMed.d103.s868.p151	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN1 is a novel PROTEIN which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s868.p152	N	We have cloned cDNAs encoding three novel TAFIIs [ PROTEIN ( PROTEIN )-associated factors] from the human (h) HeLa cell PROTEIN complexes PROTEIN , PROTEIN and PROTEIN . PROTEIN is a core PROTEIN present in both of the previously described PROTEIN species which either lack or contain PROTEIN ( PROTEIN and PROTEIN respectively), and is the homologue of Drosophila (d) PROTEIN . PROTEIN is a novel PROTEIN1 which shows homology to the N-terminal region of the yeast PROTEIN2 , but has no known Drosophila counterpart.
AIMed.d103.s869.p0	N	In contrast to PROTEIN1 , PROTEIN2 is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p2	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN2 -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p3	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN -specific PROTEIN2 . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p4	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN2 is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p5	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN2 , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p6	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p7	N	In contrast to PROTEIN1 , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN2 ).
AIMed.d103.s869.p9	N	In contrast to PROTEIN , PROTEIN1 is a PROTEIN2 -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p10	N	In contrast to PROTEIN , PROTEIN1 is a PROTEIN -specific PROTEIN2 . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p12	N	In contrast to PROTEIN , PROTEIN1 is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN2 , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p13	N	In contrast to PROTEIN , PROTEIN1 is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p14	N	In contrast to PROTEIN , PROTEIN1 is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN2 ).
AIMed.d103.s869.p21	N	In contrast to PROTEIN , PROTEIN is a PROTEIN1 -specific PROTEIN2 . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p22	N	In contrast to PROTEIN , PROTEIN is a PROTEIN1 -specific PROTEIN . PROTEIN2 is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p23	N	In contrast to PROTEIN , PROTEIN is a PROTEIN1 -specific PROTEIN . PROTEIN is the homologue of PROTEIN2 , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p24	N	In contrast to PROTEIN , PROTEIN is a PROTEIN1 -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p25	N	In contrast to PROTEIN , PROTEIN is a PROTEIN1 -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN2 ).
AIMed.d103.s869.p26	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN1 . PROTEIN2 is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p27	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN1 . PROTEIN is the homologue of PROTEIN2 , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p28	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN1 . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p30	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN1 is the homologue of PROTEIN2 , an alternatively spliced form of d PROTEIN ( PROTEIN ).
AIMed.d103.s869.p31	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN1 is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p33	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN1 , an alternatively spliced form of d PROTEIN2 ( PROTEIN ).
AIMed.d103.s869.p34	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN1 , an alternatively spliced form of d PROTEIN ( PROTEIN2 ).
AIMed.d103.s869.p35	N	In contrast to PROTEIN , PROTEIN is a PROTEIN -specific PROTEIN . PROTEIN is the homologue of PROTEIN , an alternatively spliced form of d PROTEIN1 ( PROTEIN2 ).
AIMed.d103.s871.p0	P	We show that PROTEIN1 interacts with PROTEIN2 both in vitro and intracellularly; in contrast to its Drosophila homologue, PROTEIN also interacts directly with PROTEIN .
AIMed.d103.s871.p2	N	We show that PROTEIN1 interacts with PROTEIN both in vitro and intracellularly; in contrast to its Drosophila homologue, PROTEIN also interacts directly with PROTEIN2 .
AIMed.d103.s871.p3	N	We show that PROTEIN interacts with PROTEIN1 both in vitro and intracellularly; in contrast to its Drosophila homologue, PROTEIN2 also interacts directly with PROTEIN .
AIMed.d103.s871.p4	N	We show that PROTEIN interacts with PROTEIN1 both in vitro and intracellularly; in contrast to its Drosophila homologue, PROTEIN also interacts directly with PROTEIN2 .
AIMed.d103.s871.p5	P	We show that PROTEIN interacts with PROTEIN both in vitro and intracellularly; in contrast to its Drosophila homologue, PROTEIN1 also interacts directly with PROTEIN2 .
AIMed.d103.s872.p0	N	Deletion analysis indicates that PROTEIN1 and PROTEIN2 bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p1	P	Deletion analysis indicates that PROTEIN1 and PROTEIN bind to distinct domains of PROTEIN2 . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p2	N	Deletion analysis indicates that PROTEIN1 and PROTEIN bind to distinct domains of PROTEIN . PROTEIN2 also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p4	N	Deletion analysis indicates that PROTEIN1 and PROTEIN bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN2 and PROTEIN .
AIMed.d103.s872.p6	P	Deletion analysis indicates that PROTEIN and PROTEIN1 bind to distinct domains of PROTEIN2 . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p7	N	Deletion analysis indicates that PROTEIN and PROTEIN1 bind to distinct domains of PROTEIN . PROTEIN2 also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p8	N	Deletion analysis indicates that PROTEIN and PROTEIN1 bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN2 , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p9	N	Deletion analysis indicates that PROTEIN and PROTEIN1 bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN2 and PROTEIN .
AIMed.d103.s872.p13	N	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN1 . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN2 and PROTEIN .
AIMed.d103.s872.p14	N	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN1 . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN2 .
AIMed.d103.s872.p15	P	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN1 also interacts with PROTEIN2 , but it interacts more strongly with PROTEIN and PROTEIN .
AIMed.d103.s872.p16	P	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN1 also interacts with PROTEIN , but it interacts more strongly with PROTEIN2 and PROTEIN .
AIMed.d103.s872.p17	P	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN1 also interacts with PROTEIN , but it interacts more strongly with PROTEIN and PROTEIN2 .
AIMed.d103.s872.p18	N	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN1 , but it interacts more strongly with PROTEIN2 and PROTEIN .
AIMed.d103.s872.p19	N	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN1 , but it interacts more strongly with PROTEIN and PROTEIN2 .
AIMed.d103.s872.p20	N	Deletion analysis indicates that PROTEIN and PROTEIN bind to distinct domains of PROTEIN . PROTEIN also interacts with PROTEIN , but it interacts more strongly with PROTEIN1 and PROTEIN2 .
AIMed.d103.s873.p0	N	The binding of PROTEIN1 and PROTEIN2 requires distinct domains of PROTEIN .
AIMed.d103.s873.p1	P	The binding of PROTEIN1 and PROTEIN requires distinct domains of PROTEIN2 .
AIMed.d103.s873.p2	P	The binding of PROTEIN and PROTEIN1 requires distinct domains of PROTEIN2 .
AIMed.d103.s874.p0	P	As observed with the homologous Drosophila proteins, PROTEIN1 interacts directly with PROTEIN2 ; however, additional interactions between PROTEIN and PROTEIN or PROTEIN were detected.
AIMed.d103.s874.p1	N	As observed with the homologous Drosophila proteins, PROTEIN1 interacts directly with PROTEIN ; however, additional interactions between PROTEIN2 and PROTEIN or PROTEIN were detected.
AIMed.d103.s874.p3	N	As observed with the homologous Drosophila proteins, PROTEIN1 interacts directly with PROTEIN ; however, additional interactions between PROTEIN and PROTEIN or PROTEIN2 were detected.
AIMed.d103.s874.p4	N	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN1 ; however, additional interactions between PROTEIN2 and PROTEIN or PROTEIN were detected.
AIMed.d103.s874.p5	N	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN1 ; however, additional interactions between PROTEIN and PROTEIN2 or PROTEIN were detected.
AIMed.d103.s874.p6	N	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN1 ; however, additional interactions between PROTEIN and PROTEIN or PROTEIN2 were detected.
AIMed.d103.s874.p7	P	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN ; however, additional interactions between PROTEIN1 and PROTEIN2 or PROTEIN were detected.
AIMed.d103.s874.p8	P	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN ; however, additional interactions between PROTEIN1 and PROTEIN or PROTEIN2 were detected.
AIMed.d103.s874.p9	N	As observed with the homologous Drosophila proteins, PROTEIN interacts directly with PROTEIN ; however, additional interactions between PROTEIN and PROTEIN1 or PROTEIN2 were detected.
AIMed.d103.s875.p0	N	These results reveal differences not only in subunit composition, but also in the organization of PROTEIN1 and PROTEIN2 complexes.
AIMed.d104.s878.p0	N	This transcriptional activity is inhibited by association with the PROTEIN1 ( PROTEIN2 ) or its relatives PROTEIN and PROTEIN .
AIMed.d104.s878.p1	N	This transcriptional activity is inhibited by association with the PROTEIN1 ( PROTEIN ) or its relatives PROTEIN2 and PROTEIN .
AIMed.d104.s878.p2	N	This transcriptional activity is inhibited by association with the PROTEIN1 ( PROTEIN ) or its relatives PROTEIN and PROTEIN2 .
AIMed.d104.s878.p3	N	This transcriptional activity is inhibited by association with the PROTEIN ( PROTEIN1 ) or its relatives PROTEIN2 and PROTEIN .
AIMed.d104.s878.p4	N	This transcriptional activity is inhibited by association with the PROTEIN ( PROTEIN1 ) or its relatives PROTEIN and PROTEIN2 .
AIMed.d104.s878.p5	N	This transcriptional activity is inhibited by association with the PROTEIN ( PROTEIN ) or its relatives PROTEIN1 and PROTEIN2 .
AIMed.d104.s879.p0	N	The first cDNA from the PROTEIN1 family to be cloned was designated PROTEIN2 , and multiple PROTEIN family members have now been identified.
AIMed.d104.s879.p1	N	The first cDNA from the PROTEIN1 family to be cloned was designated PROTEIN , and multiple PROTEIN2 family members have now been identified.
AIMed.d104.s879.p2	N	The first cDNA from the PROTEIN family to be cloned was designated PROTEIN1 , and multiple PROTEIN2 family members have now been identified.
AIMed.d104.s881.p0	N	Here we demonstrate that DP is also a family of polypeptides with at least two members ( PROTEIN1 and PROTEIN2 ).
AIMed.d104.s882.p0	N	Both PROTEIN1 and PROTEIN2 bind to all PROTEIN family members in vivo, and each complex is capable of activating transcription.
AIMed.d104.s882.p1	N	Both PROTEIN1 and PROTEIN bind to all PROTEIN2 family members in vivo, and each complex is capable of activating transcription.
AIMed.d104.s882.p2	N	Both PROTEIN and PROTEIN1 bind to all PROTEIN2 family members in vivo, and each complex is capable of activating transcription.
AIMed.d104.s883.p0	N	However, the various PROTEIN1 /DP complexes display strong differences in the ability to bind to either PROTEIN2 or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p1	N	However, the various PROTEIN1 /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN2 in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p2	N	However, the various PROTEIN1 /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN in vivo, and the specificity of PROTEIN2 or PROTEIN binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p3	N	However, the various PROTEIN1 /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN2 binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p4	N	However, the various PROTEIN1 /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN2 subunit.
AIMed.d104.s883.p5	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN1 or PROTEIN2 in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p7	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN1 or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN2 binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p8	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN1 or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN2 subunit.
AIMed.d104.s883.p9	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN1 in vivo, and the specificity of PROTEIN2 or PROTEIN binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p10	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN1 in vivo, and the specificity of PROTEIN or PROTEIN2 binding is mediated by the PROTEIN subunit.
AIMed.d104.s883.p11	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN1 in vivo, and the specificity of PROTEIN or PROTEIN binding is mediated by the PROTEIN2 subunit.
AIMed.d104.s883.p14	N	However, the various PROTEIN /DP complexes display strong differences in the ability to bind to either PROTEIN or PROTEIN in vivo, and the specificity of PROTEIN or PROTEIN1 binding is mediated by the PROTEIN2 subunit.
AIMed.d105.s884.p0	P	Two distinct and independent sites on PROTEIN1 trigger PROTEIN2 dimer formation and signalling.
AIMed.d105.s885.p0	P	The helical cytokine PROTEIN1 and its specific binding subunit PROTEIN2 form a 1:1 complex which, by promoting homodimerization of the signalling subunit PROTEIN on the surface of target cells, triggers intracellular responses.
AIMed.d105.s885.p1	N	The helical cytokine PROTEIN1 and its specific binding subunit PROTEIN form a 1:1 complex which, by promoting homodimerization of the signalling subunit PROTEIN2 on the surface of target cells, triggers intracellular responses.
AIMed.d105.s885.p2	N	The helical cytokine PROTEIN and its specific binding subunit PROTEIN1 form a 1:1 complex which, by promoting homodimerization of the signalling subunit PROTEIN2 on the surface of target cells, triggers intracellular responses.
AIMed.d105.s886.p0	N	We expressed differently tagged forms of PROTEIN1 and used them in solution-phase binding assays to show that the soluble extracellular domains of PROTEIN2 undergo dimerization in the absence of membranes.
AIMed.d105.s889.p0	P	We demonstrate here that both the site 2 and site 3 PROTEIN1 variants complexed with PROTEIN2 bind a single PROTEIN molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with PROTEIN .
AIMed.d105.s889.p1	P	We demonstrate here that both the site 2 and site 3 PROTEIN1 variants complexed with PROTEIN bind a single PROTEIN2 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with PROTEIN .
AIMed.d105.s889.p2	N	We demonstrate here that both the site 2 and site 3 PROTEIN1 variants complexed with PROTEIN bind a single PROTEIN molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with PROTEIN2 .
AIMed.d105.s889.p3	P	We demonstrate here that both the site 2 and site 3 PROTEIN variants complexed with PROTEIN1 bind a single PROTEIN2 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with PROTEIN .
AIMed.d105.s889.p4	N	We demonstrate here that both the site 2 and site 3 PROTEIN variants complexed with PROTEIN1 bind a single PROTEIN molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with PROTEIN2 .
AIMed.d105.s890.p0	N	The binding properties of these variants in vitro, and the result of using a neutralizing monoclonal antibody directed against site 3, lead to the conclusion that PROTEIN1 dimer is formed through direct binding at two independent and differently oriented sites on PROTEIN2 .
AIMed.d105.s891.p0	P	Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two PROTEIN1 , two PROTEIN2 and two PROTEIN molecules.
AIMed.d105.s891.p1	P	Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two PROTEIN1 , two PROTEIN and two PROTEIN2 molecules.
AIMed.d105.s891.p2	P	Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two PROTEIN , two PROTEIN1 and two PROTEIN2 molecules.
AIMed.d106.s893.p0	P	PROTEIN1 interaction with PROTEIN2 ties mitogenic signal transduction to cell cycle activation.
AIMed.d106.s894.p0	N	The PROTEIN1 and PROTEIN2 proto-oncogenes transduce extracellular signals that promote cell growth.
AIMed.d106.s896.p0	P	We show here that PROTEIN1 associates with PROTEIN2 in somatic mammalian cells and in meiotic frog oocytes.
AIMed.d106.s897.p0	P	Furthermore, PROTEIN1 can be activated in vitro in a PROTEIN2 -dependent manner.
AIMed.d106.s898.p1	N	We suggest that activation of the cell cycle by the PROTEIN1 / PROTEIN pathways might be mediated in part by PROTEIN2 .
AIMed.d106.s898.p2	N	We suggest that activation of the cell cycle by the PROTEIN / PROTEIN1 pathways might be mediated in part by PROTEIN2 .
AIMed.d107.s899.p0	P	A direct interaction between PROTEIN1 subunits and the PROTEIN2 .
AIMed.d107.s900.p1	N	PROTEIN1 is a serine/threonine protein kinase positioned downstream of PROTEIN in the PROTEIN2 cascade.
AIMed.d107.s900.p2	N	PROTEIN is a serine/threonine protein kinase positioned downstream of PROTEIN1 in the PROTEIN2 cascade.
AIMed.d107.s901.p0	P	Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate PROTEIN1 , we isolated a clone encoding the carboxyl-terminal half of the PROTEIN2 of heterotrimeric G-proteins.
AIMed.d107.s902.p1	P	In vitro, purified PROTEIN1 subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of PROTEIN ( PROTEIN2 ).
AIMed.d107.s902.p2	N	In vitro, purified PROTEIN subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of PROTEIN1 ( PROTEIN2 ).
AIMed.d107.s903.p0	N	Binding assays with truncation mutants of GST- PROTEIN1 indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with PROTEIN2 .
AIMed.d107.s904.p1	N	In competition experiments, the carboxyl terminus of PROTEIN1 ( PROTEIN ) blocked the binding of PROTEIN2 to PROTEIN ; however, the PROTEIN -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p2	N	In competition experiments, the carboxyl terminus of PROTEIN1 ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN2 ; however, the PROTEIN -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p3	N	In competition experiments, the carboxyl terminus of PROTEIN1 ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN ; however, the PROTEIN2 -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p4	N	In competition experiments, the carboxyl terminus of PROTEIN1 ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN ; however, the PROTEIN -binding proteins, PROTEIN2 and 14-3-3, had no effect.
AIMed.d107.s904.p5	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN1 ) blocked the binding of PROTEIN2 to PROTEIN ; however, the PROTEIN -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p6	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN1 ) blocked the binding of PROTEIN to PROTEIN2 ; however, the PROTEIN -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p7	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN1 ) blocked the binding of PROTEIN to PROTEIN ; however, the PROTEIN2 -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p8	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN1 ) blocked the binding of PROTEIN to PROTEIN ; however, the PROTEIN -binding proteins, PROTEIN2 and 14-3-3, had no effect.
AIMed.d107.s904.p9	P	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN ) blocked the binding of PROTEIN1 to PROTEIN2 ; however, the PROTEIN -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p11	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN ) blocked the binding of PROTEIN1 to PROTEIN ; however, the PROTEIN -binding proteins, PROTEIN2 and 14-3-3, had no effect.
AIMed.d107.s904.p12	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN1 ; however, the PROTEIN2 -binding proteins, PROTEIN and 14-3-3, had no effect.
AIMed.d107.s904.p13	N	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN1 ; however, the PROTEIN -binding proteins, PROTEIN2 and 14-3-3, had no effect.
AIMed.d107.s904.p14	P	In competition experiments, the carboxyl terminus of PROTEIN ( PROTEIN ) blocked the binding of PROTEIN to PROTEIN ; however, the PROTEIN1 -binding proteins, PROTEIN2 and 14-3-3, had no effect.
AIMed.d107.s905.p0	P	Scatchard analysis of in vitro binding between PROTEIN1 and PROTEIN2 revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN and PROTEIN (Kd = 87 +/- 24 nM).
AIMed.d107.s905.p1	N	Scatchard analysis of in vitro binding between PROTEIN1 and PROTEIN revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN2 and PROTEIN (Kd = 87 +/- 24 nM).
AIMed.d107.s905.p2	N	Scatchard analysis of in vitro binding between PROTEIN1 and PROTEIN revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN and PROTEIN2 (Kd = 87 +/- 24 nM).
AIMed.d107.s905.p3	N	Scatchard analysis of in vitro binding between PROTEIN and PROTEIN1 revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN2 and PROTEIN (Kd = 87 +/- 24 nM).
AIMed.d107.s905.p4	N	Scatchard analysis of in vitro binding between PROTEIN and PROTEIN1 revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN and PROTEIN2 (Kd = 87 +/- 24 nM).
AIMed.d107.s905.p5	P	Scatchard analysis of in vitro binding between PROTEIN and PROTEIN revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between PROTEIN1 and PROTEIN2 (Kd = 87 +/- 24 nM).
AIMed.d107.s906.p0	N	The formation of native heterotrimeric PROTEIN1 complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of PROTEIN2 , with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.
AIMed.d107.s907.p0	P	In vivo complexes of PROTEIN1 and PROTEIN2 were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged PROTEIN .
AIMed.d107.s907.p1	N	In vivo complexes of PROTEIN1 and PROTEIN were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged PROTEIN2 .
AIMed.d108.s909.p0	P	PROTEIN1 transcriptional activation mediated by coactivators PROTEIN2 and PROTEIN .
AIMed.d108.s909.p1	P	PROTEIN1 transcriptional activation mediated by coactivators PROTEIN and PROTEIN2 .
AIMed.d108.s909.p2	N	PROTEIN transcriptional activation mediated by coactivators PROTEIN1 and PROTEIN2 .
AIMed.d108.s911.p0	N	The multisubunit PROTEIN1 ( PROTEIN2 ) is thought to be a primary target for site-specific activators of transcription.
AIMed.d108.s912.p0	N	Here, a direct interaction between the activation domain of PROTEIN1 and two subunits of the PROTEIN2 complex, PROTEIN and PROTEIN , is reported.
AIMed.d108.s912.p1	P	Here, a direct interaction between the activation domain of PROTEIN1 and two subunits of the PROTEIN complex, PROTEIN2 and PROTEIN , is reported.
AIMed.d108.s912.p2	P	Here, a direct interaction between the activation domain of PROTEIN1 and two subunits of the PROTEIN complex, PROTEIN and PROTEIN2 , is reported.
AIMed.d108.s912.p3	N	Here, a direct interaction between the activation domain of PROTEIN and two subunits of the PROTEIN1 complex, PROTEIN2 and PROTEIN , is reported.
AIMed.d108.s912.p4	N	Here, a direct interaction between the activation domain of PROTEIN and two subunits of the PROTEIN1 complex, PROTEIN and PROTEIN2 , is reported.
AIMed.d108.s912.p5	N	Here, a direct interaction between the activation domain of PROTEIN and two subunits of the PROTEIN complex, PROTEIN1 and PROTEIN2 , is reported.
AIMed.d108.s913.p0	P	A double point mutation in the activation domain of PROTEIN1 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both PROTEIN2 and PROTEIN .
AIMed.d108.s913.p1	P	A double point mutation in the activation domain of PROTEIN1 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both PROTEIN and PROTEIN2 .
AIMed.d108.s913.p2	N	A double point mutation in the activation domain of PROTEIN impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both PROTEIN1 and PROTEIN2 .
AIMed.d108.s914.p0	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN2 ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p1	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN2 ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p2	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN2 , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p3	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN2 , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p4	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN2 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p5	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN2 or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p7	N	Furthermore, a partial PROTEIN1 complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p9	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN1 ( PROTEIN ), human PROTEIN2 , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p10	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN1 ( PROTEIN ), human PROTEIN , PROTEIN2 , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p11	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN1 ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN2 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p12	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN1 ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN2 or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p14	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN1 ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p15	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN1 ), human PROTEIN2 , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p18	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN1 ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN2 or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p19	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN1 ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN2 and PROTEIN did not.
AIMed.d108.s914.p20	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN1 ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p22	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN1 , PROTEIN , and PROTEIN2 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p24	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN1 , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN2 and PROTEIN did not.
AIMed.d108.s914.p25	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN1 , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p26	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN1 , and PROTEIN2 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p27	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN1 , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN2 or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p28	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN1 , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN2 and PROTEIN did not.
AIMed.d108.s914.p29	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN1 , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p30	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN1 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN2 or a subcomplex lacking PROTEIN and PROTEIN did not.
AIMed.d108.s914.p31	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN1 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN2 and PROTEIN did not.
AIMed.d108.s914.p32	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN1 supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p33	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN1 or a subcomplex lacking PROTEIN2 and PROTEIN did not.
AIMed.d108.s914.p34	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN1 or a subcomplex lacking PROTEIN and PROTEIN2 did not.
AIMed.d108.s914.p35	N	Furthermore, a partial PROTEIN complex containing Drosophila PROTEIN ( PROTEIN ), human PROTEIN , PROTEIN , and PROTEIN supported activation by a Gal4-p53 fusion protein in vitro, whereas PROTEIN or a subcomplex lacking PROTEIN1 and PROTEIN2 did not.
AIMed.d108.s915.p0	N	Together, these results suggest that PROTEIN1 and PROTEIN2 are important targets for transmitting activation signals between PROTEIN and the initiation complex.
AIMed.d108.s915.p1	P	Together, these results suggest that PROTEIN1 and PROTEIN are important targets for transmitting activation signals between PROTEIN2 and the initiation complex.
AIMed.d108.s915.p2	P	Together, these results suggest that PROTEIN and PROTEIN1 are important targets for transmitting activation signals between PROTEIN2 and the initiation complex.
AIMed.d109.s916.p0	P	Crystal structure of the heterodimeric bZIP transcription factor PROTEIN1 - PROTEIN2 bound to DNA.
AIMed.d109.s917.p0	P	The PROTEIN1 and PROTEIN2 families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements.
AIMed.d109.s918.p0	P	We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of PROTEIN1 and PROTEIN2 bound to DNA.
AIMed.d109.s921.p0	P	Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the PROTEIN1 - PROTEIN2 heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation.
AIMed.d110.s924.p1	N	PROTEIN1 is a multisubunit protein complex comprised of the PROTEIN ( PROTEIN2 ) and multiple TBP-associated factors (TAFs).
AIMed.d110.s924.p2	N	PROTEIN is a multisubunit protein complex comprised of the PROTEIN1 ( PROTEIN2 ) and multiple TBP-associated factors (TAFs).
AIMed.d110.s926.p0	N	The cloning of a complementary DNA encoding a human PROTEIN1 TAF, PROTEIN2 , that has no known homolog in Drosophila PROTEIN is now described.
AIMed.d110.s926.p1	N	The cloning of a complementary DNA encoding a human PROTEIN1 TAF, PROTEIN , that has no known homolog in Drosophila PROTEIN2 is now described.
AIMed.d110.s926.p2	N	The cloning of a complementary DNA encoding a human PROTEIN TAF, PROTEIN1 , that has no known homolog in Drosophila PROTEIN2 is now described.
AIMed.d110.s927.p0	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN2 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p2	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p3	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p4	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p5	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p6	P	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p7	N	PROTEIN1 is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p8	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN2 through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p9	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p11	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN2 , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p12	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p13	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p14	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN1 ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p15	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN1 through its central region and with multiple activators--including PROTEIN2 , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p16	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN1 through its central region and with multiple activators--including PROTEIN , PROTEIN2 , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p18	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN1 through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN2 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p20	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN1 through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p21	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p22	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p24	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p25	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p26	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p27	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p28	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p29	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p30	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p31	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p32	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p33	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , adenoviral PROTEIN2 , and human immunodeficiency virus-type 1 PROTEIN proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p34	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , adenoviral PROTEIN , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s927.p35	N	PROTEIN is shown to interact with the largest subunit ( PROTEIN ) of human PROTEIN through its central region and with multiple activators--including PROTEIN , PROTEIN , PROTEIN , PROTEIN , adenoviral PROTEIN1 , and human immunodeficiency virus-type 1 PROTEIN2 proteins--through a distinct amino-terminal domain.
AIMed.d110.s928.p1	N	The PROTEIN1 -interacting region of PROTEIN was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila PROTEIN2 .
AIMed.d110.s928.p2	P	The PROTEIN -interacting region of PROTEIN1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila PROTEIN2 .
AIMed.d111.s930.p1	N	Mutagenesis of the regulatory subunit ( PROTEIN1 ) of PROTEIN reveals hydrophobic amino acids that are essential for PROTEIN2 dimerization and/or anchoring PROTEIN to the cytoskeleton.
AIMed.d111.s930.p2	N	Mutagenesis of the regulatory subunit ( PROTEIN1 ) of PROTEIN reveals hydrophobic amino acids that are essential for PROTEIN dimerization and/or anchoring PROTEIN2 to the cytoskeleton.
AIMed.d111.s930.p4	N	Mutagenesis of the regulatory subunit ( PROTEIN ) of PROTEIN1 reveals hydrophobic amino acids that are essential for PROTEIN dimerization and/or anchoring PROTEIN2 to the cytoskeleton.
AIMed.d111.s931.p0	N	In neurons PROTEIN1 ( PROTEIN2 ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( PROTEIN ) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
AIMed.d111.s931.p1	N	In neurons PROTEIN1 ( PROTEIN ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( PROTEIN2 ) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
AIMed.d111.s931.p2	N	In neurons PROTEIN ( PROTEIN1 ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( PROTEIN2 ) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
AIMed.d111.s932.p0	P	The prototypic neuronal anchor protein PROTEIN1 has a COOH-terminal 22-residue PROTEIN2 binding (tethering) site.
AIMed.d111.s934.p0	P	Mutagenesis, recombinant protein expression, and physicochemical characterization were used to investigate the structural basis for the homodimerization and PROTEIN1 binding activities of PROTEIN2 .
AIMed.d111.s936.p0	N	Substitution of Ala for Leu13 or Phe36 generates monomeric PROTEIN1 subunits that cannot bind PROTEIN2 .
AIMed.d111.s937.p0	N	The results are not due to general misfolding since mutant PROTEIN1 monomers bind cAMP and inhibit the catalytic subunit of PROTEIN2 with the same affinity and efficacy as wild-type PROTEIN dimers.
AIMed.d111.s937.p1	N	The results are not due to general misfolding since mutant PROTEIN1 monomers bind cAMP and inhibit the catalytic subunit of PROTEIN with the same affinity and efficacy as wild-type PROTEIN2 dimers.
AIMed.d111.s937.p2	N	The results are not due to general misfolding since mutant PROTEIN monomers bind cAMP and inhibit the catalytic subunit of PROTEIN1 with the same affinity and efficacy as wild-type PROTEIN2 dimers.
AIMed.d111.s939.p0	P	Evidently, large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing PROTEIN1 - PROTEIN2 interactions.
AIMed.d111.s940.p0	N	A secondary consequence of destabilizing PROTEIN1 dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind PROTEIN2 .
AIMed.d111.s941.p0	P	Other NH2-terminal residues directly modulate the affinity of PROTEIN1 dimers for the PROTEIN2 tethering site.
AIMed.d111.s942.p0	P	Replacement of Val20-Leu21 with Ala-Ala produced a dimeric PROTEIN1 protein that binds PROTEIN2 approximately 4% as avidly as wild-type PROTEIN .
AIMed.d111.s942.p1	N	Replacement of Val20-Leu21 with Ala-Ala produced a dimeric PROTEIN1 protein that binds PROTEIN approximately 4% as avidly as wild-type PROTEIN2 .
AIMed.d111.s942.p2	N	Replacement of Val20-Leu21 with Ala-Ala produced a dimeric PROTEIN protein that binds PROTEIN1 approximately 4% as avidly as wild-type PROTEIN2 .
AIMed.d112.s944.p0	P	Human spleen tyrosine kinase PROTEIN1 associates with the Src-family kinase PROTEIN2 / PROTEIN and a PROTEIN .
AIMed.d112.s944.p1	P	Human spleen tyrosine kinase PROTEIN1 associates with the Src-family kinase PROTEIN / PROTEIN2 and a PROTEIN .
AIMed.d112.s944.p2	P	Human spleen tyrosine kinase PROTEIN1 associates with the Src-family kinase PROTEIN / PROTEIN and a PROTEIN2 .
AIMed.d112.s944.p3	N	Human spleen tyrosine kinase PROTEIN associates with the Src-family kinase PROTEIN1 / PROTEIN2 and a PROTEIN .
AIMed.d112.s944.p4	N	Human spleen tyrosine kinase PROTEIN associates with the Src-family kinase PROTEIN1 / PROTEIN and a PROTEIN2 .
AIMed.d112.s944.p5	N	Human spleen tyrosine kinase PROTEIN associates with the Src-family kinase PROTEIN / PROTEIN1 and a PROTEIN2 .
AIMed.d112.s945.p0	N	The 72-kDa spleen tyrosine kinase ( PROTEIN1 ) and Src-family kinase PROTEIN2 / PROTEIN ( PROTEIN ) contribute to signaling via the B-cell antigen receptor complex.
AIMed.d112.s945.p1	N	The 72-kDa spleen tyrosine kinase ( PROTEIN1 ) and Src-family kinase PROTEIN / PROTEIN2 ( PROTEIN ) contribute to signaling via the B-cell antigen receptor complex.
AIMed.d112.s945.p3	N	The 72-kDa spleen tyrosine kinase ( PROTEIN ) and Src-family kinase PROTEIN1 / PROTEIN2 ( PROTEIN ) contribute to signaling via the B-cell antigen receptor complex.
AIMed.d112.s945.p4	N	The 72-kDa spleen tyrosine kinase ( PROTEIN ) and Src-family kinase PROTEIN1 / PROTEIN ( PROTEIN2 ) contribute to signaling via the B-cell antigen receptor complex.
AIMed.d112.s945.p5	N	The 72-kDa spleen tyrosine kinase ( PROTEIN ) and Src-family kinase PROTEIN / PROTEIN1 ( PROTEIN2 ) contribute to signaling via the B-cell antigen receptor complex.
AIMed.d112.s946.p0	P	Here we show that PROTEIN1 and PROTEIN2 from human B lymphocytes can interact directly.
AIMed.d112.s947.p0	P	PROTEIN1 and PROTEIN2 coimmunoprecipitated from mature and activated B-cell lines, and gel-purified PROTEIN and PROTEIN reassociated in vitro, demonstrating their direct interaction.
AIMed.d112.s947.p1	N	PROTEIN1 and PROTEIN coimmunoprecipitated from mature and activated B-cell lines, and gel-purified PROTEIN2 and PROTEIN reassociated in vitro, demonstrating their direct interaction.
AIMed.d112.s947.p2	N	PROTEIN1 and PROTEIN coimmunoprecipitated from mature and activated B-cell lines, and gel-purified PROTEIN and PROTEIN2 reassociated in vitro, demonstrating their direct interaction.
AIMed.d112.s947.p3	N	PROTEIN and PROTEIN1 coimmunoprecipitated from mature and activated B-cell lines, and gel-purified PROTEIN2 and PROTEIN reassociated in vitro, demonstrating their direct interaction.
AIMed.d112.s948.p0	P	This PROTEIN1 - PROTEIN2 interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p1	N	This PROTEIN1 - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN2 - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p2	N	This PROTEIN1 - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN2 associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p4	N	This PROTEIN1 - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN2 in vitro.
AIMed.d112.s948.p5	N	This PROTEIN - PROTEIN1 interaction may be dependent on the stage of B-cell differentiation, since PROTEIN2 - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p6	N	This PROTEIN - PROTEIN1 interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN2 associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p7	N	This PROTEIN - PROTEIN1 interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN2 from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p8	N	This PROTEIN - PROTEIN1 interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN2 in vitro.
AIMed.d112.s948.p9	P	This PROTEIN - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN1 - PROTEIN2 associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN in vitro.
AIMed.d112.s948.p11	N	This PROTEIN - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN1 - PROTEIN associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN2 in vitro.
AIMed.d112.s948.p13	N	This PROTEIN - PROTEIN interaction may be dependent on the stage of B-cell differentiation, since PROTEIN - PROTEIN1 associations were not detected in pre-B and myeloma cell lines and PROTEIN from an immature B-cell line did not reassociate with PROTEIN2 in vitro.
AIMed.d112.s950.p0	N	Crosslinking of cell surface IgM led to rapid activation of both tyrosine and serine/threonine protein kinase activities that resulted in phosphorylation in vitro of proteins coprecipitating with PROTEIN1 --in particular, a serine/threonine phosphorylated protein 120 kDa in size ( PROTEIN2 ).
AIMed.d112.s951.p0	N	Several phosphoproteins, including one of 72 kDa and one of 120 kDa, coprecipitated with PROTEIN1 ( PROTEIN2 ).
AIMed.d112.s952.p0	P	Sequential immunoprecipitation identified the 72-kDa protein associated with PROTEIN1 as PROTEIN2 .
AIMed.d112.s953.p0	N	The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PROTEIN1 resembled the PROTEIN2 -associated PROTEIN by several criteria.
AIMed.d112.s953.p1	N	The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PROTEIN1 resembled the PROTEIN -associated PROTEIN2 by several criteria.
AIMed.d112.s953.p2	P	The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PROTEIN resembled the PROTEIN1 -associated PROTEIN2 by several criteria.
AIMed.d112.s954.p1	P	Thus, PROTEIN1 may serve as a link between PROTEIN and PROTEIN2 , coupling the B-cell antigen receptor to the phosphatidylinositol pathway.
AIMed.d112.s954.p2	P	Thus, PROTEIN may serve as a link between PROTEIN1 and PROTEIN2 , coupling the B-cell antigen receptor to the phosphatidylinositol pathway.
AIMed.d113.s955.p1	N	Cloning and functional analysis of PROTEIN1 : a novel PROTEIN2 with anti-cell death activity.
AIMed.d113.s957.p0	N	The PROTEIN1 protein shares no significant homology with PROTEIN2 or other PROTEIN family proteins, which can form homo- and heterodimers.
AIMed.d113.s957.p1	N	The PROTEIN1 protein shares no significant homology with PROTEIN or other PROTEIN2 family proteins, which can form homo- and heterodimers.
AIMed.d113.s957.p2	N	The PROTEIN protein shares no significant homology with PROTEIN1 or other PROTEIN2 family proteins, which can form homo- and heterodimers.
AIMed.d113.s958.p0	N	In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of PROTEIN1 and PROTEIN2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either PROTEIN or PROTEIN protein alone.
AIMed.d113.s958.p1	N	In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of PROTEIN1 and PROTEIN provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either PROTEIN2 or PROTEIN protein alone.
AIMed.d113.s958.p2	N	In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of PROTEIN1 and PROTEIN provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either PROTEIN or PROTEIN2 protein alone.
AIMed.d113.s958.p3	N	In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of PROTEIN and PROTEIN1 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either PROTEIN2 or PROTEIN protein alone.
AIMed.d113.s958.p5	N	In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of PROTEIN and PROTEIN provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either PROTEIN1 or PROTEIN2 protein alone.
AIMed.d113.s960.p0	N	The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to PROTEIN1 -independent pathways may instead reflect a need for the combination of PROTEIN2 and PROTEIN .
AIMed.d113.s960.p1	N	The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to PROTEIN1 -independent pathways may instead reflect a need for the combination of PROTEIN and PROTEIN2 .
AIMed.d113.s960.p2	N	The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to PROTEIN -independent pathways may instead reflect a need for the combination of PROTEIN1 and PROTEIN2 .
AIMed.d114.s961.p0	N	PROTEIN1 binds to an alternatively spliced exon of PROTEIN2 .
AIMed.d114.s964.p0	N	We expressed the cDNA of human PROTEIN1 and the COOH terminus of human PROTEIN2 in reticulocyte lysates using an in vitro transcription/translation system.
AIMed.d114.s966.p0	P	We demonstrate that the 53 amino acids encoded on exon 74 of PROTEIN1 , an alternatively spliced exon, are necessary and sufficient for interaction with translated PROTEIN2 in our assay.
AIMed.d114.s968.p1	N	In this recombinant expression system, the PROTEIN1 relatives, human PROTEIN2 ( PROTEIN or PROTEIN ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p2	N	In this recombinant expression system, the PROTEIN1 relatives, human PROTEIN ( PROTEIN2 or PROTEIN ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p3	N	In this recombinant expression system, the PROTEIN1 relatives, human PROTEIN ( PROTEIN or PROTEIN2 ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p4	N	In this recombinant expression system, the PROTEIN1 relatives, human PROTEIN ( PROTEIN or PROTEIN ) and the PROTEIN2 from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p5	N	In this recombinant expression system, the PROTEIN1 relatives, human PROTEIN ( PROTEIN or PROTEIN ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN2 .
AIMed.d114.s968.p11	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN1 ( PROTEIN2 or PROTEIN ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p12	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN1 ( PROTEIN or PROTEIN2 ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p13	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN1 ( PROTEIN or PROTEIN ) and the PROTEIN2 from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p14	P	In this recombinant expression system, the PROTEIN relatives, human PROTEIN1 ( PROTEIN or PROTEIN ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN2 .
AIMed.d114.s968.p15	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN ( PROTEIN1 or PROTEIN2 ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p16	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN ( PROTEIN1 or PROTEIN ) and the PROTEIN2 from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p18	N	In this recombinant expression system, the PROTEIN relatives, human PROTEIN ( PROTEIN or PROTEIN1 ) and the PROTEIN2 from Torpedo electric organ, also bind to translated PROTEIN .
AIMed.d114.s968.p19	P	In this recombinant expression system, the PROTEIN relatives, human PROTEIN ( PROTEIN or PROTEIN1 ) and the PROTEIN from Torpedo electric organ, also bind to translated PROTEIN2 .
AIMed.d114.s968.p20	P	In this recombinant expression system, the PROTEIN relatives, human PROTEIN ( PROTEIN or PROTEIN ) and the PROTEIN1 from Torpedo electric organ, also bind to translated PROTEIN2 .
AIMed.d114.s969.p0	P	We have found a COOH-terminal 37-kD fragment of PROTEIN1 sufficient to interact with translated PROTEIN2 and its homologues, suggesting that the PROTEIN binding site on PROTEIN occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d114.s969.p1	N	We have found a COOH-terminal 37-kD fragment of PROTEIN1 sufficient to interact with translated PROTEIN and its homologues, suggesting that the PROTEIN2 binding site on PROTEIN occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d114.s969.p2	N	We have found a COOH-terminal 37-kD fragment of PROTEIN1 sufficient to interact with translated PROTEIN and its homologues, suggesting that the PROTEIN binding site on PROTEIN2 occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d114.s969.p3	N	We have found a COOH-terminal 37-kD fragment of PROTEIN sufficient to interact with translated PROTEIN1 and its homologues, suggesting that the PROTEIN2 binding site on PROTEIN occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d114.s969.p4	N	We have found a COOH-terminal 37-kD fragment of PROTEIN sufficient to interact with translated PROTEIN1 and its homologues, suggesting that the PROTEIN binding site on PROTEIN2 occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d114.s969.p5	P	We have found a COOH-terminal 37-kD fragment of PROTEIN sufficient to interact with translated PROTEIN and its homologues, suggesting that the PROTEIN1 binding site on PROTEIN2 occurs on a region that is conserved among the three syntrophin homologues.
AIMed.d115.s970.p0	N	Interaction with PROTEIN1 subunit of PROTEIN2 is required for transcriptional activation by PROTEIN .
AIMed.d115.s970.p1	P	Interaction with PROTEIN1 subunit of PROTEIN is required for transcriptional activation by PROTEIN2 .
AIMed.d115.s970.p2	N	Interaction with PROTEIN subunit of PROTEIN1 is required for transcriptional activation by PROTEIN2 .
AIMed.d115.s971.p0	N	A few general transcription factors, in particular PROTEIN1 and PROTEIN2 , have been found to bind transcriptional activators.
AIMed.d115.s972.p1	N	Here we show that the general transcription factor PROTEIN1 is also a target for a transcriptional activator, namely PROTEIN ( PROTEIN2 ), which binds to the PROTEIN promoter.
AIMed.d115.s972.p3	N	Here we show that the general transcription factor PROTEIN is also a target for a transcriptional activator, namely PROTEIN1 ( PROTEIN2 ), which binds to the PROTEIN promoter.
AIMed.d115.s972.p4	N	Here we show that the general transcription factor PROTEIN is also a target for a transcriptional activator, namely PROTEIN1 ( PROTEIN ), which binds to the PROTEIN2 promoter.
AIMed.d115.s973.p0	P	Using a yeast interaction assay, we find that PROTEIN1 binds the PROTEIN2 subunit of PROTEIN and that PROTEIN 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s973.p1	N	Using a yeast interaction assay, we find that PROTEIN1 binds the PROTEIN subunit of PROTEIN2 and that PROTEIN 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s973.p2	N	Using a yeast interaction assay, we find that PROTEIN1 binds the PROTEIN subunit of PROTEIN and that PROTEIN2 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s973.p3	N	Using a yeast interaction assay, we find that PROTEIN binds the PROTEIN1 subunit of PROTEIN2 and that PROTEIN 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s973.p4	N	Using a yeast interaction assay, we find that PROTEIN binds the PROTEIN1 subunit of PROTEIN and that PROTEIN2 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s973.p5	N	Using a yeast interaction assay, we find that PROTEIN binds the PROTEIN subunit of PROTEIN1 and that PROTEIN2 's transcriptional activation domain is the region involved in this binding.
AIMed.d115.s974.p0	N	Further, PROTEIN1 's central charged cluster domain is required for binding to PROTEIN2 's activation domain.
AIMed.d115.s975.p0	N	Deletion of this domain impairs PROTEIN1 's ability to support PROTEIN2 -activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support PROTEIN -activated transcription.
AIMed.d115.s975.p1	N	Deletion of this domain impairs PROTEIN1 's ability to support PROTEIN -activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support PROTEIN2 -activated transcription.
AIMed.d115.s975.p2	N	Deletion of this domain impairs PROTEIN 's ability to support PROTEIN1 -activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support PROTEIN2 -activated transcription.
AIMed.d115.s976.p0	P	The correlation of PROTEIN1 - PROTEIN2 binding with transcriptional activation suggests that PROTEIN is a critical target for PROTEIN -activated transcription.
AIMed.d115.s976.p1	N	The correlation of PROTEIN1 - PROTEIN binding with transcriptional activation suggests that PROTEIN2 is a critical target for PROTEIN -activated transcription.
AIMed.d115.s976.p2	N	The correlation of PROTEIN1 - PROTEIN binding with transcriptional activation suggests that PROTEIN is a critical target for PROTEIN2 -activated transcription.
AIMed.d115.s976.p3	N	The correlation of PROTEIN - PROTEIN1 binding with transcriptional activation suggests that PROTEIN2 is a critical target for PROTEIN -activated transcription.
AIMed.d115.s976.p4	N	The correlation of PROTEIN - PROTEIN1 binding with transcriptional activation suggests that PROTEIN is a critical target for PROTEIN2 -activated transcription.
AIMed.d115.s976.p5	P	The correlation of PROTEIN - PROTEIN binding with transcriptional activation suggests that PROTEIN1 is a critical target for PROTEIN2 -activated transcription.
AIMed.d116.s977.p0	P	Activity of RNA polymerase I transcription factor PROTEIN1 blocked by PROTEIN2 gene product.
AIMed.d116.s978.p0	N	The protein encoded by the PROTEIN1 ( PROTEIN2 ) functions as a tumour suppressor and negative growth regulator.
AIMed.d116.s980.p0	N	Here we report that (1) there is an accumulation of PROTEIN1 protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN2 to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN ) in vitro.
AIMed.d116.s980.p2	N	Here we report that (1) there is an accumulation of PROTEIN1 protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN2 specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN ) in vitro.
AIMed.d116.s980.p3	N	Here we report that (1) there is an accumulation of PROTEIN1 protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN2 ( PROTEIN ) in vitro.
AIMed.d116.s980.p4	N	Here we report that (1) there is an accumulation of PROTEIN1 protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN2 ) in vitro.
AIMed.d116.s980.p5	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN1 to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN2 pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN ) in vitro.
AIMed.d116.s980.p6	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN1 to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN2 specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN ) in vitro.
AIMed.d116.s980.p7	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN1 to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN2 ( PROTEIN ) in vitro.
AIMed.d116.s980.p8	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN1 to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN2 ) in vitro.
AIMed.d116.s980.p11	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN1 pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN ( PROTEIN2 ) in vitro.
AIMed.d116.s980.p12	P	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN1 specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN2 ( PROTEIN ) in vitro.
AIMed.d116.s980.p14	N	Here we report that (1) there is an accumulation of PROTEIN protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of PROTEIN to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional PROTEIN pocket; and (4) PROTEIN specifically inhibits the activity of the RNA polymerase I transcription factor PROTEIN1 ( PROTEIN2 ) in vitro.
AIMed.d116.s981.p0	P	This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between PROTEIN1 and PROTEIN2 .
AIMed.d116.s982.p0	N	These results indicate that there is an additional mechanism by which PROTEIN1 suppresses cell growth, namely that PROTEIN2 directly represses transcription of the rRNA genes.
AIMed.d117.s987.p0	N	Activin type I receptors, PROTEIN1 and PROTEIN2 , were first cloned from well differentiated human hepatoma cells (HepG2).
AIMed.d117.s989.p0	P	Here we show that beta: PROTEIN1 binds to the PROTEIN2 ( PROTEIN ) which induces activin binding to the type I receptor kinase PROTEIN to form PROTEIN .beta:beta.
AIMed.d117.s989.p2	N	Here we show that beta: PROTEIN1 binds to the PROTEIN ( PROTEIN ) which induces activin binding to the type I receptor kinase PROTEIN2 to form PROTEIN .beta:beta.
AIMed.d117.s989.p3	N	Here we show that beta: PROTEIN1 binds to the PROTEIN ( PROTEIN ) which induces activin binding to the type I receptor kinase PROTEIN to form PROTEIN2 .beta:beta.
AIMed.d117.s989.p4	N	Here we show that beta: PROTEIN binds to the PROTEIN1 ( PROTEIN2 ) which induces activin binding to the type I receptor kinase PROTEIN to form PROTEIN .beta:beta.
AIMed.d117.s989.p6	N	Here we show that beta: PROTEIN binds to the PROTEIN1 ( PROTEIN ) which induces activin binding to the type I receptor kinase PROTEIN to form PROTEIN2 .beta:beta.
AIMed.d117.s989.p7	N	Here we show that beta: PROTEIN binds to the PROTEIN ( PROTEIN1 ) which induces activin binding to the type I receptor kinase PROTEIN2 to form PROTEIN .beta:beta.
AIMed.d117.s989.p8	N	Here we show that beta: PROTEIN binds to the PROTEIN ( PROTEIN1 ) which induces activin binding to the type I receptor kinase PROTEIN to form PROTEIN2 .beta:beta.
AIMed.d117.s989.p9	N	Here we show that beta: PROTEIN binds to the PROTEIN ( PROTEIN ) which induces activin binding to the type I receptor kinase PROTEIN1 to form PROTEIN2 .beta:beta.
AIMed.d117.s990.p0	N	PROTEIN1 complexes in which an PROTEIN2 chain occupies each receptor subunit.
AIMed.d117.s991.p0	P	PROTEIN1 also binds to PROTEIN2 through its beta subunit, competes with the binding of activin to PROTEIN , but fails to form the PROTEIN .
AIMed.d117.s991.p1	N	PROTEIN1 also binds to PROTEIN through its beta subunit, competes with the binding of activin to PROTEIN2 , but fails to form the PROTEIN .
AIMed.d117.s991.p2	N	PROTEIN1 also binds to PROTEIN through its beta subunit, competes with the binding of activin to PROTEIN , but fails to form the PROTEIN2 .
AIMed.d117.s991.p3	N	PROTEIN also binds to PROTEIN1 through its beta subunit, competes with the binding of activin to PROTEIN2 , but fails to form the PROTEIN .
AIMed.d117.s991.p4	N	PROTEIN also binds to PROTEIN1 through its beta subunit, competes with the binding of activin to PROTEIN , but fails to form the PROTEIN2 .
AIMed.d117.s991.p5	N	PROTEIN also binds to PROTEIN through its beta subunit, competes with the binding of activin to PROTEIN1 , but fails to form the PROTEIN2 .
AIMed.d118.s997.p0	N	The PROTEIN1 tumour-suppressor protein controls the expression of a gene encoding the PROTEIN2 cyclin-dependent protein kinase (CDK) regulator.
AIMed.d118.s998.p0	N	Levels of PROTEIN1 protein are increased in senescent cells and PROTEIN2 overexpression blocks the growth of tumour cells.
AIMed.d118.s999.p0	P	In normal human cells, but not in many tumour cells, PROTEIN1 exists in a quaternary complex with a cyclin, a CDK, and the PROTEIN2 ( PROTEIN ).
AIMed.d118.s999.p1	P	In normal human cells, but not in many tumour cells, PROTEIN1 exists in a quaternary complex with a cyclin, a CDK, and the PROTEIN ( PROTEIN2 ).
AIMed.d118.s999.p2	N	In normal human cells, but not in many tumour cells, PROTEIN exists in a quaternary complex with a cyclin, a CDK, and the PROTEIN1 ( PROTEIN2 ).
AIMed.d118.s1000.p0	N	PROTEIN1 controls CDK activity, thereby affecting cell-cycle control, whereas PROTEIN2 functions in both DNA replication and repair.
AIMed.d118.s1001.p0	P	Here we use simian virus 40 DNA replication in vitro to show than PROTEIN1 directly inhibits PROTEIN2 -dependent DNA replication in the absence of a cyclin/CDK.
AIMed.d118.s1002.p0	P	Furthermore, PROTEIN1 blocks the ability of PROTEIN2 to activate PROTEIN , the principal replicative DNA polymerase.
AIMed.d118.s1002.p1	N	Furthermore, PROTEIN1 blocks the ability of PROTEIN to activate PROTEIN2 , the principal replicative DNA polymerase.
AIMed.d118.s1002.p2	P	Furthermore, PROTEIN blocks the ability of PROTEIN1 to activate PROTEIN2 , the principal replicative DNA polymerase.
AIMed.d118.s1003.p0	P	This regulation results from a direct interaction between PROTEIN1 and PROTEIN2 .
AIMed.d118.s1004.p1	N	Thus, during PROTEIN1 -mediated suppression of cell proliferation, PROTEIN and PROTEIN2 may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
AIMed.d118.s1004.p2	N	Thus, during PROTEIN -mediated suppression of cell proliferation, PROTEIN1 and PROTEIN2 may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
AIMed.d119.s1005.p0	P	Nuclear protein PROTEIN1 is a coactivator for the transcription factor PROTEIN2 .
AIMed.d119.s1007.p0	P	PROTEIN1 is activated through phosphorylation by PROTEIN2 ( PROTEIN ), but precisely how phosphorylation stimulates PROTEIN function is unknown.
AIMed.d119.s1007.p1	P	PROTEIN1 is activated through phosphorylation by PROTEIN ( PROTEIN2 ), but precisely how phosphorylation stimulates PROTEIN function is unknown.
AIMed.d119.s1007.p2	N	PROTEIN1 is activated through phosphorylation by PROTEIN ( PROTEIN ), but precisely how phosphorylation stimulates PROTEIN2 function is unknown.
AIMed.d119.s1007.p3	N	PROTEIN is activated through phosphorylation by PROTEIN1 ( PROTEIN2 ), but precisely how phosphorylation stimulates PROTEIN function is unknown.
AIMed.d119.s1007.p4	N	PROTEIN is activated through phosphorylation by PROTEIN1 ( PROTEIN ), but precisely how phosphorylation stimulates PROTEIN2 function is unknown.
AIMed.d119.s1007.p5	N	PROTEIN is activated through phosphorylation by PROTEIN ( PROTEIN1 ), but precisely how phosphorylation stimulates PROTEIN2 function is unknown.
AIMed.d119.s1009.p0	N	We have previously identified a nuclear protein of M(r)265K, PROTEIN1 , that binds specifically to the PROTEIN2 -phosphorylated form of PROTEIN .
AIMed.d119.s1009.p1	P	We have previously identified a nuclear protein of M(r)265K, PROTEIN1 , that binds specifically to the PROTEIN -phosphorylated form of PROTEIN2 .
AIMed.d119.s1009.p2	P	We have previously identified a nuclear protein of M(r)265K, PROTEIN , that binds specifically to the PROTEIN1 -phosphorylated form of PROTEIN2 .
AIMed.d119.s1010.p0	P	We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the PROTEIN1 : PROTEIN2 interaction and report here that PROTEIN can activate transcription through a region in its carboxy terminus.
AIMed.d119.s1010.p1	N	We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the PROTEIN1 : PROTEIN interaction and report here that PROTEIN2 can activate transcription through a region in its carboxy terminus.
AIMed.d119.s1010.p2	N	We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the PROTEIN : PROTEIN1 interaction and report here that PROTEIN2 can activate transcription through a region in its carboxy terminus.
AIMed.d119.s1011.p0	N	The activation domain of PROTEIN1 interacts with the basal transcription factor PROTEIN2 through a domain that is conserved in the yeast coactivator PROTEIN (ref. 8).
AIMed.d119.s1011.p1	P	The activation domain of PROTEIN1 interacts with the basal transcription factor PROTEIN through a domain that is conserved in the yeast coactivator PROTEIN2 (ref. 8).
AIMed.d119.s1011.p2	N	The activation domain of PROTEIN interacts with the basal transcription factor PROTEIN1 through a domain that is conserved in the yeast coactivator PROTEIN2 (ref. 8).
AIMed.d119.s1012.p0	P	Consistent with its role as a coactivator, PROTEIN1 augments the activity of phosphorylated PROTEIN2 to activate transcription of cAMP-responsive genes.
AIMed.d120.s1013.p0	P	Specific binding of the transglutaminase, PROTEIN1 , to PROTEIN2 .
AIMed.d120.s1017.p0	N	To identify specific PROTEIN1 -protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with PROTEIN2 from human platelet lysates and erythroleukemia cells.
AIMed.d120.s1020.p0	P	Immunoblotting studies were used to confirm the binding of PROTEIN1 from fresh platelet lysates to the PROTEIN2 fusion protein.
AIMed.d120.s1021.p0	P	PROTEIN1 also was shown to coprecipitate with PROTEIN2 in immunoprecipitation studies and to colocalize with PROTEIN in immunofluorescence studies of intact glass-activated platelets.
AIMed.d120.s1021.p1	N	PROTEIN1 also was shown to coprecipitate with PROTEIN in immunoprecipitation studies and to colocalize with PROTEIN2 in immunofluorescence studies of intact glass-activated platelets.
AIMed.d120.s1021.p2	N	PROTEIN also was shown to coprecipitate with PROTEIN1 in immunoprecipitation studies and to colocalize with PROTEIN2 in immunofluorescence studies of intact glass-activated platelets.
AIMed.d120.s1022.p0	P	The data thus demonstrate specific binding of platelet PROTEIN1 to PROTEIN2 and suggest that PROTEIN may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN .
AIMed.d120.s1022.p1	N	The data thus demonstrate specific binding of platelet PROTEIN1 to PROTEIN and suggest that PROTEIN2 may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN .
AIMed.d120.s1022.p2	N	The data thus demonstrate specific binding of platelet PROTEIN1 to PROTEIN and suggest that PROTEIN may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN2 .
AIMed.d120.s1022.p3	N	The data thus demonstrate specific binding of platelet PROTEIN to PROTEIN1 and suggest that PROTEIN2 may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN .
AIMed.d120.s1022.p4	N	The data thus demonstrate specific binding of platelet PROTEIN to PROTEIN1 and suggest that PROTEIN may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN2 .
AIMed.d120.s1022.p5	P	The data thus demonstrate specific binding of platelet PROTEIN to PROTEIN and suggest that PROTEIN1 may participate in the cellular localization and/or enzymatic regulation of platelet PROTEIN2 .
AIMed.d121.s1023.p0	P	Several hydrophobic amino acids in the PROTEIN1 amino-terminal domain are required for transcriptional activation, binding to PROTEIN2 and the adenovirus PROTEIN 55-kD protein.
AIMed.d121.s1023.p2	P	Several hydrophobic amino acids in the PROTEIN1 amino-terminal domain are required for transcriptional activation, binding to PROTEIN and the adenovirus PROTEIN2 55-kD protein.
AIMed.d121.s1023.p4	N	Several hydrophobic amino acids in the PROTEIN amino-terminal domain are required for transcriptional activation, binding to PROTEIN1 and the adenovirus PROTEIN2 55-kD protein.
AIMed.d121.s1025.p0	P	The acidic amino terminus of the PROTEIN1 protein has been shown to contain this trans-activation activity as well as the domains for PROTEIN2 and adenovirus PROTEIN 55-kD protein binding.
AIMed.d121.s1025.p2	P	The acidic amino terminus of the PROTEIN1 protein has been shown to contain this trans-activation activity as well as the domains for PROTEIN and adenovirus PROTEIN2 55-kD protein binding.
AIMed.d121.s1025.p4	N	The acidic amino terminus of the PROTEIN protein has been shown to contain this trans-activation activity as well as the domains for PROTEIN1 and adenovirus PROTEIN2 55-kD protein binding.
AIMed.d121.s1028.p0	P	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN1 are both required for trans-activation activity, binding to the adenovirus PROTEIN2 55-kD protein and the human PROTEIN - PROTEIN protein in vitro.
AIMed.d121.s1028.p1	N	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN1 are both required for trans-activation activity, binding to the adenovirus PROTEIN 55-kD protein and the human PROTEIN2 - PROTEIN protein in vitro.
AIMed.d121.s1028.p2	N	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN1 are both required for trans-activation activity, binding to the adenovirus PROTEIN 55-kD protein and the human PROTEIN - PROTEIN2 protein in vitro.
AIMed.d121.s1028.p3	N	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN are both required for trans-activation activity, binding to the adenovirus PROTEIN1 55-kD protein and the human PROTEIN2 - PROTEIN protein in vitro.
AIMed.d121.s1028.p4	N	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN are both required for trans-activation activity, binding to the adenovirus PROTEIN1 55-kD protein and the human PROTEIN - PROTEIN2 protein in vitro.
AIMed.d121.s1028.p5	P	Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human PROTEIN are both required for trans-activation activity, binding to the adenovirus PROTEIN 55-kD protein and the human PROTEIN1 - PROTEIN2 protein in vitro.
AIMed.d121.s1029.p2	N	In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between PROTEIN and human PROTEIN1 ( PROTEIN2 ).
AIMed.d121.s1031.p0	N	These mutations have no impact on the ability of the PROTEIN1 protein to bind to a PROTEIN2 -specific DNA element.
AIMed.d121.s1033.p0	N	These very same hydrophobic residues contact the PROTEIN1 and Ad5 PROTEIN2 55-kD oncogene products.
AIMed.d122.s1036.p0	P	In previous studies (Scott, J. D., Stofko, R. E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of PROTEIN1 was required for interaction with the cytoskeletal component PROTEIN2 .
AIMed.d122.s1041.p0	P	Measurement of PROTEIN1 I3A,I5A interaction with the human PROTEIN2 , PROTEIN , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
AIMed.d122.s1041.p1	P	Measurement of PROTEIN1 I3A,I5A interaction with the human PROTEIN , PROTEIN2 , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
AIMed.d122.s1041.p2	N	Measurement of PROTEIN I3A,I5A interaction with the human PROTEIN1 , PROTEIN2 , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
AIMed.d123.s1043.p0	P	Characterization of an interaction between PROTEIN1 and the PROTEIN2 by using the two-hybrid system.
AIMed.d123.s1044.p1	P	PROTEIN1 ( PROTEIN ) is a major substrate of the PROTEIN2 and has been implicated in PROTEIN signaling.
AIMed.d123.s1044.p2	N	PROTEIN1 ( PROTEIN ) is a major substrate of the PROTEIN and has been implicated in PROTEIN2 signaling.
AIMed.d123.s1044.p3	P	PROTEIN ( PROTEIN1 ) is a major substrate of the PROTEIN2 and has been implicated in PROTEIN signaling.
AIMed.d123.s1044.p4	N	PROTEIN ( PROTEIN1 ) is a major substrate of the PROTEIN and has been implicated in PROTEIN2 signaling.
AIMed.d123.s1045.p1	P	Although PROTEIN1 is thought to interact with the PROTEIN2 , the nature of the interaction has not been defined.
AIMed.d123.s1046.p1	P	In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human PROTEIN1 and the PROTEIN2 .
AIMed.d123.s1047.p0	P	We demonstrate that PROTEIN1 forms a specific complex with the cytoplasmic domain of the PROTEIN2 when both are expressed as hybrid proteins in yeast cells.
AIMed.d124.s1055.p0	P	The protein PROTEIN1 , a key mediator of mitogenesis and differentiation, associates with PROTEIN2 (refs 1-3).
AIMed.d124.s1058.p0	N	These proteins, PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ), are members of the 14-3-3 family of proteins.
AIMed.d124.s1058.p1	N	These proteins, PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ), are members of the 14-3-3 family of proteins.
AIMed.d124.s1058.p3	N	These proteins, PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ), are members of the 14-3-3 family of proteins.
AIMed.d124.s1058.p4	N	These proteins, PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ), are members of the 14-3-3 family of proteins.
AIMed.d124.s1058.p5	N	These proteins, PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ), are members of the 14-3-3 family of proteins.
AIMed.d124.s1059.p0	N	Expression of 14-3-3 proteins in Xenopus oocytes enhanced PROTEIN1 activity and promoted PROTEIN2 -dependent oocyte maturation.
AIMed.d125.s1062.p1	P	Interactions of the PROTEIN1 protein with itself and other members of the PROTEIN family, including PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p2	P	Interactions of the PROTEIN1 protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p3	P	Interactions of the PROTEIN1 protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p4	P	Interactions of the PROTEIN1 protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p5	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN1 family, including PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p6	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN1 family, including PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p7	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN1 family, including PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p8	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN1 family, including PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p9	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p10	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p11	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p12	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p13	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 , were explored with a yeast two-hybrid system.
AIMed.d125.s1062.p14	N	Interactions of the PROTEIN protein with itself and other members of the PROTEIN family, including PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 , were explored with a yeast two-hybrid system.
AIMed.d125.s1066.p0	P	PROTEIN1 also interacted with PROTEIN2 and PROTEIN and with the dominant inhibitors PROTEIN and PROTEIN .
AIMed.d125.s1066.p1	P	PROTEIN1 also interacted with PROTEIN and PROTEIN2 and with the dominant inhibitors PROTEIN and PROTEIN .
AIMed.d125.s1066.p3	P	PROTEIN1 also interacted with PROTEIN and PROTEIN and with the dominant inhibitors PROTEIN and PROTEIN2 .
AIMed.d125.s1066.p4	N	PROTEIN also interacted with PROTEIN1 and PROTEIN2 and with the dominant inhibitors PROTEIN and PROTEIN .
AIMed.d125.s1066.p5	N	PROTEIN also interacted with PROTEIN1 and PROTEIN and with the dominant inhibitors PROTEIN2 and PROTEIN .
AIMed.d125.s1066.p6	N	PROTEIN also interacted with PROTEIN1 and PROTEIN and with the dominant inhibitors PROTEIN and PROTEIN2 .
AIMed.d125.s1066.p7	N	PROTEIN also interacted with PROTEIN and PROTEIN1 and with the dominant inhibitors PROTEIN2 and PROTEIN .
AIMed.d125.s1066.p8	N	PROTEIN also interacted with PROTEIN and PROTEIN1 and with the dominant inhibitors PROTEIN and PROTEIN2 .
AIMed.d125.s1066.p9	N	PROTEIN also interacted with PROTEIN and PROTEIN and with the dominant inhibitors PROTEIN1 and PROTEIN2 .
AIMed.d125.s1067.p0	N	PROTEIN1 displayed the same pattern of combinatorial interactions with PROTEIN2 family proteins as PROTEIN .
AIMed.d125.s1067.p2	N	PROTEIN displayed the same pattern of combinatorial interactions with PROTEIN1 family proteins as PROTEIN2 .
AIMed.d125.s1068.p0	N	Use of deletion mutants of PROTEIN1 suggested that PROTEIN2 homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p1	N	Use of deletion mutants of PROTEIN1 suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN2 protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p2	N	Use of deletion mutants of PROTEIN1 suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p3	N	Use of deletion mutants of PROTEIN1 suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN2 amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p4	N	Use of deletion mutants of PROTEIN1 suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN2 amino acids 83-218.
AIMed.d125.s1068.p5	N	Use of deletion mutants of PROTEIN suggested that PROTEIN1 homodimerization involves interactions between two distinct regions within the PROTEIN2 protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p6	N	Use of deletion mutants of PROTEIN suggested that PROTEIN1 homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p7	N	Use of deletion mutants of PROTEIN suggested that PROTEIN1 homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN2 amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p8	N	Use of deletion mutants of PROTEIN suggested that PROTEIN1 homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN2 amino acids 83-218.
AIMed.d125.s1068.p10	N	Use of deletion mutants of PROTEIN suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN1 protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN2 amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p11	N	Use of deletion mutants of PROTEIN suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN1 protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN2 amino acids 83-218.
AIMed.d125.s1068.p12	N	Use of deletion mutants of PROTEIN suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN1 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN2 amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN amino acids 83-218.
AIMed.d125.s1068.p13	N	Use of deletion mutants of PROTEIN suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN1 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN2 amino acids 83-218.
AIMed.d125.s1068.p14	N	Use of deletion mutants of PROTEIN suggested that PROTEIN homodimerization involves interactions between two distinct regions within the PROTEIN protein, since a LexA protein containing PROTEIN amino acids 83-218 mediated functional interactions with a B42 fusion protein containing PROTEIN1 amino acids 1-81 but did not complement a B42 fusion protein containing PROTEIN2 amino acids 83-218.
AIMed.d125.s1070.p1	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN1 , PROTEIN , or PROTEIN2 but not those containing PROTEIN (an alternatively spliced form of PROTEIN that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p2	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN1 , PROTEIN , or PROTEIN but not those containing PROTEIN2 (an alternatively spliced form of PROTEIN that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p3	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN1 , PROTEIN , or PROTEIN but not those containing PROTEIN (an alternatively spliced form of PROTEIN2 that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p4	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN1 , or PROTEIN2 but not those containing PROTEIN (an alternatively spliced form of PROTEIN that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p5	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN1 , or PROTEIN but not those containing PROTEIN2 (an alternatively spliced form of PROTEIN that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p6	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN1 , or PROTEIN but not those containing PROTEIN (an alternatively spliced form of PROTEIN2 that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p7	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN , or PROTEIN1 but not those containing PROTEIN2 (an alternatively spliced form of PROTEIN that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p8	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN , or PROTEIN1 but not those containing PROTEIN (an alternatively spliced form of PROTEIN2 that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1070.p9	N	This cytotoxicity could be abrogated by B42 fusion proteins containing PROTEIN , PROTEIN , or PROTEIN but not those containing PROTEIN1 (an alternatively spliced form of PROTEIN2 that lacks a well-conserved 63-amino acid region).
AIMed.d125.s1071.p1	N	The findings suggest a model whereby PROTEIN1 and PROTEIN differentially regulate PROTEIN2 function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p2	N	The findings suggest a model whereby PROTEIN1 and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN2 / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p3	N	The findings suggest a model whereby PROTEIN1 and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN2 heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p5	N	The findings suggest a model whereby PROTEIN1 and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN2 homodimerization.
AIMed.d125.s1071.p6	N	The findings suggest a model whereby PROTEIN and PROTEIN1 differentially regulate PROTEIN2 function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p7	N	The findings suggest a model whereby PROTEIN and PROTEIN1 differentially regulate PROTEIN function, and indicate that requirements for PROTEIN2 / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p8	N	The findings suggest a model whereby PROTEIN and PROTEIN1 differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN2 heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p10	N	The findings suggest a model whereby PROTEIN and PROTEIN1 differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN2 homodimerization.
AIMed.d125.s1071.p11	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN1 function, and indicate that requirements for PROTEIN2 / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p12	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN1 function, and indicate that requirements for PROTEIN / PROTEIN2 heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p13	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN1 function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN2 / PROTEIN homodimerization.
AIMed.d125.s1071.p14	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN1 function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN2 homodimerization.
AIMed.d125.s1071.p15	P	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN1 / PROTEIN2 heterodimerization may be different from those for PROTEIN / PROTEIN homodimerization.
AIMed.d125.s1071.p16	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN1 / PROTEIN heterodimerization may be different from those for PROTEIN2 / PROTEIN homodimerization.
AIMed.d125.s1071.p17	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN1 / PROTEIN heterodimerization may be different from those for PROTEIN / PROTEIN2 homodimerization.
AIMed.d125.s1071.p18	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN1 heterodimerization may be different from those for PROTEIN2 / PROTEIN homodimerization.
AIMed.d125.s1071.p19	N	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN1 heterodimerization may be different from those for PROTEIN / PROTEIN2 homodimerization.
AIMed.d125.s1071.p20	P	The findings suggest a model whereby PROTEIN and PROTEIN differentially regulate PROTEIN function, and indicate that requirements for PROTEIN / PROTEIN heterodimerization may be different from those for PROTEIN1 / PROTEIN2 homodimerization.
AIMed.d126.s1072.p0	N	The rates of commitment to renaturation of PROTEIN1 and PROTEIN2 in the presence of the groE chaperonins.
AIMed.d126.s1074.p0	N	Using immunoprecipitation techniques, we have determined the rates at which PROTEIN1 and PROTEIN2 ( PROTEIN ) are released from PROTEIN in a form committed to refold to active enzyme.
AIMed.d126.s1074.p1	N	Using immunoprecipitation techniques, we have determined the rates at which PROTEIN1 and PROTEIN ( PROTEIN2 ) are released from PROTEIN in a form committed to refold to active enzyme.
AIMed.d126.s1074.p2	P	Using immunoprecipitation techniques, we have determined the rates at which PROTEIN1 and PROTEIN ( PROTEIN ) are released from PROTEIN2 in a form committed to refold to active enzyme.
AIMed.d126.s1074.p4	P	Using immunoprecipitation techniques, we have determined the rates at which PROTEIN and PROTEIN1 ( PROTEIN ) are released from PROTEIN2 in a form committed to refold to active enzyme.
AIMed.d126.s1075.p0	N	PROTEIN1 and PROTEIN2 were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable "folding arrested" complexes with PROTEIN .
AIMed.d126.s1075.p1	P	PROTEIN1 and PROTEIN were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable "folding arrested" complexes with PROTEIN2 .
AIMed.d126.s1075.p2	P	PROTEIN and PROTEIN1 were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable "folding arrested" complexes with PROTEIN2 .
AIMed.d126.s1078.p0	N	At 25 degrees C, the rate profiles indicate the release and commitment to folding of PROTEIN1 to its native state occurs far earlier (t1/2 < 1 min) than for PROTEIN2 (t1/2 = 5 min).
AIMed.d126.s1080.p0	N	In contrast, the renaturation rate for PROTEIN1 with the groE chaperonins mirrored the committed renaturation rates following PROTEIN2 depletion.
AIMed.d126.s1081.p0	P	This suggests that PROTEIN1 must interact with PROTEIN2 throughout most of its folding reaction before it acquires a folding competent (groE independent) state.
AIMed.d126.s1082.p0	N	If current models of chaperonin mechanism are correct, PROTEIN1 undergoes more rebinding and release cycles than does PROTEIN2 .
AIMed.d127.s1084.p0	P	Interaction of PROTEIN1 and gamma c chains with PROTEIN2 and PROTEIN : implications for XSCID and XCID.
AIMed.d127.s1084.p1	P	Interaction of PROTEIN1 and gamma c chains with PROTEIN and PROTEIN2 : implications for XSCID and XCID.
AIMed.d127.s1084.p2	N	Interaction of PROTEIN and gamma c chains with PROTEIN1 and PROTEIN2 : implications for XSCID and XCID.
AIMed.d127.s1085.p0	N	PROTEIN1 ( PROTEIN2 ) signaling requires the dimerization of the PROTEIN .( PROTEIN ) and common gamma (gamma c) chains.
AIMed.d127.s1085.p2	N	PROTEIN1 ( PROTEIN ) signaling requires the dimerization of the PROTEIN2 .( PROTEIN ) and common gamma (gamma c) chains.
AIMed.d127.s1085.p3	N	PROTEIN1 ( PROTEIN ) signaling requires the dimerization of the PROTEIN .( PROTEIN2 ) and common gamma (gamma c) chains.
AIMed.d127.s1085.p5	N	PROTEIN ( PROTEIN1 ) signaling requires the dimerization of the PROTEIN2 .( PROTEIN ) and common gamma (gamma c) chains.
AIMed.d127.s1085.p6	N	PROTEIN ( PROTEIN1 ) signaling requires the dimerization of the PROTEIN .( PROTEIN2 ) and common gamma (gamma c) chains.
AIMed.d127.s1085.p9	N	PROTEIN ( PROTEIN ) signaling requires the dimerization of the PROTEIN1 .( PROTEIN2 ) and common gamma (gamma c) chains.
AIMed.d127.s1087.p0	N	PROTEIN1 , PROTEIN2 , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p1	N	PROTEIN1 , PROTEIN , PROTEIN2 (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p2	N	PROTEIN1 , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN2 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p3	N	PROTEIN1 , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN2 and PROTEIN .
AIMed.d127.s1087.p4	N	PROTEIN1 , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN2 .
AIMed.d127.s1087.p5	N	PROTEIN , PROTEIN1 , PROTEIN2 (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p6	N	PROTEIN , PROTEIN1 , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN2 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p7	N	PROTEIN , PROTEIN1 , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN2 and PROTEIN .
AIMed.d127.s1087.p9	N	PROTEIN , PROTEIN , PROTEIN1 (whose receptors are known to contain gamma c), and PROTEIN2 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN .
AIMed.d127.s1087.p11	N	PROTEIN , PROTEIN , PROTEIN1 (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN2 .
AIMed.d127.s1087.p12	N	PROTEIN , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN1 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN2 and PROTEIN .
AIMed.d127.s1087.p13	N	PROTEIN , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN1 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN and PROTEIN2 .
AIMed.d127.s1087.p14	N	PROTEIN , PROTEIN , PROTEIN (whose receptors are known to contain gamma c), and PROTEIN (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases PROTEIN1 and PROTEIN2 .
AIMed.d127.s1088.p0	N	PROTEIN1 and PROTEIN2 associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p1	P	PROTEIN1 and PROTEIN associated with PROTEIN2 and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p2	N	PROTEIN1 and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN2 induced PROTEIN - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p3	N	PROTEIN1 and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN2 - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p4	N	PROTEIN1 and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN2 and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p5	N	PROTEIN1 and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1088.p7	N	PROTEIN and PROTEIN1 associated with PROTEIN and gamma c, respectively; PROTEIN2 induced PROTEIN - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p9	N	PROTEIN and PROTEIN1 associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN2 and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p10	N	PROTEIN and PROTEIN1 associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1088.p11	N	PROTEIN and PROTEIN associated with PROTEIN1 and gamma c, respectively; PROTEIN2 induced PROTEIN - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p12	N	PROTEIN and PROTEIN associated with PROTEIN1 and gamma c, respectively; PROTEIN induced PROTEIN2 - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p13	N	PROTEIN and PROTEIN associated with PROTEIN1 and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN2 and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p14	N	PROTEIN and PROTEIN associated with PROTEIN1 and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1088.p15	N	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN1 induced PROTEIN2 - PROTEIN and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p16	N	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN1 induced PROTEIN - PROTEIN2 and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p17	N	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN1 induced PROTEIN - PROTEIN and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1088.p18	P	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN1 - PROTEIN2 and increased PROTEIN -gamma c associations.
AIMed.d127.s1088.p19	N	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN1 - PROTEIN and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1088.p20	N	PROTEIN and PROTEIN associated with PROTEIN and gamma c, respectively; PROTEIN induced PROTEIN - PROTEIN1 and increased PROTEIN2 -gamma c associations.
AIMed.d127.s1090.p0	N	Thus, gamma c mutations in at least some XSCID and XCID patients prevent normal PROTEIN1 activation, suggesting that mutations of PROTEIN2 may result in an XSCID-like phenotype.
AIMed.d128.s1091.p0	N	The X-ray structure of a PROTEIN1 - PROTEIN2 receptor complex.
AIMed.d128.s1092.p0	N	The human pituitary hormones, PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.
AIMed.d128.s1092.p1	N	The human pituitary hormones, PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.
AIMed.d128.s1092.p2	N	The human pituitary hormones, PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.
AIMed.d128.s1092.p3	N	The human pituitary hormones, PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.
AIMed.d128.s1092.p5	N	The human pituitary hormones, PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.
AIMed.d128.s1094.p0	N	The PROTEIN1 and PROTEIN2 receptors ( PROTEIN and PROTEIN , respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.
AIMed.d128.s1094.p1	P	The PROTEIN1 and PROTEIN receptors ( PROTEIN2 and PROTEIN , respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.
AIMed.d128.s1094.p3	N	The PROTEIN and PROTEIN1 receptors ( PROTEIN2 and PROTEIN , respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.
AIMed.d128.s1094.p4	P	The PROTEIN and PROTEIN1 receptors ( PROTEIN and PROTEIN2 , respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.
AIMed.d128.s1097.p0	N	In the case of PROTEIN1 , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN2 does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p1	N	In the case of PROTEIN1 , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN2 receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p2	N	In the case of PROTEIN1 , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN2 binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p3	N	In the case of PROTEIN1 , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN2 and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p5	N	In the case of PROTEIN1 , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1097.p6	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN1 does not bind to the PROTEIN2 receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p7	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN1 does not bind to the PROTEIN receptor, but PROTEIN2 binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p8	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN1 does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN2 and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p9	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN1 does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN and PROTEIN2 , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p10	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN1 does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1097.p11	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN1 receptor, but PROTEIN2 binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p12	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN1 receptor, but PROTEIN binds to both the PROTEIN2 and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p13	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN1 receptor, but PROTEIN binds to both the PROTEIN and PROTEIN2 , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p14	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN1 receptor, but PROTEIN binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1097.p15	P	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN1 binds to both the PROTEIN2 and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p16	P	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN1 binds to both the PROTEIN and PROTEIN2 , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p17	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN1 binds to both the PROTEIN and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1097.p18	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN1 and PROTEIN2 , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN overlap.
AIMed.d128.s1097.p19	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN1 and PROTEIN , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1097.p20	N	In the case of PROTEIN , activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. PROTEIN does not bind to the PROTEIN receptor, but PROTEIN binds to both the PROTEIN and PROTEIN1 , and mutagenesis studies have shown that the receptor-binding sites on PROTEIN2 overlap.
AIMed.d128.s1098.p0	P	We present here the crystal structure of the 1:1 complex of PROTEIN1 bound to the extracellular domain of the PROTEIN2 .
AIMed.d128.s1099.p0	P	Comparisons with the PROTEIN1 - PROTEIN2 complex reveal how PROTEIN can bind to the two distinctly different receptor binding surfaces.
AIMed.d128.s1099.p1	N	Comparisons with the PROTEIN1 - PROTEIN complex reveal how PROTEIN2 can bind to the two distinctly different receptor binding surfaces.
AIMed.d128.s1099.p2	N	Comparisons with the PROTEIN - PROTEIN1 complex reveal how PROTEIN2 can bind to the two distinctly different receptor binding surfaces.
AIMed.d129.s1101.p0	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN1 , PROTEIN2 , and three additional proteins, PROTEIN , PROTEIN , and PROTEIN .
AIMed.d129.s1101.p1	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN1 , PROTEIN , and three additional proteins, PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d129.s1101.p2	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN1 , PROTEIN , and three additional proteins, PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d129.s1101.p3	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN1 , PROTEIN , and three additional proteins, PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d129.s1101.p4	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN1 , and three additional proteins, PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d129.s1101.p5	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN1 , and three additional proteins, PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d129.s1101.p6	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN1 , and three additional proteins, PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d129.s1101.p7	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN , and three additional proteins, PROTEIN1 , PROTEIN2 , and PROTEIN .
AIMed.d129.s1101.p8	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN , and three additional proteins, PROTEIN1 , PROTEIN , and PROTEIN2 .
AIMed.d129.s1101.p9	N	Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of PROTEIN , PROTEIN , and three additional proteins, PROTEIN , PROTEIN1 , and PROTEIN2 .
AIMed.d129.s1102.p0	N	PROTEIN1 is also present in immunoaffinity-purified PROTEIN2 complexes along with PROTEIN and another protein, PROTEIN .
AIMed.d129.s1102.p1	N	PROTEIN1 is also present in immunoaffinity-purified PROTEIN complexes along with PROTEIN2 and another protein, PROTEIN .
AIMed.d129.s1102.p2	N	PROTEIN1 is also present in immunoaffinity-purified PROTEIN complexes along with PROTEIN and another protein, PROTEIN2 .
AIMed.d129.s1102.p3	N	PROTEIN is also present in immunoaffinity-purified PROTEIN1 complexes along with PROTEIN2 and another protein, PROTEIN .
AIMed.d129.s1102.p4	N	PROTEIN is also present in immunoaffinity-purified PROTEIN1 complexes along with PROTEIN and another protein, PROTEIN2 .
AIMed.d129.s1102.p5	N	PROTEIN is also present in immunoaffinity-purified PROTEIN complexes along with PROTEIN1 and another protein, PROTEIN2 .
AIMed.d129.s1104.p0	N	Antibodies to PROTEIN1 detect similar levels of PROTEIN2 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that PROTEIN is a conserved protein of broad tissue distribution.
AIMed.d129.s1104.p1	N	Antibodies to PROTEIN1 detect similar levels of PROTEIN in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that PROTEIN2 is a conserved protein of broad tissue distribution.
AIMed.d129.s1104.p2	N	Antibodies to PROTEIN detect similar levels of PROTEIN1 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that PROTEIN2 is a conserved protein of broad tissue distribution.
AIMed.d129.s1110.p0	N	Bacterially overexpressed human PROTEIN1 was used to raise several monoclonal antibodies to PROTEIN2 .
AIMed.d129.s1111.p0	P	These antibodies specifically immunoprecipitate PROTEIN1 in complex with PROTEIN2 in all tissues tested and can be used to immunoaffinity isolate progesterone receptor complexes from chicken oviduct cytosol.
AIMed.d130.s1112.p0	N	Cloning of the complete coding region for human PROTEIN1 using the two hybrid system and expression of PROTEIN2 in E. coli.
AIMed.d131.s1120.p0	N	cDNA clones encoding a human PROTEIN1 ( PROTEIN2 ) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds PROTEIN specifically.
AIMed.d131.s1120.p1	P	cDNA clones encoding a human PROTEIN1 ( PROTEIN ) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds PROTEIN2 specifically.
AIMed.d131.s1121.p0	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN2 ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p1	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN2 ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p2	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN2 expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p3	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN2 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p4	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN2 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p5	N	The predicted amino acid sequence of PROTEIN1 is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1121.p6	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN1 ( PROTEIN2 ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p7	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN1 ( PROTEIN ). PROTEIN2 expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p8	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN1 ( PROTEIN ). PROTEIN expressed in an PROTEIN2 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p9	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN1 ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN2 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p10	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN1 ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1121.p11	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN1 ). PROTEIN2 expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p12	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN1 ). PROTEIN expressed in an PROTEIN2 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p13	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN1 ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN2 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p14	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN1 ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1121.p15	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN1 expressed in an PROTEIN2 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p16	P	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN1 expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN2 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p17	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN1 expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1121.p18	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN1 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN2 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN .
AIMed.d131.s1121.p19	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN1 -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1121.p20	N	The predicted amino acid sequence of PROTEIN is 60% identical and 73% similar to mouse PROTEIN ( PROTEIN ). PROTEIN expressed in an PROTEIN -dependent mouse pro-B cell line (Ba/F3) binds PROTEIN1 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to PROTEIN2 .
AIMed.d131.s1122.p0	N	Mouse PROTEIN1 does not bind to PROTEIN2 , and PROTEIN -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN .
AIMed.d131.s1122.p1	N	Mouse PROTEIN1 does not bind to PROTEIN , and PROTEIN2 -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN .
AIMed.d131.s1122.p2	N	Mouse PROTEIN1 does not bind to PROTEIN , and PROTEIN -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN2 .
AIMed.d131.s1122.p3	N	Mouse PROTEIN does not bind to PROTEIN1 , and PROTEIN2 -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN .
AIMed.d131.s1122.p4	N	Mouse PROTEIN does not bind to PROTEIN1 , and PROTEIN -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN2 .
AIMed.d131.s1122.p5	N	Mouse PROTEIN does not bind to PROTEIN , and PROTEIN1 -expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of PROTEIN2 .
AIMed.d131.s1124.p0	N	In a number of human T cell clones, expression of PROTEIN1 mRNA is down-regulated after activation of the cells with anti- PROTEIN2 Ab and phorbol ester.
AIMed.d131.s1126.p0	N	Like PROTEIN1 , PROTEIN2 is structurally related to PROTEIN .
AIMed.d131.s1126.p1	N	Like PROTEIN1 , PROTEIN is structurally related to PROTEIN2 .
AIMed.d131.s1126.p2	N	Like PROTEIN , PROTEIN1 is structurally related to PROTEIN2 .
AIMed.d131.s1127.p0	N	Because PROTEIN1 inhibits macrophage activation by PROTEIN2 , this relationship suggests possible shared receptor or signal transduction pathway components.
AIMed.d132.s1128.p4	N	Functional participation of the PROTEIN1 chain in PROTEIN2 complexes.
AIMed.d132.s1129.p8	N	The gamma chain of the interleukin-2 (IL-2) receptor  PROTEIN1 is shared with the functional PROTEIN2 and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
AIMed.d133.s1132.p0	N	PROTEIN1 : a protein kinase stimulated by UV light and PROTEIN2 that binds and phosphorylates the PROTEIN activation domain.
AIMed.d133.s1132.p1	P	PROTEIN1 : a protein kinase stimulated by UV light and PROTEIN that binds and phosphorylates the PROTEIN2 activation domain.
AIMed.d133.s1132.p2	N	PROTEIN : a protein kinase stimulated by UV light and PROTEIN1 that binds and phosphorylates the PROTEIN2 activation domain.
AIMed.d133.s1134.p0	N	The effect on PROTEIN1 transcriptional activity results, in part, from enhanced phosphorylation of the PROTEIN2 NH2-terminal activation domain.
AIMed.d133.s1135.p0	N	Here, we describe the molecular cloning and characterization of PROTEIN1 , a distant relative of the PROTEIN2 group that is activated by dual phosphorylation at Thr and Tyr during the UV response.
AIMed.d133.s1136.p0	P	Significantly, PROTEIN1 partially activates PROTEIN2 and potentiates the activation caused by UV.
AIMed.d133.s1137.p0	P	PROTEIN1 binds to the PROTEIN2 transactivation domain and phosphorylates it on Ser-63 and Ser-73.
AIMed.d134.s1140.p1	P	PROTEIN1 is a ligand for the PROTEIN2 .
AIMed.d134.s1141.p2	N	A protein ligand for the PROTEIN1 has been isolated by using the extracellular domain ( PROTEIN2 -X) of the receptor as an affinity reagent.
AIMed.d134.s1143.p0	N	Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of PROTEIN1 , a protein previously identified as the product of an early response gene induced by PROTEIN2 .
AIMed.d134.s1144.p0	P	We report here that recombinant PROTEIN1 induces autophosphorylation of PROTEIN2 in intact cells, consistent with PROTEIN being an authentic ligand for PROTEIN .
AIMed.d134.s1144.p1	N	We report here that recombinant PROTEIN1 induces autophosphorylation of PROTEIN in intact cells, consistent with PROTEIN2 being an authentic ligand for PROTEIN .
AIMed.d134.s1144.p3	N	We report here that recombinant PROTEIN induces autophosphorylation of PROTEIN1 in intact cells, consistent with PROTEIN2 being an authentic ligand for PROTEIN .
AIMed.d134.s1144.p4	N	We report here that recombinant PROTEIN induces autophosphorylation of PROTEIN1 in intact cells, consistent with PROTEIN being an authentic ligand for PROTEIN2 .
AIMed.d134.s1144.p5	P	We report here that recombinant PROTEIN induces autophosphorylation of PROTEIN in intact cells, consistent with PROTEIN1 being an authentic ligand for PROTEIN2 .
AIMed.d134.s1145.p0	N	PROTEIN1 is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to PROTEIN2 , and can be isolated in the same way.
AIMed.d135.s1147.p0	N	Tumor necrosis factor (TNF) and PROTEIN1 ( PROTEIN2 ) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses.
AIMed.d135.s1148.p0	P	The cell surface form of PROTEIN1 is assembled during biosynthesis as a heteromeric complex with PROTEIN2 ( PROTEIN ), a type II transmembrane protein that is another member of the TNF ligand family.
AIMed.d135.s1148.p1	P	The cell surface form of PROTEIN1 is assembled during biosynthesis as a heteromeric complex with PROTEIN ( PROTEIN2 ), a type II transmembrane protein that is another member of the TNF ligand family.
AIMed.d135.s1148.p2	N	The cell surface form of PROTEIN is assembled during biosynthesis as a heteromeric complex with PROTEIN1 ( PROTEIN2 ), a type II transmembrane protein that is another member of the TNF ligand family.
AIMed.d135.s1149.p0	N	Secreted PROTEIN1 is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface PROTEIN2 - PROTEIN complex.
AIMed.d135.s1149.p1	N	Secreted PROTEIN1 is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface PROTEIN - PROTEIN2 complex.
AIMed.d135.s1149.p2	P	Secreted PROTEIN is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface PROTEIN1 - PROTEIN2 complex.
AIMed.d135.s1150.p0	N	A receptor specific for human PROTEIN1 was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted PROTEIN2 .
AIMed.d136.s1153.p0	N	The cytokine, designated PROTEIN1 ( PROTEIN2 ), is produced by a wide variety of cells and tissues and shares many biological properties with PROTEIN .
AIMed.d136.s1153.p1	N	The cytokine, designated PROTEIN1 ( PROTEIN ), is produced by a wide variety of cells and tissues and shares many biological properties with PROTEIN2 .
AIMed.d136.s1153.p2	N	The cytokine, designated PROTEIN ( PROTEIN1 ), is produced by a wide variety of cells and tissues and shares many biological properties with PROTEIN2 .
AIMed.d136.s1154.p1	N	Monoclonal antibodies to the beta chain of the PROTEIN1 receptor inhibited the biological activity of PROTEIN , and PROTEIN2 competed for binding with PROTEIN , indicating that PROTEIN uses components of the PROTEIN .
AIMed.d136.s1154.p2	N	Monoclonal antibodies to the beta chain of the PROTEIN1 receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN2 , indicating that PROTEIN uses components of the PROTEIN .
AIMed.d136.s1154.p3	N	Monoclonal antibodies to the beta chain of the PROTEIN1 receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN , indicating that PROTEIN2 uses components of the PROTEIN .
AIMed.d136.s1154.p5	N	Monoclonal antibodies to the beta chain of the PROTEIN1 receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN , indicating that PROTEIN uses components of the PROTEIN2 .
AIMed.d136.s1154.p6	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN1 , and PROTEIN2 competed for binding with PROTEIN , indicating that PROTEIN uses components of the PROTEIN .
AIMed.d136.s1154.p7	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN1 , and PROTEIN competed for binding with PROTEIN2 , indicating that PROTEIN uses components of the PROTEIN .
AIMed.d136.s1154.p8	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN1 , and PROTEIN competed for binding with PROTEIN , indicating that PROTEIN2 uses components of the PROTEIN .
AIMed.d136.s1154.p10	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN1 , and PROTEIN competed for binding with PROTEIN , indicating that PROTEIN uses components of the PROTEIN2 .
AIMed.d136.s1154.p11	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN1 competed for binding with PROTEIN2 , indicating that PROTEIN uses components of the PROTEIN .
AIMed.d136.s1154.p12	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN1 competed for binding with PROTEIN , indicating that PROTEIN2 uses components of the PROTEIN .
AIMed.d136.s1154.p14	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN1 competed for binding with PROTEIN , indicating that PROTEIN uses components of the PROTEIN2 .
AIMed.d136.s1154.p15	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN1 , indicating that PROTEIN2 uses components of the PROTEIN .
AIMed.d136.s1154.p17	N	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN1 , indicating that PROTEIN uses components of the PROTEIN2 .
AIMed.d136.s1154.p19	P	Monoclonal antibodies to the beta chain of the PROTEIN receptor inhibited the biological activity of PROTEIN , and PROTEIN competed for binding with PROTEIN , indicating that PROTEIN1 uses components of the PROTEIN2 .
AIMed.d137.s1155.p0	N	The POU domains of the PROTEIN1 and PROTEIN2 transcription factors mediate specific interaction with PROTEIN .
AIMed.d137.s1155.p1	P	The POU domains of the PROTEIN1 and PROTEIN transcription factors mediate specific interaction with PROTEIN2 .
AIMed.d137.s1155.p2	P	The POU domains of the PROTEIN and PROTEIN1 transcription factors mediate specific interaction with PROTEIN2 .
AIMed.d137.s1156.p0	N	We had previously shown that the ubiquitous PROTEIN1 and the lymphoid-specific PROTEIN2 transcription factors stimulate transcription at the level of stable preinitiation complex formation.
AIMed.d137.s1157.p2	N	We have therefore investigated whether the octamer binding proteins might physically interact with PROTEIN , the PROTEIN1 component of the PROTEIN2 factor.
AIMed.d137.s1158.p0	P	By using several different experimental systems we show that PROTEIN1 efficiently associates with PROTEIN2 and PROTEIN .
AIMed.d137.s1158.p2	N	By using several different experimental systems we show that PROTEIN efficiently associates with PROTEIN1 and PROTEIN2 .
AIMed.d137.s1161.p0	P	We show that the POU homeodomain of PROTEIN1 and the evolutionarily conserved C-terminal core domain of PROTEIN2 are both required and sufficient for the interaction.
AIMed.d137.s1162.p0	N	The PROTEIN1 POU domain, which is highly homologous to the PROTEIN2 POU domain, likewise mediates interaction with PROTEIN .
AIMed.d137.s1162.p1	P	The PROTEIN1 POU domain, which is highly homologous to the PROTEIN POU domain, likewise mediates interaction with PROTEIN2 .
AIMed.d137.s1162.p2	N	The PROTEIN POU domain, which is highly homologous to the PROTEIN1 POU domain, likewise mediates interaction with PROTEIN2 .
AIMed.d137.s1163.p0	P	The interaction can also be observed in vivo, as PROTEIN1 can be co-precipitated with PROTEIN2 from co-transfected Cos1 cells and PROTEIN co-immunoprecipitates with the endogenous PROTEIN from HeLa cells.
AIMed.d137.s1163.p1	N	The interaction can also be observed in vivo, as PROTEIN1 can be co-precipitated with PROTEIN from co-transfected Cos1 cells and PROTEIN2 co-immunoprecipitates with the endogenous PROTEIN from HeLa cells.
AIMed.d137.s1163.p3	N	The interaction can also be observed in vivo, as PROTEIN can be co-precipitated with PROTEIN1 from co-transfected Cos1 cells and PROTEIN2 co-immunoprecipitates with the endogenous PROTEIN from HeLa cells.
AIMed.d137.s1163.p4	N	The interaction can also be observed in vivo, as PROTEIN can be co-precipitated with PROTEIN1 from co-transfected Cos1 cells and PROTEIN co-immunoprecipitates with the endogenous PROTEIN2 from HeLa cells.
AIMed.d137.s1163.p5	P	The interaction can also be observed in vivo, as PROTEIN can be co-precipitated with PROTEIN from co-transfected Cos1 cells and PROTEIN1 co-immunoprecipitates with the endogenous PROTEIN2 from HeLa cells.
AIMed.d137.s1164.p0	N	Co-transfection of human PROTEIN1 and PROTEIN2 expression vectors into B cells resulted in a synergistic activation of an octamer motif containing promoter.
AIMed.d138.s1165.p0	P	Interaction of mammalian splicing factor PROTEIN1 with PROTEIN2 and relation of its 60-kD subunit to yeast PROTEIN .
AIMed.d138.s1165.p1	N	Interaction of mammalian splicing factor PROTEIN1 with PROTEIN and relation of its 60-kD subunit to yeast PROTEIN2 .
AIMed.d138.s1166.p0	N	In the assembly of a prespliceosome, PROTEIN1 (snRNP) functions in pre-messenger RNA (mRNA) splicing together with splicing factors (SFs) 3a, PROTEIN2 , and several other proteins.
AIMed.d138.s1168.p0	N	Here it is shown that the PROTEIN1 subunits correspond to three of the 17S PROTEIN2 -specific polypeptides.
AIMed.d138.s1169.p0	P	PROTEIN1 interacts with PROTEIN2 in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p1	N	PROTEIN1 interacts with PROTEIN in the presence of PROTEIN2 to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p2	N	PROTEIN1 interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN2 , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p3	N	PROTEIN1 interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN2 and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p4	N	PROTEIN1 interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN2 in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p5	N	PROTEIN1 interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1169.p6	N	PROTEIN interacts with PROTEIN1 in the presence of PROTEIN2 to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p7	N	PROTEIN interacts with PROTEIN1 in the presence of PROTEIN to generate a structure similar to 17S PROTEIN2 , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p8	N	PROTEIN interacts with PROTEIN1 in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN2 and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p9	N	PROTEIN interacts with PROTEIN1 in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN2 in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p10	N	PROTEIN interacts with PROTEIN1 in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1169.p11	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN1 to generate a structure similar to 17S PROTEIN2 , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p13	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN1 to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN2 in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p14	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN1 to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1169.p15	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN1 , which suggests a function for PROTEIN2 and PROTEIN in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p16	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN1 , which suggests a function for PROTEIN and PROTEIN2 in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p17	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN1 , which suggests a function for PROTEIN and PROTEIN in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1169.p18	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN1 and PROTEIN2 in the incorporation of PROTEIN into the spliceosome.
AIMed.d138.s1169.p19	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN1 and PROTEIN in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1169.p20	N	PROTEIN interacts with PROTEIN in the presence of PROTEIN to generate a structure similar to 17S PROTEIN , which suggests a function for PROTEIN and PROTEIN1 in the incorporation of PROTEIN2 into the spliceosome.
AIMed.d138.s1170.p0	N	Furthermore, the 60-kilodalton subunit of PROTEIN1 is related to the yeast splicing protein PROTEIN2 .
AIMed.d139.s1171.p0	N	PROTEIN1 . an Ala-->Gly substitution in helix 1 of PROTEIN2 repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer.
AIMed.d139.s1173.p0	P	The self-association site appears to be formed by interactions between helices 1 and 2 of PROTEIN1 repeat 17 of one dimer with helix 3 of PROTEIN2 repeat 1 of the other dimer to form two combined alpha-beta triple-helical segments.
AIMed.d139.s1177.p0	N	Following linkage studies which were most consistent with a PROTEIN1 gene mutation, a nucleotide change was identified in codon 2018, resulting in an Ala-->Gly substitution in the first helical domain of PROTEIN2 repeat 17.
AIMed.d140.s1180.p0	P	PROTEIN1 , a human G1 and S phase protein phosphatase that associates with PROTEIN2 .
AIMed.d140.s1181.p0	N	We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human PROTEIN1 ( PROTEIN2 ).
AIMed.d140.s1182.p0	P	In yeast, PROTEIN1 interacts with cyclin-dependent kinases, including human PROTEIN2 , PROTEIN , and PROTEIN , but not with PROTEIN .
AIMed.d140.s1182.p2	P	In yeast, PROTEIN1 interacts with cyclin-dependent kinases, including human PROTEIN , PROTEIN , and PROTEIN2 , but not with PROTEIN .
AIMed.d140.s1182.p4	N	In yeast, PROTEIN interacts with cyclin-dependent kinases, including human PROTEIN1 , PROTEIN2 , and PROTEIN , but not with PROTEIN .
AIMed.d140.s1182.p5	N	In yeast, PROTEIN interacts with cyclin-dependent kinases, including human PROTEIN1 , PROTEIN , and PROTEIN2 , but not with PROTEIN .
AIMed.d140.s1182.p6	N	In yeast, PROTEIN interacts with cyclin-dependent kinases, including human PROTEIN1 , PROTEIN , and PROTEIN , but not with PROTEIN2 .
AIMed.d140.s1182.p7	N	In yeast, PROTEIN interacts with cyclin-dependent kinases, including human PROTEIN , PROTEIN1 , and PROTEIN2 , but not with PROTEIN .
AIMed.d140.s1182.p9	N	In yeast, PROTEIN interacts with cyclin-dependent kinases, including human PROTEIN , PROTEIN , and PROTEIN1 , but not with PROTEIN2 .
AIMed.d140.s1183.p0	P	In HeLa cells, PROTEIN1 is expressed at the G1 to S transition, and the protein forms stable complexes with PROTEIN2 .
AIMed.d140.s1186.p0	N	Overexpression of wild-type PROTEIN1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on PROTEIN2 phosphatase activity.
AIMed.d141.s1189.p0	N	The cyclin-dependent kinase PROTEIN1 associates with PROTEIN2 , D, and E and has been implicated in the control of the G1 to S phase transition in mammals.
AIMed.d141.s1191.p0	N	PROTEIN1 encodes a novel 21 kd protein that is found in PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN immunoprecipitates.
AIMed.d141.s1191.p1	N	PROTEIN1 encodes a novel 21 kd protein that is found in PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN immunoprecipitates.
AIMed.d141.s1191.p2	N	PROTEIN1 encodes a novel 21 kd protein that is found in PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN immunoprecipitates.
AIMed.d141.s1191.p3	N	PROTEIN1 encodes a novel 21 kd protein that is found in PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 immunoprecipitates.
AIMed.d141.s1191.p4	N	PROTEIN encodes a novel 21 kd protein that is found in PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN immunoprecipitates.
AIMed.d141.s1191.p6	N	PROTEIN encodes a novel 21 kd protein that is found in PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 immunoprecipitates.
AIMed.d141.s1191.p7	N	PROTEIN encodes a novel 21 kd protein that is found in PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN immunoprecipitates.
AIMed.d141.s1191.p9	N	PROTEIN encodes a novel 21 kd protein that is found in PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 immunoprecipitates.
AIMed.d141.s1192.p1	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p2	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p3	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p4	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p5	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p6	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p7	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p8	N	PROTEIN1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p9	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p10	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p11	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p12	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p13	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p14	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p15	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p16	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN1 by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p17	P	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN2 , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p18	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p19	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p20	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p21	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p22	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p23	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN1 - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p24	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN2 - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p25	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN - PROTEIN2 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p26	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , PROTEIN2 - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p27	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p28	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p29	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p30	P	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN1 - PROTEIN2 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p32	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN1 - PROTEIN , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p34	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN1 - PROTEIN , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p35	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , PROTEIN2 - PROTEIN , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p36	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , PROTEIN - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p37	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p38	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , PROTEIN - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p39	P	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN1 - PROTEIN2 , and PROTEIN - PROTEIN complexes.
AIMed.d141.s1192.p41	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN1 - PROTEIN , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p42	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , and PROTEIN2 - PROTEIN complexes.
AIMed.d141.s1192.p43	N	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN1 , and PROTEIN - PROTEIN2 complexes.
AIMed.d141.s1192.p44	P	PROTEIN is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of PROTEIN by PROTEIN - PROTEIN , PROTEIN - PROTEIN , PROTEIN - PROTEIN , and PROTEIN1 - PROTEIN2 complexes.
AIMed.d141.s1193.p0	N	Cotransfection experiments indicate that PROTEIN1 and PROTEIN2 function in a mutually antagonistic manner to control cell cycle progression.
AIMed.d142.s1194.p0	P	Evidence for physical interaction between the zinc-finger transcription factors PROTEIN1 and PROTEIN2 .
AIMed.d142.s1197.p0	N	The recently cloned PROTEIN1 is such an PROTEIN2 .
AIMed.d142.s1199.p0	N	The ability of PROTEIN1 to initiate transcription is augmented by the presence of a TATA motif or binding sites for transcription factor PROTEIN2 .
AIMed.d142.s1200.p0	N	To study the mechanism underlying the apparent functional cooperation between PROTEIN1 and PROTEIN2 , we explored the possibility of protein-protein interactions between these two transcription factors.
AIMed.d142.s1201.p0	P	We found that PROTEIN1 and PROTEIN2 can form a physical complex.
AIMed.d142.s1202.p0	P	In addition, we identified domains within PROTEIN1 and PROTEIN2 that mediate their interactions with each other.
AIMed.d142.s1203.p0	P	The physical interaction between PROTEIN1 and PROTEIN2 may thus form the basis for the functional interplay observed previously.
AIMed.d143.s1204.p0	N	Involvement of PROTEIN1 signal transducer PROTEIN2 in PROTEIN -mediated signal transduction.
AIMed.d143.s1204.p1	N	Involvement of PROTEIN1 signal transducer PROTEIN in PROTEIN2 -mediated signal transduction.
AIMed.d143.s1204.p2	N	Involvement of PROTEIN signal transducer PROTEIN1 in PROTEIN2 -mediated signal transduction.
AIMed.d143.s1206.p0	N	We have previously identified PROTEIN1 specific binding protein which is distinct from that of PROTEIN2 in a number of cell lines.
AIMed.d143.s1207.p0	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN1 and PROTEIN2 prompted us to investigate whether PROTEIN shares common signal transduction mechanisms with PROTEIN .
AIMed.d143.s1207.p1	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN1 and PROTEIN prompted us to investigate whether PROTEIN2 shares common signal transduction mechanisms with PROTEIN .
AIMed.d143.s1207.p2	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN1 and PROTEIN prompted us to investigate whether PROTEIN shares common signal transduction mechanisms with PROTEIN2 .
AIMed.d143.s1207.p3	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN and PROTEIN1 prompted us to investigate whether PROTEIN2 shares common signal transduction mechanisms with PROTEIN .
AIMed.d143.s1207.p4	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN and PROTEIN1 prompted us to investigate whether PROTEIN shares common signal transduction mechanisms with PROTEIN2 .
AIMed.d143.s1207.p5	N	The similarities in biofunctions and differences in ligand binding proteins between PROTEIN and PROTEIN prompted us to investigate whether PROTEIN1 shares common signal transduction mechanisms with PROTEIN2 .
AIMed.d143.s1208.p0	N	We have examined early signals triggered by PROTEIN1 or PROTEIN2 in a multifactor-dependent human erythroleukemic cell line, TF-1.
AIMed.d143.s1209.p0	N	The results showed that PROTEIN1 and PROTEIN2 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene ( PROTEIN ) expression in TF-1 cells.
AIMed.d143.s1209.p1	P	The results showed that PROTEIN1 and PROTEIN can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene ( PROTEIN2 ) expression in TF-1 cells.
AIMed.d143.s1209.p2	P	The results showed that PROTEIN and PROTEIN1 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene ( PROTEIN2 ) expression in TF-1 cells.
AIMed.d143.s1210.p0	N	These findings imply that PROTEIN1 and PROTEIN2 share similar early signaling events with the possibility of using the same signal transducer, PROTEIN .
AIMed.d143.s1210.p1	N	These findings imply that PROTEIN1 and PROTEIN share similar early signaling events with the possibility of using the same signal transducer, PROTEIN2 .
AIMed.d143.s1210.p2	N	These findings imply that PROTEIN and PROTEIN1 share similar early signaling events with the possibility of using the same signal transducer, PROTEIN2 .
AIMed.d143.s1211.p0	N	We next tested whether PROTEIN1 induced signaling can be inhibited by anti- PROTEIN2 antibodies which blocked PROTEIN -mediated functions.
AIMed.d143.s1211.p1	N	We next tested whether PROTEIN1 induced signaling can be inhibited by anti- PROTEIN antibodies which blocked PROTEIN2 -mediated functions.
AIMed.d143.s1211.p2	N	We next tested whether PROTEIN induced signaling can be inhibited by anti- PROTEIN1 antibodies which blocked PROTEIN2 -mediated functions.
AIMed.d143.s1212.p0	N	It was observed that anti- PROTEIN1 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN2 gene expression elicited by PROTEIN or PROTEIN in TF-1 cells.
AIMed.d143.s1212.p1	N	It was observed that anti- PROTEIN1 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN gene expression elicited by PROTEIN2 or PROTEIN in TF-1 cells.
AIMed.d143.s1212.p2	N	It was observed that anti- PROTEIN1 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN gene expression elicited by PROTEIN or PROTEIN2 in TF-1 cells.
AIMed.d143.s1212.p3	N	It was observed that anti- PROTEIN antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN1 gene expression elicited by PROTEIN2 or PROTEIN in TF-1 cells.
AIMed.d143.s1212.p4	N	It was observed that anti- PROTEIN antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN1 gene expression elicited by PROTEIN or PROTEIN2 in TF-1 cells.
AIMed.d143.s1212.p5	N	It was observed that anti- PROTEIN antibodies abolished cell proliferation, protein tyrosine phosphorylation, and PROTEIN gene expression elicited by PROTEIN1 or PROTEIN2 in TF-1 cells.
AIMed.d143.s1214.p0	N	Finally, anti- PROTEIN1 antibody inhibited the ability of PROTEIN2 , but not PROTEIN , to transduce early signals in TF-1 cells.
AIMed.d143.s1214.p1	N	Finally, anti- PROTEIN1 antibody inhibited the ability of PROTEIN , but not PROTEIN2 , to transduce early signals in TF-1 cells.
AIMed.d143.s1214.p2	N	Finally, anti- PROTEIN antibody inhibited the ability of PROTEIN1 , but not PROTEIN2 , to transduce early signals in TF-1 cells.
AIMed.d143.s1215.p0	N	These results demonstrate that PROTEIN1 and PROTEIN2 utilize different ligand binding proteins, but share common signal transducer, PROTEIN , in TF-1 cells.
AIMed.d143.s1215.p1	N	These results demonstrate that PROTEIN1 and PROTEIN utilize different ligand binding proteins, but share common signal transducer, PROTEIN2 , in TF-1 cells.
AIMed.d143.s1215.p2	N	These results demonstrate that PROTEIN and PROTEIN1 utilize different ligand binding proteins, but share common signal transducer, PROTEIN2 , in TF-1 cells.
AIMed.d144.s1216.p0	P	The PROTEIN1 associates with the PROTEIN2 catalytic subunit.
AIMed.d144.s1217.p0	N	The PROTEIN1 ( PROTEIN2 ) interacts with many cellular proteins in complexes potentially important for its growth-suppressing function.
AIMed.d144.s1219.p0	N	One clone encodes a novel PROTEIN1 catalytic subunit ( PROTEIN2 ), which differs from the originally defined PROTEIN by an amino-terminal 11-amino-acid insert.
AIMed.d144.s1219.p1	N	One clone encodes a novel PROTEIN1 catalytic subunit ( PROTEIN ), which differs from the originally defined PROTEIN2 by an amino-terminal 11-amino-acid insert.
AIMed.d144.s1219.p2	N	One clone encodes a novel PROTEIN catalytic subunit ( PROTEIN1 ), which differs from the originally defined PROTEIN2 by an amino-terminal 11-amino-acid insert.
AIMed.d144.s1220.p0	P	In vitro-binding assays demonstrated that PROTEIN1 isoforms preferentially bind the hypophosphorylated form of PROTEIN2 .
AIMed.d144.s1221.p0	P	Moreover, similar PROTEIN1 sequences are required for binding PROTEIN2 and PROTEIN .
AIMed.d144.s1221.p1	P	Moreover, similar PROTEIN1 sequences are required for binding PROTEIN and PROTEIN2 .
AIMed.d144.s1221.p2	N	Moreover, similar PROTEIN sequences are required for binding PROTEIN1 and PROTEIN2 .
AIMed.d145.s1229.p0	N	The novel fold of the TNF receptor structure is likely to be representative of the PROTEIN1 ( PROTEIN2 )/TNF receptor family as a whole.
AIMed.d146.s1230.p2	N	Characterization of a novel high affinity human PROTEIN1 . Expression on T cells and association with PROTEIN2 driven proliferation.
AIMed.d146.s1233.p0	N	We have previously demonstrated such changes by affinity cross-linking studies, and have shown that unstimulated human T cells express a single PROTEIN1 of 90 kDa, whereas activated T cells express an additional 76-kDa PROTEIN2 binding protein.
AIMed.d146.s1234.p0	N	In this study the origin and function of the PROTEIN1 and PROTEIN2 molecules have been investigated.
AIMed.d146.s1236.p0	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN1 correlated with expression of the PROTEIN2  PROTEIN , and not with expression of the PROTEIN  PROTEIN .
AIMed.d146.s1236.p1	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN1 correlated with expression of the PROTEIN  PROTEIN2 , and not with expression of the PROTEIN  PROTEIN .
AIMed.d146.s1236.p2	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN1 correlated with expression of the PROTEIN  PROTEIN , and not with expression of the PROTEIN2  PROTEIN .
AIMed.d146.s1236.p3	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN1 correlated with expression of the PROTEIN  PROTEIN , and not with expression of the PROTEIN  PROTEIN2 .
AIMed.d146.s1236.p4	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN1  PROTEIN2 , and not with expression of the PROTEIN  PROTEIN .
AIMed.d146.s1236.p5	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN1  PROTEIN , and not with expression of the PROTEIN2  PROTEIN .
AIMed.d146.s1236.p6	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN1  PROTEIN , and not with expression of the PROTEIN  PROTEIN2 .
AIMed.d146.s1236.p7	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN  PROTEIN1 , and not with expression of the PROTEIN2  PROTEIN .
AIMed.d146.s1236.p8	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN  PROTEIN1 , and not with expression of the PROTEIN  PROTEIN2 .
AIMed.d146.s1236.p9	N	These analyses showed that the ability of PBMC to proliferate to PROTEIN correlated with expression of the PROTEIN  PROTEIN , and not with expression of the PROTEIN1  PROTEIN2 .
AIMed.d146.s1237.p0	N	PROTEIN1 -driven proliferation is mediated via high affinity PROTEIN2 , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p1	N	PROTEIN1 -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN2  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p3	N	PROTEIN1 -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN2  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p4	N	PROTEIN1 -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN2 bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p5	N	PROTEIN1 -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p6	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN1 , and accordingly, Scatchard analysis revealed that, like the PROTEIN2  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p7	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN1 , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN2 , the PROTEIN  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p8	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN1 , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN2  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p9	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN1 , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN2 bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p10	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN1 , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p11	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN1  PROTEIN2 , the PROTEIN  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p12	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN1  PROTEIN , the PROTEIN2  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p13	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN1  PROTEIN , the PROTEIN  PROTEIN2 bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p14	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN1  PROTEIN , the PROTEIN  PROTEIN bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p15	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN1 , the PROTEIN2  PROTEIN bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p16	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN1 , the PROTEIN  PROTEIN2 bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p17	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN1 , the PROTEIN  PROTEIN bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p18	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN1  PROTEIN2 bound PROTEIN with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p19	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN1  PROTEIN bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1237.p20	N	PROTEIN -driven proliferation is mediated via high affinity PROTEIN , and accordingly, Scatchard analysis revealed that, like the PROTEIN  PROTEIN , the PROTEIN  PROTEIN1 bound PROTEIN2 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
AIMed.d146.s1238.p0	N	Deglycosylation studies showed that the PROTEIN1 and PROTEIN2  PROTEIN are not simply differently glycosylated isoforms of a single receptor.
AIMed.d146.s1238.p1	N	Deglycosylation studies showed that the PROTEIN1 and PROTEIN  PROTEIN2 are not simply differently glycosylated isoforms of a single receptor.
AIMed.d146.s1238.p2	N	Deglycosylation studies showed that the PROTEIN and PROTEIN1  PROTEIN2 are not simply differently glycosylated isoforms of a single receptor.
AIMed.d146.s1239.p0	N	In agreement, mAb to the previously cloned PROTEIN1 were found to stain unstimulated T cells that express only the PROTEIN2  PROTEIN but not T-cell clones that express predominantly the PROTEIN  PROTEIN .
AIMed.d146.s1239.p2	N	In agreement, mAb to the previously cloned PROTEIN1 were found to stain unstimulated T cells that express only the PROTEIN  PROTEIN but not T-cell clones that express predominantly the PROTEIN2  PROTEIN .
AIMed.d146.s1239.p3	N	In agreement, mAb to the previously cloned PROTEIN1 were found to stain unstimulated T cells that express only the PROTEIN  PROTEIN but not T-cell clones that express predominantly the PROTEIN  PROTEIN2 .
AIMed.d146.s1239.p4	N	In agreement, mAb to the previously cloned PROTEIN were found to stain unstimulated T cells that express only the PROTEIN1  PROTEIN2 but not T-cell clones that express predominantly the PROTEIN  PROTEIN .
AIMed.d146.s1239.p5	N	In agreement, mAb to the previously cloned PROTEIN were found to stain unstimulated T cells that express only the PROTEIN1  PROTEIN but not T-cell clones that express predominantly the PROTEIN2  PROTEIN .
AIMed.d146.s1239.p6	N	In agreement, mAb to the previously cloned PROTEIN were found to stain unstimulated T cells that express only the PROTEIN1  PROTEIN but not T-cell clones that express predominantly the PROTEIN  PROTEIN2 .
AIMed.d146.s1239.p7	N	In agreement, mAb to the previously cloned PROTEIN were found to stain unstimulated T cells that express only the PROTEIN  PROTEIN1 but not T-cell clones that express predominantly the PROTEIN2  PROTEIN .
AIMed.d146.s1239.p8	N	In agreement, mAb to the previously cloned PROTEIN were found to stain unstimulated T cells that express only the PROTEIN  PROTEIN1 but not T-cell clones that express predominantly the PROTEIN  PROTEIN2 .
AIMed.d146.s1240.p0	N	These antibodies also immunoprecipitated the cloned PROTEIN1 as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa PROTEIN2 .
AIMed.d146.s1241.p0	N	In addition, PCR analysis of PROTEIN1 -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN2 , thereby excluding the possibility that the PROTEIN  PROTEIN is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p1	N	In addition, PCR analysis of PROTEIN1 -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN , thereby excluding the possibility that the PROTEIN2  PROTEIN is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p2	N	In addition, PCR analysis of PROTEIN1 -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN , thereby excluding the possibility that the PROTEIN  PROTEIN2 is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p4	N	In addition, PCR analysis of PROTEIN -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN1 , thereby excluding the possibility that the PROTEIN2  PROTEIN is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p5	N	In addition, PCR analysis of PROTEIN -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN1 , thereby excluding the possibility that the PROTEIN  PROTEIN2 is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p6	N	In addition, PCR analysis of PROTEIN -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN1 , thereby excluding the possibility that the PROTEIN  PROTEIN is a previously undescribed splice variant of the cloned PROTEIN2 .
AIMed.d146.s1241.p7	N	In addition, PCR analysis of PROTEIN -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN , thereby excluding the possibility that the PROTEIN1  PROTEIN2 is a previously undescribed splice variant of the cloned PROTEIN .
AIMed.d146.s1241.p8	N	In addition, PCR analysis of PROTEIN -expressing cells could not detect splicing of the extracellular domain of the cloned PROTEIN , thereby excluding the possibility that the PROTEIN1  PROTEIN is a previously undescribed splice variant of the cloned PROTEIN2 .
AIMed.d146.s1242.p0	N	These data demonstrate that the PROTEIN1  PROTEIN2 is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN and PROTEIN  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p2	N	These data demonstrate that the PROTEIN1  PROTEIN is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN2 and PROTEIN  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p3	N	These data demonstrate that the PROTEIN1  PROTEIN is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN and PROTEIN2  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p4	N	These data demonstrate that the PROTEIN1  PROTEIN is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN and PROTEIN  PROTEIN2 have different extracellular domains.
AIMed.d146.s1242.p5	N	These data demonstrate that the PROTEIN  PROTEIN1 is the T-cell homologue of the cloned PROTEIN2 , and imply that the PROTEIN and PROTEIN  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p6	N	These data demonstrate that the PROTEIN  PROTEIN1 is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN2 and PROTEIN  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p7	N	These data demonstrate that the PROTEIN  PROTEIN1 is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN and PROTEIN2  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p8	N	These data demonstrate that the PROTEIN  PROTEIN1 is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN and PROTEIN  PROTEIN2 have different extracellular domains.
AIMed.d146.s1242.p9	N	These data demonstrate that the PROTEIN  PROTEIN is the T-cell homologue of the cloned PROTEIN1 , and imply that the PROTEIN2 and PROTEIN  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p10	N	These data demonstrate that the PROTEIN  PROTEIN is the T-cell homologue of the cloned PROTEIN1 , and imply that the PROTEIN and PROTEIN2  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p11	N	These data demonstrate that the PROTEIN  PROTEIN is the T-cell homologue of the cloned PROTEIN1 , and imply that the PROTEIN and PROTEIN  PROTEIN2 have different extracellular domains.
AIMed.d146.s1242.p12	N	These data demonstrate that the PROTEIN  PROTEIN is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN1 and PROTEIN2  PROTEIN have different extracellular domains.
AIMed.d146.s1242.p13	N	These data demonstrate that the PROTEIN  PROTEIN is the T-cell homologue of the cloned PROTEIN , and imply that the PROTEIN1 and PROTEIN  PROTEIN2 have different extracellular domains.
AIMed.d146.s1243.p0	N	Taken together these data suggest that the 76-kDa receptor is a novel high affinity PROTEIN1 that may be necessary for PROTEIN2 driven proliferation in human T cells.
AIMed.d147.s1244.p0	P	Characterization of the PROTEIN1 binding proteins PROTEIN2 and PROTEIN .
AIMed.d147.s1244.p1	P	Characterization of the PROTEIN1 binding proteins PROTEIN and PROTEIN2 .
AIMed.d147.s1244.p2	N	Characterization of the PROTEIN binding proteins PROTEIN1 and PROTEIN2 .
AIMed.d147.s1245.p0	N	The PROTEIN1 gene product, PROTEIN2 , regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.
AIMed.d147.s1248.p0	N	We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, PROTEIN1 and PROTEIN2 , cloned originally by their interaction with PROTEIN .
AIMed.d147.s1248.p1	P	We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, PROTEIN1 and PROTEIN , cloned originally by their interaction with PROTEIN2 .
AIMed.d147.s1248.p2	P	We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, PROTEIN and PROTEIN1 , cloned originally by their interaction with PROTEIN2 .
AIMed.d147.s1249.p0	N	The products of the PROTEIN1 and PROTEIN2 genes are ubiquitously expressed, large (200 kDa for PROTEIN and 195 kDa for PROTEIN ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
AIMed.d147.s1249.p1	N	The products of the PROTEIN1 and PROTEIN genes are ubiquitously expressed, large (200 kDa for PROTEIN2 and 195 kDa for PROTEIN ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
AIMed.d147.s1249.p3	N	The products of the PROTEIN and PROTEIN1 genes are ubiquitously expressed, large (200 kDa for PROTEIN2 and 195 kDa for PROTEIN ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
AIMed.d147.s1249.p4	N	The products of the PROTEIN and PROTEIN1 genes are ubiquitously expressed, large (200 kDa for PROTEIN and 195 kDa for PROTEIN2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
AIMed.d147.s1249.p5	N	The products of the PROTEIN and PROTEIN genes are ubiquitously expressed, large (200 kDa for PROTEIN1 and 195 kDa for PROTEIN2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
AIMed.d147.s1250.p0	P	In addition we have been able to identify complexes of PROTEIN1 and PROTEIN2 in vivo that are dissociated in the presence of purified human papillomavirus PROTEIN protein.
AIMed.d147.s1250.p1	N	In addition we have been able to identify complexes of PROTEIN1 and PROTEIN in vivo that are dissociated in the presence of purified human papillomavirus PROTEIN2 protein.
AIMed.d147.s1250.p2	N	In addition we have been able to identify complexes of PROTEIN and PROTEIN1 in vivo that are dissociated in the presence of purified human papillomavirus PROTEIN2 protein.
AIMed.d148.s1251.p0	N	Two potentially oncogenic cyclins, PROTEIN1 and PROTEIN2 , share common properties of subunit configuration, tyrosine phosphorylation and physical association with the PROTEIN protein
AIMed.d148.s1251.p1	P	Two potentially oncogenic cyclins, PROTEIN1 and PROTEIN , share common properties of subunit configuration, tyrosine phosphorylation and physical association with the PROTEIN2 protein
AIMed.d148.s1251.p2	P	Two potentially oncogenic cyclins, PROTEIN and PROTEIN1 , share common properties of subunit configuration, tyrosine phosphorylation and physical association with the PROTEIN2 protein
AIMed.d148.s1252.p0	N	.Originally identified as a 'mitotic cyclin', PROTEIN1 exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an PROTEIN2 ( PROTEIN ) as well as a candidate proto-oncogene.
AIMed.d148.s1252.p1	N	.Originally identified as a 'mitotic cyclin', PROTEIN1 exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an PROTEIN ( PROTEIN2 ) as well as a candidate proto-oncogene.
AIMed.d148.s1252.p2	N	.Originally identified as a 'mitotic cyclin', PROTEIN exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an PROTEIN1 ( PROTEIN2 ) as well as a candidate proto-oncogene.
AIMed.d148.s1253.p0	N	Other recent studies have identified human PROTEIN1 ( PROTEIN2 ) as a putative G1 cyclin and candidate proto-oncogene.
AIMed.d148.s1257.p2	P	Moreover, PROTEIN was found to be phosphorylated on tyrosine residues in vivo and, like PROTEIN1 , was readily phosphorylated by PROTEIN2 in vitro.
AIMed.d148.s1258.p0	P	In synchronized human osteosarcoma cells, PROTEIN1 is induced in early G1 and becomes associated with PROTEIN2 , a Cdk-binding subunit.
AIMed.d148.s1259.p0	P	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN1 is associated with both PROTEIN2 and PROTEIN , and that PROTEIN immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d148.s1259.p1	P	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN1 is associated with both PROTEIN and PROTEIN2 , and that PROTEIN immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d148.s1259.p2	N	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN1 is associated with both PROTEIN and PROTEIN , and that PROTEIN2 immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d148.s1259.p3	N	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN is associated with both PROTEIN1 and PROTEIN2 , and that PROTEIN immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d148.s1259.p4	N	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN is associated with both PROTEIN1 and PROTEIN , and that PROTEIN2 immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d148.s1259.p5	N	Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that PROTEIN is associated with both PROTEIN and PROTEIN1 , and that PROTEIN2 immune complexes exhibit appreciable histone H1 kinase activity.
AIMed.d149.s1262.p0	P	The SH2/SH3 domain-containing protein PROTEIN1 interacts with tyrosine-phosphorylated PROTEIN2 and PROTEIN : implications for insulin control of PROTEIN signalling.
AIMed.d149.s1262.p1	P	The SH2/SH3 domain-containing protein PROTEIN1 interacts with tyrosine-phosphorylated PROTEIN and PROTEIN2 : implications for insulin control of PROTEIN signalling.
AIMed.d149.s1262.p2	N	The SH2/SH3 domain-containing protein PROTEIN1 interacts with tyrosine-phosphorylated PROTEIN and PROTEIN : implications for insulin control of PROTEIN2 signalling.
AIMed.d149.s1262.p3	N	The SH2/SH3 domain-containing protein PROTEIN interacts with tyrosine-phosphorylated PROTEIN1 and PROTEIN2 : implications for insulin control of PROTEIN signalling.
AIMed.d149.s1262.p4	N	The SH2/SH3 domain-containing protein PROTEIN interacts with tyrosine-phosphorylated PROTEIN1 and PROTEIN : implications for insulin control of PROTEIN2 signalling.
AIMed.d149.s1262.p5	N	The SH2/SH3 domain-containing protein PROTEIN interacts with tyrosine-phosphorylated PROTEIN and PROTEIN1 : implications for insulin control of PROTEIN2 signalling.
AIMed.d149.s1263.p0	N	PROTEIN1 , a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, PROTEIN2 .
AIMed.d149.s1264.p0	N	Both PROTEIN1 and PROTEIN2 have been implicated in a highly conserved mechanism that regulates PROTEIN signalling by receptor tyrosine kinases.
AIMed.d149.s1264.p1	N	Both PROTEIN1 and PROTEIN have been implicated in a highly conserved mechanism that regulates PROTEIN2 signalling by receptor tyrosine kinases.
AIMed.d149.s1264.p2	N	Both PROTEIN and PROTEIN1 have been implicated in a highly conserved mechanism that regulates PROTEIN2 signalling by receptor tyrosine kinases.
AIMed.d149.s1265.p0	N	In this report we show that in response to PROTEIN1 , PROTEIN2 forms a stable complex with two tyrosine-phosphorylated proteins.
AIMed.d149.s1266.p0	N	One protein is the major insulin receptor substrate PROTEIN1 and the second is the SH2 domain-containing oncogenic protein, PROTEIN2 .
AIMed.d149.s1267.p0	N	The interactions between PROTEIN1 and these two proteins require ligand activation of the PROTEIN2 and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN and PROTEIN .
AIMed.d149.s1267.p1	N	The interactions between PROTEIN1 and these two proteins require ligand activation of the PROTEIN and are mediated by the binding of the SH2 domain of PROTEIN2 to phosphotyrosines on both PROTEIN and PROTEIN .
AIMed.d149.s1267.p2	N	The interactions between PROTEIN1 and these two proteins require ligand activation of the PROTEIN and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN2 and PROTEIN .
AIMed.d149.s1267.p3	N	The interactions between PROTEIN1 and these two proteins require ligand activation of the PROTEIN and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN and PROTEIN2 .
AIMed.d149.s1267.p4	N	The interactions between PROTEIN and these two proteins require ligand activation of the PROTEIN1 and are mediated by the binding of the SH2 domain of PROTEIN2 to phosphotyrosines on both PROTEIN and PROTEIN .
AIMed.d149.s1267.p5	N	The interactions between PROTEIN and these two proteins require ligand activation of the PROTEIN1 and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN2 and PROTEIN .
AIMed.d149.s1267.p6	N	The interactions between PROTEIN and these two proteins require ligand activation of the PROTEIN1 and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN and PROTEIN2 .
AIMed.d149.s1267.p8	P	The interactions between PROTEIN and these two proteins require ligand activation of the PROTEIN and are mediated by the binding of the SH2 domain of PROTEIN1 to phosphotyrosines on both PROTEIN and PROTEIN2 .
AIMed.d149.s1267.p9	N	The interactions between PROTEIN and these two proteins require ligand activation of the PROTEIN and are mediated by the binding of the SH2 domain of PROTEIN to phosphotyrosines on both PROTEIN1 and PROTEIN2 .
AIMed.d149.s1268.p0	P	Although PROTEIN1 associates with PROTEIN2 and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p1	P	Although PROTEIN1 associates with PROTEIN and PROTEIN2 , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p2	N	Although PROTEIN1 associates with PROTEIN and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN2 stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p3	N	Although PROTEIN1 associates with PROTEIN and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN2 is not a substrate for the insulin receptor.
AIMed.d149.s1268.p4	N	Although PROTEIN associates with PROTEIN1 and PROTEIN2 , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p5	N	Although PROTEIN associates with PROTEIN1 and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN2 stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p6	N	Although PROTEIN associates with PROTEIN1 and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN2 is not a substrate for the insulin receptor.
AIMed.d149.s1268.p7	N	Although PROTEIN associates with PROTEIN and PROTEIN1 , it is not tyrosine-phosphorylated after PROTEIN2 stimulation, implying that PROTEIN is not a substrate for the insulin receptor.
AIMed.d149.s1268.p8	N	Although PROTEIN associates with PROTEIN and PROTEIN1 , it is not tyrosine-phosphorylated after PROTEIN stimulation, implying that PROTEIN2 is not a substrate for the insulin receptor.
AIMed.d149.s1268.p9	N	Although PROTEIN associates with PROTEIN and PROTEIN , it is not tyrosine-phosphorylated after PROTEIN1 stimulation, implying that PROTEIN2 is not a substrate for the insulin receptor.
AIMed.d149.s1269.p1	N	Furthermore, we have identified a short sequence motif (YV/IN) present in PROTEIN1 , PROTEIN and PROTEIN2 , which specifically binds the SH2 domain of PROTEIN with high affinity.
AIMed.d149.s1269.p2	P	Furthermore, we have identified a short sequence motif (YV/IN) present in PROTEIN1 , PROTEIN and PROTEIN , which specifically binds the SH2 domain of PROTEIN2 with high affinity.
AIMed.d149.s1269.p3	N	Furthermore, we have identified a short sequence motif (YV/IN) present in PROTEIN , PROTEIN1 and PROTEIN2 , which specifically binds the SH2 domain of PROTEIN with high affinity.
AIMed.d149.s1269.p4	P	Furthermore, we have identified a short sequence motif (YV/IN) present in PROTEIN , PROTEIN1 and PROTEIN , which specifically binds the SH2 domain of PROTEIN2 with high affinity.
AIMed.d149.s1269.p5	P	Furthermore, we have identified a short sequence motif (YV/IN) present in PROTEIN , PROTEIN and PROTEIN1 , which specifically binds the SH2 domain of PROTEIN2 with high affinity.
AIMed.d149.s1270.p0	N	Interestingly, both PROTEIN1 and PROTEIN2 can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN molecule, suggesting a mechanism whereby PROTEIN could provide the core for a large signalling complex.
AIMed.d149.s1270.p1	P	Interestingly, both PROTEIN1 and PROTEIN can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN2 molecule, suggesting a mechanism whereby PROTEIN could provide the core for a large signalling complex.
AIMed.d149.s1270.p2	N	Interestingly, both PROTEIN1 and PROTEIN can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN molecule, suggesting a mechanism whereby PROTEIN2 could provide the core for a large signalling complex.
AIMed.d149.s1270.p3	P	Interestingly, both PROTEIN and PROTEIN1 can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN2 molecule, suggesting a mechanism whereby PROTEIN could provide the core for a large signalling complex.
AIMed.d149.s1270.p4	N	Interestingly, both PROTEIN and PROTEIN1 can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN molecule, suggesting a mechanism whereby PROTEIN2 could provide the core for a large signalling complex.
AIMed.d149.s1270.p5	N	Interestingly, both PROTEIN and PROTEIN can simultaneously bind distinct tyrosine phosphorylated regions on the same PROTEIN1 molecule, suggesting a mechanism whereby PROTEIN2 could provide the core for a large signalling complex.
AIMed.d149.s1271.p0	P	We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between PROTEIN1 and the two targets PROTEIN2 and PROTEIN .
AIMed.d149.s1271.p1	P	We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between PROTEIN1 and the two targets PROTEIN and PROTEIN2 .
AIMed.d149.s1271.p2	N	We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between PROTEIN and the two targets PROTEIN1 and PROTEIN2 .
AIMed.d150.s1273.p1	N	Regulation of the PROTEIN1 -related transcription factor PROTEIN by binding to the PROTEIN2 protein.
AIMed.d150.s1273.p2	P	Regulation of the PROTEIN -related transcription factor PROTEIN1 by binding to the PROTEIN2 protein.
AIMed.d150.s1274.p0	N	The PROTEIN1 gene product ( PROTEIN2 ) is a nuclear phosphoprotein that regulates cell cycle progression.
AIMed.d150.s1275.p0	N	PROTEIN1 is a lymphoid-specific PROTEIN2 transcription factor that regulates inducible gene expression during T cell activation.
AIMed.d150.s1276.p0	N	In this report, it is demonstrated that PROTEIN1 contains a sequence motif that is highly related to the PROTEIN2 binding sites of several viral oncoproteins and binds to the pocket region of PROTEIN both in vitro and in vivo.
AIMed.d150.s1276.p1	P	In this report, it is demonstrated that PROTEIN1 contains a sequence motif that is highly related to the PROTEIN binding sites of several viral oncoproteins and binds to the pocket region of PROTEIN2 both in vitro and in vivo.
AIMed.d150.s1276.p2	N	In this report, it is demonstrated that PROTEIN contains a sequence motif that is highly related to the PROTEIN1 binding sites of several viral oncoproteins and binds to the pocket region of PROTEIN2 both in vitro and in vivo.
AIMed.d150.s1277.p0	N	PROTEIN1 binds exclusively to the underphosphorylated form of PROTEIN2 and fails to bind to PROTEIN mutants derived from patients with retinoblastoma.
AIMed.d150.s1277.p1	N	PROTEIN1 binds exclusively to the underphosphorylated form of PROTEIN and fails to bind to PROTEIN2 mutants derived from patients with retinoblastoma.
AIMed.d150.s1277.p2	N	PROTEIN binds exclusively to the underphosphorylated form of PROTEIN1 and fails to bind to PROTEIN2 mutants derived from patients with retinoblastoma.
AIMed.d150.s1278.p0	P	Co-immunoprecipitation experiments demonstrated an association between PROTEIN1 and PROTEIN2 in resting normal human T cells.
AIMed.d150.s1279.p0	N	After T cell activation, the phosphorylation of PROTEIN1 results in the release of PROTEIN2 , which is correlated temporally with the activation of PROTEIN -mediated transcription.
AIMed.d150.s1279.p1	N	After T cell activation, the phosphorylation of PROTEIN1 results in the release of PROTEIN , which is correlated temporally with the activation of PROTEIN2 -mediated transcription.
AIMed.d150.s1279.p2	N	After T cell activation, the phosphorylation of PROTEIN results in the release of PROTEIN1 , which is correlated temporally with the activation of PROTEIN2 -mediated transcription.
AIMed.d150.s1281.p0	N	These results demonstrate that PROTEIN1 interacts specifically with a lineage-restricted PROTEIN2 transcription factor.
AIMed.d151.s1284.p0	N	The PROTEIN1 ( PROTEIN2 ) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA (snRNA) genes.
AIMed.d151.s1285.p1	N	We previously have shown that PROTEIN1 purified from human HeLa cells is a multisubunit complex of four polypeptides designated PROTEIN2 , -beta, -gamma, and -delta.
AIMed.d151.s1286.p0	N	We now report the isolation and expression of cDNAs encoding PROTEIN1 gamma and PROTEIN2 delta, as well as functional studies with cognate antibodies that recognize the native PROTEIN complex in HeLa extracts.
AIMed.d151.s1286.p1	N	We now report the isolation and expression of cDNAs encoding PROTEIN1 gamma and PROTEIN delta, as well as functional studies with cognate antibodies that recognize the native PROTEIN2 complex in HeLa extracts.
AIMed.d151.s1286.p2	N	We now report the isolation and expression of cDNAs encoding PROTEIN gamma and PROTEIN1 delta, as well as functional studies with cognate antibodies that recognize the native PROTEIN2 complex in HeLa extracts.
AIMed.d151.s1287.p0	N	Immunoprecipitation studies confirm that the four PROTEIN1 subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex; they further show that the PROTEIN2 so defined, including the gamma and delta subunits specifically, is essential for transcription of both class II and class III snRNA genes.
AIMed.d151.s1288.p0	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN2 ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p1	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN2 , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p2	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN2 -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p3	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN2 ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p4	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN2 and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p5	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p6	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN1 ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN2 gamma reported here.
AIMed.d151.s1288.p7	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN1 ) with PROTEIN2 , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p8	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN1 ) with PROTEIN , consistent with the previous report of a PROTEIN2 -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p10	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN1 ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN2 and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p11	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN1 ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p12	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN1 ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN2 gamma reported here.
AIMed.d151.s1288.p13	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN1 , consistent with the previous report of a PROTEIN2 -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p15	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN1 , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN2 and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p16	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN1 , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p17	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN1 , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN2 gamma reported here.
AIMed.d151.s1288.p19	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN1 -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN2 and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p20	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN1 -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p22	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN1 ) containing substoichiometric levels of PROTEIN2 and a component ( PROTEIN ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p23	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN1 ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p24	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN1 ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN ) identical in sequence to the PROTEIN2 gamma reported here.
AIMed.d151.s1288.p25	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN1 and a component ( PROTEIN2 ) identical in sequence to the PROTEIN gamma reported here.
AIMed.d151.s1288.p27	N	Immunoprecipitation assays also show a weak substoichiometric association of the PROTEIN ( PROTEIN ) with PROTEIN , consistent with the previous report of a PROTEIN -related complex ( PROTEIN ) containing substoichiometric levels of PROTEIN and a component ( PROTEIN1 ) identical in sequence to the PROTEIN2 gamma reported here.
AIMed.d151.s1289.p0	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN2 delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p1	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN2 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p2	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN2 with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p3	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN2 in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p4	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN2 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p5	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p6	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p7	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN1 gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p8	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN2 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p9	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN , consistent either with the natural association of PROTEIN2 with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p10	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN2 in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p12	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p13	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p14	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN1 delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p15	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN1 , consistent either with the natural association of PROTEIN2 with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p17	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN1 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN2 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p18	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN1 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p19	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN1 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p20	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN1 , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p21	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN1 with PROTEIN2 in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p22	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN1 with PROTEIN in a semistable PROTEIN2 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p23	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN1 with PROTEIN in a semistable PROTEIN - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p24	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN1 with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p25	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN1 with PROTEIN in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p26	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN1 in a semistable PROTEIN2 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p27	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN1 in a semistable PROTEIN - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p28	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN1 in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p29	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN1 in a semistable PROTEIN - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p30	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN1 - PROTEIN2 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p31	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN1 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p32	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN1 - PROTEIN -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1289.p33	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN1 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN2 and TATA-bound PROTEIN during promoter activation.
AIMed.d151.s1289.p34	N	Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PROTEIN gamma and PROTEIN delta with PROTEIN , consistent either with the natural association of PROTEIN with PROTEIN in a semistable PROTEIN - PROTEIN1 -associated factor complex or with possible functional interactions between PSE-bound PROTEIN and TATA-bound PROTEIN2 during promoter activation.
AIMed.d151.s1290.p0	N	In addition, we show that in extracts depleted of PROTEIN1 and PROTEIN2 -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p1	N	In addition, we show that in extracts depleted of PROTEIN1 and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN2 but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p3	N	In addition, we show that in extracts depleted of PROTEIN1 and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN2 , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p4	N	In addition, we show that in extracts depleted of PROTEIN1 and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN2 complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p5	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN1 -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN2 but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p6	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN1 -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN2 or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p7	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN1 -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN2 , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p8	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN1 -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN2 complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p9	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN1 but not by PROTEIN2 or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p10	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN1 but not by PROTEIN or PROTEIN2 , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p11	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN1 but not by PROTEIN or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN2 complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p12	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN1 or PROTEIN2 , indicating that transcription of class II snRNA genes requires a PROTEIN complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p13	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN1 or PROTEIN , indicating that transcription of class II snRNA genes requires a PROTEIN2 complex different from the one used for mRNA-encoding genes.
AIMed.d151.s1290.p14	N	In addition, we show that in extracts depleted of PROTEIN and PROTEIN -associated factors, transcription from the U1 promoter is restored by recombinant PROTEIN but not by PROTEIN or PROTEIN1 , indicating that transcription of class II snRNA genes requires a PROTEIN2 complex different from the one used for mRNA-encoding genes.
AIMed.d152.s1291.p0	P	PROTEIN1 - PROTEIN2 and PROTEIN - PROTEIN interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p1	N	PROTEIN1 - PROTEIN and PROTEIN2 - PROTEIN interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p2	N	PROTEIN1 - PROTEIN and PROTEIN - PROTEIN2 interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p3	N	PROTEIN1 - PROTEIN and PROTEIN - PROTEIN interactions define two distinct PROTEIN2 signal transduction pathways.
AIMed.d152.s1291.p4	N	PROTEIN - PROTEIN1 and PROTEIN2 - PROTEIN interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p5	N	PROTEIN - PROTEIN1 and PROTEIN - PROTEIN2 interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p6	N	PROTEIN - PROTEIN1 and PROTEIN - PROTEIN interactions define two distinct PROTEIN2 signal transduction pathways.
AIMed.d152.s1291.p7	P	PROTEIN - PROTEIN and PROTEIN1 - PROTEIN2 interactions define two distinct PROTEIN signal transduction pathways.
AIMed.d152.s1291.p8	N	PROTEIN - PROTEIN and PROTEIN1 - PROTEIN interactions define two distinct PROTEIN2 signal transduction pathways.
AIMed.d152.s1291.p9	N	PROTEIN - PROTEIN and PROTEIN - PROTEIN1 interactions define two distinct PROTEIN2 signal transduction pathways.
AIMed.d152.s1292.p0	N	Tumor necrosis factor (TNF) can induce apoptosis and activate PROTEIN1 through signaling cascades emanating from PROTEIN2 ( PROTEIN ).
AIMed.d152.s1292.p1	N	Tumor necrosis factor (TNF) can induce apoptosis and activate PROTEIN1 through signaling cascades emanating from PROTEIN ( PROTEIN2 ).
AIMed.d152.s1292.p2	N	Tumor necrosis factor (TNF) can induce apoptosis and activate PROTEIN through signaling cascades emanating from PROTEIN1 ( PROTEIN2 ).
AIMed.d152.s1293.p0	N	PROTEIN1 is a PROTEIN2 -associated signal transducer that is involved in activating both pathways.
AIMed.d152.s1294.p1	P	Here we show that PROTEIN1 directly interacts with PROTEIN and PROTEIN2 , signal transducers that activate PROTEIN and induce apoptosis, respectively.
AIMed.d152.s1294.p2	N	Here we show that PROTEIN1 directly interacts with PROTEIN and PROTEIN , signal transducers that activate PROTEIN2 and induce apoptosis, respectively.
AIMed.d152.s1294.p3	N	Here we show that PROTEIN directly interacts with PROTEIN1 and PROTEIN2 , signal transducers that activate PROTEIN and induce apoptosis, respectively.
AIMed.d152.s1294.p4	P	Here we show that PROTEIN directly interacts with PROTEIN1 and PROTEIN , signal transducers that activate PROTEIN2 and induce apoptosis, respectively.
AIMed.d152.s1294.p5	P	Here we show that PROTEIN directly interacts with PROTEIN and PROTEIN1 , signal transducers that activate PROTEIN2 and induce apoptosis, respectively.
AIMed.d152.s1295.p0	N	A PROTEIN1 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated PROTEIN2 activation, but does not affect TNF-induced apoptosis.
AIMed.d152.s1297.p1	N	Thus, these two PROTEIN1 - PROTEIN signaling cascades appear to bifurcate at PROTEIN2 .
AIMed.d152.s1297.p2	N	Thus, these two PROTEIN - PROTEIN1 signaling cascades appear to bifurcate at PROTEIN2 .
AIMed.d153.s1298.p0	P	Characterization of PROTEIN1 binding to human PROTEIN2 on T cells and its biologic role in immune response.
AIMed.d153.s1299.p1	P	PROTEIN1 , a T cell activation Ag, also known as PROTEIN ,is directly associated with PROTEIN2 ( PROTEIN ) on the surface of T cells and T cell lines.
AIMed.d153.s1299.p2	P	PROTEIN1 , a T cell activation Ag, also known as PROTEIN ,is directly associated with PROTEIN ( PROTEIN2 ) on the surface of T cells and T cell lines.
AIMed.d153.s1299.p4	P	PROTEIN , a T cell activation Ag, also known as PROTEIN1 ,is directly associated with PROTEIN ( PROTEIN2 ) on the surface of T cells and T cell lines.
AIMed.d153.s1300.p0	P	In the present study, we examined both the binding of PROTEIN1 and PROTEIN2 and the functional consequences of this interaction.
AIMed.d153.s1301.p0	P	We found that PROTEIN1 was associated with PROTEIN2 on T cell lines lacking either PROTEIN or PROTEIN enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p1	N	We found that PROTEIN1 was associated with PROTEIN on T cell lines lacking either PROTEIN2 or PROTEIN enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p2	N	We found that PROTEIN1 was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN2 enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p3	N	We found that PROTEIN1 was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN enzymatic activity, indicating that the association between PROTEIN2 and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p4	N	We found that PROTEIN1 was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN enzymatic activity, indicating that the association between PROTEIN and PROTEIN2 did not require enzymatic activity.
AIMed.d153.s1301.p5	N	We found that PROTEIN was associated with PROTEIN1 on T cell lines lacking either PROTEIN2 or PROTEIN enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p6	N	We found that PROTEIN was associated with PROTEIN1 on T cell lines lacking either PROTEIN or PROTEIN2 enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p9	N	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN1 or PROTEIN2 enzymatic activity, indicating that the association between PROTEIN and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p10	N	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN1 or PROTEIN enzymatic activity, indicating that the association between PROTEIN2 and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p11	N	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN1 or PROTEIN enzymatic activity, indicating that the association between PROTEIN and PROTEIN2 did not require enzymatic activity.
AIMed.d153.s1301.p12	N	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN1 enzymatic activity, indicating that the association between PROTEIN2 and PROTEIN did not require enzymatic activity.
AIMed.d153.s1301.p13	N	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN1 enzymatic activity, indicating that the association between PROTEIN and PROTEIN2 did not require enzymatic activity.
AIMed.d153.s1301.p14	P	We found that PROTEIN was associated with PROTEIN on T cell lines lacking either PROTEIN or PROTEIN enzymatic activity, indicating that the association between PROTEIN1 and PROTEIN2 did not require enzymatic activity.
AIMed.d153.s1302.p0	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN1 and PROTEIN2 co-localized on the cell surface, but not inside cells, suggesting that PROTEIN did not transport PROTEIN to the surface.
AIMed.d153.s1302.p1	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN1 and PROTEIN co-localized on the cell surface, but not inside cells, suggesting that PROTEIN2 did not transport PROTEIN to the surface.
AIMed.d153.s1302.p2	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN1 and PROTEIN co-localized on the cell surface, but not inside cells, suggesting that PROTEIN did not transport PROTEIN2 to the surface.
AIMed.d153.s1302.p3	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN and PROTEIN1 co-localized on the cell surface, but not inside cells, suggesting that PROTEIN2 did not transport PROTEIN to the surface.
AIMed.d153.s1302.p4	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN and PROTEIN1 co-localized on the cell surface, but not inside cells, suggesting that PROTEIN did not transport PROTEIN2 to the surface.
AIMed.d153.s1302.p5	N	Moreover, using immunoelectron microscopy, we demonstrated that PROTEIN and PROTEIN co-localized on the cell surface, but not inside cells, suggesting that PROTEIN1 did not transport PROTEIN2 to the surface.
AIMed.d153.s1303.p0	N	In keeping with this observation, we showed that human PROTEIN1 -transfected murine pre-B cell lines lacking human PROTEIN2 acquired PROTEIN from an extracellular source.
AIMed.d153.s1303.p1	N	In keeping with this observation, we showed that human PROTEIN1 -transfected murine pre-B cell lines lacking human PROTEIN acquired PROTEIN2 from an extracellular source.
AIMed.d153.s1303.p2	N	In keeping with this observation, we showed that human PROTEIN -transfected murine pre-B cell lines lacking human PROTEIN1 acquired PROTEIN2 from an extracellular source.
AIMed.d153.s1304.p0	N	More importantly, adenosine in the absence of cell surface PROTEIN1 inhibited T cell proliferation and PROTEIN2 production induced by various stimuli.
AIMed.d153.s1306.p0	N	These data suggest that PROTEIN1 on the cell surface is involved in an important immunoregulatory mechanism by which released PROTEIN2 binds to cell surface PROTEIN , and this complex is capable of reducing the local concentration of adenosine.
AIMed.d153.s1306.p1	N	These data suggest that PROTEIN1 on the cell surface is involved in an important immunoregulatory mechanism by which released PROTEIN binds to cell surface PROTEIN2 , and this complex is capable of reducing the local concentration of adenosine.
AIMed.d153.s1306.p2	P	These data suggest that PROTEIN on the cell surface is involved in an important immunoregulatory mechanism by which released PROTEIN1 binds to cell surface PROTEIN2 , and this complex is capable of reducing the local concentration of adenosine.
AIMed.d154.s1309.p0	N	We have cloned and characterized human PROTEIN1 and a second isoform of human PROTEIN2 .
AIMed.d154.s1311.p0	N	The deduced amino acid sequences of human alpha 1- and PROTEIN1 are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like PROTEIN2 , human PROTEIN has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.
AIMed.d154.s1311.p1	N	The deduced amino acid sequences of human alpha 1- and PROTEIN1 are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like PROTEIN , human PROTEIN2 has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.
AIMed.d154.s1311.p2	N	The deduced amino acid sequences of human alpha 1- and PROTEIN are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like PROTEIN1 , human PROTEIN2 has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.
AIMed.d154.s1313.p0	N	Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: PROTEIN1 to chromosome 16q22-23 and PROTEIN2 to chromosome 20q11.2.
AIMed.d154.s1314.p1	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN1 , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN2 , PROTEIN / PROTEIN , and the PROTEIN .
AIMed.d154.s1314.p2	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN1 , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN2 / PROTEIN , and the PROTEIN .
AIMed.d154.s1314.p4	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN1 , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN / PROTEIN2 , and the PROTEIN .
AIMed.d154.s1314.p5	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN1 , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN / PROTEIN , and the PROTEIN2 .
AIMed.d154.s1314.p6	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN1 interact with peptides encoding the syntrophin-binding region of PROTEIN2 , PROTEIN / PROTEIN , and the PROTEIN .
AIMed.d154.s1314.p7	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN1 interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN2 / PROTEIN , and the PROTEIN .
AIMed.d154.s1314.p9	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN1 interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN / PROTEIN2 , and the PROTEIN .
AIMed.d154.s1314.p10	P	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN1 interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN / PROTEIN , and the PROTEIN2 .
AIMed.d154.s1314.p11	N	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN1 , PROTEIN2 / PROTEIN , and the PROTEIN .
AIMed.d154.s1314.p13	N	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN1 , PROTEIN / PROTEIN2 , and the PROTEIN .
AIMed.d154.s1314.p14	N	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN1 , PROTEIN / PROTEIN , and the PROTEIN2 .
AIMed.d154.s1314.p16	N	Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like PROTEIN , both beta 2- and PROTEIN interact with peptides encoding the syntrophin-binding region of PROTEIN , PROTEIN1 / PROTEIN2 , and the PROTEIN .
AIMed.d155.s1316.p0	N	The general transcription factor PROTEIN1 nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced PROTEIN2 recruitment or conformational changes in PROTEIN -promoter complexes.
AIMed.d155.s1316.p1	N	The general transcription factor PROTEIN1 nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced PROTEIN recruitment or conformational changes in PROTEIN2 -promoter complexes.
AIMed.d155.s1316.p2	N	The general transcription factor PROTEIN nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced PROTEIN1 recruitment or conformational changes in PROTEIN2 -promoter complexes.
AIMed.d155.s1317.p0	N	Molecular studies of the multiprotein PROTEIN1 complex have identified a primary PROTEIN2 ( PROTEIN ), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.
AIMed.d155.s1317.p1	N	Molecular studies of the multiprotein PROTEIN1 complex have identified a primary PROTEIN ( PROTEIN2 ), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.
AIMed.d155.s1317.p2	N	Molecular studies of the multiprotein PROTEIN complex have identified a primary PROTEIN1 ( PROTEIN2 ), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.
AIMed.d155.s1318.p0	N	Here we present biochemical evidence for the structural relevance of histone homologies in the human PROTEIN1 subunits PROTEIN2 , PROTEIN and PROTEIN .
AIMed.d155.s1318.p2	N	Here we present biochemical evidence for the structural relevance of histone homologies in the human PROTEIN1 subunits PROTEIN , PROTEIN and PROTEIN2 .
AIMed.d155.s1318.p3	N	Here we present biochemical evidence for the structural relevance of histone homologies in the human PROTEIN subunits PROTEIN1 , PROTEIN2 and PROTEIN .
AIMed.d155.s1318.p4	N	Here we present biochemical evidence for the structural relevance of histone homologies in the human PROTEIN subunits PROTEIN1 , PROTEIN and PROTEIN2 .
AIMed.d155.s1318.p5	N	Here we present biochemical evidence for the structural relevance of histone homologies in the human PROTEIN subunits PROTEIN , PROTEIN1 and PROTEIN2 .
AIMed.d155.s1319.p0	N	Together with analyses of native PROTEIN1 complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within PROTEIN2 .
AIMed.d156.s1320.p0	P	PROTEIN1 : a kinase associated with the PROTEIN2 .
AIMed.d156.s1321.p0	N	The pleiotropic biological activities of PROTEIN1 ( PROTEIN2 ) are mediated by its type I receptor ( PROTEIN ).
AIMed.d156.s1321.p1	P	The pleiotropic biological activities of PROTEIN1 ( PROTEIN ) are mediated by its type I receptor ( PROTEIN2 ).
AIMed.d156.s1321.p2	P	The pleiotropic biological activities of PROTEIN ( PROTEIN1 ) are mediated by its type I receptor ( PROTEIN2 ).
AIMed.d156.s1322.p1	N	When the ligand binds, PROTEIN1 initiates a signaling cascade that results in the activation of the transcription regulator PROTEIN ( PROTEIN2 ).
AIMed.d156.s1322.p2	N	When the ligand binds, PROTEIN initiates a signaling cascade that results in the activation of the transcription regulator PROTEIN1 ( PROTEIN2 ).
AIMed.d156.s1323.p1	N	A protein kinase designated PROTEIN1 ( PROTEIN2 ) was purified, and its complementary DNA was molecularly cloned.
AIMed.d156.s1324.p1	N	When human embryonic kidney cells (cell line 293) over-expressing PROTEIN1 or HeLa cells were exposed to PROTEIN , PROTEIN2 rapidly associated with the PROTEIN complex and was phosphorylated.
AIMed.d156.s1324.p2	N	When human embryonic kidney cells (cell line 293) over-expressing PROTEIN1 or HeLa cells were exposed to PROTEIN , PROTEIN rapidly associated with the PROTEIN2 complex and was phosphorylated.
AIMed.d156.s1324.p3	N	When human embryonic kidney cells (cell line 293) over-expressing PROTEIN or HeLa cells were exposed to PROTEIN1 , PROTEIN2 rapidly associated with the PROTEIN complex and was phosphorylated.
AIMed.d156.s1324.p4	N	When human embryonic kidney cells (cell line 293) over-expressing PROTEIN or HeLa cells were exposed to PROTEIN1 , PROTEIN rapidly associated with the PROTEIN2 complex and was phosphorylated.
AIMed.d156.s1324.p5	P	When human embryonic kidney cells (cell line 293) over-expressing PROTEIN or HeLa cells were exposed to PROTEIN , PROTEIN1 rapidly associated with the PROTEIN2 complex and was phosphorylated.
AIMed.d156.s1325.p0	N	The primary amino acid sequence of PROTEIN1 shares similarity with that of pelle,a protein kinase that is essential for the activation of a PROTEIN2 homolog in Drosophila.
AIMed.d157.s1328.p0	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN1 ) and PROTEIN2 [ PROTEIN ( PROTEIN )] are complexed by an PROTEIN , PROTEIN .
AIMed.d157.s1328.p2	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN1 ) and PROTEIN [ PROTEIN ( PROTEIN2 )] are complexed by an PROTEIN , PROTEIN .
AIMed.d157.s1328.p3	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN1 ) and PROTEIN [ PROTEIN ( PROTEIN )] are complexed by an PROTEIN2 , PROTEIN .
AIMed.d157.s1328.p4	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN1 ) and PROTEIN [ PROTEIN ( PROTEIN )] are complexed by an PROTEIN , PROTEIN2 .
AIMed.d157.s1328.p6	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN1 [ PROTEIN ( PROTEIN2 )] are complexed by an PROTEIN , PROTEIN .
AIMed.d157.s1328.p8	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN1 [ PROTEIN ( PROTEIN )] are complexed by an PROTEIN , PROTEIN2 .
AIMed.d157.s1328.p9	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN [ PROTEIN1 ( PROTEIN2 )] are complexed by an PROTEIN , PROTEIN .
AIMed.d157.s1328.p10	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN [ PROTEIN1 ( PROTEIN )] are complexed by an PROTEIN2 , PROTEIN .
AIMed.d157.s1328.p11	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN [ PROTEIN1 ( PROTEIN )] are complexed by an PROTEIN , PROTEIN2 .
AIMed.d157.s1328.p12	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN [ PROTEIN ( PROTEIN1 )] are complexed by an PROTEIN2 , PROTEIN .
AIMed.d157.s1328.p14	N	Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ( PROTEIN ) and PROTEIN [ PROTEIN ( PROTEIN )] are complexed by an PROTEIN1 , PROTEIN2 .
AIMed.d157.s1329.p0	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN1 ( PROTEIN2 ), binds PROTEIN at a site distinct from those bound by PROTEIN or PROTEIN .
AIMed.d157.s1329.p1	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN1 ( PROTEIN ), binds PROTEIN2 at a site distinct from those bound by PROTEIN or PROTEIN .
AIMed.d157.s1329.p2	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN1 ( PROTEIN ), binds PROTEIN at a site distinct from those bound by PROTEIN2 or PROTEIN .
AIMed.d157.s1329.p3	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN1 ( PROTEIN ), binds PROTEIN at a site distinct from those bound by PROTEIN or PROTEIN2 .
AIMed.d157.s1329.p4	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN ( PROTEIN1 ), binds PROTEIN2 at a site distinct from those bound by PROTEIN or PROTEIN .
AIMed.d157.s1329.p5	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN ( PROTEIN1 ), binds PROTEIN at a site distinct from those bound by PROTEIN2 or PROTEIN .
AIMed.d157.s1329.p6	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN ( PROTEIN1 ), binds PROTEIN at a site distinct from those bound by PROTEIN or PROTEIN2 .
AIMed.d157.s1329.p7	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN ( PROTEIN ), binds PROTEIN1 at a site distinct from those bound by PROTEIN2 or PROTEIN .
AIMed.d157.s1329.p9	N	Deletion analysis and binding studies demonstrate that a third enzyme, PROTEIN ( PROTEIN ), binds PROTEIN at a site distinct from those bound by PROTEIN1 or PROTEIN2 .
AIMed.d157.s1330.p0	N	The subcellular distributions of PROTEIN1 and PROTEIN2 were similar in neurons.
AIMed.d158.s1332.p0	N	TNF-dependent recruitment of the protein kinase PROTEIN1 to the PROTEIN2 signaling complex.
AIMed.d158.s1333.p0	N	The death domain of PROTEIN1 ( PROTEIN2 ) triggers distinct signaling pathways leading to apoptosis and PROTEIN activation through its interaction with the death domain protein PROTEIN .
AIMed.d158.s1333.p2	P	The death domain of PROTEIN1 ( PROTEIN ) triggers distinct signaling pathways leading to apoptosis and PROTEIN activation through its interaction with the death domain protein PROTEIN2 .
AIMed.d158.s1333.p3	N	The death domain of PROTEIN ( PROTEIN1 ) triggers distinct signaling pathways leading to apoptosis and PROTEIN2 activation through its interaction with the death domain protein PROTEIN .
AIMed.d158.s1333.p4	P	The death domain of PROTEIN ( PROTEIN1 ) triggers distinct signaling pathways leading to apoptosis and PROTEIN activation through its interaction with the death domain protein PROTEIN2 .
AIMed.d158.s1333.p5	N	The death domain of PROTEIN ( PROTEIN ) triggers distinct signaling pathways leading to apoptosis and PROTEIN1 activation through its interaction with the death domain protein PROTEIN2 .
AIMed.d158.s1334.p0	P	Here, we show that PROTEIN1 interacts strongly with PROTEIN2 , another death domain protein that was shown previously to associate with PROTEIN antigen.
AIMed.d158.s1334.p1	N	Here, we show that PROTEIN1 interacts strongly with PROTEIN , another death domain protein that was shown previously to associate with PROTEIN2 antigen.
AIMed.d158.s1334.p2	P	Here, we show that PROTEIN interacts strongly with PROTEIN1 , another death domain protein that was shown previously to associate with PROTEIN2 antigen.
AIMed.d158.s1335.p0	N	We also show that PROTEIN1 is a serine-threonine kinase that is recruited by PROTEIN2 to PROTEIN in a TNF-dependent process.
AIMed.d158.s1335.p1	N	We also show that PROTEIN1 is a serine-threonine kinase that is recruited by PROTEIN to PROTEIN2 in a TNF-dependent process.
AIMed.d158.s1335.p2	N	We also show that PROTEIN is a serine-threonine kinase that is recruited by PROTEIN1 to PROTEIN2 in a TNF-dependent process.
AIMed.d158.s1336.p0	N	Overexpression of the intact PROTEIN1 protein induces both PROTEIN2 activation and apoptosis.
AIMed.d158.s1337.p0	N	However, expression of the death domain of PROTEIN1 Induces apoptosis, but potently inhibits PROTEIN2 activation by TNF.
AIMed.d158.s1338.p0	N	These results suggest that distinct domains of PROTEIN1 participate in the TNF signaling cascades leading to apoptosis and PROTEIN2 activation.
AIMed.d159.s1340.p0	P	The carboxy-terminal region of PROTEIN1 has previously been shown to interact directly with PROTEIN2 , a cytoplasmic component of the PROTEIN -glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
AIMed.d159.s1340.p1	N	The carboxy-terminal region of PROTEIN1 has previously been shown to interact directly with PROTEIN , a cytoplasmic component of the PROTEIN2 -glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
AIMed.d159.s1340.p2	N	The carboxy-terminal region of PROTEIN has previously been shown to interact directly with PROTEIN1 , a cytoplasmic component of the PROTEIN2 -glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
AIMed.d160.s1343.p0	N	Identification of vascular endothelial growth factor determinants for binding PROTEIN1 and PROTEIN2 receptors. Generation of receptor-selective PROTEIN variants by site-directed mutagenesis.
AIMed.d160.s1343.p2	N	Identification of vascular endothelial growth factor determinants for binding PROTEIN and PROTEIN1 receptors. Generation of receptor-selective PROTEIN2 variants by site-directed mutagenesis.
AIMed.d160.s1344.p0	N	PROTEIN1 ( PROTEIN2 ) expression in various cell types is induced by hypoxia and other stimuli.
AIMed.d160.s1345.p0	N	PROTEIN1 mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN2 ( PROTEIN )/ PROTEIN ( PROTEIN ) and PROTEIN .
AIMed.d160.s1345.p1	N	PROTEIN1 mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN2 )/ PROTEIN ( PROTEIN ) and PROTEIN .
AIMed.d160.s1345.p2	N	PROTEIN1 mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN )/ PROTEIN2 ( PROTEIN ) and PROTEIN .
AIMed.d160.s1345.p3	N	PROTEIN1 mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN )/ PROTEIN ( PROTEIN2 ) and PROTEIN .
AIMed.d160.s1345.p5	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN1 ( PROTEIN2 )/ PROTEIN ( PROTEIN ) and PROTEIN .
AIMed.d160.s1345.p7	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN1 ( PROTEIN )/ PROTEIN ( PROTEIN2 ) and PROTEIN .
AIMed.d160.s1345.p9	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN1 )/ PROTEIN2 ( PROTEIN ) and PROTEIN .
AIMed.d160.s1345.p10	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN1 )/ PROTEIN ( PROTEIN2 ) and PROTEIN .
AIMed.d160.s1345.p11	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN1 )/ PROTEIN ( PROTEIN ) and PROTEIN2 .
AIMed.d160.s1345.p12	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN )/ PROTEIN1 ( PROTEIN2 ) and PROTEIN .
AIMed.d160.s1345.p13	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN )/ PROTEIN1 ( PROTEIN ) and PROTEIN2 .
AIMed.d160.s1345.p14	N	PROTEIN mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, PROTEIN ( PROTEIN )/ PROTEIN ( PROTEIN1 ) and PROTEIN2 .
AIMed.d160.s1346.p0	N	Alanine-scanning mutagenesis was used to identify a positively charged surface in PROTEIN1 that mediates binding to PROTEIN2 / PROTEIN .
AIMed.d160.s1346.p1	N	Alanine-scanning mutagenesis was used to identify a positively charged surface in PROTEIN1 that mediates binding to PROTEIN / PROTEIN2 .
AIMed.d160.s1346.p2	N	Alanine-scanning mutagenesis was used to identify a positively charged surface in PROTEIN that mediates binding to PROTEIN1 / PROTEIN2 .
AIMed.d160.s1347.p0	N	Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding PROTEIN1 / PROTEIN2 , while negatively charged residues, Asp63, Glu64, and Glu67, were associated with PROTEIN binding.
AIMed.d160.s1347.p1	N	Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding PROTEIN1 / PROTEIN , while negatively charged residues, Asp63, Glu64, and Glu67, were associated with PROTEIN2 binding.
AIMed.d160.s1347.p2	N	Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding PROTEIN / PROTEIN1 , while negatively charged residues, Asp63, Glu64, and Glu67, were associated with PROTEIN2 binding.
AIMed.d160.s1348.p0	N	A PROTEIN1 model based on PROTEIN2 indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.
AIMed.d160.s1349.p0	N	Mutations within the PROTEIN1 site had minimal effect on PROTEIN2 binding, and mutants deficient in PROTEIN binding did not affect PROTEIN binding.
AIMed.d160.s1349.p1	N	Mutations within the PROTEIN1 site had minimal effect on PROTEIN binding, and mutants deficient in PROTEIN2 binding did not affect PROTEIN binding.
AIMed.d160.s1349.p2	N	Mutations within the PROTEIN1 site had minimal effect on PROTEIN binding, and mutants deficient in PROTEIN binding did not affect PROTEIN2 binding.
AIMed.d160.s1349.p3	N	Mutations within the PROTEIN site had minimal effect on PROTEIN1 binding, and mutants deficient in PROTEIN2 binding did not affect PROTEIN binding.
AIMed.d160.s1349.p4	N	Mutations within the PROTEIN site had minimal effect on PROTEIN1 binding, and mutants deficient in PROTEIN binding did not affect PROTEIN2 binding.
AIMed.d160.s1349.p5	N	Mutations within the PROTEIN site had minimal effect on PROTEIN binding, and mutants deficient in PROTEIN1 binding did not affect PROTEIN2 binding.
AIMed.d160.s1350.p0	N	Endothelial cell mitogenesis was abolished in mutants lacking PROTEIN1 affinity; however, PROTEIN2 deficient mutants induced normal proliferation.
AIMed.d160.s1352.p0	N	Furthermore, this mutational analysis implicates PROTEIN1 , but not PROTEIN2 , in PROTEIN induction of endothelial cell proliferation.
AIMed.d160.s1352.p1	N	Furthermore, this mutational analysis implicates PROTEIN1 , but not PROTEIN , in PROTEIN2 induction of endothelial cell proliferation.
AIMed.d160.s1352.p2	N	Furthermore, this mutational analysis implicates PROTEIN , but not PROTEIN1 , in PROTEIN2 induction of endothelial cell proliferation.
AIMed.d161.s1353.p0	P	Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, PROTEIN1 , with another SH2-containing protein, PROTEIN2 .
AIMed.d161.s1355.p2	P	PROTEIN1 associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN2 after ligand stimulation, and binding of PROTEIN to this receptor promotes tyrosine phosphorylation of PROTEIN .
AIMed.d161.s1355.p3	N	PROTEIN1 associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN after ligand stimulation, and binding of PROTEIN2 to this receptor promotes tyrosine phosphorylation of PROTEIN .
AIMed.d161.s1355.p4	N	PROTEIN1 associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN after ligand stimulation, and binding of PROTEIN to this receptor promotes tyrosine phosphorylation of PROTEIN2 .
AIMed.d161.s1355.p12	N	PROTEIN associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN1 after ligand stimulation, and binding of PROTEIN2 to this receptor promotes tyrosine phosphorylation of PROTEIN .
AIMed.d161.s1355.p13	N	PROTEIN associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN1 after ligand stimulation, and binding of PROTEIN to this receptor promotes tyrosine phosphorylation of PROTEIN2 .
AIMed.d161.s1355.p14	N	PROTEIN associates with the platelet-derived growth factor (PDGF) receptor  PROTEIN after ligand stimulation, and binding of PROTEIN1 to this receptor promotes tyrosine phosphorylation of PROTEIN2 .
AIMed.d161.s1357.p0	N	Using PROTEIN1 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that PROTEIN2 interacts with another signaling protein, PROTEIN .
AIMed.d161.s1358.p0	N	We have localized the region of interaction to tyrosine 580 in the carboxyl end of PROTEIN1 and to the SH2 domain in the carboxy-terminus of PROTEIN2 .
AIMed.d161.s1359.p0	P	We demonstrate that PROTEIN1 binds to PROTEIN2 in vitro under conditions where the latter is tyrosine-phosphorylated.
AIMed.d162.s1367.p1	P	We found that the human PROTEIN1 ( PROTEIN ) physically interacted with PROTEIN2 via its DNA binding domain.
AIMed.d162.s1367.p2	P	We found that the human PROTEIN ( PROTEIN1 ) physically interacted with PROTEIN2 via its DNA binding domain.
AIMed.d162.s1368.p0	P	As a result of this physical interaction, binding of PROTEIN1 to its hormone response elements either as homodimer or as a heterodimer with the PROTEIN2 was inhibited by PROTEIN in a concentration-dependent manner.
AIMed.d162.s1368.p1	N	As a result of this physical interaction, binding of PROTEIN1 to its hormone response elements either as homodimer or as a heterodimer with the PROTEIN was inhibited by PROTEIN2 in a concentration-dependent manner.
AIMed.d162.s1368.p2	N	As a result of this physical interaction, binding of PROTEIN to its hormone response elements either as homodimer or as a heterodimer with the PROTEIN1 was inhibited by PROTEIN2 in a concentration-dependent manner.
AIMed.d162.s1369.p0	P	In transfected cells, wild-type PROTEIN1 repressed the hormone-dependent transcriptional activation of PROTEIN2 .
AIMed.d162.s1370.p0	N	In contrast, mutant PROTEIN1 either had no effect or activated the transcriptional activity of PROTEIN2 depending on the type of hormone response elements.
AIMed.d163.s1372.p0	N	Enhanced degradation of PROTEIN1 receptors by a sorting PROTEIN2 , PROTEIN .
AIMed.d163.s1372.p1	N	Enhanced degradation of PROTEIN1 receptors by a sorting PROTEIN , PROTEIN2 .
AIMed.d163.s1372.p2	N	Enhanced degradation of PROTEIN receptors by a sorting PROTEIN1 , PROTEIN2 .
AIMed.d163.s1374.p0	N	A protein, PROTEIN1 ( PROTEIN2 ), was identified in a human cell line that bound to a region of the PROTEIN ( PROTEIN ) containing the lysosomal targeting code.
AIMed.d163.s1374.p1	P	A protein, PROTEIN1 ( PROTEIN ), was identified in a human cell line that bound to a region of the PROTEIN2 ( PROTEIN ) containing the lysosomal targeting code.
AIMed.d163.s1374.p2	P	A protein, PROTEIN1 ( PROTEIN ), was identified in a human cell line that bound to a region of the PROTEIN ( PROTEIN2 ) containing the lysosomal targeting code.
AIMed.d163.s1374.p4	P	A protein, PROTEIN ( PROTEIN1 ), was identified in a human cell line that bound to a region of the PROTEIN ( PROTEIN2 ) containing the lysosomal targeting code.
AIMed.d163.s1374.p5	N	A protein, PROTEIN ( PROTEIN ), was identified in a human cell line that bound to a region of the PROTEIN1 ( PROTEIN2 ) containing the lysosomal targeting code.
AIMed.d163.s1375.p0	N	PROTEIN1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of PROTEIN2 decreased the amount of PROTEIN on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
AIMed.d163.s1375.p1	N	PROTEIN1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of PROTEIN decreased the amount of PROTEIN2 on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
AIMed.d163.s1375.p2	N	PROTEIN contains a region of homology to a yeast vacuolar sorting protein, and overexpression of PROTEIN1 decreased the amount of PROTEIN2 on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
AIMed.d163.s1376.p0	N	Thus, PROTEIN1 is likely to play a role in sorting PROTEIN2 to lysosomes.
AIMed.d164.s1378.p0	P	The splicing factor U2AF (U2 snRNP auxiliary factor) is a heterodimer with subunits of 65 and 35 kD ( PROTEIN1 and PROTEIN2 ).
AIMed.d164.s1379.p0	N	PROTEIN1 binds specifically to 3' splice sites, but previous studies failed to demonstrate a function for PROTEIN2 .
AIMed.d164.s1381.p0	N	Nuclear extracts deficient in PROTEIN1 were inactive; however, both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant PROTEIN2 .
AIMed.d164.s1382.p0	N	In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that PROTEIN1 directly mediates interactions between PROTEIN2 and proteins bound to the enhancers.
AIMed.d164.s1383.p0	N	Thus, PROTEIN1 functions as a bridge between PROTEIN2 and the enhancer complex to recruit PROTEIN to the adjacent intron.
AIMed.d164.s1383.p1	N	Thus, PROTEIN1 functions as a bridge between PROTEIN and the enhancer complex to recruit PROTEIN2 to the adjacent intron.
AIMed.d164.s1383.p2	N	Thus, PROTEIN functions as a bridge between PROTEIN1 and the enhancer complex to recruit PROTEIN2 to the adjacent intron.
AIMed.d165.s1384.p0	N	Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex PROTEIN1 , the nucleotide excision repair protein PROTEIN2 , and PROTEIN .
AIMed.d165.s1384.p2	N	Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex PROTEIN1 , the nucleotide excision repair protein PROTEIN , and PROTEIN2 .
AIMed.d165.s1388.p0	N	At least two of the subunits of PROTEIN1 ( PROTEIN2 and PROTEIN proteins) are implicated in the disease xeroderma pigmentosum (XP).
AIMed.d165.s1388.p1	N	At least two of the subunits of PROTEIN1 ( PROTEIN and PROTEIN2 proteins) are implicated in the disease xeroderma pigmentosum (XP).
AIMed.d165.s1388.p2	N	At least two of the subunits of PROTEIN ( PROTEIN1 and PROTEIN2 proteins) are implicated in the disease xeroderma pigmentosum (XP).
AIMed.d165.s1389.p0	N	We have exploited the availability of the cloned PROTEIN1 , PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p1	N	We have exploited the availability of the cloned PROTEIN1 , PROTEIN , PROTEIN2 , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p2	N	We have exploited the availability of the cloned PROTEIN1 , PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p3	N	We have exploited the availability of the cloned PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p4	N	We have exploited the availability of the cloned PROTEIN1 , PROTEIN , PROTEIN , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN2 ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p5	N	We have exploited the availability of the cloned PROTEIN , PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p6	N	We have exploited the availability of the cloned PROTEIN , PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p7	N	We have exploited the availability of the cloned PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p8	N	We have exploited the availability of the cloned PROTEIN , PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN2 ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p9	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p10	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p11	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN2 ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p12	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 genes (all of which encode polypeptide subunits of PROTEIN ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p13	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN genes (all of which encode polypeptide subunits of PROTEIN2 ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1389.p14	N	We have exploited the availability of the cloned PROTEIN , PROTEIN , PROTEIN , PROTEIN , and PROTEIN1 genes (all of which encode polypeptide subunits of PROTEIN2 ) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.
AIMed.d165.s1390.p0	N	Additionally we have examined interactions between PROTEIN1 components, the human NER protein PROTEIN2 , and the PROTEIN protein which is implicated in Cockayne syndrome (CS).
AIMed.d165.s1390.p1	N	Additionally we have examined interactions between PROTEIN1 components, the human NER protein PROTEIN , and the PROTEIN2 protein which is implicated in Cockayne syndrome (CS).
AIMed.d165.s1390.p2	N	Additionally we have examined interactions between PROTEIN components, the human NER protein PROTEIN1 , and the PROTEIN2 protein which is implicated in Cockayne syndrome (CS).
AIMed.d165.s1391.p0	P	Our analyses demonstrate that the PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN proteins interact with each other.
AIMed.d165.s1391.p1	N	Our analyses demonstrate that the PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN proteins interact with each other.
AIMed.d165.s1391.p2	N	Our analyses demonstrate that the PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 proteins interact with each other.
AIMed.d165.s1391.p3	N	Our analyses demonstrate that the PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN proteins interact with each other.
AIMed.d165.s1391.p4	N	Our analyses demonstrate that the PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 proteins interact with each other.
AIMed.d165.s1391.p5	N	Our analyses demonstrate that the PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 proteins interact with each other.
AIMed.d165.s1392.p0	N	PROTEIN1 protein interacts with multiple subunits of PROTEIN2 and with PROTEIN protein.
AIMed.d165.s1392.p1	P	PROTEIN1 protein interacts with multiple subunits of PROTEIN and with PROTEIN2 protein.
AIMed.d165.s1392.p2	N	PROTEIN protein interacts with multiple subunits of PROTEIN1 and with PROTEIN2 protein.
AIMed.d166.s1394.p0	N	Residues in human PROTEIN1 ( PROTEIN2 ) crucial for binding to both the human PROTEIN (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p1	P	Residues in human PROTEIN1 ( PROTEIN ) crucial for binding to both the human PROTEIN2 (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p2	P	Residues in human PROTEIN1 ( PROTEIN ) crucial for binding to both the human PROTEIN (R) and PROTEIN2 were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p3	N	Residues in human PROTEIN1 ( PROTEIN ) crucial for binding to both the human PROTEIN (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN2 in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p4	P	Residues in human PROTEIN ( PROTEIN1 ) crucial for binding to both the human PROTEIN2 (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p5	P	Residues in human PROTEIN ( PROTEIN1 ) crucial for binding to both the human PROTEIN (R) and PROTEIN2 were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p6	N	Residues in human PROTEIN ( PROTEIN1 ) crucial for binding to both the human PROTEIN (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN2 in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p7	N	Residues in human PROTEIN ( PROTEIN ) crucial for binding to both the human PROTEIN1 (R) and PROTEIN2 were identified by analysis of alanine scanning mutants of PROTEIN in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p8	N	Residues in human PROTEIN ( PROTEIN ) crucial for binding to both the human PROTEIN1 (R) and PROTEIN were identified by analysis of alanine scanning mutants of PROTEIN2 in assays for both receptor binding and bioactivity.
AIMed.d166.s1394.p9	N	Residues in human PROTEIN ( PROTEIN ) crucial for binding to both the human PROTEIN (R) and PROTEIN1 were identified by analysis of alanine scanning mutants of PROTEIN2 in assays for both receptor binding and bioactivity.
AIMed.d166.s1395.p0	P	The region of PROTEIN1 most important for binding to the PROTEIN2 is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop.
AIMed.d166.s1399.p0	P	A second region of PROTEIN1 that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on PROTEIN2 binding.
AIMed.d166.s1400.p0	P	Residues in PROTEIN1 from both the A- and C-helices are involved in binding the PROTEIN2 co-receptor.
AIMed.d166.s1401.p0	P	Abolition of the PROTEIN1 binding site in PROTEIN2 created antagonists of PROTEIN action.
AIMed.d166.s1401.p1	N	Abolition of the PROTEIN1 binding site in PROTEIN created antagonists of PROTEIN2 action.
AIMed.d166.s1401.p2	N	Abolition of the PROTEIN binding site in PROTEIN1 created antagonists of PROTEIN2 action.
AIMed.d167.s1402.p0	P	The PROTEIN1 glucose transporter interacts with PROTEIN2 and PROTEIN .
AIMed.d167.s1402.p1	P	The PROTEIN1 glucose transporter interacts with PROTEIN and PROTEIN2 .
AIMed.d167.s1402.p2	N	The PROTEIN glucose transporter interacts with PROTEIN1 and PROTEIN2 .
AIMed.d167.s1405.p0	N	A truncated version of the integral membrane glycoprotein PROTEIN1 ( PROTEIN2 ) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes.
AIMed.d167.s1406.p0	P	Following immunoprecipitation with an anticalnexin antiserum, a cross-linker-independent association was observed between PROTEIN1 and PROTEIN2 .
AIMed.d167.s1407.p0	P	In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of PROTEIN1 and a protein of approximately 60 kDa designated PROTEIN2 ( PROTEIN of 60 kDa).
AIMed.d167.s1407.p1	P	In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of PROTEIN1 and a protein of approximately 60 kDa designated PROTEIN ( PROTEIN2 of 60 kDa).
AIMed.d167.s1407.p2	N	In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of PROTEIN and a protein of approximately 60 kDa designated PROTEIN1 ( PROTEIN2 of 60 kDa).
AIMed.d167.s1408.p0	P	Both the PROTEIN1 - PROTEIN2 and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p1	N	Both the PROTEIN1 - PROTEIN and the PROTEIN2 - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p2	N	Both the PROTEIN1 - PROTEIN and the PROTEIN - PROTEIN2 interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p3	N	Both the PROTEIN1 - PROTEIN and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN2 , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p4	N	Both the PROTEIN1 - PROTEIN and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN2 interactions.
AIMed.d167.s1408.p5	N	Both the PROTEIN - PROTEIN1 and the PROTEIN2 - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p6	N	Both the PROTEIN - PROTEIN1 and the PROTEIN - PROTEIN2 interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p7	N	Both the PROTEIN - PROTEIN1 and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN2 , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p8	N	Both the PROTEIN - PROTEIN1 and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN2 interactions.
AIMed.d167.s1408.p9	P	Both the PROTEIN - PROTEIN and the PROTEIN1 - PROTEIN2 interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p10	N	Both the PROTEIN - PROTEIN and the PROTEIN1 - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN2 , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p11	N	Both the PROTEIN - PROTEIN and the PROTEIN1 - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN2 interactions.
AIMed.d167.s1408.p12	N	Both the PROTEIN - PROTEIN and the PROTEIN - PROTEIN1 interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN2 , a characteristic of many PROTEIN interactions.
AIMed.d167.s1408.p13	N	Both the PROTEIN - PROTEIN and the PROTEIN - PROTEIN1 interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN , a characteristic of many PROTEIN2 interactions.
AIMed.d167.s1408.p14	N	Both the PROTEIN - PROTEIN and the PROTEIN - PROTEIN interactions were dependent on the presence of a correctly modified oligosaccharide group on PROTEIN1 , a characteristic of many PROTEIN2 interactions.
AIMed.d167.s1409.p0	N	A PROTEIN1 mutant that was not glycosylated (AGGT155) did not associate with PROTEIN2 or PROTEIN .
AIMed.d167.s1409.p1	N	A PROTEIN1 mutant that was not glycosylated (AGGT155) did not associate with PROTEIN or PROTEIN2 .
AIMed.d167.s1409.p2	N	A PROTEIN mutant that was not glycosylated (AGGT155) did not associate with PROTEIN1 or PROTEIN2 .
AIMed.d167.s1410.p0	N	PROTEIN1 , the soluble homologue of PROTEIN2 , was also shown to interact with PROTEIN only when the protein bore a correctly modified oligosaccharide group.
AIMed.d167.s1410.p1	P	PROTEIN1 , the soluble homologue of PROTEIN , was also shown to interact with PROTEIN2 only when the protein bore a correctly modified oligosaccharide group.
AIMed.d167.s1410.p2	N	PROTEIN , the soluble homologue of PROTEIN1 , was also shown to interact with PROTEIN2 only when the protein bore a correctly modified oligosaccharide group.
AIMed.d167.s1411.p0	N	Thus, our data show that both PROTEIN1 and PROTEIN2 interact with PROTEIN in a glycosylation-dependent manner.
AIMed.d167.s1411.p1	P	Thus, our data show that both PROTEIN1 and PROTEIN interact with PROTEIN2 in a glycosylation-dependent manner.
AIMed.d167.s1411.p2	P	Thus, our data show that both PROTEIN and PROTEIN1 interact with PROTEIN2 in a glycosylation-dependent manner.
AIMed.d168.s1413.p2	N	The PROTEIN1 ( PROTEIN2 ) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.
AIMed.d168.s1414.p0	P	We have used site-specific mutagenesis within the extracellular domain of the PROTEIN1 to search for amino acid residues involved in PROTEIN2 ( PROTEIN ) binding.
AIMed.d168.s1414.p2	N	We have used site-specific mutagenesis within the extracellular domain of the PROTEIN to search for amino acid residues involved in PROTEIN1 ( PROTEIN2 ) binding.
AIMed.d168.s1415.p0	P	Mutant proteins were expressed in bacteria as soluble PROTEIN1 binding proteins ( PROTEIN2 ) and characterized for PROTEIN binding activity in a number of different assays.
AIMed.d168.s1415.p1	N	Mutant proteins were expressed in bacteria as soluble PROTEIN1 binding proteins ( PROTEIN ) and characterized for PROTEIN2 binding activity in a number of different assays.
AIMed.d168.s1415.p2	N	Mutant proteins were expressed in bacteria as soluble PROTEIN binding proteins ( PROTEIN1 ) and characterized for PROTEIN2 binding activity in a number of different assays.
AIMed.d168.s1416.p0	P	Substitution of phenylalanine at position 93 (Phe93) with alanine (F93A mutation) resulted in a drastic reduction in PROTEIN1 binding in the PROTEIN2 .
AIMed.d168.s1419.p0	P	Furthermore, the F93A mutation in full-length PROTEIN1 expressed in COS cells abolished detectable PROTEIN2 binding.
AIMed.d169.s1424.p1	N	Cloning and characterization of a specific PROTEIN1 binding protein structurally related to the PROTEIN2 alpha chain.
AIMed.d169.s1425.p0	N	PROTEIN1 ( PROTEIN2 ) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with PROTEIN .
AIMed.d169.s1425.p1	N	PROTEIN1 ( PROTEIN ) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with PROTEIN2 .
AIMed.d169.s1425.p2	N	PROTEIN ( PROTEIN1 ) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with PROTEIN2 .
AIMed.d169.s1427.p0	N	Two proteins have been described as constituents of the PROTEIN1 receptor, a approximately 140-kDa glycoprotein ( PROTEIN2 ) and the gamma chain (gammac) of the PROTEIN , but neither of these proteins binds PROTEIN .
AIMed.d169.s1427.p2	N	Two proteins have been described as constituents of the PROTEIN1 receptor, a approximately 140-kDa glycoprotein ( PROTEIN ) and the gamma chain (gammac) of the PROTEIN2 , but neither of these proteins binds PROTEIN .
AIMed.d169.s1427.p5	N	Two proteins have been described as constituents of the PROTEIN receptor, a approximately 140-kDa glycoprotein ( PROTEIN1 ) and the gamma chain (gammac) of the PROTEIN2 , but neither of these proteins binds PROTEIN .
AIMed.d169.s1427.p6	N	Two proteins have been described as constituents of the PROTEIN receptor, a approximately 140-kDa glycoprotein ( PROTEIN1 ) and the gamma chain (gammac) of the PROTEIN , but neither of these proteins binds PROTEIN2 .
AIMed.d169.s1427.p9	N	Two proteins have been described as constituents of the PROTEIN receptor, a approximately 140-kDa glycoprotein ( PROTEIN ) and the gamma chain (gammac) of the PROTEIN1 , but neither of these proteins binds PROTEIN2 .
AIMed.d169.s1428.p0	P	We have cloned a cDNA encoding an PROTEIN1 binding protein ( PROTEIN2 ) from the Caki-1 human renal carcinoma cell line.
AIMed.d169.s1430.p0	N	The PROTEIN1 shows homology with the PROTEIN2 receptor, and to a lesser extent, with the prolactin receptor.
AIMed.d169.s1431.p0	P	COS-7 cells transfected with the PROTEIN1 cDNA bind PROTEIN2 with high affinity but do not bind PROTEIN .
AIMed.d169.s1431.p1	N	COS-7 cells transfected with the PROTEIN1 cDNA bind PROTEIN with high affinity but do not bind PROTEIN2 .
AIMed.d169.s1431.p2	N	COS-7 cells transfected with the PROTEIN cDNA bind PROTEIN1 with high affinity but do not bind PROTEIN2 .
AIMed.d169.s1432.p0	N	COS-7 cells co-transfected with the cloned PROTEIN1 cDNA and PROTEIN2 cDNA resulted in the reconstitution of a small number of receptors that recognized both PROTEIN and PROTEIN .
AIMed.d169.s1432.p1	N	COS-7 cells co-transfected with the cloned PROTEIN1 cDNA and PROTEIN cDNA resulted in the reconstitution of a small number of receptors that recognized both PROTEIN2 and PROTEIN .
AIMed.d169.s1432.p3	N	COS-7 cells co-transfected with the cloned PROTEIN cDNA and PROTEIN1 cDNA resulted in the reconstitution of a small number of receptors that recognized both PROTEIN2 and PROTEIN .
AIMed.d169.s1432.p5	N	COS-7 cells co-transfected with the cloned PROTEIN cDNA and PROTEIN cDNA resulted in the reconstitution of a small number of receptors that recognized both PROTEIN1 and PROTEIN2 .
AIMed.d170.s1438.p0	N	The phagocyte PROTEIN1 is a complex of membrane PROTEIN2 (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p2	N	The phagocyte PROTEIN1 is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN2 ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p3	N	The phagocyte PROTEIN1 is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN2 , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p4	N	The phagocyte PROTEIN1 is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN2 , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p7	N	The phagocyte PROTEIN is a complex of membrane PROTEIN1 (comprised of subunits PROTEIN2 and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p8	N	The phagocyte PROTEIN is a complex of membrane PROTEIN1 (comprised of subunits PROTEIN and PROTEIN2 ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p9	N	The phagocyte PROTEIN is a complex of membrane PROTEIN1 (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN2 , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p10	N	The phagocyte PROTEIN is a complex of membrane PROTEIN1 (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN2 , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p11	N	The phagocyte PROTEIN is a complex of membrane PROTEIN1 (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN2 ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p13	P	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN1 and PROTEIN2 ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p15	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN1 and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN2 , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p16	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN1 and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN2 ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p17	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN1 and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN2 .
AIMed.d170.s1438.p18	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN1 ) and three cytosol proteins ( PROTEIN2 , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p19	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN1 ) and three cytosol proteins ( PROTEIN , PROTEIN2 , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p20	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN1 ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN2 ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p21	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN1 ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN2 .
AIMed.d170.s1438.p22	P	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN1 , PROTEIN2 , and PROTEIN ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p23	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN1 , PROTEIN , and PROTEIN2 ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p24	P	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN1 , PROTEIN , and PROTEIN ) that translocate to membrane and bind to PROTEIN2 .
AIMed.d170.s1438.p25	N	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN1 , and PROTEIN2 ) that translocate to membrane and bind to PROTEIN .
AIMed.d170.s1438.p26	P	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN1 , and PROTEIN ) that translocate to membrane and bind to PROTEIN2 .
AIMed.d170.s1438.p27	P	The phagocyte PROTEIN is a complex of membrane PROTEIN (comprised of subunits PROTEIN and PROTEIN ) and three cytosol proteins ( PROTEIN , PROTEIN , and PROTEIN1 ) that translocate to membrane and bind to PROTEIN2 .
AIMed.d170.s1439.p0	N	This is the first report to demonstrate that two of cytosolic components of PROTEIN1 , PROTEIN2 binding to PROTEIN each other.
AIMed.d170.s1439.p1	N	This is the first report to demonstrate that two of cytosolic components of PROTEIN1 , PROTEIN binding to PROTEIN2 each other.
AIMed.d170.s1439.p2	P	This is the first report to demonstrate that two of cytosolic components of PROTEIN , PROTEIN1 binding to PROTEIN2 each other.
AIMed.d171.s1441.p0	P	Crystal structure of the PROTEIN1 cyclin-dependent-kinase inhibitor bound to the PROTEIN2 - PROTEIN complex.
AIMed.d171.s1441.p1	P	Crystal structure of the PROTEIN1 cyclin-dependent-kinase inhibitor bound to the PROTEIN - PROTEIN2 complex.
AIMed.d171.s1441.p2	P	Crystal structure of the PROTEIN cyclin-dependent-kinase inhibitor bound to the PROTEIN1 - PROTEIN2 complex.
AIMed.d171.s1442.p0	P	The crystal structure of the human PROTEIN1 inhibitory domain bound to the phosphorylated PROTEIN2 - PROTEIN ( PROTEIN ) complex has been determined at 2.3 angstrom.
AIMed.d171.s1442.p1	N	The crystal structure of the human PROTEIN1 inhibitory domain bound to the phosphorylated PROTEIN - PROTEIN2 ( PROTEIN ) complex has been determined at 2.3 angstrom.
AIMed.d171.s1442.p2	P	The crystal structure of the human PROTEIN1 inhibitory domain bound to the phosphorylated PROTEIN - PROTEIN ( PROTEIN2 ) complex has been determined at 2.3 angstrom.
AIMed.d171.s1442.p5	N	The crystal structure of the human PROTEIN inhibitory domain bound to the phosphorylated PROTEIN - PROTEIN1 ( PROTEIN2 ) complex has been determined at 2.3 angstrom.
AIMed.d171.s1443.p0	P	PROTEIN1 binds the complex as an extended structure interacting with both PROTEIN2 and PROTEIN .
AIMed.d171.s1443.p1	P	PROTEIN1 binds the complex as an extended structure interacting with both PROTEIN and PROTEIN2 .
AIMed.d171.s1443.p2	N	PROTEIN binds the complex as an extended structure interacting with both PROTEIN1 and PROTEIN2 .
AIMed.d172.s1446.p2	P	PROTEIN1 : a ligand and specific activator of the tyrosine kinase receptor PROTEIN2 .
AIMed.d172.s1447.p0	N	The tyrosine kinases PROTEIN1 , PROTEIN2 , and PROTEIN (or PROTEIN ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1447.p1	N	The tyrosine kinases PROTEIN1 , PROTEIN , and PROTEIN2 (or PROTEIN ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1447.p2	N	The tyrosine kinases PROTEIN1 , PROTEIN , and PROTEIN (or PROTEIN2 ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1447.p3	N	The tyrosine kinases PROTEIN , PROTEIN1 , and PROTEIN2 (or PROTEIN ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1447.p4	N	The tyrosine kinases PROTEIN , PROTEIN1 , and PROTEIN (or PROTEIN2 ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1447.p5	N	The tyrosine kinases PROTEIN , PROTEIN , and PROTEIN1 (or PROTEIN2 ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
AIMed.d172.s1448.p0	N	PROTEIN1 and PROTEIN2 have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN ( PROTEIN ).
AIMed.d172.s1448.p1	P	PROTEIN1 and PROTEIN have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN2 ( PROTEIN ).
AIMed.d172.s1448.p2	P	PROTEIN1 and PROTEIN have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN ( PROTEIN2 ).
AIMed.d172.s1448.p3	P	PROTEIN and PROTEIN1 have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN2 ( PROTEIN ).
AIMed.d172.s1448.p4	P	PROTEIN and PROTEIN1 have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN ( PROTEIN2 ).
AIMed.d172.s1448.p5	N	PROTEIN and PROTEIN have been shown to play key roles in vascular development; these two receptors bind and are activated by PROTEIN1 ( PROTEIN2 ).
AIMed.d172.s1451.p4	N	This protein, designated PROTEIN1 ( PROTEIN2 ), specifically binds to the extracellular domain of PROTEIN , stimulates the tyrosine phosphorylation of PROTEIN expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1451.p5	P	This protein, designated PROTEIN1 ( PROTEIN ), specifically binds to the extracellular domain of PROTEIN2 , stimulates the tyrosine phosphorylation of PROTEIN expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1451.p6	N	This protein, designated PROTEIN1 ( PROTEIN ), specifically binds to the extracellular domain of PROTEIN , stimulates the tyrosine phosphorylation of PROTEIN2 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1451.p7	P	This protein, designated PROTEIN ( PROTEIN1 ), specifically binds to the extracellular domain of PROTEIN2 , stimulates the tyrosine phosphorylation of PROTEIN expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1451.p8	N	This protein, designated PROTEIN ( PROTEIN1 ), specifically binds to the extracellular domain of PROTEIN , stimulates the tyrosine phosphorylation of PROTEIN2 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1451.p9	N	This protein, designated PROTEIN ( PROTEIN ), specifically binds to the extracellular domain of PROTEIN1 , stimulates the tyrosine phosphorylation of PROTEIN2 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
AIMed.d172.s1452.p0	N	PROTEIN1 fails to bind appreciably to the extracellular domain of PROTEIN2 or PROTEIN .
AIMed.d172.s1452.p1	N	PROTEIN1 fails to bind appreciably to the extracellular domain of PROTEIN or PROTEIN2 .
AIMed.d172.s1452.p2	N	PROTEIN fails to bind appreciably to the extracellular domain of PROTEIN1 or PROTEIN2 .
AIMed.d173.s1459.p0	N	Fusion proteins were created by linking the PROTEIN1 fragment to a PROTEIN2 DNA-binding domain (bait) and also to a PROTEIN transactivation domain (prey).
AIMed.d173.s1459.p1	N	Fusion proteins were created by linking the PROTEIN1 fragment to a PROTEIN DNA-binding domain (bait) and also to a PROTEIN2 transactivation domain (prey).
AIMed.d173.s1459.p2	N	Fusion proteins were created by linking the PROTEIN fragment to a PROTEIN1 DNA-binding domain (bait) and also to a PROTEIN2 transactivation domain (prey).
AIMed.d173.s1460.p0	N	Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) genes under the control of LexA-dependent operators.
AIMed.d173.s1460.p1	N	Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) genes under the control of LexA-dependent operators.
AIMed.d173.s1460.p3	N	Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) genes under the control of LexA-dependent operators.
AIMed.d173.s1460.p4	N	Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) genes under the control of LexA-dependent operators.
AIMed.d173.s1460.p5	N	Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) genes under the control of LexA-dependent operators.
AIMed.d173.s1462.p0	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN2 ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p1	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN ( PROTEIN2 - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p3	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN2 fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p4	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN2 , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p5	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p6	N	PROTEIN1 protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p7	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN2 - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p8	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN - PROTEIN2 ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p9	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN2 fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p10	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN2 , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p11	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p12	N	PROTEIN protein fused to the Drosophila protein PROTEIN1 ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p13	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN1 - PROTEIN2 ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p14	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN1 - PROTEIN ) failed to interact with the PROTEIN2 fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p15	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN1 - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN2 , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p16	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN1 - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p17	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN1 - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p18	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN1 ) failed to interact with the PROTEIN2 fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p20	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN1 ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p21	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN1 ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p22	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN1 fragment fused to PROTEIN2 , indicating that the observed PROTEIN - PROTEIN interaction was specific.
AIMed.d173.s1462.p23	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN1 fragment fused to PROTEIN , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p24	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN1 fragment fused to PROTEIN , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p25	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN1 , indicating that the observed PROTEIN2 - PROTEIN interaction was specific.
AIMed.d173.s1462.p26	N	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN1 , indicating that the observed PROTEIN - PROTEIN2 interaction was specific.
AIMed.d173.s1462.p27	P	PROTEIN protein fused to the Drosophila protein PROTEIN ( PROTEIN - PROTEIN ) failed to interact with the PROTEIN fragment fused to PROTEIN , indicating that the observed PROTEIN1 - PROTEIN2 interaction was specific.
AIMed.d173.s1463.p0	N	Specificity was further shown by the finding that no significant interaction was observed in yeast expressing PROTEIN1 - PROTEIN2 bait when the PROTEIN transactivation domain was fused to an PROTEIN fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.
AIMed.d173.s1463.p1	N	Specificity was further shown by the finding that no significant interaction was observed in yeast expressing PROTEIN1 - PROTEIN bait when the PROTEIN2 transactivation domain was fused to an PROTEIN fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.
AIMed.d173.s1463.p3	N	Specificity was further shown by the finding that no significant interaction was observed in yeast expressing PROTEIN - PROTEIN1 bait when the PROTEIN2 transactivation domain was fused to an PROTEIN fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.
AIMed.d173.s1463.p4	N	Specificity was further shown by the finding that no significant interaction was observed in yeast expressing PROTEIN - PROTEIN1 bait when the PROTEIN transactivation domain was fused to an PROTEIN2 fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.
AIMed.d173.s1463.p5	N	Specificity was further shown by the finding that no significant interaction was observed in yeast expressing PROTEIN - PROTEIN bait when the PROTEIN1 transactivation domain was fused to an PROTEIN2 fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.
AIMed.d174.s1466.p0	N	Influence of PROTEIN1 ( PROTEIN2 ) dimerization on formation of the high affinity hexameric PROTEIN complex.
AIMed.d174.s1466.p2	N	Influence of PROTEIN1 ( PROTEIN ) dimerization on formation of the high affinity hexameric PROTEIN2 complex.
AIMed.d174.s1466.p4	N	Influence of PROTEIN ( PROTEIN1 ) dimerization on formation of the high affinity hexameric PROTEIN2 complex.
AIMed.d174.s1467.p0	N	The high affinity PROTEIN1 ( PROTEIN2 ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p1	N	The high affinity PROTEIN1 ( PROTEIN ) signaling complex consists of PROTEIN2 and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p3	N	The high affinity PROTEIN1 ( PROTEIN ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN2 and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p4	N	The high affinity PROTEIN1 ( PROTEIN ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN2 .
AIMed.d174.s1467.p5	N	The high affinity PROTEIN ( PROTEIN1 ) signaling complex consists of PROTEIN2 and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p7	N	The high affinity PROTEIN ( PROTEIN1 ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN2 and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p8	N	The high affinity PROTEIN ( PROTEIN1 ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN2 .
AIMed.d174.s1467.p10	P	The high affinity PROTEIN ( PROTEIN ) signaling complex consists of PROTEIN1 and two membrane-associated receptor components: a low affinity but specific PROTEIN2 and the affinity converter/signal transducing protein PROTEIN .
AIMed.d174.s1467.p11	N	The high affinity PROTEIN ( PROTEIN ) signaling complex consists of PROTEIN1 and two membrane-associated receptor components: a low affinity but specific PROTEIN and the affinity converter/signal transducing protein PROTEIN2 .
AIMed.d174.s1467.p14	N	The high affinity PROTEIN ( PROTEIN ) signaling complex consists of PROTEIN and two membrane-associated receptor components: a low affinity but specific PROTEIN1 and the affinity converter/signal transducing protein PROTEIN2 .
AIMed.d174.s1468.p0	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN2 ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p1	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN2 and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p3	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN2 ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p4	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN2 ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p5	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN2 have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p6	N	Monomeric ( PROTEIN1 ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN2 dimerization on binding to the receptor complex.
AIMed.d174.s1468.p7	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN1 ) forms of Escherichia coli-derived human PROTEIN2 and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p9	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN1 ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN2 ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p10	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN1 ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN2 ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p11	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN1 ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN2 have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p12	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN1 ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN2 dimerization on binding to the receptor complex.
AIMed.d174.s1468.p14	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN1 and the extracellular ("soluble") portions of the PROTEIN2 ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p15	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN1 and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN2 ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p16	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN1 and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN2 have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p17	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN1 and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN2 dimerization on binding to the receptor complex.
AIMed.d174.s1468.p22	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN1 ( PROTEIN2 ) and PROTEIN have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p23	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN1 ( PROTEIN ) and PROTEIN2 have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p24	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN1 ( PROTEIN ) and PROTEIN have been purified in order to investigate the effect of PROTEIN2 dimerization on binding to the receptor complex.
AIMed.d174.s1468.p25	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN1 ) and PROTEIN2 have been purified in order to investigate the effect of PROTEIN dimerization on binding to the receptor complex.
AIMed.d174.s1468.p26	N	Monomeric ( PROTEIN ) and dimeric ( PROTEIN ) forms of Escherichia coli-derived human PROTEIN and the extracellular ("soluble") portions of the PROTEIN ( PROTEIN1 ) and PROTEIN have been purified in order to investigate the effect of PROTEIN2 dimerization on binding to the receptor complex.
AIMed.d174.s1469.p0	P	Although PROTEIN1 has a higher binding affinity for immobilized PROTEIN2 , as determined by biosensor analysis employing surface plasmon resonance detection, PROTEIN is more potent than PROTEIN in a STAT3 phosphorylation assay.
AIMed.d174.s1469.p2	N	Although PROTEIN1 has a higher binding affinity for immobilized PROTEIN , as determined by biosensor analysis employing surface plasmon resonance detection, PROTEIN is more potent than PROTEIN2 in a STAT3 phosphorylation assay.
AIMed.d174.s1469.p3	N	Although PROTEIN has a higher binding affinity for immobilized PROTEIN1 , as determined by biosensor analysis employing surface plasmon resonance detection, PROTEIN2 is more potent than PROTEIN in a STAT3 phosphorylation assay.
AIMed.d174.s1469.p4	N	Although PROTEIN has a higher binding affinity for immobilized PROTEIN1 , as determined by biosensor analysis employing surface plasmon resonance detection, PROTEIN is more potent than PROTEIN2 in a STAT3 phosphorylation assay.
AIMed.d174.s1469.p5	N	Although PROTEIN has a higher binding affinity for immobilized PROTEIN , as determined by biosensor analysis employing surface plasmon resonance detection, PROTEIN1 is more potent than PROTEIN2 in a STAT3 phosphorylation assay.
AIMed.d174.s1472.p0	N	Studies of the PROTEIN1 ternary complex formation demonstrated that the reduced biological potency of PROTEIN2 resulted from a decreased ability of the PROTEIN ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN .
AIMed.d174.s1472.p1	N	Studies of the PROTEIN1 ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN2 ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN .
AIMed.d174.s1472.p2	N	Studies of the PROTEIN1 ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN ( PROTEIN2 )2 complex to couple with the soluble portion of PROTEIN .
AIMed.d174.s1472.p3	N	Studies of the PROTEIN1 ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN2 .
AIMed.d174.s1472.p4	N	Studies of the PROTEIN ternary complex formation demonstrated that the reduced biological potency of PROTEIN1 resulted from a decreased ability of the PROTEIN2 ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN .
AIMed.d174.s1472.p6	N	Studies of the PROTEIN ternary complex formation demonstrated that the reduced biological potency of PROTEIN1 resulted from a decreased ability of the PROTEIN ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN2 .
AIMed.d174.s1472.p7	P	Studies of the PROTEIN ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN1 ( PROTEIN2 )2 complex to couple with the soluble portion of PROTEIN .
AIMed.d174.s1472.p8	N	Studies of the PROTEIN ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN1 ( PROTEIN )2 complex to couple with the soluble portion of PROTEIN2 .
AIMed.d174.s1472.p9	N	Studies of the PROTEIN ternary complex formation demonstrated that the reduced biological potency of PROTEIN resulted from a decreased ability of the PROTEIN ( PROTEIN1 )2 complex to couple with the soluble portion of PROTEIN2 .
AIMed.d174.s1473.p0	N	These data imply that PROTEIN1 -induced dimerization of PROTEIN2 is not the driving force in promoting formation of the hexameric ( PROTEIN  PROTEIN  PROTEIN )2 complex.
AIMed.d174.s1473.p1	N	These data imply that PROTEIN1 -induced dimerization of PROTEIN is not the driving force in promoting formation of the hexameric ( PROTEIN2  PROTEIN  PROTEIN )2 complex.
AIMed.d174.s1473.p3	N	These data imply that PROTEIN1 -induced dimerization of PROTEIN is not the driving force in promoting formation of the hexameric ( PROTEIN  PROTEIN  PROTEIN2 )2 complex.
AIMed.d174.s1473.p5	N	These data imply that PROTEIN -induced dimerization of PROTEIN1 is not the driving force in promoting formation of the hexameric ( PROTEIN  PROTEIN2  PROTEIN )2 complex.
AIMed.d174.s1473.p6	N	These data imply that PROTEIN -induced dimerization of PROTEIN1 is not the driving force in promoting formation of the hexameric ( PROTEIN  PROTEIN  PROTEIN2 )2 complex.
AIMed.d174.s1473.p7	P	These data imply that PROTEIN -induced dimerization of PROTEIN is not the driving force in promoting formation of the hexameric ( PROTEIN1  PROTEIN2  PROTEIN )2 complex.
AIMed.d174.s1473.p8	N	These data imply that PROTEIN -induced dimerization of PROTEIN is not the driving force in promoting formation of the hexameric ( PROTEIN1  PROTEIN  PROTEIN2 )2 complex.
AIMed.d174.s1473.p9	N	These data imply that PROTEIN -induced dimerization of PROTEIN is not the driving force in promoting formation of the hexameric ( PROTEIN  PROTEIN1  PROTEIN2 )2 complex.
AIMed.d174.s1474.p0	P	A model is presented whereby the trimeric complex of PROTEIN1 , PROTEIN2 , and PROTEIN forms before the functional hexamer.
AIMed.d174.s1474.p1	N	A model is presented whereby the trimeric complex of PROTEIN1 , PROTEIN , and PROTEIN2 forms before the functional hexamer.
AIMed.d174.s1474.p2	N	A model is presented whereby the trimeric complex of PROTEIN , PROTEIN1 , and PROTEIN2 forms before the functional hexamer.
AIMed.d174.s1475.p0	N	Due to its increased affinity for the PROTEIN1 but its decreased ability to couple with PROTEIN2 , we suggest that a stable PROTEIN dimer may be an efficient PROTEIN antagonist.
AIMed.d174.s1475.p1	P	Due to its increased affinity for the PROTEIN1 but its decreased ability to couple with PROTEIN , we suggest that a stable PROTEIN2 dimer may be an efficient PROTEIN antagonist.
AIMed.d174.s1475.p2	N	Due to its increased affinity for the PROTEIN1 but its decreased ability to couple with PROTEIN , we suggest that a stable PROTEIN dimer may be an efficient PROTEIN2 antagonist.
AIMed.d174.s1475.p3	P	Due to its increased affinity for the PROTEIN but its decreased ability to couple with PROTEIN1 , we suggest that a stable PROTEIN2 dimer may be an efficient PROTEIN antagonist.
AIMed.d174.s1475.p4	N	Due to its increased affinity for the PROTEIN but its decreased ability to couple with PROTEIN1 , we suggest that a stable PROTEIN dimer may be an efficient PROTEIN2 antagonist.
AIMed.d174.s1475.p5	N	Due to its increased affinity for the PROTEIN but its decreased ability to couple with PROTEIN , we suggest that a stable PROTEIN1 dimer may be an efficient PROTEIN2 antagonist.
AIMed.d175.s1476.p0	P	Physical interaction of mammalian PROTEIN1 with PROTEIN2
AIMed.d175.s1477.p0	N	PROTEIN1 was originally identified as a Start gene in budding yeast and has been shown to be required for association of PROTEIN2 with cyclins.
AIMed.d175.s1479.p0	N	PROTEIN1 is a PROTEIN2 that controls progression through G1 of the mammalian cell cycle.
AIMed.d175.s1480.p0	P	We have detected a specific association of PROTEIN1 with the molecular chaperon PROTEIN2 and a 44-kDa protein that we identify as mammalian PROTEIN .
AIMed.d175.s1480.p2	N	We have detected a specific association of PROTEIN with the molecular chaperon PROTEIN1 and a 44-kDa protein that we identify as mammalian PROTEIN2 .
AIMed.d175.s1481.p0	P	A physical interaction between PROTEIN1 and PROTEIN2 suggests that PROTEIN may regulate the mammalian cell cycle through a direct effect on PROTEIN .
AIMed.d175.s1481.p1	N	A physical interaction between PROTEIN1 and PROTEIN suggests that PROTEIN2 may regulate the mammalian cell cycle through a direct effect on PROTEIN .
AIMed.d175.s1481.p2	N	A physical interaction between PROTEIN1 and PROTEIN suggests that PROTEIN may regulate the mammalian cell cycle through a direct effect on PROTEIN2 .
AIMed.d175.s1481.p3	N	A physical interaction between PROTEIN and PROTEIN1 suggests that PROTEIN2 may regulate the mammalian cell cycle through a direct effect on PROTEIN .
AIMed.d175.s1481.p4	N	A physical interaction between PROTEIN and PROTEIN1 suggests that PROTEIN may regulate the mammalian cell cycle through a direct effect on PROTEIN2 .
AIMed.d175.s1482.p0	P	Association of PROTEIN1 with both PROTEIN2 and PROTEIN may also imply a mechanistic link between the functions of PROTEIN and PROTEIN .
AIMed.d175.s1482.p1	P	Association of PROTEIN1 with both PROTEIN and PROTEIN2 may also imply a mechanistic link between the functions of PROTEIN and PROTEIN .
AIMed.d175.s1482.p2	N	Association of PROTEIN1 with both PROTEIN and PROTEIN may also imply a mechanistic link between the functions of PROTEIN2 and PROTEIN .
AIMed.d175.s1482.p3	N	Association of PROTEIN1 with both PROTEIN and PROTEIN may also imply a mechanistic link between the functions of PROTEIN and PROTEIN2 .
AIMed.d175.s1482.p4	N	Association of PROTEIN with both PROTEIN1 and PROTEIN2 may also imply a mechanistic link between the functions of PROTEIN and PROTEIN .
AIMed.d175.s1482.p5	N	Association of PROTEIN with both PROTEIN1 and PROTEIN may also imply a mechanistic link between the functions of PROTEIN2 and PROTEIN .
AIMed.d175.s1482.p6	N	Association of PROTEIN with both PROTEIN1 and PROTEIN may also imply a mechanistic link between the functions of PROTEIN and PROTEIN2 .
AIMed.d175.s1482.p7	N	Association of PROTEIN with both PROTEIN and PROTEIN1 may also imply a mechanistic link between the functions of PROTEIN2 and PROTEIN .
AIMed.d175.s1482.p8	N	Association of PROTEIN with both PROTEIN and PROTEIN1 may also imply a mechanistic link between the functions of PROTEIN and PROTEIN2 .
AIMed.d175.s1482.p9	N	Association of PROTEIN with both PROTEIN and PROTEIN may also imply a mechanistic link between the functions of PROTEIN1 and PROTEIN2 .
AIMed.d176.s1483.p0	N	Interactions of PROTEIN1 , a mediator of PROTEIN2 assembly, with heat shock proteins PROTEIN and PROTEIN .
AIMed.d176.s1483.p1	P	Interactions of PROTEIN1 , a mediator of PROTEIN assembly, with heat shock proteins PROTEIN2 and PROTEIN .
AIMed.d176.s1483.p2	P	Interactions of PROTEIN1 , a mediator of PROTEIN assembly, with heat shock proteins PROTEIN and PROTEIN2 .
AIMed.d176.s1483.p3	N	Interactions of PROTEIN , a mediator of PROTEIN1 assembly, with heat shock proteins PROTEIN2 and PROTEIN .
AIMed.d176.s1483.p4	N	Interactions of PROTEIN , a mediator of PROTEIN1 assembly, with heat shock proteins PROTEIN and PROTEIN2 .
AIMed.d176.s1483.p5	N	Interactions of PROTEIN , a mediator of PROTEIN assembly, with heat shock proteins PROTEIN1 and PROTEIN2 .
AIMed.d176.s1484.p0	N	Previous studies on the assembly of PROTEIN1 ( PROTEIN2 ) complexes in vitro have suggested that PROTEIN assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.
AIMed.d176.s1484.p1	N	Previous studies on the assembly of PROTEIN1 ( PROTEIN ) complexes in vitro have suggested that PROTEIN2 assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.
AIMed.d176.s1484.p2	N	Previous studies on the assembly of PROTEIN ( PROTEIN1 ) complexes in vitro have suggested that PROTEIN2 assembly is a dynamic, ordered process involving at least eight nonreceptor proteins.
AIMed.d176.s1486.p0	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN2 complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p1	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN2 ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p3	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN2 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p4	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN2 complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p5	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN2 and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p6	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p7	N	In the present study we observe that a monoclonal antibody specific for PROTEIN1 can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p8	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN2 ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p9	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN ( PROTEIN2 ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p10	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN ( PROTEIN ), PROTEIN2 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p11	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN2 complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p13	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p14	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN1 complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p15	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN1 ( PROTEIN2 ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p16	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN1 ( PROTEIN ), PROTEIN2 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p17	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN1 ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN2 complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p18	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN1 ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN2 and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p19	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN1 ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p21	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN1 ), PROTEIN2 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p22	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN1 ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN2 complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p24	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN1 ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p25	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN1 ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p26	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN1 , and immunophilins and, on the other, enhance recovery of early PROTEIN2 complexes containing PROTEIN and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p27	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN1 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN2 and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p28	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN1 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p29	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN1 , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p30	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN1 complexes containing PROTEIN2 and PROTEIN ( PROTEIN ).
AIMed.d176.s1486.p31	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN1 complexes containing PROTEIN and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p32	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN1 complexes containing PROTEIN and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p33	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN1 and PROTEIN2 ( PROTEIN ).
AIMed.d176.s1486.p34	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN1 and PROTEIN ( PROTEIN2 ).
AIMed.d176.s1486.p35	N	In the present study we observe that a monoclonal antibody specific for PROTEIN can, on the one hand, inhibit formation of mature PROTEIN complexes containing PROTEIN ( PROTEIN ), PROTEIN , and immunophilins and, on the other, enhance recovery of early PROTEIN complexes containing PROTEIN and PROTEIN1 ( PROTEIN2 ).
AIMed.d176.s1487.p0	N	This observation supports a model in which PROTEIN1 functions at an intermediate stage of PROTEIN2 assembly to facilitate formation of subsequent PROTEIN complexes lacking PROTEIN .
AIMed.d176.s1487.p1	N	This observation supports a model in which PROTEIN1 functions at an intermediate stage of PROTEIN assembly to facilitate formation of subsequent PROTEIN2 complexes lacking PROTEIN .
AIMed.d176.s1487.p2	N	This observation supports a model in which PROTEIN1 functions at an intermediate stage of PROTEIN assembly to facilitate formation of subsequent PROTEIN complexes lacking PROTEIN2 .
AIMed.d176.s1487.p3	N	This observation supports a model in which PROTEIN functions at an intermediate stage of PROTEIN1 assembly to facilitate formation of subsequent PROTEIN2 complexes lacking PROTEIN .
AIMed.d176.s1487.p4	N	This observation supports a model in which PROTEIN functions at an intermediate stage of PROTEIN1 assembly to facilitate formation of subsequent PROTEIN complexes lacking PROTEIN2 .
AIMed.d176.s1487.p5	N	This observation supports a model in which PROTEIN functions at an intermediate stage of PROTEIN assembly to facilitate formation of subsequent PROTEIN1 complexes lacking PROTEIN2 .
AIMed.d176.s1488.p0	P	Since PROTEIN1 is typically found in a complex with PROTEIN2 and PROTEIN , we have further characterized its interactions with these proteins.
AIMed.d176.s1488.p1	P	Since PROTEIN1 is typically found in a complex with PROTEIN and PROTEIN2 , we have further characterized its interactions with these proteins.
AIMed.d176.s1488.p2	N	Since PROTEIN is typically found in a complex with PROTEIN1 and PROTEIN2 , we have further characterized its interactions with these proteins.
AIMed.d176.s1489.p0	P	PROTEIN1 can bind either PROTEIN2 or PROTEIN independently and in an ATP-independent manner.
AIMed.d176.s1489.p1	P	PROTEIN1 can bind either PROTEIN or PROTEIN2 independently and in an ATP-independent manner.
AIMed.d176.s1489.p2	N	PROTEIN can bind either PROTEIN1 or PROTEIN2 independently and in an ATP-independent manner.
AIMed.d176.s1490.p0	N	Since PROTEIN1 and PROTEIN2 do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN - PROTEIN - PROTEIN complex.
AIMed.d176.s1490.p2	N	Since PROTEIN1 and PROTEIN do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN2 - PROTEIN - PROTEIN complex.
AIMed.d176.s1490.p3	N	Since PROTEIN1 and PROTEIN do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN - PROTEIN2 - PROTEIN complex.
AIMed.d176.s1490.p5	N	Since PROTEIN and PROTEIN1 do not readily associate on their own, it appears that PROTEIN2 is the central organizing component of an PROTEIN - PROTEIN - PROTEIN complex.
AIMed.d176.s1490.p6	N	Since PROTEIN and PROTEIN1 do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN2 - PROTEIN - PROTEIN complex.
AIMed.d176.s1490.p7	N	Since PROTEIN and PROTEIN1 do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN - PROTEIN2 - PROTEIN complex.
AIMed.d176.s1490.p8	N	Since PROTEIN and PROTEIN1 do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN - PROTEIN - PROTEIN2 complex.
AIMed.d176.s1490.p9	N	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN1 is the central organizing component of an PROTEIN2 - PROTEIN - PROTEIN complex.
AIMed.d176.s1490.p10	N	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN1 is the central organizing component of an PROTEIN - PROTEIN2 - PROTEIN complex.
AIMed.d176.s1490.p11	N	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN1 is the central organizing component of an PROTEIN - PROTEIN - PROTEIN2 complex.
AIMed.d176.s1490.p12	P	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN1 - PROTEIN2 - PROTEIN complex.
AIMed.d176.s1490.p13	N	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN1 - PROTEIN - PROTEIN2 complex.
AIMed.d176.s1490.p14	N	Since PROTEIN and PROTEIN do not readily associate on their own, it appears that PROTEIN is the central organizing component of an PROTEIN - PROTEIN1 - PROTEIN2 complex.
AIMed.d176.s1491.p0	P	Mutational analysis of PROTEIN1 indicates that the N terminus is required for PROTEIN2 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding PROTEIN and PROTEIN .
AIMed.d176.s1491.p1	P	Mutational analysis of PROTEIN1 indicates that the N terminus is required for PROTEIN binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding PROTEIN2 and PROTEIN .
AIMed.d176.s1491.p2	P	Mutational analysis of PROTEIN1 indicates that the N terminus is required for PROTEIN binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding PROTEIN and PROTEIN2 .
AIMed.d176.s1491.p4	N	Mutational analysis of PROTEIN indicates that the N terminus is required for PROTEIN1 binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding PROTEIN and PROTEIN2 .
AIMed.d176.s1491.p5	N	Mutational analysis of PROTEIN indicates that the N terminus is required for PROTEIN binding, and a central region containing tetratricopeptide repeat motifs is necessary for binding PROTEIN1 and PROTEIN2 .
AIMed.d176.s1492.p1	N	The PROTEIN1 - PROTEIN - PROTEIN2 multichaperone complex is highly dynamic and does not appear to be affected by the PROTEIN -binding drug geldanamycin.
AIMed.d176.s1492.p2	N	The PROTEIN1 - PROTEIN - PROTEIN multichaperone complex is highly dynamic and does not appear to be affected by the PROTEIN2 -binding drug geldanamycin.
AIMed.d176.s1492.p3	N	The PROTEIN - PROTEIN1 - PROTEIN2 multichaperone complex is highly dynamic and does not appear to be affected by the PROTEIN -binding drug geldanamycin.
AIMed.d176.s1492.p4	N	The PROTEIN - PROTEIN1 - PROTEIN multichaperone complex is highly dynamic and does not appear to be affected by the PROTEIN2 -binding drug geldanamycin.
AIMed.d176.s1492.p5	N	The PROTEIN - PROTEIN - PROTEIN1 multichaperone complex is highly dynamic and does not appear to be affected by the PROTEIN2 -binding drug geldanamycin.
AIMed.d176.s1493.p0	P	The interactions of PROTEIN1 and PROTEIN2 in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p1	N	The interactions of PROTEIN1 and PROTEIN in intermediate PROTEIN2 complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p2	N	The interactions of PROTEIN1 and PROTEIN in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN2 complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p3	N	The interactions of PROTEIN1 and PROTEIN in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN2 ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p4	N	The interactions of PROTEIN1 and PROTEIN in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN ) or in mature PROTEIN2 complexes (hsp90).
AIMed.d176.s1493.p5	N	The interactions of PROTEIN and PROTEIN1 in intermediate PROTEIN2 complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p6	N	The interactions of PROTEIN and PROTEIN1 in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN2 complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p8	N	The interactions of PROTEIN and PROTEIN1 in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN ) or in mature PROTEIN2 complexes (hsp90).
AIMed.d176.s1493.p9	N	The interactions of PROTEIN and PROTEIN in intermediate PROTEIN1 complexes are shown to be distinct from their separate interactions in early PROTEIN2 complexes ( PROTEIN ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p10	N	The interactions of PROTEIN and PROTEIN in intermediate PROTEIN1 complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN2 ) or in mature PROTEIN complexes (hsp90).
AIMed.d176.s1493.p13	N	The interactions of PROTEIN and PROTEIN in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN1 complexes ( PROTEIN ) or in mature PROTEIN2 complexes (hsp90).
AIMed.d176.s1493.p14	N	The interactions of PROTEIN and PROTEIN in intermediate PROTEIN complexes are shown to be distinct from their separate interactions in early PROTEIN complexes ( PROTEIN1 ) or in mature PROTEIN2 complexes (hsp90).
AIMed.d176.s1494.p0	N	From these results, it appears that PROTEIN1 is a key mediator in the chaperoned assembly and functional maturation of PROTEIN2 complexes.
AIMed.d177.s1503.p0	P	We have selected such mutations in the transcription factor PROTEIN1 that affect its ability to heterodimerize with PROTEIN2 .
AIMed.d178.s1508.p0	P	In vitro and in nonproliferating cells, PROTEIN1 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either PROTEIN2 , PROTEIN , or PROTEIN .
AIMed.d178.s1508.p1	P	In vitro and in nonproliferating cells, PROTEIN1 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either PROTEIN , PROTEIN2 , or PROTEIN .
AIMed.d178.s1508.p2	P	In vitro and in nonproliferating cells, PROTEIN1 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either PROTEIN , PROTEIN , or PROTEIN2 .
AIMed.d178.s1508.p3	N	In vitro and in nonproliferating cells, PROTEIN associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either PROTEIN1 , PROTEIN2 , or PROTEIN .
AIMed.d178.s1508.p5	N	In vitro and in nonproliferating cells, PROTEIN associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either PROTEIN , PROTEIN1 , or PROTEIN2 .
AIMed.d178.s1509.p0	N	Although many different types of proliferating cells contain PROTEIN1 protein, neither the interactions of PROTEIN2 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.
AIMed.d178.s1511.p0	P	In addition, PROTEIN1 associates with three different CDKs: PROTEIN2 , PROTEIN , and PROTEIN .
AIMed.d178.s1511.p1	P	In addition, PROTEIN1 associates with three different CDKs: PROTEIN , PROTEIN2 , and PROTEIN .
AIMed.d178.s1511.p2	P	In addition, PROTEIN1 associates with three different CDKs: PROTEIN , PROTEIN , and PROTEIN2 .
AIMed.d178.s1511.p3	N	In addition, PROTEIN associates with three different CDKs: PROTEIN1 , PROTEIN2 , and PROTEIN .
AIMed.d178.s1511.p4	N	In addition, PROTEIN associates with three different CDKs: PROTEIN1 , PROTEIN , and PROTEIN2 .
AIMed.d178.s1511.p5	N	In addition, PROTEIN associates with three different CDKs: PROTEIN , PROTEIN1 , and PROTEIN2 .
AIMed.d178.s1512.p0	N	Furthermore, the amount of PROTEIN1 is significantly lower than the amount of PROTEIN2 in these cells.
AIMed.d178.s1513.p0	N	The amount of PROTEIN1 and PROTEIN2 associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN associated with PROTEIN is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p2	N	The amount of PROTEIN1 and PROTEIN associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN2 associated with PROTEIN is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p3	N	The amount of PROTEIN1 and PROTEIN associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN associated with PROTEIN2 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p4	P	The amount of PROTEIN and PROTEIN1 associated with PROTEIN2 does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN associated with PROTEIN is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p5	N	The amount of PROTEIN and PROTEIN1 associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN2 associated with PROTEIN is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p6	N	The amount of PROTEIN and PROTEIN1 associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN associated with PROTEIN2 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p7	N	The amount of PROTEIN and PROTEIN associated with PROTEIN1 does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN2 associated with PROTEIN is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p8	N	The amount of PROTEIN and PROTEIN associated with PROTEIN1 does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN associated with PROTEIN2 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1513.p9	P	The amount of PROTEIN and PROTEIN associated with PROTEIN does not change in a cell cycle-dependent fashion; in contrast, the amount of PROTEIN1 associated with PROTEIN2 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.
AIMed.d178.s1516.p0	N	The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a PROTEIN1 -specific antibody suggest that the PROTEIN2 protein mediates, in part, the PROTEIN -associated PROTEIN -kinase activity.
AIMed.d178.s1516.p2	N	The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a PROTEIN1 -specific antibody suggest that the PROTEIN protein mediates, in part, the PROTEIN -associated PROTEIN2 -kinase activity.
AIMed.d178.s1516.p3	N	The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a PROTEIN -specific antibody suggest that the PROTEIN1 protein mediates, in part, the PROTEIN2 -associated PROTEIN -kinase activity.
AIMed.d178.s1516.p4	N	The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a PROTEIN -specific antibody suggest that the PROTEIN1 protein mediates, in part, the PROTEIN -associated PROTEIN2 -kinase activity.
AIMed.d178.s1516.p5	N	The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a PROTEIN -specific antibody suggest that the PROTEIN protein mediates, in part, the PROTEIN1 -associated PROTEIN2 -kinase activity.
AIMed.d178.s1517.p0	P	In contrast, PROTEIN1 complexes containing PROTEIN2 are incapable of phosphorylating PROTEIN .
AIMed.d178.s1517.p1	N	In contrast, PROTEIN1 complexes containing PROTEIN are incapable of phosphorylating PROTEIN2 .
AIMed.d178.s1517.p2	N	In contrast, PROTEIN complexes containing PROTEIN1 are incapable of phosphorylating PROTEIN2 .
AIMed.d178.s1518.p0	N	These data are consistent with a model wherein PROTEIN1 /CDK complexes sequester the PROTEIN2 -dependent kinase inhibitory activity of PROTEIN .
AIMed.d178.s1518.p1	N	These data are consistent with a model wherein PROTEIN1 /CDK complexes sequester the PROTEIN -dependent kinase inhibitory activity of PROTEIN2 .
AIMed.d178.s1518.p2	N	These data are consistent with a model wherein PROTEIN /CDK complexes sequester the PROTEIN1 -dependent kinase inhibitory activity of PROTEIN2 .
AIMed.d179.s1519.p2	P	PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN2 and its association with PROTEIN and the PROTEIN .
AIMed.d179.s1519.p3	N	PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN and its association with PROTEIN2 and the PROTEIN .
AIMed.d179.s1519.p4	N	PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN and its association with PROTEIN and the PROTEIN2 .
AIMed.d179.s1519.p12	P	PROTEIN stimulates tyrosine phosphorylation of PROTEIN1 and its association with PROTEIN2 and the PROTEIN .
AIMed.d179.s1519.p13	P	PROTEIN stimulates tyrosine phosphorylation of PROTEIN1 and its association with PROTEIN and the PROTEIN2 .
AIMed.d179.s1519.p14	N	PROTEIN stimulates tyrosine phosphorylation of PROTEIN and its association with PROTEIN1 and the PROTEIN2 .
AIMed.d179.s1520.p0	N	The growth-promoting effects of PROTEIN1 on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the PROTEIN2 / PROTEIN , which belongs to the family of G protein-coupled receptors.
AIMed.d179.s1520.p1	N	The growth-promoting effects of PROTEIN1 on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the PROTEIN / PROTEIN2 , which belongs to the family of G protein-coupled receptors.
AIMed.d179.s1522.p1	P	In the present study, we demonstrate that PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN2 ( PROTEIN ), the major cytoplasmic substrate of the PROTEIN .
AIMed.d179.s1522.p2	P	In the present study, we demonstrate that PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN ( PROTEIN2 ), the major cytoplasmic substrate of the PROTEIN .
AIMed.d179.s1522.p4	N	In the present study, we demonstrate that PROTEIN1 stimulates tyrosine phosphorylation of PROTEIN ( PROTEIN ), the major cytoplasmic substrate of the PROTEIN2 .
AIMed.d179.s1522.p9	N	In the present study, we demonstrate that PROTEIN stimulates tyrosine phosphorylation of PROTEIN1 ( PROTEIN2 ), the major cytoplasmic substrate of the PROTEIN .
AIMed.d179.s1522.p11	N	In the present study, we demonstrate that PROTEIN stimulates tyrosine phosphorylation of PROTEIN1 ( PROTEIN ), the major cytoplasmic substrate of the PROTEIN2 .
AIMed.d179.s1522.p13	N	In the present study, we demonstrate that PROTEIN stimulates tyrosine phosphorylation of PROTEIN ( PROTEIN1 ), the major cytoplasmic substrate of the PROTEIN2 .
AIMed.d179.s1523.p0	P	The PROTEIN1 -induced phosphorylation of PROTEIN2 was rapid and transient, occurring within 30 s of treatment and diminishing thereafter.
AIMed.d179.s1525.p0	N	Following PROTEIN1 stimulation, we observed a time- and dose-dependent association of PROTEIN2 with the PROTEIN regulatory subunit of PROTEIN ( PROTEIN ).
AIMed.d179.s1525.p1	N	Following PROTEIN1 stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN2 regulatory subunit of PROTEIN ( PROTEIN ).
AIMed.d179.s1525.p2	N	Following PROTEIN1 stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN regulatory subunit of PROTEIN2 ( PROTEIN ).
AIMed.d179.s1525.p3	N	Following PROTEIN1 stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN regulatory subunit of PROTEIN ( PROTEIN2 ).
AIMed.d179.s1525.p4	N	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN1 with the PROTEIN2 regulatory subunit of PROTEIN ( PROTEIN ).
AIMed.d179.s1525.p5	P	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN1 with the PROTEIN regulatory subunit of PROTEIN2 ( PROTEIN ).
AIMed.d179.s1525.p6	P	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN1 with the PROTEIN regulatory subunit of PROTEIN ( PROTEIN2 ).
AIMed.d179.s1525.p7	N	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN1 regulatory subunit of PROTEIN2 ( PROTEIN ).
AIMed.d179.s1525.p8	N	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN1 regulatory subunit of PROTEIN ( PROTEIN2 ).
AIMed.d179.s1525.p9	N	Following PROTEIN stimulation, we observed a time- and dose-dependent association of PROTEIN with the PROTEIN regulatory subunit of PROTEIN1 ( PROTEIN2 ).
AIMed.d179.s1526.p0	N	In addition, activation of PROTEIN1 was detected in anti- PROTEIN2 immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p1	N	In addition, activation of PROTEIN1 was detected in anti- PROTEIN immunoprecipitates from PROTEIN2 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p2	N	In addition, activation of PROTEIN1 was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN2 , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p3	N	In addition, activation of PROTEIN1 was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN2 , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p5	N	In addition, activation of PROTEIN1 was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN2 .
AIMed.d179.s1526.p6	N	In addition, activation of PROTEIN was detected in anti- PROTEIN1 immunoprecipitates from PROTEIN2 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p7	N	In addition, activation of PROTEIN was detected in anti- PROTEIN1 immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN2 , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p8	N	In addition, activation of PROTEIN was detected in anti- PROTEIN1 immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN2 , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p9	N	In addition, activation of PROTEIN was detected in anti- PROTEIN1 immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN2 to activate PROTEIN .
AIMed.d179.s1526.p10	N	In addition, activation of PROTEIN was detected in anti- PROTEIN1 immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN2 .
AIMed.d179.s1526.p11	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN1 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN2 , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p12	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN1 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN2 , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p13	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN1 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN2 to activate PROTEIN .
AIMed.d179.s1526.p14	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN1 -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN2 .
AIMed.d179.s1526.p15	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN1 , which leads to the rapid recruitment of PROTEIN2 , might be one mechanism used by PROTEIN to activate PROTEIN .
AIMed.d179.s1526.p16	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN1 , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN2 to activate PROTEIN .
AIMed.d179.s1526.p17	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN1 , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN to activate PROTEIN2 .
AIMed.d179.s1526.p18	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN1 , might be one mechanism used by PROTEIN2 to activate PROTEIN .
AIMed.d179.s1526.p19	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN1 , might be one mechanism used by PROTEIN to activate PROTEIN2 .
AIMed.d179.s1526.p20	N	In addition, activation of PROTEIN was detected in anti- PROTEIN immunoprecipitates from PROTEIN -treated cells, suggesting that tyrosine phosphorylation of PROTEIN , which leads to the rapid recruitment of PROTEIN , might be one mechanism used by PROTEIN1 to activate PROTEIN2 .
AIMed.d179.s1527.p0	P	We have previously reported that tyrosine phosphorylation of PROTEIN1 and its association with the PROTEIN2 - PROTEIN complex may contribute to the activation of the PROTEIN pathway by PROTEIN .
AIMed.d179.s1527.p1	P	We have previously reported that tyrosine phosphorylation of PROTEIN1 and its association with the PROTEIN - PROTEIN2 complex may contribute to the activation of the PROTEIN pathway by PROTEIN .
AIMed.d179.s1527.p2	N	We have previously reported that tyrosine phosphorylation of PROTEIN1 and its association with the PROTEIN - PROTEIN complex may contribute to the activation of the PROTEIN2 pathway by PROTEIN .
AIMed.d179.s1527.p3	N	We have previously reported that tyrosine phosphorylation of PROTEIN1 and its association with the PROTEIN - PROTEIN complex may contribute to the activation of the PROTEIN pathway by PROTEIN2 .
AIMed.d179.s1527.p4	P	We have previously reported that tyrosine phosphorylation of PROTEIN and its association with the PROTEIN1 - PROTEIN2 complex may contribute to the activation of the PROTEIN pathway by PROTEIN .
AIMed.d179.s1527.p5	N	We have previously reported that tyrosine phosphorylation of PROTEIN and its association with the PROTEIN1 - PROTEIN complex may contribute to the activation of the PROTEIN2 pathway by PROTEIN .
AIMed.d179.s1527.p7	N	We have previously reported that tyrosine phosphorylation of PROTEIN and its association with the PROTEIN - PROTEIN1 complex may contribute to the activation of the PROTEIN2 pathway by PROTEIN .
AIMed.d179.s1527.p8	N	We have previously reported that tyrosine phosphorylation of PROTEIN and its association with the PROTEIN - PROTEIN1 complex may contribute to the activation of the PROTEIN pathway by PROTEIN2 .
AIMed.d179.s1527.p9	N	We have previously reported that tyrosine phosphorylation of PROTEIN and its association with the PROTEIN - PROTEIN complex may contribute to the activation of the PROTEIN1 pathway by PROTEIN2 .
AIMed.d179.s1528.p0	P	We report here that PROTEIN1 also interacts with tyrosine-phosphorylated PROTEIN2 in response to PROTEIN .
AIMed.d179.s1528.p1	N	We report here that PROTEIN1 also interacts with tyrosine-phosphorylated PROTEIN in response to PROTEIN2 .
AIMed.d179.s1528.p2	N	We report here that PROTEIN also interacts with tyrosine-phosphorylated PROTEIN1 in response to PROTEIN2 .
AIMed.d179.s1529.p0	N	Taken together, our results suggest that PROTEIN1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN2 / PROTEIN and the PROTEIN .
AIMed.d179.s1529.p2	N	Taken together, our results suggest that PROTEIN1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN / PROTEIN2 and the PROTEIN .
AIMed.d179.s1529.p4	N	Taken together, our results suggest that PROTEIN1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN / PROTEIN and the PROTEIN2 .
AIMed.d179.s1529.p6	N	Taken together, our results suggest that PROTEIN may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN1 / PROTEIN2 and the PROTEIN .
AIMed.d179.s1529.p8	N	Taken together, our results suggest that PROTEIN may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN1 / PROTEIN and the PROTEIN2 .
AIMed.d179.s1529.p13	N	Taken together, our results suggest that PROTEIN may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the PROTEIN / PROTEIN1 and the PROTEIN2 .
AIMed.d180.s1532.p0	N	PROTEIN1 ( PROTEIN2 , PROTEIN , PROTEIN ), a PROTEIN ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p1	N	PROTEIN1 ( PROTEIN , PROTEIN2 , PROTEIN ), a PROTEIN ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p3	P	PROTEIN1 ( PROTEIN , PROTEIN , PROTEIN ), a PROTEIN2 ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p4	P	PROTEIN1 ( PROTEIN , PROTEIN , PROTEIN ), a PROTEIN ( PROTEIN2 ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p5	N	PROTEIN ( PROTEIN1 , PROTEIN2 , PROTEIN ), a PROTEIN ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p6	N	PROTEIN ( PROTEIN1 , PROTEIN , PROTEIN2 ), a PROTEIN ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p7	P	PROTEIN ( PROTEIN1 , PROTEIN , PROTEIN ), a PROTEIN2 ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p8	P	PROTEIN ( PROTEIN1 , PROTEIN , PROTEIN ), a PROTEIN ( PROTEIN2 ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p9	N	PROTEIN ( PROTEIN , PROTEIN1 , PROTEIN2 ), a PROTEIN ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p10	P	PROTEIN ( PROTEIN , PROTEIN1 , PROTEIN ), a PROTEIN2 ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p11	P	PROTEIN ( PROTEIN , PROTEIN1 , PROTEIN ), a PROTEIN ( PROTEIN2 ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p12	P	PROTEIN ( PROTEIN , PROTEIN , PROTEIN1 ), a PROTEIN2 ( PROTEIN ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p13	P	PROTEIN ( PROTEIN , PROTEIN , PROTEIN1 ), a PROTEIN ( PROTEIN2 ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1532.p14	N	PROTEIN ( PROTEIN , PROTEIN , PROTEIN ), a PROTEIN1 ( PROTEIN2 ) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
AIMed.d180.s1533.p0	N	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN1 and the PROTEIN2 , PROTEIN ( PROTEIN ).
AIMed.d180.s1533.p1	P	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN1 and the PROTEIN , PROTEIN2 ( PROTEIN ).
AIMed.d180.s1533.p2	P	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN1 and the PROTEIN , PROTEIN ( PROTEIN2 ).
AIMed.d180.s1533.p3	N	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN and the PROTEIN1 , PROTEIN2 ( PROTEIN ).
AIMed.d180.s1533.p4	N	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN and the PROTEIN1 , PROTEIN ( PROTEIN2 ).
AIMed.d180.s1533.p5	N	In the yeast-based cloning system, the only strong interaction that was detected between PROTEIN and the PROTEIN , PROTEIN1 ( PROTEIN2 ).
AIMed.d180.s1534.p0	P	PROTEIN1 phosphorylates PROTEIN2 on serine 41.
AIMed.d180.s1536.p0	P	Surprisingly, the N-terminal third of PROTEIN1 alone bound PROTEIN2 more strongly than did intact PROTEIN , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN .
AIMed.d180.s1536.p1	N	Surprisingly, the N-terminal third of PROTEIN1 alone bound PROTEIN more strongly than did intact PROTEIN2 , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN .
AIMed.d180.s1536.p2	N	Surprisingly, the N-terminal third of PROTEIN1 alone bound PROTEIN more strongly than did intact PROTEIN , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN2 .
AIMed.d180.s1536.p3	P	Surprisingly, the N-terminal third of PROTEIN alone bound PROTEIN1 more strongly than did intact PROTEIN2 , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN .
AIMed.d180.s1536.p4	N	Surprisingly, the N-terminal third of PROTEIN alone bound PROTEIN1 more strongly than did intact PROTEIN , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN2 .
AIMed.d180.s1536.p5	N	Surprisingly, the N-terminal third of PROTEIN alone bound PROTEIN more strongly than did intact PROTEIN1 , suggesting that the protein's C-terminus may play a role in modulating the interaction with PROTEIN2 .
AIMed.d180.s1537.p0	P	These results, along with other recent findings, suggest a novel role for the interaction between PROTEIN1 and PROTEIN2 .
AIMed.d181.s1540.p0	P	The core domain contains the sequence-specific DNA binding activity and the in vitro PROTEIN1 protein binding activity of PROTEIN2 .
AIMed.d181.s1541.p1	N	The crystal structure of the PROTEIN1 core domain bound to the PROTEIN protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of PROTEIN2 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of PROTEIN .
AIMed.d181.s1541.p2	N	The crystal structure of the PROTEIN1 core domain bound to the PROTEIN protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of PROTEIN in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of PROTEIN2 .
AIMed.d181.s1541.p3	N	The crystal structure of the PROTEIN core domain bound to the PROTEIN1 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of PROTEIN2 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of PROTEIN .
AIMed.d181.s1541.p4	N	The crystal structure of the PROTEIN core domain bound to the PROTEIN1 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of PROTEIN in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of PROTEIN2 .
AIMed.d181.s1541.p5	N	The crystal structure of the PROTEIN core domain bound to the PROTEIN protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of PROTEIN1 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of PROTEIN2 .
AIMed.d181.s1542.p0	P	The structure of the complex shows that the PROTEIN1 binding site on the PROTEIN2 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.
AIMed.d181.s1543.p0	P	The six most frequently observed PROTEIN1 mutations disrupt PROTEIN2 binding in vitro.
AIMed.d181.s1544.p0	P	The structure provides evidence that the PROTEIN1 - PROTEIN2 complex forms in vivo and may have a critical role in the PROTEIN pathway of tumor suppression.
AIMed.d181.s1544.p1	N	The structure provides evidence that the PROTEIN1 - PROTEIN complex forms in vivo and may have a critical role in the PROTEIN2 pathway of tumor suppression.
AIMed.d181.s1544.p2	N	The structure provides evidence that the PROTEIN - PROTEIN1 complex forms in vivo and may have a critical role in the PROTEIN2 pathway of tumor suppression.
AIMed.d182.s1545.p0	P	Structure of the PROTEIN1 oncoprotein bound to the PROTEIN2 tumor suppressor transactivation domain.
AIMed.d182.s1546.p0	P	The PROTEIN1 oncoprotein is a cellular inhibitor of the PROTEIN2 tumor suppressor in that it can bind the transactivation domain of PROTEIN and downregulate its ability to activate transcription.
AIMed.d182.s1546.p2	N	The PROTEIN oncoprotein is a cellular inhibitor of the PROTEIN1 tumor suppressor in that it can bind the transactivation domain of PROTEIN2 and downregulate its ability to activate transcription.
AIMed.d182.s1547.p0	N	In certain cancers, PROTEIN1 amplification is a common event and contributes to the inactivation of PROTEIN2 .
AIMed.d182.s1548.p0	P	The crystal structure of the 109-residue amino-terminal domain of PROTEIN1 bound to a 15-residue transactivation domain peptide of PROTEIN2 revealed that PROTEIN has a deep hydrophobic cleft on which the PROTEIN peptide binds as an amphipathic alpha helix.
AIMed.d182.s1548.p1	N	The crystal structure of the 109-residue amino-terminal domain of PROTEIN1 bound to a 15-residue transactivation domain peptide of PROTEIN revealed that PROTEIN2 has a deep hydrophobic cleft on which the PROTEIN peptide binds as an amphipathic alpha helix.
AIMed.d182.s1548.p3	N	The crystal structure of the 109-residue amino-terminal domain of PROTEIN bound to a 15-residue transactivation domain peptide of PROTEIN1 revealed that PROTEIN2 has a deep hydrophobic cleft on which the PROTEIN peptide binds as an amphipathic alpha helix.
AIMed.d182.s1548.p4	N	The crystal structure of the 109-residue amino-terminal domain of PROTEIN bound to a 15-residue transactivation domain peptide of PROTEIN1 revealed that PROTEIN has a deep hydrophobic cleft on which the PROTEIN2 peptide binds as an amphipathic alpha helix.
AIMed.d182.s1548.p5	P	The crystal structure of the 109-residue amino-terminal domain of PROTEIN bound to a 15-residue transactivation domain peptide of PROTEIN revealed that PROTEIN1 has a deep hydrophobic cleft on which the PROTEIN2 peptide binds as an amphipathic alpha helix.
AIMed.d182.s1549.p0	N	The interface relies on the steric complementarity between the PROTEIN1 cleft and the hydrophobic face of the PROTEIN2 alpha helix and, in particular, on a triad of PROTEIN amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN cleft.
AIMed.d182.s1549.p1	N	The interface relies on the steric complementarity between the PROTEIN1 cleft and the hydrophobic face of the PROTEIN alpha helix and, in particular, on a triad of PROTEIN2 amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN cleft.
AIMed.d182.s1549.p2	N	The interface relies on the steric complementarity between the PROTEIN1 cleft and the hydrophobic face of the PROTEIN alpha helix and, in particular, on a triad of PROTEIN amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN2 cleft.
AIMed.d182.s1549.p3	N	The interface relies on the steric complementarity between the PROTEIN cleft and the hydrophobic face of the PROTEIN1 alpha helix and, in particular, on a triad of PROTEIN2 amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN cleft.
AIMed.d182.s1549.p4	N	The interface relies on the steric complementarity between the PROTEIN cleft and the hydrophobic face of the PROTEIN1 alpha helix and, in particular, on a triad of PROTEIN amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN2 cleft.
AIMed.d182.s1549.p5	P	The interface relies on the steric complementarity between the PROTEIN cleft and the hydrophobic face of the PROTEIN alpha helix and, in particular, on a triad of PROTEIN1 amino acids-Phe19, Trp23, and Leu26-which insert deep into the PROTEIN2 cleft.
AIMed.d182.s1550.p0	N	These same PROTEIN1 residues are also involved in transactivation, supporting the hypothesis that PROTEIN2 inactivates PROTEIN by concealing its transactivation domain.
AIMed.d182.s1550.p1	N	These same PROTEIN1 residues are also involved in transactivation, supporting the hypothesis that PROTEIN inactivates PROTEIN2 by concealing its transactivation domain.
AIMed.d182.s1550.p2	P	These same PROTEIN residues are also involved in transactivation, supporting the hypothesis that PROTEIN1 inactivates PROTEIN2 by concealing its transactivation domain.
AIMed.d183.s1552.p0	P	The cytokine-activated tyrosine kinase PROTEIN1 activates PROTEIN2 in a PROTEIN -dependent manner.
AIMed.d183.s1552.p1	N	The cytokine-activated tyrosine kinase PROTEIN1 activates PROTEIN in a PROTEIN2 -dependent manner.
AIMed.d183.s1552.p2	N	The cytokine-activated tyrosine kinase PROTEIN activates PROTEIN1 in a PROTEIN2 -dependent manner.
AIMed.d183.s1553.p0	P	PROTEIN1 , a member of the Janus kinase superfamily was found to interact functionally with PROTEIN2 , a central component of the PROTEIN / PROTEIN signal transduction pathway.
AIMed.d183.s1553.p2	N	PROTEIN1 , a member of the Janus kinase superfamily was found to interact functionally with PROTEIN , a central component of the PROTEIN / PROTEIN2 signal transduction pathway.
AIMed.d183.s1553.p3	N	PROTEIN , a member of the Janus kinase superfamily was found to interact functionally with PROTEIN1 , a central component of the PROTEIN2 / PROTEIN signal transduction pathway.
AIMed.d183.s1553.p4	N	PROTEIN , a member of the Janus kinase superfamily was found to interact functionally with PROTEIN1 , a central component of the PROTEIN / PROTEIN2 signal transduction pathway.
AIMed.d183.s1553.p5	N	PROTEIN , a member of the Janus kinase superfamily was found to interact functionally with PROTEIN , a central component of the PROTEIN1 / PROTEIN2 signal transduction pathway.
AIMed.d183.s1554.p1	P	PROTEIN1 and several other cytokines that are known to activate PROTEIN2 were also found to stimulate PROTEIN activity toward PROTEIN in mammalian cells.
AIMed.d183.s1554.p3	N	PROTEIN1 and several other cytokines that are known to activate PROTEIN were also found to stimulate PROTEIN2 activity toward PROTEIN in mammalian cells.
AIMed.d183.s1554.p4	N	PROTEIN1 and several other cytokines that are known to activate PROTEIN were also found to stimulate PROTEIN activity toward PROTEIN2 in mammalian cells.
AIMed.d183.s1554.p10	N	PROTEIN and several other cytokines that are known to activate PROTEIN1 were also found to stimulate PROTEIN2 activity toward PROTEIN in mammalian cells.
AIMed.d183.s1554.p11	N	PROTEIN and several other cytokines that are known to activate PROTEIN1 were also found to stimulate PROTEIN activity toward PROTEIN2 in mammalian cells.
AIMed.d183.s1554.p14	P	PROTEIN and several other cytokines that are known to activate PROTEIN were also found to stimulate PROTEIN1 activity toward PROTEIN2 in mammalian cells.
AIMed.d183.s1555.p1	N	In the baculovirus coexpression system, PROTEIN1 was activated by PROTEIN in the presence of PROTEIN2 .
AIMed.d183.s1555.p2	N	In the baculovirus coexpression system, PROTEIN was activated by PROTEIN1 in the presence of PROTEIN2 .
AIMed.d183.s1556.p0	P	Under these conditions, a ternary complex of PROTEIN1 , PROTEIN2 , and PROTEIN was observed.
AIMed.d183.s1556.p1	N	Under these conditions, a ternary complex of PROTEIN1 , PROTEIN , and PROTEIN2 was observed.
AIMed.d183.s1556.p2	N	Under these conditions, a ternary complex of PROTEIN , PROTEIN1 , and PROTEIN2 was observed.
AIMed.d183.s1557.p0	N	In contrast, in the absence of PROTEIN1 , coexpression of PROTEIN2 and PROTEIN resulted in an overall decrease in the PROTEIN kinase activity.
AIMed.d183.s1557.p1	N	In contrast, in the absence of PROTEIN1 , coexpression of PROTEIN and PROTEIN2 resulted in an overall decrease in the PROTEIN kinase activity.
AIMed.d183.s1557.p2	N	In contrast, in the absence of PROTEIN1 , coexpression of PROTEIN and PROTEIN resulted in an overall decrease in the PROTEIN2 kinase activity.
AIMed.d183.s1557.p3	N	In contrast, in the absence of PROTEIN , coexpression of PROTEIN1 and PROTEIN2 resulted in an overall decrease in the PROTEIN kinase activity.
AIMed.d183.s1557.p4	N	In contrast, in the absence of PROTEIN , coexpression of PROTEIN1 and PROTEIN resulted in an overall decrease in the PROTEIN2 kinase activity.
AIMed.d183.s1557.p5	N	In contrast, in the absence of PROTEIN , coexpression of PROTEIN and PROTEIN1 resulted in an overall decrease in the PROTEIN2 kinase activity.
AIMed.d183.s1558.p1	N	In addition, PROTEIN1 phosphorylated PROTEIN at sites different from those phosphorylated by PROTEIN2 .
AIMed.d183.s1558.p2	P	In addition, PROTEIN phosphorylated PROTEIN1 at sites different from those phosphorylated by PROTEIN2 .
AIMed.d183.s1559.p2	N	In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of PROTEIN coimmunoprecipitated with PROTEIN1 in lysates of cells in which PROTEIN2 was activated as judged by its state of tyrosine phosphorylation.
AIMed.d183.s1560.p0	P	Taken together, these data suggest that PROTEIN1 and PROTEIN2 cooperate to activate PROTEIN .
AIMed.d183.s1560.p1	N	Taken together, these data suggest that PROTEIN1 and PROTEIN cooperate to activate PROTEIN2 .
AIMed.d183.s1560.p2	N	Taken together, these data suggest that PROTEIN and PROTEIN1 cooperate to activate PROTEIN2 .
AIMed.d184.s1561.p0	P	PROTEIN1 -induced interaction of primary HIV-1 PROTEIN2 glycoproteins with the chemokine receptor PROTEIN .
AIMed.d184.s1561.p1	N	PROTEIN1 -induced interaction of primary HIV-1 PROTEIN glycoproteins with the chemokine receptor PROTEIN2 .
AIMed.d184.s1562.p0	N	For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, PROTEIN1 and PROTEIN2 , respectively, as well as the primary receptor PROTEIN (refs 1-6).
AIMed.d184.s1562.p1	N	For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, PROTEIN1 and PROTEIN , respectively, as well as the primary receptor PROTEIN2 (refs 1-6).
AIMed.d184.s1563.p0	P	Here we show that a complex of PROTEIN1 , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN2 interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p1	P	Here we show that a complex of PROTEIN1 , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN2 and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p2	N	Here we show that a complex of PROTEIN1 , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN2 ligands, PROTEIN and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p3	N	Here we show that a complex of PROTEIN1 , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN2 and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p4	N	Here we show that a complex of PROTEIN1 , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN2 (refs 7, 8).
AIMed.d184.s1563.p5	P	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN1 interacts specifically with PROTEIN2 and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p6	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN1 interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN2 ligands, PROTEIN and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p7	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN1 interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN2 and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p8	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN1 interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN2 (refs 7, 8).
AIMed.d184.s1563.p10	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN1 and inhibits the binding of the natural PROTEIN ligands, PROTEIN2 and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p11	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN1 and inhibits the binding of the natural PROTEIN ligands, PROTEIN and PROTEIN2 (refs 7, 8).
AIMed.d184.s1563.p12	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN1 ligands, PROTEIN2 and PROTEIN (refs 7, 8).
AIMed.d184.s1563.p13	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN1 ligands, PROTEIN and PROTEIN2 (refs 7, 8).
AIMed.d184.s1563.p14	N	Here we show that a complex of PROTEIN , the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble PROTEIN interacts specifically with PROTEIN and inhibits the binding of the natural PROTEIN ligands, PROTEIN1 and PROTEIN2 (refs 7, 8).
AIMed.d184.s1564.p0	P	The apparent affinity of the interaction between PROTEIN1 and PROTEIN2 was dramatically lower in the absence of soluble PROTEIN .
AIMed.d184.s1564.p2	N	The apparent affinity of the interaction between PROTEIN and PROTEIN1 was dramatically lower in the absence of soluble PROTEIN2 .
AIMed.d184.s1565.p0	N	Additionally, in the absence of PROTEIN1 , an interaction between a two-domain PROTEIN2 fragment and PROTEIN was observed.
AIMed.d184.s1565.p1	N	Additionally, in the absence of PROTEIN1 , an interaction between a two-domain PROTEIN fragment and PROTEIN2 was observed.
AIMed.d184.s1565.p2	P	Additionally, in the absence of PROTEIN , an interaction between a two-domain PROTEIN1 fragment and PROTEIN2 was observed.
AIMed.d184.s1566.p0	P	A PROTEIN1 fragment retaining the PROTEIN2 -binding site and overlapping epitopes was able to interact with PROTEIN only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.
AIMed.d184.s1566.p1	P	A PROTEIN1 fragment retaining the PROTEIN -binding site and overlapping epitopes was able to interact with PROTEIN2 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.
AIMed.d184.s1566.p2	N	A PROTEIN fragment retaining the PROTEIN1 -binding site and overlapping epitopes was able to interact with PROTEIN2 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.
AIMed.d184.s1567.p1	N	Neutralizing antibodies directed against either PROTEIN1 -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN2 - PROTEIN complexes with PROTEIN .
AIMed.d184.s1567.p2	N	Neutralizing antibodies directed against either PROTEIN1 -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN - PROTEIN2 complexes with PROTEIN .
AIMed.d184.s1567.p3	N	Neutralizing antibodies directed against either PROTEIN1 -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN - PROTEIN complexes with PROTEIN2 .
AIMed.d184.s1567.p5	N	Neutralizing antibodies directed against either PROTEIN -induced or V3 epitopes on PROTEIN1 blocked the interaction of PROTEIN - PROTEIN2 complexes with PROTEIN .
AIMed.d184.s1567.p6	N	Neutralizing antibodies directed against either PROTEIN -induced or V3 epitopes on PROTEIN1 blocked the interaction of PROTEIN - PROTEIN complexes with PROTEIN2 .
AIMed.d184.s1567.p7	P	Neutralizing antibodies directed against either PROTEIN -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN1 - PROTEIN2 complexes with PROTEIN .
AIMed.d184.s1567.p8	P	Neutralizing antibodies directed against either PROTEIN -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN1 - PROTEIN complexes with PROTEIN2 .
AIMed.d184.s1567.p9	P	Neutralizing antibodies directed against either PROTEIN -induced or V3 epitopes on PROTEIN blocked the interaction of PROTEIN - PROTEIN1 complexes with PROTEIN2 .
AIMed.d184.s1568.p0	N	These results suggest that HIV-1 attachment to PROTEIN1 creates a high-affinity binding site for PROTEIN2 , leading to membrane fusion and virus entry.
AIMed.d185.s1569.p1	P	PROTEIN1 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the PROTEIN2 intracellular domain.
AIMed.d185.s1571.p5	N	To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor  PROTEIN1 , the STAT proteins activated by PROTEIN2 in different cell populations were first defined using electrophoretic mobility shift assays.
AIMed.d185.s1572.p0	P	In all cells tested, PROTEIN1 activated PROTEIN2 and PROTEIN and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.
AIMed.d185.s1572.p1	P	In all cells tested, PROTEIN1 activated PROTEIN and PROTEIN2 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.
AIMed.d185.s1572.p2	N	In all cells tested, PROTEIN activated PROTEIN1 and PROTEIN2 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.
AIMed.d185.s1573.p0	P	PROTEIN1 also activated PROTEIN2 in Ba/F3 cells that stably expressed the murine PROTEIN .
AIMed.d185.s1573.p2	N	PROTEIN1 also activated PROTEIN in Ba/F3 cells that stably expressed the murine PROTEIN2 .
AIMed.d185.s1573.p4	N	PROTEIN also activated PROTEIN1 in Ba/F3 cells that stably expressed the murine PROTEIN2 .
AIMed.d185.s1574.p3	P	Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine PROTEIN1 were found to be redundantly required for receptor function and for activation of PROTEIN2 but not for PROTEIN or Stat5.
AIMed.d185.s1574.p4	N	Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine PROTEIN1 were found to be redundantly required for receptor function and for activation of PROTEIN but not for PROTEIN2 or Stat5.
AIMed.d185.s1574.p5	N	Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine PROTEIN were found to be redundantly required for receptor function and for activation of PROTEIN1 but not for PROTEIN2 or Stat5.
AIMed.d185.s1575.p0	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN1 but not PROTEIN2 and blocked PROTEIN -induced PROTEIN phosphorylation in a cell-free system.
AIMed.d185.s1575.p1	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN1 but not PROTEIN and blocked PROTEIN2 -induced PROTEIN phosphorylation in a cell-free system.
AIMed.d185.s1575.p2	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN1 but not PROTEIN and blocked PROTEIN -induced PROTEIN2 phosphorylation in a cell-free system.
AIMed.d185.s1575.p3	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN but not PROTEIN1 and blocked PROTEIN2 -induced PROTEIN phosphorylation in a cell-free system.
AIMed.d185.s1575.p4	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN but not PROTEIN1 and blocked PROTEIN -induced PROTEIN2 phosphorylation in a cell-free system.
AIMed.d185.s1575.p5	N	Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated PROTEIN but not PROTEIN and blocked PROTEIN1 -induced PROTEIN2 phosphorylation in a cell-free system.
AIMed.d185.s1576.p0	N	In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with PROTEIN1 or block PROTEIN2 activation.
AIMed.d185.s1577.p0	N	These data demonstrate that PROTEIN1 but not PROTEIN2 or PROTEIN is directly recruited to the ligand-activated PROTEIN by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d185.s1577.p1	N	These data demonstrate that PROTEIN1 but not PROTEIN or PROTEIN2 is directly recruited to the ligand-activated PROTEIN by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d185.s1577.p3	P	These data demonstrate that PROTEIN1 but not PROTEIN or PROTEIN is directly recruited to the ligand-activated PROTEIN2 by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d185.s1577.p4	N	These data demonstrate that PROTEIN but not PROTEIN1 or PROTEIN2 is directly recruited to the ligand-activated PROTEIN by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d185.s1577.p6	N	These data demonstrate that PROTEIN but not PROTEIN1 or PROTEIN is directly recruited to the ligand-activated PROTEIN2 by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d185.s1577.p8	N	These data demonstrate that PROTEIN but not PROTEIN or PROTEIN1 is directly recruited to the ligand-activated PROTEIN2 by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.
AIMed.d186.s1580.p5	N	We have cloned cDNAs corresponding to the human PROTEIN1 ( PROTEIN2 ).
AIMed.d186.s1582.p0	P	Only weak PROTEIN1 binding activity was found in cells transfected with only PROTEIN2 ; however, the combination of both PROTEIN and PROTEIN resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN .
AIMed.d186.s1582.p1	N	Only weak PROTEIN1 binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN2 and PROTEIN resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN .
AIMed.d186.s1582.p2	N	Only weak PROTEIN1 binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN and PROTEIN2 resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN .
AIMed.d186.s1582.p4	N	Only weak PROTEIN1 binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN and PROTEIN resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN2 .
AIMed.d186.s1582.p6	N	Only weak PROTEIN binding activity was found in cells transfected with only PROTEIN1 ; however, the combination of both PROTEIN and PROTEIN2 resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN .
AIMed.d186.s1582.p8	N	Only weak PROTEIN binding activity was found in cells transfected with only PROTEIN1 ; however, the combination of both PROTEIN and PROTEIN resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN2 .
AIMed.d186.s1582.p9	N	Only weak PROTEIN binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN1 and PROTEIN2 resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN .
AIMed.d186.s1582.p11	N	Only weak PROTEIN binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN1 and PROTEIN resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN2 .
AIMed.d186.s1582.p13	N	Only weak PROTEIN binding activity was found in cells transfected with only PROTEIN ; however, the combination of both PROTEIN and PROTEIN1 resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the PROTEIN2 .
AIMed.d186.s1583.p0	N	Whereas PROTEIN1 serves as an alternative accessory protein to the common PROTEIN2 ( PROTEIN ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p1	N	Whereas PROTEIN1 serves as an alternative accessory protein to the common PROTEIN ( PROTEIN2 ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p4	N	Whereas PROTEIN1 serves as an alternative accessory protein to the common PROTEIN ( PROTEIN ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN2 binding activity.
AIMed.d186.s1583.p5	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN1 ( PROTEIN2 ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p6	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN1 ( PROTEIN ) for PROTEIN2 signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p7	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN1 ( PROTEIN ) for PROTEIN signaling, it could not replace the function of PROTEIN2 in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p8	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN1 ( PROTEIN ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN2 binding activity.
AIMed.d186.s1583.p9	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN1 ) for PROTEIN2 signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p10	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN1 ) for PROTEIN signaling, it could not replace the function of PROTEIN2 in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p11	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN1 ) for PROTEIN signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN2 binding activity.
AIMed.d186.s1583.p12	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN ) for PROTEIN1 signaling, it could not replace the function of PROTEIN2 in allowing enhanced PROTEIN binding activity.
AIMed.d186.s1583.p13	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN ) for PROTEIN1 signaling, it could not replace the function of PROTEIN in allowing enhanced PROTEIN2 binding activity.
AIMed.d186.s1583.p14	N	Whereas PROTEIN serves as an alternative accessory protein to the common PROTEIN ( PROTEIN ) for PROTEIN signaling, it could not replace the function of PROTEIN1 in allowing enhanced PROTEIN2 binding activity.
AIMed.d186.s1584.p0	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN1 and PROTEIN2 are similar, and like PROTEIN , PROTEIN is located on chromosome X.
AIMed.d186.s1584.p1	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN1 and PROTEIN are similar, and like PROTEIN2 , PROTEIN is located on chromosome X.
AIMed.d186.s1584.p2	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN1 and PROTEIN are similar, and like PROTEIN , PROTEIN2 is located on chromosome X.
AIMed.d186.s1584.p3	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN and PROTEIN1 are similar, and like PROTEIN2 , PROTEIN is located on chromosome X.
AIMed.d186.s1584.p4	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN and PROTEIN1 are similar, and like PROTEIN , PROTEIN2 is located on chromosome X.
AIMed.d186.s1584.p5	N	Nevertheless, the overall size and length of the cytoplasmic domain of PROTEIN and PROTEIN are similar, and like PROTEIN1 , PROTEIN2 is located on chromosome X.
AIMed.d187.s1586.p0	N	Aggregated PROTEIN1 ( PROTEIN2 ) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.
AIMed.d187.s1588.p0	N	The analysis of complexes of PROTEIN1 with CSF proteins in a KBr gradient revealed an association of PROTEIN2 only with free proteins and not with lipoprotein particles.
AIMed.d187.s1589.p0	N	PROTEIN1 ( PROTEIN2 ), a second major CSF protein, formed SDS-stable complexes with PROTEIN and significantly decreased the rate of PROTEIN fibril formation.
AIMed.d187.s1589.p1	P	PROTEIN1 ( PROTEIN ), a second major CSF protein, formed SDS-stable complexes with PROTEIN2 and significantly decreased the rate of PROTEIN fibril formation.
AIMed.d187.s1589.p2	N	PROTEIN1 ( PROTEIN ), a second major CSF protein, formed SDS-stable complexes with PROTEIN and significantly decreased the rate of PROTEIN2 fibril formation.
AIMed.d187.s1589.p3	P	PROTEIN ( PROTEIN1 ), a second major CSF protein, formed SDS-stable complexes with PROTEIN2 and significantly decreased the rate of PROTEIN fibril formation.
AIMed.d187.s1589.p4	N	PROTEIN ( PROTEIN1 ), a second major CSF protein, formed SDS-stable complexes with PROTEIN and significantly decreased the rate of PROTEIN2 fibril formation.
AIMed.d187.s1589.p5	N	PROTEIN ( PROTEIN ), a second major CSF protein, formed SDS-stable complexes with PROTEIN1 and significantly decreased the rate of PROTEIN2 fibril formation.
AIMed.d187.s1590.p0	N	In physiological buffers and CSF, PROTEIN1 exclusively decreased the level of PROTEIN2 pentamers.
AIMed.d187.s1591.p0	P	Endogenous PROTEIN1 - PROTEIN2 complexes were detected in human CSF by immunoprecipitation.
AIMed.d187.s1592.p0	P	Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the PROTEIN1 monomer that interact with PROTEIN2 .
AIMed.d187.s1594.p0	N	We propose that PROTEIN1 binding proteins play a key role in the modulation of PROTEIN2 aggregation and normally prevent amyloid formation in biological fluids and in the brain.
AIMed.d188.s1598.p0	N	In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound PROTEIN1 and PROTEIN2 .
AIMed.d188.s1599.p0	N	Peptide sequencing and Western blot analysis established that the 265-kD protein was PROTEIN1 ( PROTEIN2 ),a recently identified transcriptional coactivator.
AIMed.d188.s1600.p0	N	The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant PROTEIN1 and PROTEIN2 (a PROTEIN -related protein).
AIMed.d188.s1600.p1	N	The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant PROTEIN1 and PROTEIN (a PROTEIN2 -related protein).
AIMed.d189.s1603.p0	P	Associations of PROTEIN1 with PROTEIN2 , PROTEIN , PROTEIN , and PROTEIN proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p2	P	Associations of PROTEIN1 with PROTEIN , PROTEIN , PROTEIN2 , and PROTEIN proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p3	P	Associations of PROTEIN1 with PROTEIN , PROTEIN , PROTEIN , and PROTEIN2 proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p4	N	Associations of PROTEIN with PROTEIN1 , PROTEIN2 , PROTEIN , and PROTEIN proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p5	N	Associations of PROTEIN with PROTEIN1 , PROTEIN , PROTEIN2 , and PROTEIN proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p6	N	Associations of PROTEIN with PROTEIN1 , PROTEIN , PROTEIN , and PROTEIN2 proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p7	N	Associations of PROTEIN with PROTEIN , PROTEIN1 , PROTEIN2 , and PROTEIN proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p8	N	Associations of PROTEIN with PROTEIN , PROTEIN1 , PROTEIN , and PROTEIN2 proteins in a yeast two-hybrid system.
AIMed.d189.s1603.p9	N	Associations of PROTEIN with PROTEIN , PROTEIN , PROTEIN1 , and PROTEIN2 proteins in a yeast two-hybrid system.
AIMed.d189.s1606.p0	N	Using the human PROTEIN1 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN2 , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p1	N	Using the human PROTEIN1 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN2 , that interacts with PROTEIN , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p2	N	Using the human PROTEIN1 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN2 , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p4	N	Using the human PROTEIN1 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN2 , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p5	N	Using the human PROTEIN1 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN2 .
AIMed.d189.s1606.p6	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN1 , designated PROTEIN2 , that interacts with PROTEIN , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p7	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN1 , designated PROTEIN , that interacts with PROTEIN2 , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p8	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN1 , designated PROTEIN , that interacts with PROTEIN , PROTEIN2 , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p9	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN1 , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN2 , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p10	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN1 , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN2 .
AIMed.d189.s1606.p11	P	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN1 , that interacts with PROTEIN2 , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p12	P	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN1 , that interacts with PROTEIN , PROTEIN2 , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p13	P	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN1 , that interacts with PROTEIN , PROTEIN , PROTEIN2 , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p15	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN1 , PROTEIN2 , PROTEIN , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p17	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN1 , PROTEIN , PROTEIN , and a ubiquitin-like protein PROTEIN2 .
AIMed.d189.s1606.p18	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN , PROTEIN1 , PROTEIN2 , and a ubiquitin-like protein PROTEIN .
AIMed.d189.s1606.p20	N	Using the human PROTEIN protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast PROTEIN , designated PROTEIN , that interacts with PROTEIN , PROTEIN , PROTEIN1 , and a ubiquitin-like protein PROTEIN2 .
AIMed.d189.s1607.p0	N	These interactions are PROTEIN1 -specific, since another DNA repair-related ubiquitin-conjugating enzyme, PROTEIN2 ( PROTEIN ), does not interact with these proteins.
AIMed.d189.s1607.p1	N	These interactions are PROTEIN1 -specific, since another DNA repair-related ubiquitin-conjugating enzyme, PROTEIN ( PROTEIN2 ), does not interact with these proteins.
AIMed.d189.s1607.p2	N	These interactions are PROTEIN -specific, since another DNA repair-related ubiquitin-conjugating enzyme, PROTEIN1 ( PROTEIN2 ), does not interact with these proteins.
AIMed.d189.s1608.p1	N	The interaction of PROTEIN1 with PROTEIN is mediated by PROTEIN2 's self-association region.
AIMed.d189.s1608.p2	N	The interaction of PROTEIN with PROTEIN1 is mediated by PROTEIN2 's self-association region.
AIMed.d189.s1609.p0	N	These results suggest that the PROTEIN1 -dependent processes, cell cycle control, PROTEIN2 -mediated pathway(s), and ubiquitination interact through human PROTEIN .
AIMed.d189.s1609.p1	N	These results suggest that the PROTEIN1 -dependent processes, cell cycle control, PROTEIN -mediated pathway(s), and ubiquitination interact through human PROTEIN2 .
AIMed.d189.s1609.p2	N	These results suggest that the PROTEIN -dependent processes, cell cycle control, PROTEIN1 -mediated pathway(s), and ubiquitination interact through human PROTEIN2 .
AIMed.d190.s1610.p0	P	Discrete protein interactions with the PROTEIN1 / PROTEIN2 complex in PROTEIN - and PROTEIN -mediated myeloid cell proliferation.
AIMed.d190.s1610.p1	N	Discrete protein interactions with the PROTEIN1 / PROTEIN complex in PROTEIN2 - and PROTEIN -mediated myeloid cell proliferation.
AIMed.d190.s1610.p2	N	Discrete protein interactions with the PROTEIN1 / PROTEIN complex in PROTEIN - and PROTEIN2 -mediated myeloid cell proliferation.
AIMed.d190.s1610.p3	N	Discrete protein interactions with the PROTEIN / PROTEIN1 complex in PROTEIN2 - and PROTEIN -mediated myeloid cell proliferation.
AIMed.d190.s1610.p5	N	Discrete protein interactions with the PROTEIN / PROTEIN complex in PROTEIN1 - and PROTEIN2 -mediated myeloid cell proliferation.
AIMed.d190.s1611.p0	N	Hemopoietic cell proliferation is mediated by non-tyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the PROTEIN1 / PROTEIN2 .
AIMed.d190.s1612.p0	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN1 and the interaction of the PROTEIN2 / PROTEIN complex with signaling proteins upon activation of non-tyrosine ( PROTEIN ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p1	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN1 and the interaction of the PROTEIN / PROTEIN2 complex with signaling proteins upon activation of non-tyrosine ( PROTEIN ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p2	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN1 and the interaction of the PROTEIN / PROTEIN complex with signaling proteins upon activation of non-tyrosine ( PROTEIN2 ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p4	P	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN1 / PROTEIN2 complex with signaling proteins upon activation of non-tyrosine ( PROTEIN ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p5	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN1 / PROTEIN complex with signaling proteins upon activation of non-tyrosine ( PROTEIN2 ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p6	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN1 / PROTEIN complex with signaling proteins upon activation of non-tyrosine ( PROTEIN ) and tyrosine kinase ( PROTEIN2 ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p7	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN / PROTEIN1 complex with signaling proteins upon activation of non-tyrosine ( PROTEIN2 ) and tyrosine kinase ( PROTEIN ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p8	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN / PROTEIN1 complex with signaling proteins upon activation of non-tyrosine ( PROTEIN ) and tyrosine kinase ( PROTEIN2 ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1612.p9	N	In the present study we evaluated tyrosine phosphorylation of PROTEIN and the interaction of the PROTEIN / PROTEIN complex with signaling proteins upon activation of non-tyrosine ( PROTEIN1 ) and tyrosine kinase ( PROTEIN2 ) receptors leading to myeloid cell proliferation.
AIMed.d190.s1613.p0	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN1 and PROTEIN2 ligands, namely: PROTEIN and PROTEIN , induce PROTEIN tyrosine phosphorylation.
AIMed.d190.s1613.p2	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN1 and PROTEIN ligands, namely: PROTEIN and PROTEIN2 , induce PROTEIN tyrosine phosphorylation.
AIMed.d190.s1613.p4	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN1 ligands, namely: PROTEIN2 and PROTEIN , induce PROTEIN tyrosine phosphorylation.
AIMed.d190.s1613.p5	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN1 ligands, namely: PROTEIN and PROTEIN2 , induce PROTEIN tyrosine phosphorylation.
AIMed.d190.s1613.p6	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN1 ligands, namely: PROTEIN and PROTEIN , induce PROTEIN2 tyrosine phosphorylation.
AIMed.d190.s1613.p7	N	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN ligands, namely: PROTEIN1 and PROTEIN2 , induce PROTEIN tyrosine phosphorylation.
AIMed.d190.s1613.p8	P	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN ligands, namely: PROTEIN1 and PROTEIN , induce PROTEIN2 tyrosine phosphorylation.
AIMed.d190.s1613.p9	P	By using the growth factor dependent M-07e cell line, we found that both PROTEIN and PROTEIN ligands, namely: PROTEIN and PROTEIN1 , induce PROTEIN2 tyrosine phosphorylation.
AIMed.d190.s1614.p0	P	In these cells the adaptor protein PROTEIN1 constitutively binds a substantial fraction of PROTEIN2 through the N-terminal SH3 domain.
AIMed.d190.s1615.p0	P	In vitro experiments showed that the stable PROTEIN1 / PROTEIN2 complex interacts, through the PROTEIN SH2 domain, with the PROTEIN -activated PROTEIN .
AIMed.d190.s1615.p2	N	In vitro experiments showed that the stable PROTEIN1 / PROTEIN complex interacts, through the PROTEIN SH2 domain, with the PROTEIN2 -activated PROTEIN .
AIMed.d190.s1615.p3	N	In vitro experiments showed that the stable PROTEIN1 / PROTEIN complex interacts, through the PROTEIN SH2 domain, with the PROTEIN -activated PROTEIN2 .
AIMed.d190.s1615.p4	N	In vitro experiments showed that the stable PROTEIN / PROTEIN1 complex interacts, through the PROTEIN2 SH2 domain, with the PROTEIN -activated PROTEIN .
AIMed.d190.s1615.p5	N	In vitro experiments showed that the stable PROTEIN / PROTEIN1 complex interacts, through the PROTEIN SH2 domain, with the PROTEIN2 -activated PROTEIN .
AIMed.d190.s1615.p6	N	In vitro experiments showed that the stable PROTEIN / PROTEIN1 complex interacts, through the PROTEIN SH2 domain, with the PROTEIN -activated PROTEIN2 .
AIMed.d190.s1615.p7	N	In vitro experiments showed that the stable PROTEIN / PROTEIN complex interacts, through the PROTEIN1 SH2 domain, with the PROTEIN2 -activated PROTEIN .
AIMed.d190.s1615.p8	P	In vitro experiments showed that the stable PROTEIN / PROTEIN complex interacts, through the PROTEIN1 SH2 domain, with the PROTEIN -activated PROTEIN2 .
AIMed.d190.s1615.p9	P	In vitro experiments showed that the stable PROTEIN / PROTEIN complex interacts, through the PROTEIN SH2 domain, with the PROTEIN1 -activated PROTEIN2 .
AIMed.d190.s1616.p0	N	By contrast stimulation with PROTEIN1 leads to the formation of a PROTEIN2 complex containing PROTEIN .
AIMed.d190.s1616.p1	N	By contrast stimulation with PROTEIN1 leads to the formation of a PROTEIN complex containing PROTEIN2 .
AIMed.d190.s1616.p2	P	By contrast stimulation with PROTEIN leads to the formation of a PROTEIN1 complex containing PROTEIN2 .
AIMed.d190.s1617.p0	N	In vitro and in vivo experiments support the hypothesis that PROTEIN1 mediates the association of PROTEIN2 with PROTEIN .
AIMed.d190.s1617.p1	N	In vitro and in vivo experiments support the hypothesis that PROTEIN1 mediates the association of PROTEIN with PROTEIN2 .
AIMed.d190.s1617.p2	P	In vitro and in vivo experiments support the hypothesis that PROTEIN mediates the association of PROTEIN1 with PROTEIN2 .
AIMed.d190.s1618.p1	N	Moreover we found that, upon PROTEIN1 stimulation, the PROTEIN / PROTEIN2 complex recruits PROTEIN , probably via PROTEIN .
AIMed.d190.s1618.p2	N	Moreover we found that, upon PROTEIN1 stimulation, the PROTEIN / PROTEIN complex recruits PROTEIN2 , probably via PROTEIN .
AIMed.d190.s1618.p3	N	Moreover we found that, upon PROTEIN1 stimulation, the PROTEIN / PROTEIN complex recruits PROTEIN , probably via PROTEIN2 .
AIMed.d190.s1618.p4	P	Moreover we found that, upon PROTEIN stimulation, the PROTEIN1 / PROTEIN2 complex recruits PROTEIN , probably via PROTEIN .
AIMed.d190.s1618.p5	N	Moreover we found that, upon PROTEIN stimulation, the PROTEIN1 / PROTEIN complex recruits PROTEIN2 , probably via PROTEIN .
AIMed.d190.s1618.p6	N	Moreover we found that, upon PROTEIN stimulation, the PROTEIN1 / PROTEIN complex recruits PROTEIN , probably via PROTEIN2 .
AIMed.d190.s1618.p7	N	Moreover we found that, upon PROTEIN stimulation, the PROTEIN / PROTEIN1 complex recruits PROTEIN2 , probably via PROTEIN .
AIMed.d190.s1618.p8	N	Moreover we found that, upon PROTEIN stimulation, the PROTEIN / PROTEIN1 complex recruits PROTEIN , probably via PROTEIN2 .
AIMed.d190.s1618.p9	P	Moreover we found that, upon PROTEIN stimulation, the PROTEIN / PROTEIN complex recruits PROTEIN1 , probably via PROTEIN2 .
AIMed.d190.s1619.p1	N	By contrast the PROTEIN1 exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN2 immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p3	N	By contrast the PROTEIN1 exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN2 and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p4	N	By contrast the PROTEIN1 exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN2 / PROTEIN are present in different complexes.
AIMed.d190.s1619.p5	N	By contrast the PROTEIN1 exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN / PROTEIN2 are present in different complexes.
AIMed.d190.s1619.p6	N	By contrast the PROTEIN exchanger factor ( PROTEIN1 ) was not detected in anti- PROTEIN2 immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p8	N	By contrast the PROTEIN exchanger factor ( PROTEIN1 ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN2 and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p9	N	By contrast the PROTEIN exchanger factor ( PROTEIN1 ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN2 / PROTEIN are present in different complexes.
AIMed.d190.s1619.p10	N	By contrast the PROTEIN exchanger factor ( PROTEIN1 ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN / PROTEIN2 are present in different complexes.
AIMed.d190.s1619.p11	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN1 immunoprecipitates suggesting that PROTEIN2 / PROTEIN and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p12	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN1 immunoprecipitates suggesting that PROTEIN / PROTEIN2 and PROTEIN / PROTEIN are present in different complexes.
AIMed.d190.s1619.p13	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN1 immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN2 / PROTEIN are present in different complexes.
AIMed.d190.s1619.p14	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN1 immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN / PROTEIN2 are present in different complexes.
AIMed.d190.s1619.p16	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN1 / PROTEIN and PROTEIN2 / PROTEIN are present in different complexes.
AIMed.d190.s1619.p17	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN1 / PROTEIN and PROTEIN / PROTEIN2 are present in different complexes.
AIMed.d190.s1619.p18	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN1 and PROTEIN2 / PROTEIN are present in different complexes.
AIMed.d190.s1619.p19	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN1 and PROTEIN / PROTEIN2 are present in different complexes.
AIMed.d190.s1619.p20	N	By contrast the PROTEIN exchanger factor ( PROTEIN ) was not detected in anti- PROTEIN immunoprecipitates suggesting that PROTEIN / PROTEIN and PROTEIN1 / PROTEIN2 are present in different complexes.
AIMed.d190.s1620.p0	N	Taken together our results demonstrate that PROTEIN1 plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with PROTEIN2 / PROTEIN complex when non-tyrosine or tyrosine kinase receptors are activated.
AIMed.d190.s1620.p1	N	Taken together our results demonstrate that PROTEIN1 plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with PROTEIN / PROTEIN2 complex when non-tyrosine or tyrosine kinase receptors are activated.
AIMed.d190.s1620.p2	P	Taken together our results demonstrate that PROTEIN plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with PROTEIN1 / PROTEIN2 complex when non-tyrosine or tyrosine kinase receptors are activated.
AIMed.d191.s1623.p0	N	We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells, even though T cells have higher levels of PROTEIN1 and PROTEIN2 binding.
AIMed.d191.s1631.p0	P	PROTEIN1 interacts with PROTEIN2 and PROTEIN with PROTEIN receptors.
AIMed.d191.s1631.p1	N	PROTEIN1 interacts with PROTEIN and PROTEIN2 with PROTEIN receptors.
AIMed.d191.s1631.p2	N	PROTEIN1 interacts with PROTEIN and PROTEIN with PROTEIN2 receptors.
AIMed.d191.s1631.p3	N	PROTEIN interacts with PROTEIN1 and PROTEIN2 with PROTEIN receptors.
AIMed.d191.s1631.p4	N	PROTEIN interacts with PROTEIN1 and PROTEIN with PROTEIN2 receptors.
AIMed.d191.s1631.p5	P	PROTEIN interacts with PROTEIN and PROTEIN1 with PROTEIN2 receptors.
AIMed.d191.s1633.p0	N	DCs express more PROTEIN1 and PROTEIN2 mRNA than T cells.
AIMed.d192.s1635.p4	P	Activation of PROTEIN1 mediated by PROTEIN2 .
AIMed.d192.s1636.p7	N	The interleukin-1beta (IL-1beta) converting enzyme  PROTEIN1 ( PROTEIN2 ) processes the inactive PROTEIN precursor to the proinflammatory cytokine.
AIMed.d192.s1636.p8	N	The interleukin-1beta (IL-1beta) converting enzyme  PROTEIN1 ( PROTEIN ) processes the inactive PROTEIN2 precursor to the proinflammatory cytokine.
AIMed.d192.s1636.p9	N	The interleukin-1beta (IL-1beta) converting enzyme  PROTEIN ( PROTEIN1 ) processes the inactive PROTEIN2 precursor to the proinflammatory cytokine.
AIMed.d192.s1637.p1	P	PROTEIN1 was also shown to cleave the precursor of PROTEIN2 ( PROTEIN ) at the authentic processing site with high efficiency, thereby activating PROTEIN and facilitating its export.
AIMed.d192.s1637.p2	P	PROTEIN1 was also shown to cleave the precursor of PROTEIN ( PROTEIN2 ) at the authentic processing site with high efficiency, thereby activating PROTEIN and facilitating its export.
AIMed.d192.s1637.p3	P	PROTEIN1 was also shown to cleave the precursor of PROTEIN ( PROTEIN ) at the authentic processing site with high efficiency, thereby activating PROTEIN2 and facilitating its export.
AIMed.d192.s1637.p7	N	PROTEIN was also shown to cleave the precursor of PROTEIN1 ( PROTEIN2 ) at the authentic processing site with high efficiency, thereby activating PROTEIN and facilitating its export.
AIMed.d192.s1637.p8	N	PROTEIN was also shown to cleave the precursor of PROTEIN1 ( PROTEIN ) at the authentic processing site with high efficiency, thereby activating PROTEIN2 and facilitating its export.
AIMed.d192.s1637.p9	N	PROTEIN was also shown to cleave the precursor of PROTEIN ( PROTEIN1 ) at the authentic processing site with high efficiency, thereby activating PROTEIN2 and facilitating its export.
AIMed.d192.s1638.p0	N	Lipopolysaccharide-activated PROTEIN1 -deficient (ICE-/-) Kupffer cells synthesized the PROTEIN2 precursor but failed to process it into the active form.
AIMed.d192.s1639.p0	N	PROTEIN1 and PROTEIN2 were diminished in the sera of PROTEIN -/- mice exposed to Propionibacterium acnes and lipopolysaccharide.
AIMed.d192.s1639.p2	N	PROTEIN and PROTEIN1 were diminished in the sera of PROTEIN2 -/- mice exposed to Propionibacterium acnes and lipopolysaccharide.
AIMed.d193.s1641.p0	P	Physical and functional interactions between the transcriptional inhibitors PROTEIN1 and PROTEIN2 . Evidence toward a novel mechanism regulating muscle-specific gene expression.
AIMed.d193.s1642.p0	N	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN1 transcription factor, PROTEIN2 , that interacts with the transcriptional inhibitor PROTEIN / PROTEIN .
AIMed.d193.s1642.p1	N	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN1 transcription factor, PROTEIN , that interacts with the transcriptional inhibitor PROTEIN2 / PROTEIN .
AIMed.d193.s1642.p2	N	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN1 transcription factor, PROTEIN , that interacts with the transcriptional inhibitor PROTEIN / PROTEIN2 .
AIMed.d193.s1642.p3	P	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN transcription factor, PROTEIN1 , that interacts with the transcriptional inhibitor PROTEIN2 / PROTEIN .
AIMed.d193.s1642.p4	P	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN transcription factor, PROTEIN1 , that interacts with the transcriptional inhibitor PROTEIN / PROTEIN2 .
AIMed.d193.s1642.p5	N	We have used an interaction cloning strategy to identify an inhibitory isoform of the PROTEIN transcription factor, PROTEIN , that interacts with the transcriptional inhibitor PROTEIN1 / PROTEIN2 .
AIMed.d193.s1644.p1	N	As expected, overexpression of either PROTEIN1 / PROTEIN or PROTEIN2 effectively inhibited the activation of the muscle-specific PROTEIN promoter by the myogenic transcription factor PROTEIN .
AIMed.d193.s1644.p3	N	As expected, overexpression of either PROTEIN1 / PROTEIN or PROTEIN effectively inhibited the activation of the muscle-specific PROTEIN promoter by the myogenic transcription factor PROTEIN2 .
AIMed.d193.s1644.p4	N	As expected, overexpression of either PROTEIN / PROTEIN1 or PROTEIN2 effectively inhibited the activation of the muscle-specific PROTEIN promoter by the myogenic transcription factor PROTEIN .
AIMed.d193.s1644.p5	N	As expected, overexpression of either PROTEIN / PROTEIN1 or PROTEIN effectively inhibited the activation of the muscle-specific PROTEIN2 promoter by the myogenic transcription factor PROTEIN .
AIMed.d193.s1644.p6	N	As expected, overexpression of either PROTEIN / PROTEIN1 or PROTEIN effectively inhibited the activation of the muscle-specific PROTEIN promoter by the myogenic transcription factor PROTEIN2 .
AIMed.d193.s1644.p7	N	As expected, overexpression of either PROTEIN / PROTEIN or PROTEIN1 effectively inhibited the activation of the muscle-specific PROTEIN2 promoter by the myogenic transcription factor PROTEIN .
AIMed.d193.s1644.p8	N	As expected, overexpression of either PROTEIN / PROTEIN or PROTEIN1 effectively inhibited the activation of the muscle-specific PROTEIN promoter by the myogenic transcription factor PROTEIN2 .
AIMed.d193.s1644.p9	N	As expected, overexpression of either PROTEIN / PROTEIN or PROTEIN effectively inhibited the activation of the muscle-specific PROTEIN1 promoter by the myogenic transcription factor PROTEIN2 .
AIMed.d193.s1646.p0	N	Moreover, while PROTEIN1 inhibited the PROTEIN2 promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.
AIMed.d193.s1647.p0	P	Further investigation indicated that the PROTEIN1 / PROTEIN2 heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN / PROTEIN .
AIMed.d193.s1647.p1	N	Further investigation indicated that the PROTEIN1 / PROTEIN heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN2 / PROTEIN .
AIMed.d193.s1647.p2	N	Further investigation indicated that the PROTEIN1 / PROTEIN heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN / PROTEIN2 .
AIMed.d193.s1647.p3	N	Further investigation indicated that the PROTEIN / PROTEIN1 heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN2 / PROTEIN .
AIMed.d193.s1647.p4	N	Further investigation indicated that the PROTEIN / PROTEIN1 heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN / PROTEIN2 .
AIMed.d193.s1647.p5	N	Further investigation indicated that the PROTEIN / PROTEIN heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by PROTEIN1 / PROTEIN2 .
AIMed.d193.s1648.p0	N	Additional analysis revealed the presence of transcripts for both the activating ( PROTEIN1 ) and inhibitory ( PROTEIN2 ) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.
AIMed.d195.s1660.p0	N	Competitive binding of PROTEIN1 and PROTEIN2 to the PROTEIN .
AIMed.d195.s1660.p1	P	Competitive binding of PROTEIN1 and PROTEIN to the PROTEIN2 .
AIMed.d195.s1660.p2	P	Competitive binding of PROTEIN and PROTEIN1 to the PROTEIN2 .
AIMed.d195.s1662.p0	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN2 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p1	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN2 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p2	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN2 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p3	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN2 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p4	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN2 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p5	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN2 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p6	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p7	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p8	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN1 , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p9	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN2 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p10	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN2 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p11	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN2 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p12	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN2 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p13	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN2 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p14	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p15	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p16	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN1 , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p17	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN1 family of PROTEIN2 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p19	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN1 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN2 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p21	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN1 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p22	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN1 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p23	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN1 family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p24	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN1 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN2 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p25	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN1 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN2 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p26	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN1 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN2 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p28	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN1 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p29	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN1 -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p30	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN1 . PROTEIN2 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p31	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN1 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN2 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p32	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN1 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p33	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN1 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p34	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN1 . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p35	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN1 binds by its central rod domain to the cytoplasmic tail of both PROTEIN2 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p36	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN1 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p37	P	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN1 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p38	P	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN1 binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p39	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN1 and PROTEIN2 subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p40	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN1 and PROTEIN subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p41	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN1 and PROTEIN subunits of the PROTEIN , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1662.p42	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN1 subunits of the PROTEIN2 , and can be immunoprecipitated with NMDA receptors and PROTEIN from rat brain.
AIMed.d195.s1662.p44	N	The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of PROTEIN , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. PROTEIN , a member of the spectrin/ PROTEIN family of PROTEIN -binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PROTEIN . PROTEIN binds by its central rod domain to the cytoplasmic tail of both PROTEIN and PROTEIN subunits of the PROTEIN1 , and can be immunoprecipitated with NMDA receptors and PROTEIN2 from rat brain.
AIMed.d195.s1663.p0	N	Intriguingly, PROTEIN1 - PROTEIN2 binding is directly antagonized by Ca2+/ PROTEIN .
AIMed.d195.s1663.p1	N	Intriguingly, PROTEIN1 - PROTEIN binding is directly antagonized by Ca2+/ PROTEIN2 .
AIMed.d195.s1663.p2	N	Intriguingly, PROTEIN - PROTEIN1 binding is directly antagonized by Ca2+/ PROTEIN2 .
AIMed.d196.s1665.p0	P	PROTEIN1 interacts with protein phosphatases PROTEIN2 and PROTEIN and disrupts a G2/M cell-cycle checkpoint.
AIMed.d196.s1665.p1	P	PROTEIN1 interacts with protein phosphatases PROTEIN and PROTEIN2 and disrupts a G2/M cell-cycle checkpoint.
AIMed.d196.s1665.p2	N	PROTEIN interacts with protein phosphatases PROTEIN1 and PROTEIN2 and disrupts a G2/M cell-cycle checkpoint.
AIMed.d196.s1669.p1	P	We observed that the protein PROTEIN1 interacted with protein PROTEIN2 ( PROTEIN ), as well as PROTEIN ( PROTEIN ) in mammalian cells.
AIMed.d196.s1669.p2	P	We observed that the protein PROTEIN1 interacted with protein PROTEIN ( PROTEIN2 ), as well as PROTEIN ( PROTEIN ) in mammalian cells.
AIMed.d196.s1669.p4	P	We observed that the protein PROTEIN1 interacted with protein PROTEIN ( PROTEIN ), as well as PROTEIN ( PROTEIN2 ) in mammalian cells.
AIMed.d196.s1669.p9	N	We observed that the protein PROTEIN interacted with protein PROTEIN1 ( PROTEIN2 ), as well as PROTEIN ( PROTEIN ) in mammalian cells.
AIMed.d196.s1669.p10	N	We observed that the protein PROTEIN interacted with protein PROTEIN1 ( PROTEIN ), as well as PROTEIN2 ( PROTEIN ) in mammalian cells.
AIMed.d196.s1669.p11	N	We observed that the protein PROTEIN interacted with protein PROTEIN1 ( PROTEIN ), as well as PROTEIN ( PROTEIN2 ) in mammalian cells.
AIMed.d196.s1669.p12	N	We observed that the protein PROTEIN interacted with protein PROTEIN ( PROTEIN1 ), as well as PROTEIN2 ( PROTEIN ) in mammalian cells.
AIMed.d196.s1669.p13	N	We observed that the protein PROTEIN interacted with protein PROTEIN ( PROTEIN1 ), as well as PROTEIN ( PROTEIN2 ) in mammalian cells.
AIMed.d196.s1669.p14	N	We observed that the protein PROTEIN interacted with protein PROTEIN ( PROTEIN ), as well as PROTEIN1 ( PROTEIN2 ) in mammalian cells.
AIMed.d196.s1673.p0	P	Thus PROTEIN1 is a cellular oncogene that targets PROTEIN2 and PROTEIN , both of which are targets for oncogenic viruses and chemical tumour promoters.
AIMed.d196.s1673.p2	N	Thus PROTEIN is a cellular oncogene that targets PROTEIN1 and PROTEIN2 , both of which are targets for oncogenic viruses and chemical tumour promoters.
AIMed.d197.s1675.p1	P	Analysis of the human PROTEIN1 /human PROTEIN2 binding interface at the amino acid level: proposed mechanism of interaction.
AIMed.d197.s1676.p0	N	The interaction between PROTEIN1 ( PROTEIN2 ) and PROTEIN ( PROTEIN ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p2	P	The interaction between PROTEIN1 ( PROTEIN ) and PROTEIN2 ( PROTEIN ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p3	P	The interaction between PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN2 ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p4	N	The interaction between PROTEIN1 ( PROTEIN ) and PROTEIN ( PROTEIN ) is the initial and most specific step in the PROTEIN2 signaling pathway.
AIMed.d197.s1676.p6	P	The interaction between PROTEIN ( PROTEIN1 ) and PROTEIN2 ( PROTEIN ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p7	N	The interaction between PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN2 ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p8	N	The interaction between PROTEIN ( PROTEIN1 ) and PROTEIN ( PROTEIN ) is the initial and most specific step in the PROTEIN2 signaling pathway.
AIMed.d197.s1676.p12	N	The interaction between PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN2 ) is the initial and most specific step in the PROTEIN signaling pathway.
AIMed.d197.s1676.p13	N	The interaction between PROTEIN ( PROTEIN ) and PROTEIN1 ( PROTEIN ) is the initial and most specific step in the PROTEIN2 signaling pathway.
AIMed.d197.s1676.p14	N	The interaction between PROTEIN ( PROTEIN ) and PROTEIN ( PROTEIN1 ) is the initial and most specific step in the PROTEIN2 signaling pathway.
AIMed.d197.s1678.p0	N	We studied the human PROTEIN1 ( PROTEIN2 )/ PROTEIN binding interface by a combination of molecular modelling and site-directed mutagenesis.
AIMed.d197.s1678.p1	P	We studied the human PROTEIN1 ( PROTEIN )/ PROTEIN2 binding interface by a combination of molecular modelling and site-directed mutagenesis.
AIMed.d197.s1678.p2	P	We studied the human PROTEIN ( PROTEIN1 )/ PROTEIN2 binding interface by a combination of molecular modelling and site-directed mutagenesis.
AIMed.d197.s1681.p0	P	Following this hypothesis, we altered in PROTEIN1 and PROTEIN2 residues predicted to reside in the contact region and to interact with each other.
AIMed.d197.s1682.p0	P	We studied the capacity of these mutants to form an PROTEIN1 / PROTEIN2 complex and their ability to transduce the signal.
AIMed.d198.s1687.p4	N	Mutagenesis of the PROTEIN1 ( PROTEIN2 ) permits analysis of the contribution that individual amino acid residues make to PROTEIN ( PROTEIN ) binding.
AIMed.d198.s1687.p5	N	Mutagenesis of the PROTEIN1 ( PROTEIN ) permits analysis of the contribution that individual amino acid residues make to PROTEIN2 ( PROTEIN ) binding.
AIMed.d198.s1687.p6	N	Mutagenesis of the PROTEIN1 ( PROTEIN ) permits analysis of the contribution that individual amino acid residues make to PROTEIN ( PROTEIN2 ) binding.
AIMed.d198.s1687.p7	N	Mutagenesis of the PROTEIN ( PROTEIN1 ) permits analysis of the contribution that individual amino acid residues make to PROTEIN2 ( PROTEIN ) binding.
AIMed.d198.s1687.p8	N	Mutagenesis of the PROTEIN ( PROTEIN1 ) permits analysis of the contribution that individual amino acid residues make to PROTEIN ( PROTEIN2 ) binding.
AIMed.d198.s1687.p9	N	Mutagenesis of the PROTEIN ( PROTEIN ) permits analysis of the contribution that individual amino acid residues make to PROTEIN1 ( PROTEIN2 ) binding.
AIMed.d198.s1688.p3	N	We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as PROTEIN1 , PROTEIN2 ) of the PROTEIN .
AIMed.d198.s1688.p4	N	We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as PROTEIN1 , PROTEIN ) of the PROTEIN2 .
AIMed.d198.s1688.p5	N	We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as PROTEIN , PROTEIN1 ) of the PROTEIN2 .
AIMed.d198.s1691.p0	N	In addition, selected mutant proteins were expressed as full-length PROTEIN1 on the surface of COS cells and analyzed for 125I- PROTEIN2 binding in receptor binding assays.
AIMed.d198.s1692.p0	N	Using these methods, we have identified residues that appear to be involved in PROTEIN1 binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the PROTEIN2 .
AIMed.d199.s1695.p0	N	Stimulation of PROTEIN1 ( PROTEIN2 ) results in a variety of functional effects, including regulation of epithelial cell growth and differentiation.
AIMed.d199.s1696.p1	N	In order to characterize the signaling pathway through which PROTEIN1 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN2 and PROTEIN , that result from alternative splicing of exon III of the PROTEIN gene encoding the ligand binding domain.
AIMed.d199.s1696.p3	N	In order to characterize the signaling pathway through which PROTEIN1 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN and PROTEIN2 , that result from alternative splicing of exon III of the PROTEIN gene encoding the ligand binding domain.
AIMed.d199.s1696.p4	N	In order to characterize the signaling pathway through which PROTEIN1 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN and PROTEIN , that result from alternative splicing of exon III of the PROTEIN2 gene encoding the ligand binding domain.
AIMed.d199.s1696.p10	N	In order to characterize the signaling pathway through which PROTEIN regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN1 and PROTEIN2 , that result from alternative splicing of exon III of the PROTEIN gene encoding the ligand binding domain.
AIMed.d199.s1696.p11	N	In order to characterize the signaling pathway through which PROTEIN regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN1 and PROTEIN , that result from alternative splicing of exon III of the PROTEIN2 gene encoding the ligand binding domain.
AIMed.d199.s1696.p14	N	In order to characterize the signaling pathway through which PROTEIN regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, PROTEIN and PROTEIN1 , that result from alternative splicing of exon III of the PROTEIN2 gene encoding the ligand binding domain.
AIMed.d199.s1697.p5	N	Expression of PROTEIN1 in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN2 , -2, -4, and -6, while PROTEIN -expressing cells responded only to PROTEIN .
AIMed.d199.s1697.p7	N	Expression of PROTEIN1 in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN , -2, -4, and -6, while PROTEIN2 -expressing cells responded only to PROTEIN .
AIMed.d199.s1697.p8	N	Expression of PROTEIN1 in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN , -2, -4, and -6, while PROTEIN -expressing cells responded only to PROTEIN2 .
AIMed.d199.s1697.p10	N	Expression of PROTEIN in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN1 , -2, -4, and -6, while PROTEIN2 -expressing cells responded only to PROTEIN .
AIMed.d199.s1697.p11	N	Expression of PROTEIN in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN1 , -2, -4, and -6, while PROTEIN -expressing cells responded only to PROTEIN2 .
AIMed.d199.s1697.p14	N	Expression of PROTEIN in stably transfected L6 cells conferred growth responses to several members of the FGF family including PROTEIN , -2, -4, and -6, while PROTEIN1 -expressing cells responded only to PROTEIN2 .
AIMed.d199.s1698.p0	N	Activation of PROTEIN1 upon ligand binding resulted in activation of PROTEIN2 pathway.
AIMed.d199.s1699.p0	N	PROTEIN1 utilizes two different pools of adapter protein PROTEIN2 to link to PROTEIN .
AIMed.d199.s1699.p1	N	PROTEIN1 utilizes two different pools of adapter protein PROTEIN to link to PROTEIN2 .
AIMed.d199.s1699.p2	N	PROTEIN utilizes two different pools of adapter protein PROTEIN1 to link to PROTEIN2 .
AIMed.d199.s1700.p0	P	Activated PROTEIN1 predominantly interacts with PROTEIN2 .
AIMed.d199.s1701.p0	N	PROTEIN1 in complex with a previously identified 90-kDa protein and designated protein PROTEIN2 .
AIMed.d199.s1705.p0	N	Tyrosine phophorylation of the 66-kDa protein was dependent on ligand activation of PROTEIN1 , suggesting that the 66-kDa protein may play an important role in PROTEIN2 -specific signaling.
AIMed.d199.s1706.p0	N	In addition to this unique pathway, PROTEIN1 also links to PROTEIN2 .
AIMed.d199.s1707.p0	N	PROTEIN1 complex via the adapter protein PROTEIN2 .
AIMed.d199.s1708.p0	N	Furthermore, activated PROTEIN1 was not able to induce dissociation of PROTEIN2 .
AIMed.d199.s1709.p0	N	PROTEIN1 complex following PROTEIN2 phosphorylation.
AIMed.d199.s1710.p0	N	In summary, PROTEIN1 signaling pathway utilizes two PROTEIN2 -containing complexes; PROTEIN .
AIMed.d199.s1710.p1	N	In summary, PROTEIN1 signaling pathway utilizes two PROTEIN -containing complexes; PROTEIN2 .
AIMed.d199.s1712.p0	N	PROTEIN1 and PROTEIN2 . PROTEIN .
AIMed.d199.s1712.p1	N	PROTEIN1 and PROTEIN . PROTEIN2 .
AIMed.d199.s1712.p2	P	PROTEIN and PROTEIN1 . PROTEIN2 .
AIMed.d199.s1714.p0	N	PROTEIN1 ; these two complexes may alternatively link PROTEIN2 to PROTEIN .
AIMed.d199.s1714.p1	N	PROTEIN1 ; these two complexes may alternatively link PROTEIN to PROTEIN2 .
AIMed.d199.s1714.p2	N	PROTEIN ; these two complexes may alternatively link PROTEIN1 to PROTEIN2 .
AIMed.d199.s1715.p0	N	Finally, activated PROTEIN1 was also found to result in phosphorylation of PROTEIN2 but reduced phosphorylation of PROTEIN .
AIMed.d199.s1715.p2	N	Finally, activated PROTEIN was also found to result in phosphorylation of PROTEIN1 but reduced phosphorylation of PROTEIN2 .
AIMed.d200.s1722.p0	P	Using epitope-tagging, interaction of PROTEIN1 basic-helix-loop-helix protein with the PROTEIN2 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.
AIMed.d200.s1725.p0	N	Interactions with human PROTEIN1 and mouse PROTEIN2 were confirmed using glutathione transferase-tagged cDNAs.
AIMed.d200.s1726.p0	P	A cDNA encoding part of the PROTEIN1 protein sequence interacted with the PROTEIN2 basic-helix-loop-helix only when fused to a beta-galactosidase tag.
AIMed.d201.s1727.p0	N	PROTEIN1 is a transcriptional modulator that communicates with PROTEIN2 and the PROTEIN .
AIMed.d201.s1727.p1	N	PROTEIN1 is a transcriptional modulator that communicates with PROTEIN and the PROTEIN2 .
AIMed.d201.s1727.p2	N	PROTEIN is a transcriptional modulator that communicates with PROTEIN1 and the PROTEIN2 .
AIMed.d201.s1728.p0	N	PROTEIN1 n ( PROTEIN2 ) transactivates viral and cellular genes through a wide variety of cis-elements.
AIMed.d201.s1730.p0	P	Our finding that PROTEIN1 directly interacts with PROTEIN2 ( PROTEIN ), a common subunit of RNA polymerases, implies that PROTEIN directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).
AIMed.d201.s1730.p1	P	Our finding that PROTEIN1 directly interacts with PROTEIN ( PROTEIN2 ), a common subunit of RNA polymerases, implies that PROTEIN directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).
AIMed.d201.s1730.p2	N	Our finding that PROTEIN1 directly interacts with PROTEIN ( PROTEIN ), a common subunit of RNA polymerases, implies that PROTEIN2 directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).
AIMed.d201.s1730.p4	N	Our finding that PROTEIN directly interacts with PROTEIN1 ( PROTEIN ), a common subunit of RNA polymerases, implies that PROTEIN2 directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).
AIMed.d201.s1730.p5	N	Our finding that PROTEIN directly interacts with PROTEIN ( PROTEIN1 ), a common subunit of RNA polymerases, implies that PROTEIN2 directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).
AIMed.d201.s1731.p0	N	In this context, we examined the possibility that PROTEIN1 and PROTEIN2 interact with other general transcription factors.
AIMed.d201.s1732.p0	N	PROTEIN1 and PROTEIN2 specifically bound to PROTEIN ( PROTEIN ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1732.p1	N	PROTEIN1 and PROTEIN specifically bound to PROTEIN2 ( PROTEIN ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1732.p2	N	PROTEIN1 and PROTEIN specifically bound to PROTEIN ( PROTEIN2 ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1732.p3	N	PROTEIN and PROTEIN1 specifically bound to PROTEIN2 ( PROTEIN ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1732.p4	N	PROTEIN and PROTEIN1 specifically bound to PROTEIN ( PROTEIN2 ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1732.p5	N	PROTEIN and PROTEIN specifically bound to PROTEIN1 ( PROTEIN2 ) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
AIMed.d201.s1733.p0	P	Delineation of the binding regions of these three proteins revealed that PROTEIN1 , PROTEIN2 , and PROTEIN each has two binding regions for the other two proteins.
AIMed.d201.s1733.p1	N	Delineation of the binding regions of these three proteins revealed that PROTEIN1 , PROTEIN , and PROTEIN2 each has two binding regions for the other two proteins.
AIMed.d201.s1733.p2	N	Delineation of the binding regions of these three proteins revealed that PROTEIN , PROTEIN1 , and PROTEIN2 each has two binding regions for the other two proteins.
AIMed.d201.s1735.p0	N	Some PROTEIN1 substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN2 or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN and PROTEIN .
AIMed.d201.s1735.p1	P	Some PROTEIN1 substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN2 in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN and PROTEIN .
AIMed.d201.s1735.p2	N	Some PROTEIN1 substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN2 transactivation requires the interactions of both PROTEIN and PROTEIN .
AIMed.d201.s1735.p3	N	Some PROTEIN1 substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN2 and PROTEIN .
AIMed.d201.s1735.p4	N	Some PROTEIN1 substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN and PROTEIN2 .
AIMed.d201.s1735.p5	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN1 or PROTEIN2 in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN and PROTEIN .
AIMed.d201.s1735.p6	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN1 or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN2 transactivation requires the interactions of both PROTEIN and PROTEIN .
AIMed.d201.s1735.p7	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN1 or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN2 and PROTEIN .
AIMed.d201.s1735.p10	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN1 in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN2 and PROTEIN .
AIMed.d201.s1735.p11	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN1 in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN and PROTEIN2 .
AIMed.d201.s1735.p12	P	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN1 transactivation requires the interactions of both PROTEIN2 and PROTEIN .
AIMed.d201.s1735.p13	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN1 transactivation requires the interactions of both PROTEIN and PROTEIN2 .
AIMed.d201.s1735.p14	N	Some PROTEIN substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either PROTEIN or PROTEIN in a mutually exclusive manner, suggesting that PROTEIN transactivation requires the interactions of both PROTEIN1 and PROTEIN2 .
AIMed.d201.s1736.p0	N	These results indicated that PROTEIN1 is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN2 through communication with PROTEIN and PROTEIN .
AIMed.d201.s1736.p1	N	These results indicated that PROTEIN1 is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN through communication with PROTEIN2 and PROTEIN .
AIMed.d201.s1736.p2	N	These results indicated that PROTEIN1 is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN through communication with PROTEIN and PROTEIN2 .
AIMed.d201.s1736.p3	N	These results indicated that PROTEIN is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN1 through communication with PROTEIN2 and PROTEIN .
AIMed.d201.s1736.p4	N	These results indicated that PROTEIN is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN1 through communication with PROTEIN and PROTEIN2 .
AIMed.d201.s1736.p5	N	These results indicated that PROTEIN is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and PROTEIN through communication with PROTEIN1 and PROTEIN2 .
AIMed.d202.s1737.p2	P	Crystal structure of the PROTEIN1 complexed with PROTEIN2 .
AIMed.d202.s1738.p0	N	PROTEIN1 ( PROTEIN2 ) is an important mediator of inflammatory disease.
AIMed.d202.s1739.p0	N	The PROTEIN1 family currently consists of two agonists, PROTEIN2 and PROTEIN , and one antagonist, PROTEIN .
AIMed.d202.s1739.p1	N	The PROTEIN1 family currently consists of two agonists, PROTEIN and PROTEIN2 , and one antagonist, PROTEIN .
AIMed.d202.s1739.p2	N	The PROTEIN1 family currently consists of two agonists, PROTEIN and PROTEIN , and one antagonist, PROTEIN2 .
AIMed.d202.s1739.p3	N	The PROTEIN family currently consists of two agonists, PROTEIN1 and PROTEIN2 , and one antagonist, PROTEIN .
AIMed.d202.s1739.p4	N	The PROTEIN family currently consists of two agonists, PROTEIN1 and PROTEIN , and one antagonist, PROTEIN2 .
AIMed.d202.s1739.p5	N	The PROTEIN family currently consists of two agonists, PROTEIN and PROTEIN1 , and one antagonist, PROTEIN2 .
AIMed.d202.s1740.p2	N	Each of these molecules binds to the PROTEIN1 ( PROTEIN2 ).
AIMed.d202.s1741.p0	N	The binding of PROTEIN1 or PROTEIN2 to PROTEIN is an early step in PROTEIN signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.
AIMed.d202.s1741.p2	N	The binding of PROTEIN1 or PROTEIN to PROTEIN is an early step in PROTEIN2 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.
AIMed.d202.s1741.p3	P	The binding of PROTEIN or PROTEIN1 to PROTEIN2 is an early step in PROTEIN signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.
AIMed.d202.s1741.p4	N	The binding of PROTEIN or PROTEIN1 to PROTEIN is an early step in PROTEIN2 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.
AIMed.d202.s1741.p5	N	The binding of PROTEIN or PROTEIN to PROTEIN1 is an early step in PROTEIN2 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.
AIMed.d202.s1742.p1	P	Here we report the three-dimensional structure of PROTEIN1 bound to the extracellular domain of PROTEIN ( PROTEIN2 ) at 2.5 A resolution.
AIMed.d202.s1742.p2	N	Here we report the three-dimensional structure of PROTEIN bound to the extracellular domain of PROTEIN1 ( PROTEIN2 ) at 2.5 A resolution.
AIMed.d202.s1743.p0	P	PROTEIN1 binds to PROTEIN2 with a 1:1 stoichiometry.
AIMed.d202.s1744.p0	P	The crystal structure shows that PROTEIN1 consists of three immunoglobulin-like domains which wrap around PROTEIN2 in a manner distinct from the structures of previously described cytokine-receptor complexes.
AIMed.d203.s1747.p0	N	Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines PROTEIN1 ( PROTEIN2 ) and PROTEIN (ref. 1).
AIMed.d203.s1747.p1	N	Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines PROTEIN1 ( PROTEIN ) and PROTEIN2 (ref. 1).
AIMed.d203.s1747.p2	N	Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines PROTEIN ( PROTEIN1 ) and PROTEIN2 (ref. 1).
AIMed.d203.s1748.p8	N	Three naturally occurring ligands for the PROTEIN1 ( PROTEIN2 ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p9	P	Three naturally occurring ligands for the PROTEIN1 ( PROTEIN ) exist: the agonists PROTEIN2 and PROTEIN and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p10	N	Three naturally occurring ligands for the PROTEIN1 ( PROTEIN ) exist: the agonists PROTEIN and PROTEIN2 and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p13	N	Three naturally occurring ligands for the PROTEIN1 ( PROTEIN ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN2  PROTEIN (ref. 2).
AIMed.d203.s1748.p14	N	Three naturally occurring ligands for the PROTEIN1 ( PROTEIN ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN  PROTEIN2 (ref. 2).
AIMed.d203.s1748.p15	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN1 ) exist: the agonists PROTEIN2 and PROTEIN and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p16	P	Three naturally occurring ligands for the PROTEIN ( PROTEIN1 ) exist: the agonists PROTEIN and PROTEIN2 and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p19	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN1 ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN2  PROTEIN (ref. 2).
AIMed.d203.s1748.p20	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN1 ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN  PROTEIN2 (ref. 2).
AIMed.d203.s1748.p21	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN ) exist: the agonists PROTEIN1 and PROTEIN2 and the PROTEIN  PROTEIN (ref. 2).
AIMed.d203.s1748.p24	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN ) exist: the agonists PROTEIN1 and PROTEIN and the PROTEIN2  PROTEIN (ref. 2).
AIMed.d203.s1748.p29	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN ) exist: the agonists PROTEIN and PROTEIN1 and the PROTEIN  PROTEIN2 (ref. 2).
AIMed.d203.s1748.p35	N	Three naturally occurring ligands for the PROTEIN ( PROTEIN ) exist: the agonists PROTEIN and PROTEIN and the PROTEIN1  PROTEIN2 (ref. 2).
AIMed.d203.s1750.p2	P	Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of PROTEIN1 complexed with PROTEIN2 .
AIMed.d203.s1754.p0	N	A region that is important for biological function in PROTEIN1 , the 'receptor trigger site' is not in direct contact with the receptor in the PROTEIN2 complex.
AIMed.d204.s1756.p0	N	The catalytic domain of activated PROTEIN1 ( PROTEIN2 ) is absolutely required for interaction with its specific inhibitor, PROTEIN ( PROTEIN ).
AIMed.d204.s1756.p1	N	The catalytic domain of activated PROTEIN1 ( PROTEIN ) is absolutely required for interaction with its specific inhibitor, PROTEIN2 ( PROTEIN ).
AIMed.d204.s1756.p3	P	The catalytic domain of activated PROTEIN ( PROTEIN1 ) is absolutely required for interaction with its specific inhibitor, PROTEIN2 ( PROTEIN ).
AIMed.d204.s1756.p4	P	The catalytic domain of activated PROTEIN ( PROTEIN1 ) is absolutely required for interaction with its specific inhibitor, PROTEIN ( PROTEIN2 ).
AIMed.d204.s1756.p5	N	The catalytic domain of activated PROTEIN ( PROTEIN ) is absolutely required for interaction with its specific inhibitor, PROTEIN1 ( PROTEIN2 ).
AIMed.d204.s1757.p0	N	Here, we describe the production of PROTEIN1 ( PROTEIN2 ) and wild-type and mutant human PROTEIN ( PROTEIN ) proteins in SF9 cells by the baculovirus expression system.
AIMed.d204.s1757.p1	N	Here, we describe the production of PROTEIN1 ( PROTEIN ) and wild-type and mutant human PROTEIN2 ( PROTEIN ) proteins in SF9 cells by the baculovirus expression system.
AIMed.d204.s1757.p2	N	Here, we describe the production of PROTEIN1 ( PROTEIN ) and wild-type and mutant human PROTEIN ( PROTEIN2 ) proteins in SF9 cells by the baculovirus expression system.
AIMed.d204.s1757.p4	N	Here, we describe the production of PROTEIN ( PROTEIN1 ) and wild-type and mutant human PROTEIN ( PROTEIN2 ) proteins in SF9 cells by the baculovirus expression system.
AIMed.d204.s1757.p5	N	Here, we describe the production of PROTEIN ( PROTEIN ) and wild-type and mutant human PROTEIN1 ( PROTEIN2 ) proteins in SF9 cells by the baculovirus expression system.
AIMed.d204.s1758.p0	N	Wild-type PROTEIN1 , as well as the PROTEIN2 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN or 4-aminophenylmercuric acetate.
AIMed.d204.s1758.p1	N	Wild-type PROTEIN1 , as well as the PROTEIN mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN2 ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN or 4-aminophenylmercuric acetate.
AIMed.d204.s1758.p2	N	Wild-type PROTEIN1 , as well as the PROTEIN mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN2 or 4-aminophenylmercuric acetate.
AIMed.d204.s1758.p3	N	Wild-type PROTEIN , as well as the PROTEIN1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN2 ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN or 4-aminophenylmercuric acetate.
AIMed.d204.s1758.p4	N	Wild-type PROTEIN , as well as the PROTEIN1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN2 or 4-aminophenylmercuric acetate.
AIMed.d204.s1758.p5	N	Wild-type PROTEIN , as well as the PROTEIN mutant lacking the C-terminal hemopexin-like domain [des-(248-450)- PROTEIN1 ], exhibit enzymatic activity upon cleavage of the prodomain by treatment with PROTEIN2 or 4-aminophenylmercuric acetate.
AIMed.d204.s1760.p0	N	Deletion of the complete active-site [des-(161-228)- PROTEIN1 ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN2 proteins which are unable to digest PROTEIN or PROTEIN .
AIMed.d204.s1760.p1	N	Deletion of the complete active-site [des-(161-228)- PROTEIN1 ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN proteins which are unable to digest PROTEIN2 or PROTEIN .
AIMed.d204.s1760.p2	N	Deletion of the complete active-site [des-(161-228)- PROTEIN1 ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN proteins which are unable to digest PROTEIN or PROTEIN2 .
AIMed.d204.s1760.p3	N	Deletion of the complete active-site [des-(161-228)- PROTEIN ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN1 proteins which are unable to digest PROTEIN2 or PROTEIN .
AIMed.d204.s1760.p4	N	Deletion of the complete active-site [des-(161-228)- PROTEIN ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN1 proteins which are unable to digest PROTEIN or PROTEIN2 .
AIMed.d204.s1760.p5	N	Deletion of the complete active-site [des-(161-228)- PROTEIN ] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of PROTEIN proteins which are unable to digest PROTEIN1 or PROTEIN2 .
AIMed.d204.s1761.p0	N	In addition to co-immunoprecipitation analysis, we have established a rapid and sensitive ELISA assay using immobilized PROTEIN1 to determine the structural requirements of PROTEIN2 to form complexes with its inhibitor.
AIMed.d204.s1762.p0	P	Only the activated and not the latent forms of wild-type and C-terminal mutant des-(248-450)- PROTEIN1 proteins are able to form complexes with PROTEIN2 .
AIMed.d204.s1763.p0	N	Neither mutation of His199, nor deletion mutants des-(161-228)- PROTEIN1 and des-(161-228/248-450)- PROTEIN2 , interact with PROTEIN .
AIMed.d204.s1763.p1	N	Neither mutation of His199, nor deletion mutants des-(161-228)- PROTEIN1 and des-(161-228/248-450)- PROTEIN , interact with PROTEIN2 .
AIMed.d204.s1764.p0	N	This demonstrates that the C-terminal hemopexin domain of PROTEIN1 , in contrast to the corresponding regions of PROTEIN2 and PROTEIN , does not interact with PROTEIN .
AIMed.d204.s1764.p1	N	This demonstrates that the C-terminal hemopexin domain of PROTEIN1 , in contrast to the corresponding regions of PROTEIN and PROTEIN2 , does not interact with PROTEIN .
AIMed.d204.s1764.p2	N	This demonstrates that the C-terminal hemopexin domain of PROTEIN1 , in contrast to the corresponding regions of PROTEIN and PROTEIN , does not interact with PROTEIN2 .
AIMed.d204.s1764.p3	N	This demonstrates that the C-terminal hemopexin domain of PROTEIN , in contrast to the corresponding regions of PROTEIN1 and PROTEIN2 , does not interact with PROTEIN .
AIMed.d204.s1764.p4	P	This demonstrates that the C-terminal hemopexin domain of PROTEIN , in contrast to the corresponding regions of PROTEIN1 and PROTEIN , does not interact with PROTEIN2 .
AIMed.d204.s1764.p5	P	This demonstrates that the C-terminal hemopexin domain of PROTEIN , in contrast to the corresponding regions of PROTEIN and PROTEIN1 , does not interact with PROTEIN2 .
AIMed.d204.s1765.p0	P	In summary, we have shown that the integrity of the catalytic domain of PROTEIN1 and its ability to bind Zn2+ is absolutely required for complex formation with PROTEIN2 , which further underlines the importance of this region for proper regulation of enzymatic activity of PROTEIN .
AIMed.d204.s1765.p1	N	In summary, we have shown that the integrity of the catalytic domain of PROTEIN1 and its ability to bind Zn2+ is absolutely required for complex formation with PROTEIN , which further underlines the importance of this region for proper regulation of enzymatic activity of PROTEIN2 .
AIMed.d204.s1765.p2	N	In summary, we have shown that the integrity of the catalytic domain of PROTEIN and its ability to bind Zn2+ is absolutely required for complex formation with PROTEIN1 , which further underlines the importance of this region for proper regulation of enzymatic activity of PROTEIN2 .
AIMed.d205.s1766.p0	N	Thymocyte activation induces the association of PROTEIN1 and PROTEIN2 with PROTEIN .
AIMed.d205.s1766.p1	P	Thymocyte activation induces the association of PROTEIN1 and PROTEIN with PROTEIN2 .
AIMed.d205.s1766.p2	P	Thymocyte activation induces the association of PROTEIN and PROTEIN1 with PROTEIN2 .
AIMed.d205.s1768.p0	N	Antibody-mediated cross-linking studies or studies on PROTEIN1 knockout mice implicate PROTEIN2 as a co-stimulatory or negative regulatory molecule.
AIMed.d205.s1770.p0	N	Y429 and Y441 occur in an imperfect PROTEIN1 ( PROTEIN2 )-like sequence.
AIMed.d205.s1771.p1	N	We investigated whether PROTEIN1 , which binds to tyrosine-phosphorylated PROTEIN , interacts with PROTEIN2 following T cell activation.
AIMed.d205.s1771.p2	N	We investigated whether PROTEIN , which binds to tyrosine-phosphorylated PROTEIN1 , interacts with PROTEIN2 following T cell activation.
AIMed.d205.s1772.p0	N	PROTEIN1 activity and the regulatory PROTEIN2 subunit of PROTEIN associated with PROTEIN in pervanadate-stimulated, but not in unstimulated thymocytes.
AIMed.d205.s1772.p1	N	PROTEIN1 activity and the regulatory PROTEIN subunit of PROTEIN2 associated with PROTEIN in pervanadate-stimulated, but not in unstimulated thymocytes.
AIMed.d205.s1772.p2	N	PROTEIN1 activity and the regulatory PROTEIN subunit of PROTEIN associated with PROTEIN2 in pervanadate-stimulated, but not in unstimulated thymocytes.
AIMed.d205.s1772.p4	N	PROTEIN activity and the regulatory PROTEIN1 subunit of PROTEIN associated with PROTEIN2 in pervanadate-stimulated, but not in unstimulated thymocytes.
AIMed.d205.s1772.p5	P	PROTEIN activity and the regulatory PROTEIN subunit of PROTEIN1 associated with PROTEIN2 in pervanadate-stimulated, but not in unstimulated thymocytes.
AIMed.d205.s1773.p0	N	Cellular PROTEIN1 as well as the recombinant Src homology 2 (SH2) domains of PROTEIN2 bound a tyrosine-phosphorylated peptide encompassing Y463 with approximately threefold greater affinity than a doubly tyrosine-phosphorylated Y429-Y441 peptide.
AIMed.d205.s1775.p0	N	A PROTEIN1 ( PROTEIN2 ) associated with PROTEIN and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.
AIMed.d205.s1775.p1	P	A PROTEIN1 ( PROTEIN ) associated with PROTEIN2 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.
AIMed.d205.s1775.p2	P	A PROTEIN ( PROTEIN1 ) associated with PROTEIN2 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.
AIMed.d205.s1776.p0	N	We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PROTEIN1 and PROTEIN2 to PROTEIN .
AIMed.d205.s1776.p2	P	We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PROTEIN and PROTEIN1 to PROTEIN2 .
AIMed.d206.s1779.p0	N	As PROTEIN1 forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour, we investigated PROTEIN2 expression and function in human epidermal keratinocytes.
AIMed.d206.s1781.p0	N	There was extensive co-localisation of PROTEIN1 and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes; however, in contrast to the integrins, PROTEIN2 was not found in focal adhesions.
AIMed.d206.s1782.p0	N	PROTEIN1 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of PROTEIN2 and PROTEIN , but not of cadherins.
AIMed.d206.s1782.p1	N	PROTEIN1 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of PROTEIN and PROTEIN2 , but not of cadherins.
AIMed.d206.s1782.p2	N	PROTEIN was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of PROTEIN1 and PROTEIN2 , but not of cadherins.
AIMed.d206.s1784.p0	N	Antibodies to PROTEIN1 did not affect the proportion of keratinocytes that adhered to PROTEIN2 , PROTEIN and PROTEIN , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1784.p1	N	Antibodies to PROTEIN1 did not affect the proportion of keratinocytes that adhered to PROTEIN , PROTEIN2 and PROTEIN , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1784.p2	N	Antibodies to PROTEIN1 did not affect the proportion of keratinocytes that adhered to PROTEIN , PROTEIN and PROTEIN2 , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1784.p3	N	Antibodies to PROTEIN did not affect the proportion of keratinocytes that adhered to PROTEIN1 , PROTEIN2 and PROTEIN , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1784.p4	N	Antibodies to PROTEIN did not affect the proportion of keratinocytes that adhered to PROTEIN1 , PROTEIN and PROTEIN2 , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1784.p5	N	Antibodies to PROTEIN did not affect the proportion of keratinocytes that adhered to PROTEIN , PROTEIN1 and PROTEIN2 , but did inhibit motility of keratinocytes on tissue culture plastic.
AIMed.d206.s1785.p0	N	Like antibodies to the PROTEIN1 subunit, anti- PROTEIN2 inhibited suspension-induced terminal differentiation.
AIMed.d207.s1787.p0	N	PROTEIN1 prevents PROTEIN2 / PROTEIN containing PROTEIN complexes formation in terminally differentiated myocytes.
AIMed.d207.s1787.p1	N	PROTEIN1 prevents PROTEIN / PROTEIN2 containing PROTEIN complexes formation in terminally differentiated myocytes.
AIMed.d207.s1787.p2	N	PROTEIN1 prevents PROTEIN / PROTEIN containing PROTEIN2 complexes formation in terminally differentiated myocytes.
AIMed.d207.s1787.p3	P	PROTEIN prevents PROTEIN1 / PROTEIN2 containing PROTEIN complexes formation in terminally differentiated myocytes.
AIMed.d207.s1787.p4	N	PROTEIN prevents PROTEIN1 / PROTEIN containing PROTEIN2 complexes formation in terminally differentiated myocytes.
AIMed.d207.s1787.p5	N	PROTEIN prevents PROTEIN / PROTEIN1 containing PROTEIN2 complexes formation in terminally differentiated myocytes.
AIMed.d207.s1788.p0	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN2 ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN .
AIMed.d207.s1788.p1	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN ) protein PROTEIN2 and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN .
AIMed.d207.s1788.p2	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN2 , PROTEIN and PROTEIN / PROTEIN .
AIMed.d207.s1788.p3	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN2 and PROTEIN / PROTEIN .
AIMed.d207.s1788.p4	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d207.s1788.p5	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN1 ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d207.s1788.p6	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN1 ) protein PROTEIN2 and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN .
AIMed.d207.s1788.p8	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN1 ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN2 and PROTEIN / PROTEIN .
AIMed.d207.s1788.p9	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN1 ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d207.s1788.p10	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN1 ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d207.s1788.p11	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN1 and the pocket proteins PROTEIN2 , PROTEIN and PROTEIN / PROTEIN .
AIMed.d207.s1788.p13	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN1 and the pocket proteins PROTEIN , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d207.s1788.p14	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN1 and the pocket proteins PROTEIN , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d207.s1788.p15	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN1 , PROTEIN2 and PROTEIN / PROTEIN .
AIMed.d207.s1788.p16	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN1 , PROTEIN and PROTEIN2 / PROTEIN .
AIMed.d207.s1788.p17	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN1 , PROTEIN and PROTEIN / PROTEIN2 .
AIMed.d207.s1788.p18	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN1 and PROTEIN2 / PROTEIN .
AIMed.d207.s1788.p19	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN1 and PROTEIN / PROTEIN2 .
AIMed.d207.s1788.p20	N	Withdrawal from the cell cycle of differentiating myocytes is regulated by the PROTEIN ( PROTEIN ) protein PROTEIN and the pocket proteins PROTEIN , PROTEIN and PROTEIN1 / PROTEIN2 .
AIMed.d207.s1791.p0	N	An PROTEIN1 complex containing mainly PROTEIN2 and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p1	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN2 / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p2	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN / PROTEIN2 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p3	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN2 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p5	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p6	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p7	N	An PROTEIN1 complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1791.p8	P	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN2 / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p9	P	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN / PROTEIN2 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p11	N	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN2 / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p12	N	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p13	N	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p14	N	An PROTEIN complex containing mainly PROTEIN1 and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1791.p15	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN1 / PROTEIN2 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p16	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN1 / PROTEIN ( PROTEIN2 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p18	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN1 / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p19	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN1 / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p20	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN1 / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1791.p21	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN1 ( PROTEIN2 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p22	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN1 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN2 / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p23	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN1 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p24	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN1 ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p26	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN1 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN2 / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p27	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN1 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p28	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN1 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p29	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN1 -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1791.p30	P	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN1 / PROTEIN2 containing PROTEIN complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p31	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN1 / PROTEIN containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p32	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN1 / PROTEIN containing PROTEIN complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1791.p33	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN1 containing PROTEIN2 complex of proliferating myoblasts ( PROTEIN -G1/S complex).
AIMed.d207.s1791.p35	N	An PROTEIN complex containing mainly PROTEIN and PROTEIN / PROTEIN ( PROTEIN -G0/G1 complex) appears when DNA synthesis arrests, replacing the PROTEIN / PROTEIN containing PROTEIN1 complex of proliferating myoblasts ( PROTEIN2 -G1/S complex).
AIMed.d207.s1793.p0	N	In differentiating C2C12 cells, PROTEIN1 complexes switch and DNA synthesis in response to serum are prevented when PROTEIN2 DNA binding activity and the cdks inhibitor PROTEIN downstream effector PROTEIN are induced.
AIMed.d207.s1793.p1	N	In differentiating C2C12 cells, PROTEIN1 complexes switch and DNA synthesis in response to serum are prevented when PROTEIN DNA binding activity and the cdks inhibitor PROTEIN2 downstream effector PROTEIN are induced.
AIMed.d207.s1793.p2	N	In differentiating C2C12 cells, PROTEIN1 complexes switch and DNA synthesis in response to serum are prevented when PROTEIN DNA binding activity and the cdks inhibitor PROTEIN downstream effector PROTEIN2 are induced.
AIMed.d207.s1793.p3	N	In differentiating C2C12 cells, PROTEIN complexes switch and DNA synthesis in response to serum are prevented when PROTEIN1 DNA binding activity and the cdks inhibitor PROTEIN2 downstream effector PROTEIN are induced.
AIMed.d207.s1793.p4	N	In differentiating C2C12 cells, PROTEIN complexes switch and DNA synthesis in response to serum are prevented when PROTEIN1 DNA binding activity and the cdks inhibitor PROTEIN downstream effector PROTEIN2 are induced.
AIMed.d207.s1793.p5	N	In differentiating C2C12 cells, PROTEIN complexes switch and DNA synthesis in response to serum are prevented when PROTEIN DNA binding activity and the cdks inhibitor PROTEIN1 downstream effector PROTEIN2 are induced.
AIMed.d207.s1794.p0	P	Thus, during myogenic differentiation, formation of PROTEIN1 and PROTEIN2 / PROTEIN containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
AIMed.d207.s1794.p1	P	Thus, during myogenic differentiation, formation of PROTEIN1 and PROTEIN / PROTEIN2 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
AIMed.d207.s1794.p2	N	Thus, during myogenic differentiation, formation of PROTEIN and PROTEIN1 / PROTEIN2 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
AIMed.d207.s1795.p0	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN2 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p1	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN2 - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p2	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN - PROTEIN2 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p3	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN2 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p4	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN2 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p6	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p7	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN1 - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p8	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN2 - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p9	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN2 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p10	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN2 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p11	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN2 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p12	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN2 to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p13	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p14	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN1 ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p15	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN1 - PROTEIN2 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p16	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN1 - PROTEIN ) chimerae, we found that estrogen directed PROTEIN2 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p17	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN1 - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN2 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p20	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN1 - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p21	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN1 ) chimerae, we found that estrogen directed PROTEIN2 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p22	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN1 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN2 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p23	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN1 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN2 to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p24	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN1 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p25	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN1 ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p26	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN1 activation prevents the reassociation of PROTEIN2 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p27	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN1 activation prevents the reassociation of PROTEIN / PROTEIN2 to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p28	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN1 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p29	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN1 activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p31	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN1 / PROTEIN to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p32	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN1 / PROTEIN to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p33	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN1 to the PROTEIN2 containing complex following serum stimulation and this correlates with suppression of PROTEIN activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p34	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN1 to the PROTEIN containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1795.p35	N	Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing PROTEIN - PROTEIN ( PROTEIN - PROTEIN ) chimerae, we found that estrogen directed PROTEIN activation prevents the reassociation of PROTEIN / PROTEIN to the PROTEIN1 containing complex following serum stimulation and this correlates with suppression of PROTEIN2 activity and the inability of cells to re-enter the cell cycle.
AIMed.d207.s1796.p0	N	Our data indicate that, in differentiating myocytes, one mechanism through which PROTEIN1 induces permanent cell cycle arrest involves PROTEIN2 upregulation and suppression of the proliferation-associated cdks-containing PROTEIN complexes formation.
AIMed.d207.s1796.p1	N	Our data indicate that, in differentiating myocytes, one mechanism through which PROTEIN1 induces permanent cell cycle arrest involves PROTEIN upregulation and suppression of the proliferation-associated cdks-containing PROTEIN2 complexes formation.
AIMed.d207.s1796.p2	N	Our data indicate that, in differentiating myocytes, one mechanism through which PROTEIN induces permanent cell cycle arrest involves PROTEIN1 upregulation and suppression of the proliferation-associated cdks-containing PROTEIN2 complexes formation.
AIMed.d208.s1803.p0	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN2 / PROTEIN , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p1	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN2 , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p2	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN , PROTEIN2 , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p3	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN , PROTEIN , PROTEIN2 / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p4	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN , PROTEIN , PROTEIN / PROTEIN2 , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p5	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p6	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN1 , PROTEIN / PROTEIN , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN2 forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p7	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN1 / PROTEIN2 , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p8	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN1 / PROTEIN , PROTEIN2 , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p9	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN1 / PROTEIN , PROTEIN , PROTEIN2 / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p10	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN1 / PROTEIN , PROTEIN , PROTEIN / PROTEIN2 , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p11	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN1 / PROTEIN , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p13	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN1 , PROTEIN2 , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p14	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN1 , PROTEIN , PROTEIN2 / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p15	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN1 , PROTEIN , PROTEIN / PROTEIN2 , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p16	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN1 , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p17	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN1 , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN2 forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p18	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN1 , PROTEIN2 / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p19	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN1 , PROTEIN / PROTEIN2 , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p20	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN1 , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p21	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN1 , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN2 forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p22	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN , PROTEIN1 / PROTEIN2 , and TRAFs) associated with both of the PROTEIN and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p23	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN , PROTEIN1 / PROTEIN , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p24	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN , PROTEIN1 / PROTEIN , and TRAFs) associated with both of the PROTEIN and PROTEIN2 forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p25	P	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN , PROTEIN / PROTEIN1 , and TRAFs) associated with both of the PROTEIN2 and PROTEIN forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d208.s1803.p27	N	The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( PROTEIN , PROTEIN / PROTEIN , PROTEIN , PROTEIN / PROTEIN , and TRAFs) associated with both of the PROTEIN1 and PROTEIN2 forms of the TNF receptor and with other members of the TNF receptor superfamily.
AIMed.d209.s1806.p1	N	Human PROTEIN1 was first characterized as a PROTEIN2 based on the properties of its carboxyl-terminal domain.
AIMed.d209.s1807.p0	P	We now show that full-length PROTEIN1 interacts with activated PROTEIN2 in mammalian cells and defines a minimum region of 434 aa required for efficient PROTEIN binding.
AIMed.d209.s1807.p1	N	We now show that full-length PROTEIN1 interacts with activated PROTEIN in mammalian cells and defines a minimum region of 434 aa required for efficient PROTEIN2 binding.
AIMed.d209.s1807.p2	N	We now show that full-length PROTEIN interacts with activated PROTEIN1 in mammalian cells and defines a minimum region of 434 aa required for efficient PROTEIN2 binding.
AIMed.d209.s1808.p0	P	PROTEIN1 interacts with the "effector domain" of PROTEIN2 and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN effector.
AIMed.d209.s1808.p1	N	PROTEIN1 interacts with the "effector domain" of PROTEIN and employs some PROTEIN2 determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN effector.
AIMed.d209.s1808.p2	N	PROTEIN1 interacts with the "effector domain" of PROTEIN and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN2 , a known PROTEIN effector.
AIMed.d209.s1808.p3	N	PROTEIN1 interacts with the "effector domain" of PROTEIN and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN2 effector.
AIMed.d209.s1808.p4	N	PROTEIN interacts with the "effector domain" of PROTEIN1 and employs some PROTEIN2 determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN effector.
AIMed.d209.s1808.p5	N	PROTEIN interacts with the "effector domain" of PROTEIN1 and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN2 , a known PROTEIN effector.
AIMed.d209.s1808.p6	N	PROTEIN interacts with the "effector domain" of PROTEIN1 and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN2 effector.
AIMed.d209.s1808.p7	N	PROTEIN interacts with the "effector domain" of PROTEIN and employs some PROTEIN1 determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN2 , a known PROTEIN effector.
AIMed.d209.s1808.p8	N	PROTEIN interacts with the "effector domain" of PROTEIN and employs some PROTEIN1 determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN , a known PROTEIN2 effector.
AIMed.d209.s1808.p9	P	PROTEIN interacts with the "effector domain" of PROTEIN and employs some PROTEIN determinants that are common to, and others that are distinct from, those required for the binding of PROTEIN1 , a known PROTEIN2 effector.
AIMed.d209.s1809.p0	P	The same domain of PROTEIN1 that binds PROTEIN2 also interacts with 14-3-3 proteins, extending the similarity between PROTEIN and other PROTEIN effectors.
AIMed.d209.s1809.p1	N	The same domain of PROTEIN1 that binds PROTEIN also interacts with 14-3-3 proteins, extending the similarity between PROTEIN2 and other PROTEIN effectors.
AIMed.d209.s1809.p2	N	The same domain of PROTEIN1 that binds PROTEIN also interacts with 14-3-3 proteins, extending the similarity between PROTEIN and other PROTEIN2 effectors.
AIMed.d209.s1809.p3	N	The same domain of PROTEIN that binds PROTEIN1 also interacts with 14-3-3 proteins, extending the similarity between PROTEIN2 and other PROTEIN effectors.
AIMed.d209.s1809.p4	N	The same domain of PROTEIN that binds PROTEIN1 also interacts with 14-3-3 proteins, extending the similarity between PROTEIN and other PROTEIN2 effectors.
AIMed.d209.s1809.p5	N	The same domain of PROTEIN that binds PROTEIN also interacts with 14-3-3 proteins, extending the similarity between PROTEIN1 and other PROTEIN2 effectors.
AIMed.d209.s1810.p0	P	When expressed in mammalian cells, the PROTEIN1 binding domain of PROTEIN2 can act as a dominant negative signal transduction blocker.
AIMed.d209.s1812.p0	P	This PROTEIN1 sequence shows preferential binding to the PROTEIN2 domain in vitro.
AIMed.d209.s1813.p0	P	Moreover, the amino-terminal domain of PROTEIN1 directly associates with, and is tyrosine phosphorylated by, PROTEIN2 .
AIMed.d210.s1817.p0	P	Cross-family interaction between the bHLHZip PROTEIN1 and bZip PROTEIN2 proteins results in down-regulation of PROTEIN activity.
AIMed.d210.s1817.p1	N	Cross-family interaction between the bHLHZip PROTEIN1 and bZip PROTEIN proteins results in down-regulation of PROTEIN2 activity.
AIMed.d210.s1817.p2	N	Cross-family interaction between the bHLHZip PROTEIN and bZip PROTEIN1 proteins results in down-regulation of PROTEIN2 activity.
AIMed.d210.s1819.p0	N	To further examine the function of the bHLHZip protein, PROTEIN1 , we screened for cellular proteins which could directly interact with PROTEIN2 using the yeast two-hybrid system.
AIMed.d210.s1820.p0	P	A bZip protein, PROTEIN1 , was found to efficiently interact with PROTEIN2 .
AIMed.d210.s1821.p0	P	PROTEIN1 specifically interacts with PROTEIN2 but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p1	N	PROTEIN1 specifically interacts with PROTEIN but not with other closely related family members, PROTEIN2 , PROTEIN , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p2	N	PROTEIN1 specifically interacts with PROTEIN but not with other closely related family members, PROTEIN , PROTEIN2 , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p3	N	PROTEIN1 specifically interacts with PROTEIN but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN2 , or with PROTEIN .
AIMed.d210.s1821.p4	N	PROTEIN1 specifically interacts with PROTEIN but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN , or with PROTEIN2 .
AIMed.d210.s1821.p5	N	PROTEIN specifically interacts with PROTEIN1 but not with other closely related family members, PROTEIN2 , PROTEIN , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p6	N	PROTEIN specifically interacts with PROTEIN1 but not with other closely related family members, PROTEIN , PROTEIN2 , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p7	N	PROTEIN specifically interacts with PROTEIN1 but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN2 , or with PROTEIN .
AIMed.d210.s1821.p8	N	PROTEIN specifically interacts with PROTEIN1 but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN , or with PROTEIN2 .
AIMed.d210.s1821.p9	N	PROTEIN specifically interacts with PROTEIN but not with other closely related family members, PROTEIN1 , PROTEIN2 , PROTEIN , or with PROTEIN .
AIMed.d210.s1821.p10	N	PROTEIN specifically interacts with PROTEIN but not with other closely related family members, PROTEIN1 , PROTEIN , PROTEIN2 , or with PROTEIN .
AIMed.d210.s1821.p11	N	PROTEIN specifically interacts with PROTEIN but not with other closely related family members, PROTEIN1 , PROTEIN , PROTEIN , or with PROTEIN2 .
AIMed.d210.s1821.p12	N	PROTEIN specifically interacts with PROTEIN but not with other closely related family members, PROTEIN , PROTEIN1 , PROTEIN2 , or with PROTEIN .
AIMed.d210.s1821.p14	N	PROTEIN specifically interacts with PROTEIN but not with other closely related family members, PROTEIN , PROTEIN , PROTEIN1 , or with PROTEIN2 .
AIMed.d210.s1822.p0	P	Both the bHLHZip and the N-terminal regions of PROTEIN1 are required for efficient interaction with PROTEIN2 .
AIMed.d210.s1823.p0	P	In vivo association between PROTEIN1 and PROTEIN2 has been demonstrated by co-immunoprecipitation.
AIMed.d210.s1824.p0	N	Expression of exogenous PROTEIN1 led to a decrease in PROTEIN2 -dependent transcription in F9 cells.
AIMed.d210.s1825.p0	N	Co-expression of exogenous PROTEIN1 restored the PROTEIN2 activity in a dose-dependent manner.
AIMed.d210.s1826.p0	P	These data show that PROTEIN1 and PROTEIN2 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.
AIMed.d211.s1829.p1	N	Through their interaction with the ErbB family of receptors ( PROTEIN1 , PROTEIN and PROTEIN2 ), neuregulins help to regulate cell growth and differentiation in many tissues.
AIMed.d211.s1829.p2	N	Through their interaction with the ErbB family of receptors ( PROTEIN , PROTEIN1 and PROTEIN2 ), neuregulins help to regulate cell growth and differentiation in many tissues.
AIMed.d211.s1831.p0	N	The encoded product of the PROTEIN1 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the PROTEIN2 ( PROTEIN )-like domain gives rise to two isoforms (alpha and beta).
AIMed.d211.s1831.p2	N	The encoded product of the PROTEIN gene has a motif structure similar to that of neuregulins and an alternative splicing site in the PROTEIN1 ( PROTEIN2 )-like domain gives rise to two isoforms (alpha and beta).
AIMed.d211.s1833.p0	P	Recombinant PROTEIN1 induces the tyrosine-phosphorylation of PROTEIN2 , PROTEIN and PROTEIN in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1833.p1	P	Recombinant PROTEIN1 induces the tyrosine-phosphorylation of PROTEIN , PROTEIN2 and PROTEIN in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1833.p2	P	Recombinant PROTEIN1 induces the tyrosine-phosphorylation of PROTEIN , PROTEIN and PROTEIN2 in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1833.p3	N	Recombinant PROTEIN induces the tyrosine-phosphorylation of PROTEIN1 , PROTEIN2 and PROTEIN in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1833.p4	N	Recombinant PROTEIN induces the tyrosine-phosphorylation of PROTEIN1 , PROTEIN and PROTEIN2 in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1833.p5	N	Recombinant PROTEIN induces the tyrosine-phosphorylation of PROTEIN , PROTEIN1 and PROTEIN2 in cell lines expressing all of these ErbB-family receptors.
AIMed.d211.s1834.p0	P	However, in cell lines with defined combinations of ErbBs, PROTEIN1 only activates those with PROTEIN2 and/or PROTEIN , suggesting that signalling by PROTEIN is mediated by PROTEIN and/or PROTEIN receptors.
AIMed.d211.s1834.p1	P	However, in cell lines with defined combinations of ErbBs, PROTEIN1 only activates those with PROTEIN and/or PROTEIN2 , suggesting that signalling by PROTEIN is mediated by PROTEIN and/or PROTEIN receptors.
AIMed.d211.s1834.p3	N	However, in cell lines with defined combinations of ErbBs, PROTEIN1 only activates those with PROTEIN and/or PROTEIN , suggesting that signalling by PROTEIN is mediated by PROTEIN2 and/or PROTEIN receptors.
AIMed.d211.s1834.p5	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN1 and/or PROTEIN2 , suggesting that signalling by PROTEIN is mediated by PROTEIN and/or PROTEIN receptors.
AIMed.d211.s1834.p6	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN1 and/or PROTEIN , suggesting that signalling by PROTEIN2 is mediated by PROTEIN and/or PROTEIN receptors.
AIMed.d211.s1834.p7	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN1 and/or PROTEIN , suggesting that signalling by PROTEIN is mediated by PROTEIN2 and/or PROTEIN receptors.
AIMed.d211.s1834.p8	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN1 and/or PROTEIN , suggesting that signalling by PROTEIN is mediated by PROTEIN and/or PROTEIN2 receptors.
AIMed.d211.s1834.p9	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN and/or PROTEIN1 , suggesting that signalling by PROTEIN2 is mediated by PROTEIN and/or PROTEIN receptors.
AIMed.d211.s1834.p10	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN and/or PROTEIN1 , suggesting that signalling by PROTEIN is mediated by PROTEIN2 and/or PROTEIN receptors.
AIMed.d211.s1834.p13	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN and/or PROTEIN , suggesting that signalling by PROTEIN1 is mediated by PROTEIN and/or PROTEIN2 receptors.
AIMed.d211.s1834.p14	N	However, in cell lines with defined combinations of ErbBs, PROTEIN only activates those with PROTEIN and/or PROTEIN , suggesting that signalling by PROTEIN is mediated by PROTEIN1 and/or PROTEIN2 receptors.
AIMed.d212.s1835.p0	P	Interaction between PROTEIN1 protein and PROTEIN2 in response to DNA damage.
AIMed.d212.s1836.p0	N	The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated PROTEIN1 (for ' PROTEIN2 '), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.
AIMed.d212.s1838.p0	N	Because cells lacking the protein tyrosine kinase PROTEIN1 are also defective in radiation-induced G1 arrest, we investigated the possibility that PROTEIN2 might interact with PROTEIN in response to radiation damage.
AIMed.d212.s1839.p0	P	Here we show that PROTEIN1 binds PROTEIN2 constitutively in control cells but not in AT cells.
AIMed.d212.s1840.p0	P	Our results demonstrate that the SH3 domain of PROTEIN1 interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of PROTEIN2 .
AIMed.d212.s1842.p0	P	These findings indicate that PROTEIN1 is involved in the activation of PROTEIN2 by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.
AIMed.d213.s1846.p0	N	In addition, previous work indicated that PROTEIN1 and PROTEIN2 might be involved in PROTEIN -mediated repression.
AIMed.d213.s1846.p1	N	In addition, previous work indicated that PROTEIN1 and PROTEIN might be involved in PROTEIN2 -mediated repression.
AIMed.d213.s1846.p2	N	In addition, previous work indicated that PROTEIN and PROTEIN1 might be involved in PROTEIN2 -mediated repression.
AIMed.d213.s1851.p0	P	We show that the physical interaction between PROTEIN1 and PROTEIN2 , a coactivator for PROTEIN , is not sufficient for repression of PROTEIN -mediated transcription.
AIMed.d213.s1851.p1	N	We show that the physical interaction between PROTEIN1 and PROTEIN , a coactivator for PROTEIN2 , is not sufficient for repression of PROTEIN -mediated transcription.
AIMed.d213.s1851.p2	N	We show that the physical interaction between PROTEIN1 and PROTEIN , a coactivator for PROTEIN , is not sufficient for repression of PROTEIN2 -mediated transcription.
AIMed.d213.s1851.p3	P	We show that the physical interaction between PROTEIN and PROTEIN1 , a coactivator for PROTEIN2 , is not sufficient for repression of PROTEIN -mediated transcription.
AIMed.d213.s1851.p4	N	We show that the physical interaction between PROTEIN and PROTEIN1 , a coactivator for PROTEIN , is not sufficient for repression of PROTEIN2 -mediated transcription.
AIMed.d213.s1851.p5	N	We show that the physical interaction between PROTEIN and PROTEIN , a coactivator for PROTEIN1 , is not sufficient for repression of PROTEIN2 -mediated transcription.
AIMed.d213.s1853.p0	N	Repression of PROTEIN1 -directed transcription may be accomplished through direct physical interaction between PROTEIN2 and this activator.
AIMed.d213.s1854.p0	N	In contrast, physical interaction is not necessary for PROTEIN1 to repress PROTEIN2 - and PROTEIN -mediated transcription.
AIMed.d213.s1854.p2	N	In contrast, physical interaction is not necessary for PROTEIN to repress PROTEIN1 - and PROTEIN2 -mediated transcription.
AIMed.d214.s1858.p1	N	The molecular adapter PROTEIN1 is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN2 homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p2	P	The molecular adapter PROTEIN1 is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN2 , PROTEIN , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p4	P	The molecular adapter PROTEIN1 is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN , and PROTEIN2 , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p7	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN1 and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN2 , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p8	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN1 and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN , and PROTEIN2 , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p9	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN1 homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN2 , PROTEIN , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p10	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN1 homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN2 , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p11	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN1 homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN , and PROTEIN2 , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p12	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN1 , PROTEIN2 , and PROTEIN , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1858.p14	N	The molecular adapter PROTEIN is rapidly tyrosine phosphorylated following stimulation through the PROTEIN and associates with PROTEIN homology domain-2 (SH2)/SH3 domain-containing adapters such as PROTEIN , PROTEIN1 , and PROTEIN2 , which interact with guanine nucleotide exchange factors specific for the Ras family.
AIMed.d214.s1859.p0	N	This suggests that PROTEIN1 may link PROTEIN2 activation to molecules that regulate GTP binding proteins.
AIMed.d214.s1860.p0	N	The SH2/SH3-containing protein PROTEIN1 also contains a guanine nucleotide exchange factor domain, and PROTEIN2 has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the PROTEIN .
AIMed.d214.s1860.p1	N	The SH2/SH3-containing protein PROTEIN1 also contains a guanine nucleotide exchange factor domain, and PROTEIN has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the PROTEIN2 .
AIMed.d214.s1860.p2	N	The SH2/SH3-containing protein PROTEIN also contains a guanine nucleotide exchange factor domain, and PROTEIN1 has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the PROTEIN2 .
AIMed.d214.s1861.p0	P	Here we show that PROTEIN1 and PROTEIN2 form inducible molecular complexes in PROTEIN -activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.
AIMed.d214.s1861.p1	N	Here we show that PROTEIN1 and PROTEIN form inducible molecular complexes in PROTEIN2 -activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.
AIMed.d214.s1861.p2	N	Here we show that PROTEIN and PROTEIN1 form inducible molecular complexes in PROTEIN2 -activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.
AIMed.d214.s1862.p0	P	PROTEIN1 / PROTEIN2 interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor PROTEIN , in which PROTEIN is hyperphosphorylated on tyrosine residues.
AIMed.d214.s1862.p1	N	PROTEIN1 / PROTEIN interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor PROTEIN2 , in which PROTEIN is hyperphosphorylated on tyrosine residues.
AIMed.d214.s1862.p2	N	PROTEIN1 / PROTEIN interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor PROTEIN , in which PROTEIN2 is hyperphosphorylated on tyrosine residues.
AIMed.d214.s1862.p3	N	PROTEIN / PROTEIN1 interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor PROTEIN2 , in which PROTEIN is hyperphosphorylated on tyrosine residues.
AIMed.d214.s1862.p5	N	PROTEIN / PROTEIN interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor PROTEIN1 , in which PROTEIN2 is hyperphosphorylated on tyrosine residues.
AIMed.d214.s1863.p0	P	The interaction between PROTEIN1 and PROTEIN2 is directly mediated via the SH2 domain of PROTEIN and is dependent on tyrosine phosphorylation of PROTEIN .
AIMed.d214.s1863.p1	N	The interaction between PROTEIN1 and PROTEIN is directly mediated via the SH2 domain of PROTEIN2 and is dependent on tyrosine phosphorylation of PROTEIN .
AIMed.d214.s1863.p2	N	The interaction between PROTEIN1 and PROTEIN is directly mediated via the SH2 domain of PROTEIN and is dependent on tyrosine phosphorylation of PROTEIN2 .
AIMed.d214.s1863.p3	N	The interaction between PROTEIN and PROTEIN1 is directly mediated via the SH2 domain of PROTEIN2 and is dependent on tyrosine phosphorylation of PROTEIN .
AIMed.d214.s1863.p4	N	The interaction between PROTEIN and PROTEIN1 is directly mediated via the SH2 domain of PROTEIN and is dependent on tyrosine phosphorylation of PROTEIN2 .
AIMed.d214.s1863.p5	N	The interaction between PROTEIN and PROTEIN is directly mediated via the SH2 domain of PROTEIN1 and is dependent on tyrosine phosphorylation of PROTEIN2 .
AIMed.d214.s1864.p0	P	In addition, we show that the conserved motif Y699 MTP present in PROTEIN1 is the binding site for the PROTEIN2 SH2 domain in vitro.
AIMed.d214.s1865.p0	N	These data imply that PROTEIN1 is a molecular adapter that regulates the function of PROTEIN2 in thymocytes and peripheral T cells.
AIMed.d215.s1866.p0	P	Induction of cell migration by PROTEIN1 cleavage of PROTEIN2 .
AIMed.d215.s1868.p0	N	Specific cleavage of PROTEIN1 ( PROTEIN2 ) by PROTEIN ( PROTEIN ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1868.p1	P	Specific cleavage of PROTEIN1 ( PROTEIN ) by PROTEIN2 ( PROTEIN ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1868.p2	P	Specific cleavage of PROTEIN1 ( PROTEIN ) by PROTEIN ( PROTEIN2 ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1868.p3	P	Specific cleavage of PROTEIN ( PROTEIN1 ) by PROTEIN2 ( PROTEIN ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1868.p4	P	Specific cleavage of PROTEIN ( PROTEIN1 ) by PROTEIN ( PROTEIN2 ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1868.p5	N	Specific cleavage of PROTEIN ( PROTEIN ) by PROTEIN1 ( PROTEIN2 ) was shown to induce migration of breast epithelial cells.
AIMed.d215.s1869.p1	N	PROTEIN1 cleaved the PROTEIN2 subunit at residue 587, exposing a putative cryptic promigratory site on PROTEIN that triggers cell motility.
AIMed.d215.s1869.p5	N	PROTEIN cleaved the PROTEIN1 subunit at residue 587, exposing a putative cryptic promigratory site on PROTEIN2 that triggers cell motility.
AIMed.d215.s1871.p0	P	Cleavage of PROTEIN1 by PROTEIN2 and the resulting activation of the PROTEIN cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.
AIMed.d216.s1872.p0	P	The PROTEIN1 - PROTEIN2 complex: structural basis for GTPase activation and its loss in oncogenic PROTEIN mutants.
AIMed.d216.s1872.p1	N	The PROTEIN1 - PROTEIN complex: structural basis for GTPase activation and its loss in oncogenic PROTEIN2 mutants.
AIMed.d216.s1872.p2	N	The PROTEIN - PROTEIN1 complex: structural basis for GTPase activation and its loss in oncogenic PROTEIN2 mutants.
AIMed.d216.s1873.p0	N	The three-dimensional structure of the complex between human PROTEIN1 bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN2  PROTEIN ( PROTEIN ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1873.p1	P	The three-dimensional structure of the complex between human PROTEIN1 bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN  PROTEIN2 ( PROTEIN ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1873.p2	P	The three-dimensional structure of the complex between human PROTEIN1 bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN  PROTEIN ( PROTEIN2 ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1873.p3	N	The three-dimensional structure of the complex between human PROTEIN bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN1  PROTEIN2 ( PROTEIN ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1873.p4	N	The three-dimensional structure of the complex between human PROTEIN bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN1  PROTEIN ( PROTEIN2 ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1873.p5	N	The three-dimensional structure of the complex between human PROTEIN bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human PROTEIN  PROTEIN1 ( PROTEIN2 ) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms.
AIMed.d216.s1875.p0	N	An arginine side chain (arginine-789) of PROTEIN1 is supplied into the active site of PROTEIN2 to neutralize developing charges in the transition state.
AIMed.d216.s1876.p0	P	The switch II region of PROTEIN1 is stabilized by PROTEIN2 , thus allowing glutamine-61 of PROTEIN , mutation of which activates the oncogenic potential, to participate in catalysis.
AIMed.d216.s1876.p1	N	The switch II region of PROTEIN1 is stabilized by PROTEIN , thus allowing glutamine-61 of PROTEIN2 , mutation of which activates the oncogenic potential, to participate in catalysis.
AIMed.d216.s1876.p2	N	The switch II region of PROTEIN is stabilized by PROTEIN1 , thus allowing glutamine-61 of PROTEIN2 , mutation of which activates the oncogenic potential, to participate in catalysis.
AIMed.d216.s1878.p0	N	Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of PROTEIN1 and glutamine-61 of PROTEIN2 , and even its mutation to alanine would disturb the arrangements of residues in the transition state.
AIMed.d217.s1879.p0	N	Characterization of PROTEIN1 ( PROTEIN2 , PROTEIN )- PROTEIN interaction.
AIMed.d217.s1879.p1	N	Characterization of PROTEIN1 ( PROTEIN , PROTEIN2 )- PROTEIN interaction.
AIMed.d217.s1879.p3	P	Characterization of PROTEIN1 ( PROTEIN , PROTEIN )- PROTEIN2 interaction.
AIMed.d217.s1879.p4	N	Characterization of PROTEIN ( PROTEIN1 , PROTEIN2 )- PROTEIN interaction.
AIMed.d217.s1879.p6	P	Characterization of PROTEIN ( PROTEIN1 , PROTEIN )- PROTEIN2 interaction.
AIMed.d217.s1879.p8	P	Characterization of PROTEIN ( PROTEIN , PROTEIN1 )- PROTEIN2 interaction.
AIMed.d217.s1880.p1	P	The death-inducing receptor PROTEIN1 is activated when cross-linked by the type II membrane protein PROTEIN2 ( PROTEIN ).
AIMed.d217.s1880.p2	P	The death-inducing receptor PROTEIN1 is activated when cross-linked by the type II membrane protein PROTEIN ( PROTEIN2 ).
AIMed.d217.s1880.p5	N	The death-inducing receptor PROTEIN is activated when cross-linked by the type II membrane protein PROTEIN1 ( PROTEIN2 ).
AIMed.d217.s1881.p0	N	When human soluble PROTEIN1 (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each PROTEIN2 monomer were found to be essential for efficient secretion.
AIMed.d217.s1882.p0	P	Based on the structure of the closely related PROTEIN1 - PROTEIN2 complex, a molecular model of the PROTEIN homotrimer bound to three PROTEIN molecules was generated using knowledge-based protein modeling methods.
AIMed.d217.s1882.p2	N	Based on the structure of the closely related PROTEIN1 - PROTEIN complex, a molecular model of the PROTEIN homotrimer bound to three PROTEIN2 molecules was generated using knowledge-based protein modeling methods.
AIMed.d217.s1882.p3	N	Based on the structure of the closely related PROTEIN - PROTEIN1 complex, a molecular model of the PROTEIN2 homotrimer bound to three PROTEIN molecules was generated using knowledge-based protein modeling methods.
AIMed.d217.s1882.p4	N	Based on the structure of the closely related PROTEIN - PROTEIN1 complex, a molecular model of the PROTEIN homotrimer bound to three PROTEIN2 molecules was generated using knowledge-based protein modeling methods.
AIMed.d217.s1882.p5	P	Based on the structure of the closely related PROTEIN - PROTEIN complex, a molecular model of the PROTEIN1 homotrimer bound to three PROTEIN2 molecules was generated using knowledge-based protein modeling methods.
AIMed.d217.s1885.p0	N	Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward PROTEIN1 -positive cells with a concomitant decrease in the binding affinity for the recombinant PROTEIN2 -immunoglobulin Fc fusion proteins.
AIMed.d218.s1889.p0	N	PROTEIN1 ( PROTEIN2 ) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets.
AIMed.d218.s1890.p0	P	We sought to characterize how PROTEIN1 binds and activates its receptor, PROTEIN2 .
AIMed.d218.s1891.p0	N	The PROTEIN1 -like domain of PROTEIN2 (TPO1-153) has been fused to the PROTEIN coat protein of M13 bacteriophage.
AIMed.d218.s1891.p1	N	The PROTEIN1 -like domain of PROTEIN (TPO1-153) has been fused to the PROTEIN2 coat protein of M13 bacteriophage.
AIMed.d218.s1893.p0	N	Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the PROTEIN1 receptor and five anti- PROTEIN2 -153 monoclonal antibodies.
AIMed.d218.s1897.p0	N	In contrast, the other three monoclonal antibodies, which were effective at blocking PROTEIN1 activity but did not block initial binding of PROTEIN2 to its receptor, had epitopes predominantly on helix or 3.
AIMed.d218.s1898.p0	N	These results suggest that PROTEIN1 has two distinct receptor-binding sites that function to dimerize PROTEIN2 receptors in a sequential fashion.
AIMed.d219.s1899.p0	P	PROTEIN1 negatively regulates PROTEIN2 activity by interactions with the PROTEIN cysteine-rich domain.
AIMed.d219.s1899.p1	P	PROTEIN1 negatively regulates PROTEIN activity by interactions with the PROTEIN2 cysteine-rich domain.
AIMed.d219.s1899.p2	N	PROTEIN negatively regulates PROTEIN1 activity by interactions with the PROTEIN2 cysteine-rich domain.
AIMed.d219.s1900.p0	N	Although PROTEIN1 is a critical effector of PROTEIN2 signaling and transformation, the mechanism by which PROTEIN promotes PROTEIN activation is complex and remains poorly understood.
AIMed.d219.s1900.p1	N	Although PROTEIN1 is a critical effector of PROTEIN signaling and transformation, the mechanism by which PROTEIN2 promotes PROTEIN activation is complex and remains poorly understood.
AIMed.d219.s1900.p2	N	Although PROTEIN1 is a critical effector of PROTEIN signaling and transformation, the mechanism by which PROTEIN promotes PROTEIN2 activation is complex and remains poorly understood.
AIMed.d219.s1900.p3	N	Although PROTEIN is a critical effector of PROTEIN1 signaling and transformation, the mechanism by which PROTEIN2 promotes PROTEIN activation is complex and remains poorly understood.
AIMed.d219.s1900.p4	N	Although PROTEIN is a critical effector of PROTEIN1 signaling and transformation, the mechanism by which PROTEIN promotes PROTEIN2 activation is complex and remains poorly understood.
AIMed.d219.s1900.p5	N	Although PROTEIN is a critical effector of PROTEIN signaling and transformation, the mechanism by which PROTEIN1 promotes PROTEIN2 activation is complex and remains poorly understood.
AIMed.d219.s1901.p1	P	We recently reported that PROTEIN1 interaction with the PROTEIN2 ( PROTEIN , residues 139-184) may be required for PROTEIN activation.
AIMed.d219.s1901.p2	P	We recently reported that PROTEIN1 interaction with the PROTEIN ( PROTEIN2 , residues 139-184) may be required for PROTEIN activation.
AIMed.d219.s1901.p3	N	We recently reported that PROTEIN1 interaction with the PROTEIN ( PROTEIN , residues 139-184) may be required for PROTEIN2 activation.
AIMed.d219.s1901.p7	N	We recently reported that PROTEIN interaction with the PROTEIN1 ( PROTEIN2 , residues 139-184) may be required for PROTEIN activation.
AIMed.d219.s1901.p8	N	We recently reported that PROTEIN interaction with the PROTEIN1 ( PROTEIN , residues 139-184) may be required for PROTEIN2 activation.
AIMed.d219.s1901.p9	N	We recently reported that PROTEIN interaction with the PROTEIN ( PROTEIN1 , residues 139-184) may be required for PROTEIN2 activation.
AIMed.d219.s1902.p0	N	The PROTEIN1 is located in the NH2-terminal negative regulatory domain of PROTEIN2 and is highly homologous to cysteine-rich domains found in protein kinase C family members.
AIMed.d219.s1903.p0	N	Recent studies indicate that the structural integrity of the PROTEIN1 is also critical for PROTEIN2 interaction with 14-3-3 proteins.
AIMed.d219.s1905.p0	P	In the present study, we demonstrate that PROTEIN1 binds directly to the isolated PROTEIN2 .
AIMed.d219.s1906.p1	P	Moreover, mutation of PROTEIN1 residues 143-145 impairs binding of 14-3-3, but not PROTEIN , to the PROTEIN2 .
AIMed.d219.s1906.p2	N	Moreover, mutation of PROTEIN residues 143-145 impairs binding of 14-3-3, but not PROTEIN1 , to the PROTEIN2 .
AIMed.d219.s1908.p0	N	Thus, 14-3-3 interaction with the PROTEIN1 may serve in negative regulation of PROTEIN2 function by facilitating dissociation of 14-3-3 from the NH2 terminus of PROTEIN to promote subsequent events necessary for full activation of PROTEIN .
AIMed.d219.s1908.p1	N	Thus, 14-3-3 interaction with the PROTEIN1 may serve in negative regulation of PROTEIN function by facilitating dissociation of 14-3-3 from the NH2 terminus of PROTEIN2 to promote subsequent events necessary for full activation of PROTEIN .
AIMed.d219.s1908.p3	N	Thus, 14-3-3 interaction with the PROTEIN may serve in negative regulation of PROTEIN1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of PROTEIN2 to promote subsequent events necessary for full activation of PROTEIN .
AIMed.d219.s1908.p4	N	Thus, 14-3-3 interaction with the PROTEIN may serve in negative regulation of PROTEIN1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of PROTEIN to promote subsequent events necessary for full activation of PROTEIN2 .
AIMed.d219.s1908.p5	N	Thus, 14-3-3 interaction with the PROTEIN may serve in negative regulation of PROTEIN function by facilitating dissociation of 14-3-3 from the NH2 terminus of PROTEIN1 to promote subsequent events necessary for full activation of PROTEIN2 .
AIMed.d220.s1909.p1	P	Interactions between PROTEIN1 and the PROTEIN2 . Identification of two ligand binding domains in soluble PROTEIN by affinity separation and chemical cross-linking.
AIMed.d220.s1909.p2	N	Interactions between PROTEIN1 and the PROTEIN . Identification of two ligand binding domains in soluble PROTEIN2 by affinity separation and chemical cross-linking.
AIMed.d220.s1909.p5	N	Interactions between PROTEIN and the PROTEIN1 . Identification of two ligand binding domains in soluble PROTEIN2 by affinity separation and chemical cross-linking.
AIMed.d220.s1910.p3	P	The extracellular domain of the human PROTEIN1 expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for PROTEIN2 ( PROTEIN ).
AIMed.d220.s1920.p2	P	These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the PROTEIN1 in binding PROTEIN2 .
AIMed.d221.s1921.p3	P	A region of the beta subunit of the PROTEIN1 different from box 1 interacts with PROTEIN2 and is sufficient to activate the PROTEIN -Stat pathway and induce an antiviral state.
AIMed.d221.s1921.p5	N	A region of the beta subunit of the PROTEIN different from box 1 interacts with PROTEIN1 and is sufficient to activate the PROTEIN2 -Stat pathway and induce an antiviral state.
AIMed.d221.s1924.p0	N	Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the PROTEIN1 -Stat pathway and trigger an antiviral state after PROTEIN2 binding to the receptor.
AIMed.d222.s1928.p0	P	The protein product of PROTEIN1 proto-oncogene is known to interact with several proteins, including PROTEIN2 , PROTEIN and PROTEIN , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1928.p1	P	The protein product of PROTEIN1 proto-oncogene is known to interact with several proteins, including PROTEIN , PROTEIN2 and PROTEIN , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1928.p2	P	The protein product of PROTEIN1 proto-oncogene is known to interact with several proteins, including PROTEIN , PROTEIN and PROTEIN2 , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1928.p3	N	The protein product of PROTEIN proto-oncogene is known to interact with several proteins, including PROTEIN1 , PROTEIN2 and PROTEIN , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1928.p4	N	The protein product of PROTEIN proto-oncogene is known to interact with several proteins, including PROTEIN1 , PROTEIN and PROTEIN2 , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1928.p5	N	The protein product of PROTEIN proto-oncogene is known to interact with several proteins, including PROTEIN , PROTEIN1 and PROTEIN2 , and is thought to regulate signalling by many cell surface receptors.
AIMed.d222.s1929.p0	N	The precise function of PROTEIN1 in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that PROTEIN2 is a negative regulator of the PROTEIN .
AIMed.d222.s1929.p2	N	The precise function of PROTEIN1 in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that PROTEIN is a negative regulator of the PROTEIN2 .
AIMed.d222.s1929.p4	P	The precise function of PROTEIN in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that PROTEIN1 is a negative regulator of the PROTEIN2 .
AIMed.d222.s1931.p0	P	The screen identified interactions involving PROTEIN1 and two 14-3-3 isoforms, PROTEIN2 , human unconventional myosin IC, and a recently identified SH3 domain containing protein, PROTEIN .
AIMed.d222.s1931.p1	P	The screen identified interactions involving PROTEIN1 and two 14-3-3 isoforms, PROTEIN , human unconventional myosin IC, and a recently identified SH3 domain containing protein, PROTEIN2 .
AIMed.d223.s1934.p0	P	Interaction between cell cycle regulator, PROTEIN1 , and PROTEIN2 mediates repression of HIV-1 gene transcription.
AIMed.d223.s1936.p0	P	Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein PROTEIN1 and its partner PROTEIN2 .
AIMed.d223.s1938.p1	P	Here, we demonstrate that PROTEIN1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the PROTEIN enhancer region and to interact with the PROTEIN2 subunit, PROTEIN .
AIMed.d223.s1938.p2	P	Here, we demonstrate that PROTEIN1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the PROTEIN enhancer region and to interact with the PROTEIN subunit, PROTEIN2 .
AIMed.d223.s1938.p3	N	Here, we demonstrate that PROTEIN may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the PROTEIN1 enhancer region and to interact with the PROTEIN2 subunit, PROTEIN .
AIMed.d223.s1938.p4	N	Here, we demonstrate that PROTEIN may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the PROTEIN1 enhancer region and to interact with the PROTEIN subunit, PROTEIN2 .
AIMed.d223.s1938.p5	N	Here, we demonstrate that PROTEIN may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the PROTEIN enhancer region and to interact with the PROTEIN1 subunit, PROTEIN2 .
AIMed.d223.s1939.p0	N	Gel retardation and methylation interference assays show that PROTEIN1 is able to bind specifically to a site embedded within the two PROTEIN2 elements.
AIMed.d223.s1940.p0	N	Gel retardation/immunoblot analysis using purified PROTEIN1 and PROTEIN2 homodimers reveals the presence of complexes containing both proteins.
AIMed.d223.s1941.p0	P	Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of PROTEIN1 and PROTEIN2 in the absence of their DNA target sequences.
AIMed.d223.s1942.p0	N	In vitro transcription assay demonstrates that PROTEIN1 represses PROTEIN2 mediated transcription in a cell-free system.
AIMed.d223.s1943.p0	N	Functional studies in Jurkat T lymphocytic cells point to the importance of both the PROTEIN1 and PROTEIN2 binding sites in PROTEIN mediated repression of HIV-1 promoter, in vivo.
AIMed.d223.s1943.p1	N	Functional studies in Jurkat T lymphocytic cells point to the importance of both the PROTEIN1 and PROTEIN binding sites in PROTEIN2 mediated repression of HIV-1 promoter, in vivo.
AIMed.d223.s1943.p2	N	Functional studies in Jurkat T lymphocytic cells point to the importance of both the PROTEIN and PROTEIN1 binding sites in PROTEIN2 mediated repression of HIV-1 promoter, in vivo.
AIMed.d223.s1944.p0	P	The results of this study suggest that PROTEIN1 activity may be regulated by its interaction with the cell cycle regulatory protein, PROTEIN2 .
AIMed.d224.s1945.p0	N	PROTEIN1 - and PROTEIN2 -dependent PROTEIN surface expression correlates with the binding of an MHC class I leader peptide.
AIMed.d224.s1945.p1	N	PROTEIN1 - and PROTEIN -dependent PROTEIN2 surface expression correlates with the binding of an MHC class I leader peptide.
AIMed.d224.s1945.p2	N	PROTEIN - and PROTEIN1 -dependent PROTEIN2 surface expression correlates with the binding of an MHC class I leader peptide.
AIMed.d224.s1949.p0	N	We demonstrate that PROTEIN1 surface expression is correlated with the presence of MHC class I molecules which provide suitable leader sequence peptides capable of binding to PROTEIN2 .
AIMed.d224.s1950.p0	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN2 associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p1	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN2 ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p2	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN2 ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p3	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN2 , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p4	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN2 expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p5	N	Further studies on the interaction of PROTEIN1 with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1950.p6	P	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN1 associates with the PROTEIN2 ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p7	P	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN1 associates with the PROTEIN ( PROTEIN2 ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p8	P	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN1 associates with the PROTEIN ( PROTEIN ) and PROTEIN2 , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p9	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN1 associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN2 expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p10	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN1 associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1950.p11	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN1 ( PROTEIN2 ) and PROTEIN , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p12	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN1 ( PROTEIN ) and PROTEIN2 , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p13	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN1 ( PROTEIN ) and PROTEIN , and that PROTEIN2 expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p14	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN1 ( PROTEIN ) and PROTEIN , and that PROTEIN expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1950.p15	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN1 ) and PROTEIN2 , and that PROTEIN expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p16	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN1 ) and PROTEIN , and that PROTEIN2 expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p17	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN1 ) and PROTEIN , and that PROTEIN expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1950.p18	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN1 , and that PROTEIN2 expression is PROTEIN -dependent and tapasin-dependent.
AIMed.d224.s1950.p19	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN1 , and that PROTEIN expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1950.p20	N	Further studies on the interaction of PROTEIN with molecules in the endoplasmic reticulum revealed that PROTEIN associates with the PROTEIN ( PROTEIN ) and PROTEIN , and that PROTEIN1 expression is PROTEIN2 -dependent and tapasin-dependent.
AIMed.d224.s1951.p0	P	In addition, PROTEIN1 dissociates from PROTEIN2 upon binding of MHC class I leader sequence peptides.
AIMed.d224.s1954.p0	N	Our results also show that, although these PROTEIN1 binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the PROTEIN2 complex and loaded onto PROTEIN molecules.
AIMed.d224.s1954.p1	N	Our results also show that, although these PROTEIN1 binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the PROTEIN complex and loaded onto PROTEIN2 molecules.
AIMed.d224.s1954.p2	N	Our results also show that, although these PROTEIN binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the PROTEIN1 complex and loaded onto PROTEIN2 molecules.
